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 Very little is known about the structure of the catalytic domain of eukaryotic 
diacylglycerol kinases (DGKs), a family of interfacial enzymes implicated in a number of 
physiological roles and human diseases.  Constructs of the catalytic domain could be 
expressed in Escherichia coli and extracted, refolded, and purified from inclusion bodies, 
but when subjected to analytical gel filtration chromatography, these constructs eluted in 
the void volume in what appeared to be microscopic aggregates unsuitable for x-ray 
crystallography.  Adding glutathione S-transferase, thioredoxin, or maltose binding 
protein as N-terminal fusion tags did not improve the constructs’ solubility.   
Coexpressing with bacterial chaperones increased the yield in the supernatant after high-
speed centrifugation, but the protein still eluted in the void upon analytical gel filtration 
chromatography.  DGK constructs expressed in insect cells were likewise insoluble and 
unsuitable for x-ray crystallography.  Loss of enzymatic activity of purified DGK could 
be mitigated by including 50% (v/v) glycerol and storing at -80°C, and by including 
detergent, lipid, and protein activators following thawing.  Certain polybasic proteins and 
substrate analogs increase the in vitro enzymatic activity of purified DGK, whereas 
hirudin decreases its activity under certain conditions.  DGK is able to use certain 
diglyceride analogs as substrates.  Bimolecular fluorescence complementation was unable 
to show whether DGK-theta dimerized or interacted with tau when overexpressed in 
mammalian cells.  Thrombin was able to digest DGK-theta after folding, but none of the 
washing conditions tested were able to separate the digested fragments, so while 
digestion with thrombin appeared to activate DGK-theta, whether the activation was due 
to relief from auto-inhibition or some other effect from the thrombin could not be 
 iii 
resolved.  Photoaffinity labels were able to enzymatically inactivate purified DGK-theta 
in a probe-, ultraviolet-, and time-dependent way, but only when the linker between the 
substrate analog moiety and the photoactivatable moiety was sufficiently short.  Mass 
spectrometry studies were unable to detect peptides shifted by the predicted molecular 
weight of the photoaffinity labels or their fragments.  This work should guide future 
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Chapter 1: Introduction 
DGKs are a family of enzymes in eukaryotes that catalyze the transfer of the γ-
phosphoryl from ATP onto the hydroxyl of DAG to produce ADP and PA.  Most 
mammalian DGKs are interfacial enzymes, catalyzing reactions at the two-dimensional 
interface between the membrane and the aqueous phase. 
Eukaryotic DGKs have been implicated in a number of physiological roles and 
human diseases4,5.  Understanding the structure of these enzymes would bring insight into 
their activity, open doors to DGK modulator production and impact not only lipid 
signaling research but also medicine.  Furthermore, little is known about the function of 
lipid kinases. Unlike their relatives with soluble substrates, the interfacial properties of 
these kinases greatly increase the technical difficulty for research.  Lessons learned from 
DGKs might be applied to other lipid kinases, or indeed other interfacial enzymes.  Most 
research to date revolves around protein-protein interactions, whereas much less 
concentrates on activity between lipids and proteins. Purification techniques and 
structural studies between DGKs interactions with DAG may be applied to other proteins 
that interact with lipids. Applications for this research are endless: not only could de novo 
protein lipid interactions be developed, but also improvements to drug delivery systems 
would further advance medicine into a new era.   
Most work on eukaryotic DGKs has been conducted on those isolated from 
endogenous sources.  Eukaryotic DGKs have been partially purified from rat liver6, rat 
brain7–9, bovine brain10, bovine thymus11, human platelets12, porcine brain8, porcine 
testis13,14, porcine submaxillary glands15,16, baboon brain17, 3T3 mouse fibroblast 
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cells8,15,16,18–21, Drosophila heads22, and Caltharanthus roseus suspension-cultured cells23, 
and they have been purified to apparent homogeneity from porcine brain24–26, porcine 
thymus15,16,19,27–29, bovine brain30, bovine testis15,16,18,19, rat brain31–33, human platelets12, 
human white blood cells34, and Microsporum gypseum suspension-cultured cells35.  
While purified DGKs from endogenous sources have been invaluable for studying their 
enzymology, these sources are not amenable to producing enough protein for pursuing 
structural studies. 
Recombinant forms of eukaryotic DGKs have been expressed in E. coli36,37, in 
COS-736,38,39 and COS-1 Chlorocebus aethiops kidney cells15,16, in Jurkat human T 
cells38,40, in HEK293 human embryonic kidney cells38,41, and in Sf21 Spodoptera 
frugiperda cells42,43, and have been partially purified from HEK293 cells44, COS-7 
cells45, Dictyostelium discoideum46,47, E. coli44,48–52, and Sf21 cells53.  In only two cases 
to our knowledge has a eukaryotic DGK been purified to apparent homogeneity from a 
recombinant source: porcine DGK alpha was purified to apparent homogeneity after 
being expressed in the Saccharomyces cerevisiae strain WY29415, and human DGK-theta 
was purified to apparent homogeneity after being expressed in HEK293 cells3.  
Truncations of the accessory (not catalytic) domains of eukaryotic DGKs have been 
expressed recombinantly with more success16,39,54. 
As such, little is known about the structure of DGKs, particularly of the catalytic 
domain.  The catalytic domain is so-called because it is a region of primary sequence 
homology that makes up the gene family.  Furthermore, this domain from S. scrofa DGK-
alpha, when expressed in COS-7 cells, was reported to be catalytically competent45, 
possessing similar enzymatic properties to the full-length enzyme, demonstrating that all 
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of the determinants for the catalytic reaction, including binding sites for the two 
substrates, are located in this region of the protein.  But whereas a nuclear magnetic 
resonance (NMR) structure of the N-terminus of Homo sapiens DGK-alpha has been 
reported62, as have an NMR structure of the second C1 domain56 and an x-ray crystal 
structure of the SAM domain from H. sapiens DGK-delta57, no structures of any part of 
the catalytic domain from any eukaryotic DGK have yet been published. 
I therefore set out to recombinantly express and purify various eukaryotic DGK 
constructs in bacteria, Dictyostelium discoideum, insect cells, and mammalian cells.  In 
order to use enzymatic activity to study DGK structure and enzymology, I developed 
methods to preserve DGK activity during storage and experimental manipulation.  In 
order to gain insight into structural requirements for DGK’s enzymology, as well as to 
optimize methods for experimental manipulation, I studied the effects of activators and 
inhibitors as well as substrate specificity.  In order to probe intermolecular structural 
interactions of eukaryotic DGKs, I used bimolecular fluorescence complementation 
(BiFC).  In addition to studying genetic truncations of eukaryotic DGKs, I also used 
proteolysis to generate such truncations, in case the entire protein sequence was required 
for proper folding.  I also used a photoaffinity labeling approach in order to map the 
diacylglycerol binding site on the surface of eukaryotic DGKs.  This work should guide 
future studies not only of the structure of eukaryotic DGKs, but also of other interfacial 
enzymes, and other protein-lipid interactions. 
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Chapter 2: General Methods 
Introduction 
 The methods described in this chapter are general methods used throughout the 
different projects described in each of the dissertation chapters.  Methods specific to each 
chapter will be described in that chapter. 
Measuring Protein Concentration 
I measured protein concentration using the Bio-Rad Protein Assay (Bio-Rad 500-
0006), which works by the principle that the absorbance of Coomassie® Brilliant Blue G-
250 dye in an acidic solution at 595 nm (A595) increases upon binding protein58, and the 
protein concentration in a sample can thus be measured colorimetrically.  I blanked with 
buffer, and used known concentrations of bovine serum albumin (BSA) as a standard to 
calibrate the A595 reading as a function of protein concentration.  For the protein sample 
whose concentration I was measuring, I diluted it if necessary to interpolate into a good 
linear fit of the BSA, including zero. 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE is a method to separate macromolecules, such as proteins, by their 
size.  Because SDS, an anionic detergent, coats most proteins in a constant ratio of 1.4 g 
SDS per g protein59, the relative migration in SDS-PAGE is a linear function of the 
logarithm of molecular weight for most proteins60, so the relative migration compared to 
molecular weight standards can be used to measure the molecular weights of proteins in a 
sample.  After electrophoresis, the migration pattern of the proteins can be detected either 
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by nonspecific staining, such as by Coomassie dyes61 or silver staining62, or 
immunoblotting can be used to detect the migration pattern of specific proteins. 
In general, I first prepared a protein sample by diluting it into SDS-gel loading 
buffer (for a final concentration of 28.125 mM tris(hydroxymethyl)aminomethane (Tris), 
pH 6.8, 11.25% (v/v) glycerol (for helping the sample sink to the bottom of the well, by 
increasing its density), 0.9% (w/v) SDS, 0.01125% (w/v) bromophenol blue (for visually 
tracking the sample as it is loaded and electrophoreses), 2.5% (v/v) β-mercaptoethanol 
(BME)), adapted from Bio-Rad’s “A Guide to Polyacrylamide Gel Electrophoresis and 
Detection”) and heating at ~95°C for several minutes to ensure that the proteins were 
fully denatured and coated with SDS.  When loading an equivalent volume (to compare, 
for example, the amount of protein in a lysate to the amount of protein in a subsequent 
preparation, which may have been resuspended in a different volume), I calculated the 
equivalent volume according to Equation 1.   




Equation 1.  I calculated the equivalent volume (Lb) of sample b to load based on the volume loaded of 
sample a (La), the volume in which sample a was originally resuspended (Ra), and the volume in which 
sample b was resuspended (Rb).  For example, if the cell pellet were resuspended in 1 mL lysis buffer to 
produce 1 mL of lysate, and if after removing the supernatant I extracted the pellet with 0.2 mL of 
extraction buffer to produce 0.2 mL of extracted protein, and if I loaded 1 µL of lysate, the equivalent 
volumes of supernatant and extracted protein would be 1 µL and 0.2 µL, respectively. 
 I then loaded the samples into PAGs I had cast myself.  For the separating phase 
of the gel, which resolves the samples by molecular weight, the percentage of acrylamide 
varied, and the rest of the gel was made of 375 mM Tris, pH 8.8, 0.1% (w/v) SDS, 0.1% 
(w/v) ammonium persulfate (APS), and 0.04% (v/v) N,N,N’,N’-
tetramethylethylenediamine (TEMED) (except for 8% acrylamide gels, in which case 
TEMED was increased to 0.06%, and 6% acrylamide gels, in which case TEMED was 
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increased to .08%).  The stacking phase of the gel, which sweeps the proteins from the 
well into a tight band due to the differential mobility of anions at the lower pH63, was 
made of 250 mM Tris, pH 6.8, 0.1% (w/v) SDS, 0.1% (w/v) APS, and 0.01% (v/v) 
TEMED.  I used the gels within one week so that the buffers between the stacking and 
separating phases had not mixed by diffusion64.  I electrophoresed in electrophoresis 
buffer (30.3 g per L Tris base, 144.0 g glycine, and 10.0 g SDS) (also from Bio-Rad’s “A 
Guide to Polyacrylamide Gel Electrophoresis and Detection”) in a Mini-PROTEAN® 
apparatus (Bio-Rad) between 30 and 200 V until the dye front left the gel. 
Coomassie is an anionic dye that, as SDS does, binds nonspecifically to proteins, 
and as such has the advantage that the intensity of Coomassie staining can be used to 
estimate protein abundance.  Coomassie staining is thus a useful tool for assessing the 
purity of a protein sample, if the protein is sufficiently abundant, as in bacterial 
overexpression of recombinant protein.  If a gel’s destiny was Coomassie staining, after 
electrophoresis I destained the gel in ultrapure (Type I) water for several minutes, gently 
shaking at room temperature, in order to remove the SDS, which can interfere with the 
protein-Coomassie interaction.  Then I incubated the gel overnight, gently shaking at 
room temperature, in either ProtoBlue Safe (National Diagnostics EC-722) (combined in 
a 9:1::ProtoBlue Safe:ethanol ratio, as recommended by the manufacturer) (which, in my 
experience, was a more sensitive dye) or Bio-Safe Coomassie Stain (Bio-Rad 161-0786) 
(which, in my experience, was a less sensitive dye).  In order to reduce background 
staining, I destained the gel by gently shaking in ultrapure water for several hours, with a 
wadded up Kimwipe™ (Kimberly-Clark® TW31KWPCS) in the corner, and usually 
changed Kimwipes™ once or twice over the course of the destaining.  I sandwiched the 
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destained gel between two clear plastic sheet protectors (Office Depot® #498811) and 
scanned an image of it at 300 dots per inch (dpi). 
Silver staining is another method to visualize proteins following SDS-PAGE.  It 
can be treacherous for estimating protein concentration, not only because the degree of 
staining depends not only on the chemical composition of the protein65 but also because 
the degree of staining depends nonlinearly on the concentration of protein present.  Silver 
ions complexed to protein is less reactive than free ions, which is why the silver needs to 
be washed briefly from the gel in order to get positive and not negative staining of protein 
bands, which means not only that the degree of staining is very sensitive to the degree of 
washing after staining, but also that more concentrated protein can stain less intensely 
than less concentrated protein66.  On the other hand, silver staining can be up to thirty 
times more sensitive than Coomassie staining, so it can be a useful technique for 
observing the electrophoretic migration of protein purified from a mammalian expression 
system, where the protein’s concentration is below the threshold of detection of 
Coomassie staining.  Because of the high sensitivity of silver staining, I was careful to 
use clean containers and ultrapure water, to keep keratins (from human skin, and thus 
dust) or other abundant proteins from the environment from contaminating the gel.  I 
stained gels using the SilverQuest™ Silver Staining Kit (Life Technologies™ LC6070) 
following the manufacturer’s protocol with the following modifications: I reduced the 
sensitizing step from ten minutes to seven minutes, and I added a brief wash with 
ultrapure water between the post-sensitization 30% ethanol ten-minute wash step and the 
ten-minute ultrapure water wash step.  I also made sure during these water wash steps to 
vigorously shake the dish, if necessary, so that by the end of the ten-minute water wash 
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the solvent had sufficiently exchanged in the gel such that the gel was submerged and no 
longer floated on top of the water.  After staining, as above, I sandwiched the destained 
gel between two clear plastic sheet protectors and scanned at 300 dpi. 
A technique that can be even more sensitive than silver staining is 
immunoblotting, which, unlike Coomassie or silver staining, detects specific epitopes 
(particular surfaces of a particular protein).  Immunoblotting thus can be useful for 
detecting the migration patterns of proteins of very low concentration, such as protein 
purified from a mammalian expression system.  It can also be very useful to detect 
whether a specific protein is present in a complex mixture, even at low relative 
concentrations compared to the other proteins, and even when other proteins of similar 
size are present, such as detecting whether a recombinant protein is successfully 
expressing in a lysate.  I transferred protein from the gel to a nitrocellulose membrane 
that had been presoaked in transfer buffer (30.3 g per L Tris base, 14.4 g per L glycine, 
10% (v/v) methanol, pH 8.3), or else a polyvinylidene (PVDF) membrane, which I first 
briefly soaked in methanol before soaking in transfer buffer, in a GENIE® 
Electrophoretic Transfer apparatus (Idea Scientific 4017) at 12 V for ninety minutes or 
so. 
I used two general methods for detecting the proteins on the membrane.  One 
method was chemiluminescent.  For these membranes, if I wanted to visualize all the 
protein nonspecifically (to, for example, estimate how much of the total protein my 
protein of interest is, or check whether a bubble obstructed the transfer), I rinsed the 
membrane with ultrapure water, briefly stained with the dye Ponceau S (which binds 
proteins reversibly, and does not seem to be deleterious to later immunoblotting), then 
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briefly washed the membrane with water.  In order to reduce nonspecific interaction of 
the primary antibody with the membrane and other proteins on the membrane, I first 
blocked the membrane with 3% (w/v) BSA in TBS/T (8 g per L NaCl, 0.2 g per L KCl, 3 
g per L Tris base, 0.1% (v/v) Tween-20, adapted from Sambrook, Fritsch, and Maniatis’s 
Molecular Cloning: A Laboratory Manual67), gently shaking either at room temperature 
for an hour, or as long as overnight (or longer) at 4°C.  After blocking, I incubated the 
membrane in either blocking buffer or TBS/T along with a primary antibody raised 
against the epitope of interest, gently shaking for four hours, or as long as overnight (or 
longer) at 4°C.  The primary antibody dilution also included sodium azide as a 
preservative: I eventually learned that I produced the best results, however, when I 
always used a fresh primary antibody dilution, so the preservative was unnecessary.  
After incubation with the primary antibody, I rinsed the membrane by vigorously shaking 
in TBS/T, then incubated in the appropriate secondary antibody, raised against the 
species of the primary antibody, which was also conjugated to horseradish peroxidase 
(HRP).  After incubation with the primary antibody, I rinsed the membrane by vigorously 
shaking in TBS/T, and then incubated briefly in a chemiluminescent substrate for the 
HRP (either SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific), or 
else Immobilon Western Chemiluminescent HRP Substrate (EMD Millipore)).  The HRP 
used the chemiluminescent substrate to produce photons emanating from the region of the 
gel to which the secondary antibody had bound (which, in turn, indicated where the 
primary antibody bound, which, in turn, indicated where the epitope of interest had 
migrated), so I therefore sandwiched the membrane between plastic binder sheets and 
exposed it to film.  For each membrane, I tried multiple exposure times to optimize 
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visualization of the immunoblot signal.  If I was going to perform densitometry on a film, 
I chose exposures faint enough that I could read text through the bands of interest.  Most 
films I scanned at 300 dpi, but films selected for densitometry I scanned as 1200 dpi .tiff 
files.  I measured the densitometry of these scans with ImageJ68 (v1.46r) without 
calibration, three times from the same film.  The relative densitometry of each lane was 
normalized to the total densitometry of all the lanes on that replicate. 
Alternatively, I used the Odyssey® Infrared Imaging System (LI-COR®) to 
detect the proteins on immunoblots.  Those membranes I did not Ponceau S stain, 
because the dye gives high background in the infrared.  I was careful to keep these 
membranes in containers that were never used for Coomassie staining, because 
Coomassie likewise gives high background in the infrared.  I blocked these membranes 
with Odyssey Blocking Buffer (LI-COR®) and washed the membranes with phosphate-
buffered saline (PBS) (Cellgro® 21-040-CV).  I used secondary antibodies conjugated to 
infrared fluorophores (such as IRDye® 680LT goat anti-mouse IgG (LI-COR® 926-
68020) or IRDye® 800CW goat anti-rabbit IgG (LI-COR® 926-32211)) in Odyssey 
Blocking Buffer with 0.2% (v/v) Tween-20 and 0.01% (w/v) SDS.  I scanned the 
membranes using the Odyssey® Infrared Imaging System running Odyssey® v3.0 (LI-
COR®), with a resolution of 169 µm, quality of medium, offset of 0.0, and intensity of 5. 
Sometimes it was necessary to strip primary antibodies off the blot and reprobe 
with another primary antibody or a fresher aliquot of the same antibody.  For PVDF 
membranes, I incubated the membrane in 5 mL of fivefold diluted NewBlot™ PVDF 
Stripping Buffer (LI-COR® 928-40032) for twenty minutes, shaking at ~80 rotations per 
minute (rpm) at room temperature.  For nitrocellulose membranes, I used NewBlot™ 
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Nitro Stripping Buffer (LI-COR® 928-40030).  I generally redeveloped stripped 
membranes (and, when I remembered, reprobed with secondary antibody) to ensure the 
stripping worked, and, if necessary, stripped again and reassessed again until most of 
signal was gone. 
Protein Precipitation 
Because SDS precipitates with guanidine and with potassium, I removed any 
guanidine and/or potassium from guanidine or potassium-containing samples by ethanol-
precipitation.  I added 225 µL cold ethanol to 25 µL of protein sample, vortexed to mix, 
and stored at -20°C for ten minutes to keep cold.  If I were precipitating a protein in order 
to increase its concentration, I increased the volumes for this initial step proportionately.  
For very dilute samples, I sometimes added a carrier protein such as BSA to nucleate 
precipitation.  To pellet the precipitated proteins, I microfuged at maximum speed at 4°C 
for five minutes.  I then washed the pellet by resuspending in 250 µL cold 90% (v/v) 
ethanol, vortexing to mix, and microfuging at maximum speed at 4°C for five minutes.  I 
then resuspended the pellet in 25 µL SDS gel-loading-buffer, vortexed to mix, and heated 
to 95°C to fully solubilize the pellet.   
Alternatively, I used trichloroacetic acid (TCA) to precipitate protein.  I prepared 
the TCA by dissolving 5 g in 2.5 mL of ultrapure water.  I added 100 µL TCA solution to 
400 µL protein sample, and incubated at 4°C for five minutes.  I microfuged at maximum 
speed for five minutes to pellet the protein, and discarded the supernatant.  I washed the 
pellet twice by resuspending it in 200 µL acetone, once again pelleting the protein by 
microfuging at maximum speed for five minutes and discarding the supernatant.  I 
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evaporated any remaining acetone by placing the tube on a 95°C heating block, and 
resuspended the pelleted protein in 1 mL Bio-Rad Protein Assay buffer. 
Diacylglycerol Kinase (DGK) Activity Assays 
Radiometric Endpoint DGK Assay 
 I used a radiometric endpoint assay for determining the specific activity of DGK.  
The general principle was to incubate DGK in the presence of [γ-32P]-adenosine-5’-
triphosphate (ATP), then isolate the lipids and measure the [γ-32P]-phosphatidic acid (PA) 
produced. 
 I incorporated the lipid substrate into either detergent micelles69 or  liposomes 
(lipid bilayer spheroids 100 nm in diameter, also called large unilamellar vesicles 
(LUVs)). I measured out the lipid required into a borosilicate glass tube using a steel-and-
glass syringe, dried the lipid into a film under nitrogen gas, and stored the lipid film 
under vacuum for at least one hour prior to hydration.  For micelles, I used either octyl-β-
glucoside (OG) or else Triton X-100 (TX-100).  In order to calculate the amount of 
detergent to add, I added enough such that the mol% plus all the lipids would be 100%, 
plus the critical micelle concentration (CMC), which is the concentration of monomer 
that must be in solution before the detergent will aggregate into micelles.  I added the 
appropriate volume of buffer and detergent, and alternately bath-sonicated and vigorously 
vortexed the solution until the micelles were completely clear.  Aqueous dilutions of 
dithiothreitol (DTT), a reducing agent with limited stability in solution, were stored in 
small aliquots at -20°C, and thawed aliquots were discarded and not refrozen. 
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 In order to prepare liposomes, I hydrated the lipid film in the appropriate buffer at 
a temperature higher than the highest phase transition temperature  (Tm) of the included 
lipids for at least thirty minutes, bath-sonicating for thirty seconds every ten minutes, and 
vortexing if necessary, until the lipids appeared uniformly resuspended.  For all buffers, I 
generally adjusted the pH at the same temperature at which I planned to later use them.  I 
then extruded the lipids at least nine times (but always an odd number of times, so that 
the final liposomes ended up on the opposite site from where they started) through a 
polycarbonate membrane with a pore size of 100 nm (Avanti® Polar Lipids, Inc. 610005) 
using a Mini-Extruder set (Avanti® Polar Lipids, Inc. 610023) on a heating block at a 
temperature likewise higher than the highest Tm, until the resuspended lipids appeared 
translucent.  I always checked the membrane after extruding to make sure that it had not 
ruptured or slipped during extrusion or assembly of the Mini-Extruder. 
 When making liposomes, I experienced a perhaps one in four or five chance that 
the liposomes would be inexplicably bad (either they were exceedingly difficult to 
extrude, or looked terrible, or the assayed DGK activity would be extremely low, and 
when I went back to look at the liposomes I had made, the lipids had fallen out of 
solution and sunk to the bottom of the tube, even though they had looked fine when I had 
made them).  Sometimes I would be able to attribute a cause to the bad liposomes (one 
vial of dioleoylglycerol (DOG) produced bad liposomes, for example, or a miscalculation 
of lipid would lead to a lipid composition not amenable to extrusion), but most often, the 
bad liposomes still occasionally occurred despite my best efforts to prevent them (treating 
the tubes with Sigmacote® (Sigma-Aldrich® SL2), visually comparing different sets of 
liposomes after extrusion to make sure they appeared the same (if they were supposed to 
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be the same concentration), being patient and not using too much force to extrude, buying 
a new Mini-Extruder and cleaning it only with water and dilute detergent and no organic 
solvents, etc.).  To this day I am unsure of all of the variables that contribute to good 
extrusion, and as such, any single assay must be regarded cautiously, especially when 
comparing different sets of liposomes. 
 After incubating in various reaction conditions, temperatures and times (noted in 
each figure legend), I quenched the reaction by adding to the 50-100 µL reaction volume 
in a 13x100 mm borosilicate glass test tube 1 mL of 1 M NaCl (aqueous), 2 mL of 
methanol, and 1 mL of chloroform, and gently vortexing to mix.  I took care to set the 
vortexer to the on position, and not the touch position, to ensure that the vortexer was on 
a low enough setting to not spatter radioactive fluid.  In this proportion the solvents 
formed a single phase.   
I then extracted the lipids by adding another 1 mL each of chloroform and 1 M 
NaCl, and vortexing again to mix.  In this proportion, the solvents formed two distinct 
phases.  To improve phase separation, I briefly centrifuged the samples at room 
temperature before removing the aqueous (top) phase by aspiration.  I washed the lipids 
by adding 2 more mL 1 M NaCl and vortexing, and separated the phases by centrifuging 
again.  I removed the lipids to a clean tube using a 9” borosilicate glass Pasteur pipet, and 
evaporated the solvent by placing the tube under a stream of nitrogen gas on a heating 
block, leaving a film of lipid, and some salt, on the bottom of the tube. 
 I could not merely count the radioactivity at this point, because although most of 
the unreacted [γ-32P]-ATP should have been removed by the aqueous washes, not 
necessarily all of it had.  I therefore separated the lipids from the other chemical 
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components of the film by resuspending the film in 30 µL 95:5::chloroform:methanol and 
spotting onto either aluminum (EMD Millipore 5582-7) or glass (Analtech 31911) thin 
layer chromatography (TLC) plates.  TLC works by the principle that different solvents 
have different affinities for the matrix on the plate: as the solvent rises up the plate by 
capillary action, the solvents will separate based on their relative affinity.  Likewise, any 
molecules dissolved in the solvent (such as lipids spotted onto the plate) have different 
affinities for the different solvents and for the matrix on the plate, and will therefore 
migrate at different rates, thus separating the chemicals.  Even when scoring a 2 mm 
buffer region between each lane on the aluminum plates, I always achieved better 
resolution between lanes using glass plates with channels between the lanes than I did 
with aluminum plates, so I later learned to use only glass plates.  Initially I would spot in 
the presence of hot air from a hair dryer, but this included the risk of the radioactive lipid 
spattering into another lane or even off the plate altogether.  In later experiments, I 
therefore streaked the lipid in a region between 0.2 mm below the top of the preadsorbent 
zone and 0.5 mm above the bottom of the plate: this was a large enough area that the 30 
µL easily evaporated in the time it took to streak it and did not leak outside this region.  
To separate PA from the other lipids (including other radiolabeled lipids, as might be 
observed when assaying a sample that might contain other lipid kinase activities, such as 
a whole lysate), I developed the TLC plate in a solvent system consisting of 
50:20:15:10:5::chloroform:acetone:methanol:acetic acid:water, no more than two weeks 
old.  When making the TLC solvent, I was careful to add the acetic acid after adding the 
water.  Aluminum plates I ran about ninety minutes, and glass plates I ran about sixty 
minutes, or until the solvent front was within a few centimeters of the top of the plate. 
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 I used autoradiography in order to visualize the location of the radioactive spots 
on the plate.  After allowing the plate to dry briefly (at least ten minutes, but sometimes 
as long as overnight) I would expose the plate to film.  32P decays to 32S via β decay: the 
emitted electron interacts with the film so that when the film is developed the region 
adjacent to the radioactive material appears as a dark spot.  I found that if I did not let the 
plate dry too long, some of the silica would come off on the film, which could be helpful 
for aligning the film to the plate later.  I wrapped the plate and film together either in 
aluminum foil or else in a black plastic bag to protect the film from light, then stored 
overnight or longer at -20°C.  After developing the film, I aligned the film and the plate, 
annotated the film to record how the spots aligned to the plate, and marked on the plate 
the region corresponding to the radioactive spots.  In this solvent system, PA usually 
migrates at a relative front (Rf) of ~0.85.  For aluminum plates, I cut the region of the 
plate with the radioactive spot and placed that region of the lane in a scintillation vial 
with 4 mL scintillation fluid, taking care to capture as much of the silica as possible in the 
vial.  For glass plates, I scraped the silica from the region of interest onto a piece of clean 
aluminum foil, and then transferred the radioactive silica from the aluminum foil to a 
scintillation vial with 4 mL scintillation fluid, likewise taking care to capture as much of 
the silica as possible in the vial.  When there were enough lanes on the plate, I would 
include empty lanes as blanks; otherwise, I used scintillation fluid as blanks.  While 
cutting and scraping plates, I wore a surgical mask (Secure-Gard AT7509) to reduce the 
amount of radioactive dust I inhaled.  In later experiments, I also measured out [γ-32P]-
ATP directly into scintillation fluid to calibrate the scintillation counter. 
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 I measured the decays per minute (dpm) using a liquid scintillation counter 
(Wallac 1410).  I subtracted the average of the blank vials’ counts from each of the 
samples’ counts.  Initially, I counted on the swipes setting and summed the 32P and 35S 
channels and used that number as the counts.  In later experiments, I counted on the 32P 
setting, but also counted a known volume of [γ-32P]-ATP.  I measured the ratio of the 
counted activity of the [γ-32P]-ATP sample to its predicted activity assuming 2.2 x 109 
dpm per mCi, and divided the counts of the experimental samples by that ratio in order to 
calibrate the scintillation counter.  In this case, I propagated the uncertainty from the 
scintillation counter calibration into the final measurement of DGK activity.  Assuming a 
1:1 ratio of ATP to PA in the reaction, using the counts, the total concentration of ATP, 
and the specific activity of the [γ-32P]-ATP in the reaction, I could calculate the nmol PA 
produced.  From the amount of DGK used and the time of the reaction, assuming that the 
reaction was linear with time, I could calculate the specific activity of DGK in nmol PA 
per minute per µg DGK. 
 For all experiments using radioactivity, I performed the experiment in a region of 
the laboratory approved for radioactivity, wore a laboratory coat, gloves, and radiation 
badge, and, when possible, worked behind a shield.  When working with liquid 
radioactivity, I wore a second pair of gloves (one size larger) over the first pair.  Before 
leaving the radioactivity room, I checked my person, including the soles of my shoes, for 
radioactivity by Geiger counter.  I removed any detectable radioactive contamination by 
washing with Radiacwash™ and water.  I disposed solid radioactive waste (double-
bagged in especially thick plastic bags to prevent puncture by broken glass) in the short 
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half-life drum down the hall, liquid radioactive waste by calling Radiation Safety for 
pickup, and scintillation vials in the scintillation vial drum down the hall. 
1,2-Diacylglycerol (DAG) Isomerization to 1,3-DAG 
1,2-DAG, the lipid substrate of DGK, will spontaneously isomerize to 1,3-DAG, 
so in general I would try to proceed quickly after liposome extrusion to the rest of the 
assay, and always used DAG-containing liposomes on the same day I made them.  When 
I measured a timecourse of DAG isomerization under the conditions they face as 
liposomes, I did observe a time-dependent increase in the signal of 1,3-DAG as a 
proportion of 1,2-DAG (Figure 1), although this observation was largely a result of a 
decrease in the 1,2-DAG signal rather than an increase of the 1,3-DAG signal.  A 
decrease in signal might be a result of oxidation of the unsaturated bonds in the fatty acid 
moieties, and thus decreased affinity for the iodine vapor used to visualize the spots70.  
Even after 48 hours, only about a quarter of the 1,2-DAG had isomerized to 1,3-DAG, 




Figure 1.  Timecourse of DAG isomerization.  I made 15.1 mM liposomes (42.7:21.3:20:16::1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphoethanolamine(POPE):1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine(POPC):1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine(POPS):1-2-dioleoyl-sn-
glycerol(DOG)).  I took aliquots over time, extracted the lipids, and stored the dried lipids as a film until all 
had been collected.  (A) TLC plate of spotted lipids.  I resuspended the lipid films and spotted a volume of 
liposomes such that 64 nmol DOG would be spotted.  I also spotted standards of an equivalent amount 
directly from the lipid standard vials, either separately or together (“mixture”), either directly from the vial 
onto the plate, or else dried as a film for two days.  “RT DOG” signifies a vial of DOG (in chloroform) 
stored at room temperature rather than at -20°C.  The 8.5% DOG liposomes had been made previously, and 
the 0% DOG and 16% compound 3 liposomes were liposomes extruded at the same time, to compare 
recovery.  I ran the plates in fresh 85:15:5::toluene:chloroform:methanol, a solvent system predicted to 
separate 1,2- from 1,3-diacylglycerol71.  After briefly allowing to dry, I visualized the spots on the plate by 
incubating in a tank with iodine crystals, which produce iodine vapor, which stains isolated double bonds70, 
such as in the oleoyl fatty acid chains.  The predominant spot corresponds to 1,2-diacylglycerol; the fainter, 
upper spot corresponds to 1,3-diacylglycerol.  I sandwiched the plate between two clear plastic sheets and 
scanned as a 600 dpi greyscale .tiff file.  (B) Quantification of the signal from (A).  I performed 
densitometry on the spots using ImageJ, as described in the “Sodium Dodecyl Sulfate Polyacrylamide 
Gel Electrophoresis (SDS-PAGE)” subchapter of the “General Methods” subchapter.  In triplicate, mean 
± standard deviation (SD). 
Extracting Lipids with 1 M NaCl vs. 1% HClO4 
 Published protocols for DGK assays commonly extract the lipids after quenching 
the reaction by washing with acid72,29,73, whereas our laboratory washes with 1 M NaCl.  
I therefore tested whether this salt wash was contributing to uncertainty in my assay 
results by quenching and extracting either with 1 M NaCl, as usual, or else with 1% 
HClO4.  The method of extraction did not appear to affect the total recovered activity, in 
either micelles or liposomes and, if anything, quenching and extracting with 1% HClO4 
produced more uncertainty than 1 M NaCl, not less (Figure 2).  I therefore concluded that 
the 1 M NaCl extraction step was fine in the radiometric endpoint DGK assay, and 
continued to use 1 M NaCl. 
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continuous assay could have the advantage of being able to monitor the reaction in real 
time, could be much faster, and could use other substrates besides DOG without having 
to first optimize TLC conditions.  One common approach to designing a continuous assay 
is to couple the reaction of interest (in our case, the transfer of the γ-phosphoryl from 
ATP onto DAG to produce adenosine-5’-diphosphate (ADP) and PA) to another reaction 
that can be followed with a spectrophotometer.  Therefore, one possible future direction 
for our laboratory would be the development of a continuous assay, to complement our 
radiometric endpoint assay, for the analysis of DGK activity. 
 One such coupled assay is the ADP Quest™ assay (DiscoveRx), which couples 
ADP production to a pyruvate kinase (PK) reaction, which uses ADP to produce 
pyruvate, which is then coupled to a pyruvate oxidase reaction, which uses the produced 
pyruvate to produce hydrogen peroxide, which is then coupled to a peroxidase reaction, 
which uses the produced hydrogen peroxide to produce resorufin, whose accumulation 
can be measured at 590 nm74.  I therefore performed a preliminary investigation toward 
adapting the ADP Quest™ HS kit (DiscoveRx 90-0087S) as a DGK assay.  I found that 
while the signal at 590 nm depended linearly with good fit on the concentration of ADP 
in the buffer provided by the ADP Quest™ HS kit, the fit was much worse in our assay 
buffer (Figure 3A).  The signal at 590 nm in our buffer also drifted considerably over 
time, and while the linear fit of this drift had a high correlation coefficient (Figure 3B), 
the residuals to the fit over time were clearly nonuniformly distributed (Figure 3C), 
showing that the drift was not, in fact, linear.  Taken together, these results show that our 
assay buffer is not amenable to quantitatively measuring ADP production, and thereby 
DGK activity, using the ADP Quest™ HS kit, even without sulfonic acid-containing 
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buffers such as HEPES, reducing agents such as DTT, or ADP contamination from ATP.  
I contacted DiscoveRx, and they could not identify any of our buffer components as 
problematic for their kit.  Future directions for adapting ADP Quest™ as a DGK assay 
would require testing the individual components of our assay buffer to see which one(s) 
interfere with the proprietary reagents, finding alternatives for those components, and 
then confirming with the radiometric endpoint assay that those components do not 
interfere with DGK activity. 
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Figure 3.   The ADP Quest™ HS kit is not compatible with our assay buffer.  I combined 15 µL of 
either their assay buffer (the assay buffer included with the kit) or our assay buffer (final concentration of 
50 mM triethanolamine (TEA), pH 7.5, 100 mM NaCl, 1 mM liposomes 
(48:24:20:8::POPE:POPC:POPS:DOG), 0.6% (v/v) glycerol, 0.1 mg per mL ovalbumin, 0.005% (v/v) NP-
40) with 5 µL of different ADP standards in a black 384-well plate (freshly cleaned with ultrapure water, 
methanol, and compressed air), then added 10 µL Reagent A and 20 µL Reagent B.  I read on the plate 
reader at 37°C with preheating, with an excitation filter at 530 nm and an emission filter at 590 nm, reading 
every sixty seconds for thirty minutes, scaled to an empty well for auto sensitivity, reading from the top of 
the plate, for a plate type of Nunc 384 flat bottom size 16x24, with a top probe vertical offset of 1 mm, and 
shaking one second before each reading.  I performed the experiments with their buffer on one day 
(120606), but there was a problem with the samples using our buffer on that day, so I repeated the 
experiment with our buffer the next day (120607): because of limited reagents, I was unable to repeat the 
experiment with their buffer that day.  (A) The signal at 590 nm as a function of ADP concentration, 15 
minutes into the experiment.  I used Microsoft® Excel® to calculate the linear regression.  AU, arbitrary 
units.  (B) The signal at 590 nm as a function of time, of the three replicates of our buffer, with 0 µM ADP.  
(C) The residuals from the previous figure (I subtracted the measured signal from that predicted by the 
linear fit) as a function of time. 
 Kinase reactions are commonly coupled to PK, which uses the produced ADP to 
produce pyruvate, and then coupled to lactate dehydrogenase (LDH), which uses the 
produced pyruvate to oxidize nicotinamide adenine dinucleotide (NADH) to NAD+, 
which can be monitored spectrophotometrically75.  In preliminary investigations to 
determine whether such a LK/PDH coupled assay could be adapted for assaying DGK 
activity, I measured the sensitivity of our spectrophotometer using a clear plastic (but not 
advertised as optically clear) 384-well plate measuring the absorbance at 340 nm of 
various concentrations of NADH.  The absorbance at 340 nm depended linearly on the 
concentration of NADH with an excellent fit under the conditions tested, and from the 
sensitivity measured, I calculated that in order to observe a change in 0.01 absorbance 
units over thirty minutes, 1 ng of DGK in the assay would need a specific activity of at 
least 6.9 nmol per minute per µg DGK (Figure 4).  This assay would therefore not be 
nearly as sensitive as the radiometric assay but its greater speed and safety and 
consequent lower expense could make it useful for concentrated samples of high activity.  
The next step to adapting the PK/LDH assay as a DGK assay would be, as above with the 
ADP Quest™ assay, to determine whether NADH can be quantitatively measured in the 
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Calculating Relative Centrifugal Fields (Rcfs) 
 Centrifugation is a commonly used method to separate materials in a mixture 
based on their density.  In order to calculate the relative centrifugal field (Rcf) reported in 
a figure legend in this dissertation, I used the table found in the manual for the rotor in 
question to convert the rotor speed (in rpm) to the Rcf at the average radius (rav).  When 








Equation 2.  I calculated the Rcf for a given rotor speed v as a function of the Rcfs corresponding to the 
rotor speeds in the table above and below v.  For example, to calculate the Rcf for 31,000 rpm, I looked up 
the Rcfs for 30,000 rpm and 35,000 rpm, and interpolated according to Equation 2. 
Charring TLC Plates 
 In order to visualize spots on TLC plates, I used two methods.  As previously 
mentioned, iodine crystals produce iodine vapor, which stains isolated double bonds70.  In 
order to visualize other molecules that may not have such isolated double bonds, I 
sprayed the plate with 40% (v/v) sulfuric acid in water using a TLC sprayer kit (Analtech 
40-01), then incubated the plate in a 120°C oven until the lipids appeared as brown spots.  
Once charred, I allowed the plate to cool in a fume hood before placing into plastic 
binder sheets and scanning at 300 dpi.  While charring plates, I wore personal protective 
equipment including a laboratory coat, gloves, safety goggles, and a half facepiece drop 




To separate DNA by size, I used agarose gel electrophoresis.  I generally used 
1%-1.5% (w/v) agarose in TAE buffer.  I microwaved to melt the agarose, and when the 
agarose was uniformly melted, I added ethidium bromide, a fluorescent molecule that 
stains DNA by intercalating between base pairs, to 7 µg per 100 mL.  Because ethidium 
bromide intercalates into DNA, it is also a potent mutagen, and must be handled 
carefully.  While the gel was still liquid, I poured the gel into a cast and let the gel cool at 
room temperature to solidify.  If I did not plan to use the gel right away, I stored the gel 
wrapped in cellophane and moistened with TAE buffer at 4°C. 
I generally electrophoresed DNA gels in TAE buffer at 100 V until the dye front 
had run one-third to halfway down the gel.  Sometimes it was necessary to run the gel at 
a lower voltage (if I couldn’t supervise the gel because I was at a seminar, for example), 
or for longer times (if I needed to resolved a difference in size between two similarly-
sized molecules, for example).  I visualized the location of DNA in the gel by setting the 




Chapter 3: Expressing and Purifying DGKs 
Introduction 
In order to begin structural studies of eukaryotic DGKs, I needed to produce some 
DGK to study.  In order to be confident that the phenomena I observed were due to DGK 
and not other components of the cells, I needed to purify the DGK from the other cellular 
components.  X-ray crystallography, a common method for studying protein structure, in 
particular requires highly concentrated and purified protein.  I therefore set out to 
recombinantly express and purify various eukaryotic DGK constructs in bacteria, 
Dictyostelium discoideum, insect cells, and mammalian cells.   
Expression and Purification Methods 
Bacterial Expression Methods 
 To produce and maintain deoxyribonucleic acid (DNA), I transformed expression 
plasmids into One Shot® TOP10 Chemically Competent Escherichia coli (Life 
Technologies™), a strain especially engineered for high-efficiency plasmid propagation, 
including features such as the endA1 mutation, which inactivates periplasmic DNA-
specific endonuclease, which reduces nonspecific digestion and therefore enhances DNA 
stability during transformation76, and the recA1 mutation in the master regulator of 
recombination77, which inhibits the homologous recombination system and therefore 
reduces nonspecific recombination in cloned DNA.  I transformed the bacteria by 
incubating 2 µL of purified DNA with 20 µL just-thawed bacteria on ice in a BD 
Falcon™ round-bottom culture tube for thirty minutes before heat-shocking by 
incubating the tube in a 42°C water bath for 45 seconds and then plunging back into ice.  
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The incubation on ice allows time for the plasmid to interact with the outside of the cell 
membrane, and the heat shock causes a rapid change in the fluidity of the membrane, 
which allows the plasmid to cross the membrane at zones of adhesion (sites where the 
inner and outer membrane have fused through the cell wall layer)78.  I then added 200 µL 
of S.O.C. medium (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, 20 mM glucose) to the tube and shook at 225 rpm for one hour at 
37°C to allow the antibiotic resistance gene to express the gene product, so that when I 
plated the reaction on Bacto™ agar (BD 214010) (1.5% (w/v)) with the appropriate 
antibiotic, the bacteria with the transformed plasmid were able to survive.  The antibiotics 
I used included kanamycin (Kan) (30 µg/mL) for pT71myc and pET28-HisMBP-
FLAGpp, chloramphenicol (Cam) (35 µg/mL) for the chaperones, and carbenicillin 
(Carb) (100 µg/mL) for pGEX-4T2 and pET32a.  Carb selects against the ampicillin 
resistance gene, but is less labile to β-lactamase than ampicillin79.  I incubated these 
plates overnight at 37°C until distinct colonies formed: if necessary, I restreaked the 
plates until the colonies were well-isolated. 
 For long-term storage of bacterial strains, I made glycerol stocks from these 
plates.  I picked an individual colony and grew overnight in 4 mL Luria Broth (LB) with 
the appropriate antibiotic, shaking at 225 rpm overnight at 37°C.  The following morning, 
I combined 700 µL of the fresh culture with 300 µL autoclaved (and therefore sterile) 
50% glycerol in a sterile cryogenic vial.  I stored the cells at cold temperatures so that the 
metabolism and structure of the cells would change little, if at all, over the course of 
years.  Freezing damages cells both by dehydration and the consequent increase of 
concentration of certain electrolytes, because ice crystals outside cells exert osmotic 
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pressure on the water inside cells, as well as by physical disruption from ice crystals80.  
Glycerol acts as a cryoprotectant by acting as a solute during dehydration and thus 
preventing the increase in electrolyte concentration and has the added benefits of not 
being toxic to the cells even at high concentrations, having high solubility in water over a 
variety of temperatures, and being able to permeate the cells81.  I flash-froze the glycerol 
stock by incubating the cryogenic tube in a methanol / dry ice (solid CO2) bath.  Rapid 
freezing can prevent the formation of ice crystals, which also damage cells: instead the 
water forms a glassy solid.  I took care that the tubes were labeled with alcohol-resistant 
ink, such that the labels remained legible.  I then stored the frozen tubes at -80°C.  When 
starting colonies from the glycerol stock, I did not allow the stock to thaw, but rather 
scraped at the frozen culture with a freshly flamed (and therefore sterile) steel loop and 
either streaked onto a plate to produce well-isolated colonies, or else directly inoculated 
an LB (plus antibiotic) liquid culture. 
 To express protein, instead of the TOP10 strain of E. coli, I used the BL21(DE3) 
or Rosetta™(DE3) (Novagen®) strains of E. coli.  BL21(DE3) is deficient in the lon and 
ompT proteases82 and is therefore especially well-suited for recombinant protein 
expression.  Rosetta™(DE3) also includes a chloramphenicol-resistant plasmid that 
encodes the transfer ribonucleic acids (tRNAs) for the AGG, AGA, AUA, CUA, CCC, 
and GGA codons, which are commonly used in eukaryotes but rarely used in bacteria83.   
In order to transform plasmids into BL21(DE3), I first made the cells competent for 
transformation by pelleting the cells from a 4 mL overnight culture, then resuspending in 
25 mL cold, 0.22 µM filtered 100 mM CaCl2, and incubating on ice for two hours.  I 
harvested the cells by pelleting and resuspended again in 5 mL cold, 0.22 µM filtered 100 
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mM CaCl2.  I made glycerol stocks from these competent cells and then transformed in 
the same way as I did with the One Shot® TOP10 cells.  
To express protein, I generally inoculated LB medium (along with the appropriate 
antibiotic) either from a single colony from a freshly grown plate, or else from a glycerol 
stock, and then shook the culture at 225 rpm overnight at 37°C.  The following morning, 
I inoculated a larger culture with the starter culture, and shook it at 37°C until the 
absorbance (optical density) at 600 nm (OD600) reached 0.3-1, at which point I added 
isopropyl-β-D-thiogalactopyranoside (IPTG) to 0.1-1 mM to induce expression of the 
plasmid.  IPTG is a non-hydrolyzable analog of lactose, and, like lactose, binds to the lac 
repressor and allosterically releases it from the lac operator84.  By relieving inhibition, 
IPTG induces expression of genes regulated by the lac operon, such as in some 
recombinant plasmids.  I periodically measured the OD600 of samples of the culture, and 
used Equation 3 to predict when the OD600 would reach the desired value.  I did not 
include IPTG for uninduced controls.  I then shook the cultures either at 37°C for three 
hours, or at 16°C overnight (12-22 hours). 
𝐴! = 𝐴!(2!") 
Equation 3.  At is the absorbance at 600 nm at time t; A0 is the absorbance at time zero; and k is the growth 
rate.  By measuring the absorbance at multiple timepoints, I could estimate k and predict approximately 
when the absorbance would reach a given value. 
 To harvest the expressed protein, the following morning I pelleted the cells by 
centrifugation (15 minutes at ~300-20,000 x g at 4°C).  I resuspended the cell pellets in 
lysis buffer, generally 4 mL per gram cell pellet.  When time allowed, I froze the 
resuspended cell pellet at -80°C, and then rethawed to ensure complete lysis.  I added egg 
white lysozyme to 1 mg per mL.  Lysozyme catalyzes the hydrolysis of 1,4-β-linkages in 
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peptidoglycan, a key component of the bacterial cell wall, and thereby damages the cell 
wall, and this effect at least partially contributes to cell wall lysis (although its 
muramidase activity is actually not required to kill bacteria85, so lysozyme may also have 
additional, as of yet undescribed mechanisms for cell killing, possibly including 
activation of the CpxA-CpxR two-component system, which then leads to membrane 
depolarization and oxidative stress86).  I incubated the resuspended cell pellet on ice for 
thirty minutes, vortexing occasionally to mix.  I then lysed the resuspended cell pellet by 
probe sonication in at least ten ten-second bursts, resting on ice between each burst, until 
no longer viscous.  I removed the insoluble fraction by centrifuging at 40,000-120,000 x 
g for 65-90 minutes at 4°C. 
Dictyostelium Discoideum Expression Methods 
 FLAG-DGKA-overexpressing Dictyostelium discoideum cells were stored either 
at -80°C.  I maintained D. discoideum cells as adherent cultures on tissue culture plates at 
room temperature in a plastic, Tupperware®-style container covered with aluminum foil.  
Any time I lifted the lid of the plate (to thaw down, feed, or split the cells), I did so in a 
tissue culture hood.  I grew the cells in enriched Dicty medium (43 mL FM Defined 
Minimal Media (Formedium™ FMM0101), 500 mL 1.5x HL5 with Glucose (MP 
Biomedicals, LLC #3090-322), 15 µg per mL G418 (a drug to select for FLAG-DGKA-
expressing cells), 20 U per mL penicillin (Pen) (an antibiotic, to prevent the growth of 
bacteria), 20 µg per mL streptomycin (Strep) (another antibiotic, to likewise prevent the 
growth of bacteria)).  When the cells grew overconfluent, I split them to a new plate by 
using a pipet to use a stream of medium to displace the cells from the plate, and then re-
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seeded the new plate a lower density, usually as a function of the density of the previous 
plate (e.g., 1:10). 
Insect Cell Expression Methods 
 I maintained Sf9 Spodoptera frugiperda cells as adherent cultures on tissue 
culture plates in a 27°C incubator in Sf9 medium (500 mL Grace’s 1x Supplemented 
Insect Medium (Gibco® (Life Technologies™) 11605), 50 mL Premium fetal bovine 
serum (FBS) (Atlanta Biologicals S11150), 5.6 mL 10,000 U/mL Penicillin-Streptomycin 
(Pen-Strep) (Gibco® 15140)).  I used 10 mL medium per 10 cm plate.  If the cells had 
not been split for three days but were not yet confluent, I replaced the medium on the 
plate with fresh medium. 
 In order to split Sf9 cells, I followed a method recommended by Saki 
Phommachanh of Invitrogen™.  I first removed the medium by aspiration (using a sterile 
pipet in a tissue culture hood), then gently washed 5 mL of insect cell medium over the 
cells.  I removed the medium (including released cells) to a 50 mL conical tube, then 
repeated with another 5 mL of insect medium, and continued repeating until all of the 
cells had appeared to have let go of the plate.  I then pelleted the collected cells by 
centrifuging at minimum speed at room temperature for five minutes.  I removed all but 5 
mL of the resulting supernatant by aspiration, then gently tapped the tube to resuspend 
the cells.  I removed the resuspended cells to a clean plate at the desired density, then 
supplemented medium as necessary.  For example, for maintaining the cell lines, I 
generally used a 1:5 split, which means that I would take 1 mL (of the 5 resuspended mL) 
and add that to a new 10 cm dish already containing 9 mL of medium.   
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While splitting Sf9 cells, I generally monitored cell viability using a dye 
exclusion method.  I added trypan blue to 1x to 20 µL of resuspended cells, and gently 
pipetted the mixture into the notch on a hemocytometer, such that the resuspended cells 
filled the chamber by capillary action.  I counted the number of cells in the large square 
and multiplied by 10,000 to estimate the number of cells per mL.  Living cells are able to 
exclude trypan blue; therefore only dead cells appeared blue.  I calculated the viability by 
dividing the number of blue cells by the number of total cells. 
I measured the concentration of baculovirus using a plaque-forming assay.  I 
added 2 mL of resuspended 4.4 x 105 Sf9 cells per mL to each well of a six-well plate.  I 
allowed to adhere for one hour, then replaced the medium on the wells with 1 mL of 
virus-containing media, in 10x serial dilutions, and allowed to infect for one hour.  I then 
replaced the medium with 2 mL per well of warm plaquing medium (22.5 mL Grace’s 2x 
supplemented, 1.5 mL FBS, 12.5 mL sterile ultrapure water, 12.5 mL 4% (w/v) agarose), 
and allowed to solidify for twenty minutes at room temperature.  I then incubated the 
cells at room temperature in a humidified chamber (a plastic Tupperware®-style 
container with a wet Kimwipe™ in the corner, rehydrating the Kimwipe™ as necessary).  
After one week, I visualized the plaques by staining with 0.5 mL per well 0.1% (w/v) 
neutral red for two hours at room temperature. 
I maintained High Five™ Trichoplusia ni ovary cells as adherent cultures on 
tissue culture plates in a 27°C incubator in High Five™ medium (500 mL Grace’s 1x 
Supplemented Insect Medium, 50 mL FBS, 5.5 mL Pen-Strep).  I used 10 mL medium 
per 10 cm plate.  If the cells had not been split for three days but were not yet confluent, I 
replaced the medium on the plate with fresh medium. 
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I split High Five™ cells using a sloughing method: in a tissue culture hood, I used 
a sterile pipet to gently flow the medium of the plate over the cells until all the cells had 
released and were resuspended in the medium.  I removed the resuspended cells to a 
clean plate at the desired density, with supplemented medium as necessary.  I generally 
used a 1:15 split to maintain the High Five™ cells. 
Mammalian Cell Expression Methods 
 I maintained 293FT human embryonic kidney cells, which are a fast-growing 
variant of 293T cells, which include SV40 large T antigen, which allows very high levels 
of protein to be expressed from vectors containing the SV40 origin, as adherent cultures 
on tissue culture plates in a 37°C incubator.  I used 10 mL medium per 10 cm plate.  I 
first grew the cells in either 293FT growth medium 1 (0.88x DMEM, high glucose 
(Gibco® (Life Technologies™) 11965), 25 mL FBS).  However, without antibiotics, the 
cells were prone to bacterial infection.  I therefore switched to 293FT growth medium 2 
(500 mL DMEM, high glucose (Gibco® (Life Technologies™) 11965), 10% (v/v) FBS, 
100 U or µg per mL Pen-Strep, 1 mM sodium pyruvate (Gibco® (Life Technologies™) 
11360), 1x non-essential amino acids (Gibco® (Life Technologies™) 11140), 2 mM L-
glutamine (Gibco® (Life Technologies™) 25030), 500 µg per mL G418).  I maintained 
293T and COS-7 Chlorocebus aethiops kidney cells in 293T growth medium (0.89x 
DMEM, high glucose, 10% (v/v) FBS, 100 U or µg per mL Pen-Strep). 
 If the cells had not been split for three days but were not yet confluent, I replaced 
the medium on the plate with fresh medium.  To split the cells, I prewarmed the bottles of 
medium, PBS, and aliquots of 0.05% Trypsin-EDTA (Gibco® (Life Technologies™) 
25300) (trypsin, a protease, disrupts cell-cell interactions and the extracellular matrix, and 
 37 
EDTA chelates divalent cations, which promote cell-cell interactions: together, they help 
loosen the cells of the plate) in a 37°C water bath.  I used a sterile pipet to remove the 
medium by aspiration from the plate of cells.  I very gently washed the cells with PBS 
(being sure to pipet the PBS onto the wall of the dish, and not directly onto the cells), and 
removed the PBS by aspiration.  I then trypsinized the cells by adding 1 mL per 10 cm 
plate trypsin-EDTA, gently swishing the plate such that all the cells contacted the trypsin-
EDTA, then immediately removing excess trypsin-EDTA by aspiration.  I incubated the 
(dry) plate at 37°C for ~2-3 minutes (in practice, the time it took to label the plates for the 
split cells and aliquot medium into them), then resuspended the cells in the desired 
volume of medium, and added to the appropriate density to medium already aliquoted 
into plates. 
 To express protein recombinantly in mammalian cells, I performed a transient 
transfection.  For each 15 cm plate to transfect, I combined 20 µg of purified DNA with 
Opti-MEM® I Reduced Serum Medium (Gibco® (Life Technologies™) 31985) and 40 
µg of polyethyleneimine (PEI) with Opti-MEM®, then added the PEI solution to the 
DNA solution, and incubated at room temperature for 15 minutes.  I then added the 
mixture directly to a 15 cm plate of 293FT cells (in growth medium).  I incubated the 
plate for four hours at 37°C, then replaced the medium with growth medium. 
 Alternatively, I transfected with HiFect® Reagent (Lonza VBA-1001).  I 
preheated the HiFect® to 55°C prior to use.  For each well of a 6-well plate to transfect, I 
combined 2 µg of purified DNA with Opti-MEM® and 3 µL HiFect® with Opti-MEM®, 
then added the HiFect® to the DNA solution, vortexing to mix, and incubated at room 
temperature for 15 minutes.  I replaced the medium on the cells with prewarmed Opti-
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MEM®, and added the HiFect®/DNA solution, rocking the plate gently to thoroughly 
mix.  After several hours, I replaced the medium with growth medium. 
Protein Purification: Batch Affinity Chromatography 
In general, I purified proteins by using affinity chromatography.  The principle of 
affinity chromatography is that the resin includes a component (such as nickel-
nitrilotriacetic acid (Ni-NTA)) that has high affinity to part of the target protein, or to an 
epitope tag engineered into the protein for just such a purpose (such as a hexahistidine 
(His6) tag).  Incubating the protein sample with the resin and then washing the resin 
would thus be predicted to enrich for the target protein, as the other proteins in the 
sample with lower affinity for the resin would wash off.  The purified protein can be 
removed by washing the resin with an elution buffer, which contains a component (such 
as imidazole) that competes with the protein for binding to the resin and therefore 
displaces the protein. 
 Because of the small scale of most of my experiments, and because I was 
generally the only person in the laboratory using these methods for purifying protein, I 
generally found it more convenient to use batch chromatography rather than pouring 
columns.  In general, I would add the affinity resin to the sample to be purified, mix and 
incubate, then collect the resin by centrifugation.  The supernatant from this 
centrifugation I designated as the “flowthrough”, and it would include proteins with low 
affinity to the resin, as well as extra affinity-tagged protein if the binding sites on the 
resin had been saturated.  I would then wash the resin by resuspending it with various 
wash buffers, mixing, and incubating, and then collect the resin by centrifugation.  The 
supernatant from these steps I designated as “washes”, and it would include proteins with 
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weak affinity to the resin.  To remove the purified protein from the resin, I would 
resuspend the resin in elution buffer, and once again mix, incubate, and collect the resin 
by centrifugation.  The supernatant from this step I designated the “eluate”, and while it 
would be enriched for the target protein with the affinity tag, it could also include other 
proteins with relatively high affinity for the resin.  To determine how much protein had 
remained bound to the resin (or, because these are batch methods, precipitated and come 
down in the pellet with the resin), I resuspended the remaining resin with elution buffer 
and also included that as a sample in the SDS-PAG or activity assay. 
 Because the MagneGST™ glutathione particles (Promega V8611) are magnetic, 
instead of centrifuging the resin as I did with Ni-NTA agarose, I rather used a 
MagneSphere® Technology Magnetic Separation Stand (Promega Z5343) to collect the 
resin. 
I generally stored purified samples for DGK activity assays in small aliquots in 
50% glycerol at -80°C, and other samples at -20°C, although sometimes I briefly stored 
samples at 4°C. 
Analytical Gel Filtration 
 Gel filtration (also known as size exclusion) is a method used to separate 
molecules by their size and shape.  The gel filtration particles include an interior space, 
accessible by pores.  Molecules that are too large to fit through the pores will be excluded 
from the interior space, and elute in the void volume of the resin87.  Blue dextran is a 
large molecule with a molecular weight of 2000 kD, and is thus commonly used to mark 
the void volume of a resin, especially since its elution is easily measured at 620 nm, and 
its progression can be easily seen by eye to make sure that molecules are moving through 
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the column in a uniform manner.  If a molecule is small enough to fit inside the pore to 
access the interior space, it will interact with the particles, and it will elute more slowly 
from the column, in a larger elution volume.  The ratio of the elution volume of a protein 
on a particular column to the void volume of the column depends roughly linearly on the 
logarithm of the molecular weight of the protein88.  By comparing to the elution profile of 
molecular weight standards, therefore, the molecular weight of a protein eluting from the 
column can be estimated using its elution volume, and a protein of a known molecular 
weight can be predicted to elute at a particular volume.  The elution volume of a protein 
will also depend on its shape and on its interaction with other molecules present in the 
sample (for example, a dimer of proteins would be predicted to elute at a volume 
corresponding to a molecular weight approximately twice that of the monomer).  
 I used gel filtration column to determine whether the protein I had enriched was 
monodisperse, i.e., whether it was eluting as a single population, at a size consistent with 
either its molecular weight or at the molecular weight corresponding to that of an 
oligomer.  Large aggregations of protein would be predicted to elute at the void volume.  
Because I was not using the protein in any downstream applications, the column I used 
was small, and the technique was thus analytical gel filtration, as opposed to preparative. 
 Because the order of elution is key to interpreting the results of gel filtration 
chromatography, I could not, as I did with the affinity chromatography, use batch 
methods, but rather needed to find a column.  Because resolution is best when the sample 
volume is smaller than 1% of the total volume of the column, but there is no additional 
benefit to sample sizes smaller than 1% of the total volume89, and because I expected to 
elute in volumes of ~250 uL, I chose a 20 mL column.  I first hydrated the resin in gel 
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filtration buffer, then poured the resin into the column, then settled the resin by 
connecting the column via a tube to a beaker of buffer on a platform above the column, 
and draining the bottom of the column into another beaker, so that the buffer flowed into 
the column by gravity.  I made sure that I was able to see the top of the resin at the top of 
the column, that the surface of the resin was smooth and flat, and that there were no 
bubbles in the resin. 
 I loaded a sample by first draining the buffer to the surface of the resin.  I 
generally removed all but the last few milliliters of buffer from the headspace with a 
pipet, taking great care not to disturb the surface of the resin.  If I did disturb the surface, 
I uniformly resuspended the entire top of the resin (as much as I could conveniently reach 
with a pipet), and then allow it to settle before proceeding.  I allowed the last few 
milliliters of buffer to drain by gravity.  When the last of the buffer was absorbed, but 
before the resin started to dry and crack, I loaded the sample in a volume no more than 
200 µL (1% of the volume of the column).  I then immediately started the fraction 
collector (LKB Bromma 2212 Helirac).  Once the sample had been absorbed by the resin, 
but before the resin started to dry and crack, I loaded another ~200 µL of buffer, which 
would dilute any remaining sample that had not yet been absorbed.  After this buffer 
absorbed, I gently filled the headspace with buffer using a pipet, taking great care not to 
disturb the surface of the resin, and then attached the headspace via a tube to a beaker of 
buffer on a platform above the column, and the column eluted by gravity.  In this way I 
minimized any spreading of the signal caused by dilution of any unabsorbed sample into 
the buffer later loaded onto the column. 
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To measure void volumes, I used a fraction collector.  In order to make sure that 
the column was eluting into the proper fraction, I attached a tube to the bottom of the 
column.  The volume of the tube was ~0.5 mL, which probably led to some longitudinal 
mixing, but the length of the tube was required by the geometry of the setup.  I 
programmed the fraction collector to change collection tubes as a function of time.  
However, the fraction collector did not always shift the full distance between two tubes, 
and sometimes shifted before the appointed time, so I had to closely supervise the 
machine at all times during the elution to make sure that the eluting drops were being 
collected into tubes and not pouring onto the floor.  To measure elution volumes, I 
measured the volume of each fraction using a pipettor, and transferred the fraction to an 
Eppendorf for later analysis.  The elution volume of a fraction is thus the sum of the 
volumes of all the preceding fractions on that run. 
 I determined the elution profile for a molecule by measuring the absorbance at 
620 nm or visually (for blue dextran), at 280 nm (for proteins, especially the molecular 
weight standards, which were at a relatively high concentration), by SDS-PAGE followed 
by Coomassie staining, silver staining, or immunoblotting, or by measuring the protein 
concentration using the Bio-Rad Protein Assay. 
 In order to predict in what volume a protein of a particular size would elute (for, 
for example, selecting which fractions to load on a gel), or in order to estimate the 
molecular weight corresponding to an observed peak, I first ran molecular weight 
standards on the column, including blue dextran (Sigma-Aldrich® D4772), whose elution 
volume is the void volume.  Other molecular weight markers included sweet potato β-
amylase (200 kD) (Sigma-Aldrich® A8781), yeast alcohol dehydrogenase (150 kD) 
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(Sigma-Aldrich® A8656), bovine serum albumin (66 kD) (Sigma-Aldrich® A8531), 
bovine erythrocyte carbonic anhydrase (29 kD) (Sigma-Aldrich® C7025), and horse 
heart cytochrome c (12.4 kD) (Sigma-Aldrich® C7150).  I then plotted those elution 
volumes, represented as a ratio to the void volume of the column, as a function of the 
logarithm of each protein standard’s molecular weight.  I used Microsoft® Excel® to 
calculate a linear fit for this plot, according to Equation 4.  I then used this linear fit to 
predict the elution volume of a particular molecular weight, or to predict the molecular 
weight of a particular elution volume. 
𝑉!
𝑉!
= (𝑘 ∗ log!"𝑀𝑊)+ 𝑏   
Equation 4.  The elution volume of a protein depends linearly on the logarithm of its molecular weight.  Ve 
is the elution volume of a protein, Vo is the void volume (the elution volume of blue dextran), k is the slope 
of the linear fit, MW is the molecular weight of the protein, and b is the y-intercept of the linear fit. 
 I later added a blocking step between calibration and loading experimental 
samples, in which I loaded 200 µL (~1% of the column volume) of 10 mg per mL 
albumin or another molecular weight standard, and then washed the column with at least 
as much gel filtration buffer as that standard’s elution volume.  This step appeared to 
improve detection of the target protein in the analytical gel filtration fractions shown in 
Figure 12 and Figure 13. 
Expressing and Purifying DGK Constructs from E. coli 
Bacterial Expression Introduction 
As mentioned in the Introduction, I set out to express the catalytic domain of a 
eukaryotic DGK.  My approach was to express either full-length or just the catalytic 
domain of S. scrofa DGK-alpha (the first to be discovered and therefore best-studied of 
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the eukaryotic DGKs) in E. coli with the purpose of producing large amounts of soluble 
protein for structural studies. 
Expressing and Purifying Alphacat in pT71myc 
Introduction 
The alphacat construct consists of residues 333-733 of Sus scrofa DGK alpha 
(accession number NP_999197.1), and is so named because it includes the catalytic 
domain, which is annotated on the Conserved Domain Database90 as LCB5.  The missing 
N-terminal residues include the EF-hand motifs and C1 domains; alphacat also lacks the 
C-terminal cysteine (Figure 5).   
Results 
Alphacat was cloned into pT71myc, which adds to the N-terminus of the protein a 
fusion tag consisting of hexahistidine, a thrombin proteolytic site, a myc tag, and a 
Tobacco Etch Virus (TEV) protease site.  The total mass of this protein construct 
(including the fusion tag) is predicted to be 49.8 kD, and the isoelectric point (pI) is 6.99.  
 
Figure 5.  Schematic of alphacat in pT71myc construct.  Top, a schematic of S. scrofa DGK-alpha.  
Middle, a schematic of “alphacat”, which consists of residues 333-733 of DGK-alpha, including the LCB5 
domain, but missing the C-terminal cysteine.  Bottom, a magnification of the epitope tag region of alphacat 
in pT71myc.  pT71myc adds to the N-terminus of the protein a fusion tag consisting of a hexahistidine, a 
thrombin proteolytic site, a myc tag, and a TEV protease site.  The total mass of this protein construct 
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(including the fusion tag) and pI are predicted to be 49.8 kD and 6.99, respectively.  This figure has been 
modified from Petro and Raben1 and is used under CC BY-NC 2.5. 
I induced the expression of alphacat in the Rosetta™(DE3) (Novagen®) strain of 
E. coli by adding IPTG.  When compared to uninduced control, the induced lysate 
expressed an additional band, easily detectable by Coomassie staining, that migrated 
between the 40 kD and 50 kD molecular weight standards during SDS-PAGE, consistent 
with the predicted size of the fusion protein of 49.8 kD (Figure 6).  This band was also 
recognized by an anti(α)-histidine antibody on immunoblots (Figure 6), consistent with 
its expressing the epitope tag.  I therefore concluded that alphacat in pT71myc was 
expressing. 
 
Figure 6.  Alphacat in pT71myc expresses when induced by IPTG, is of the appropriate size, and is 
recognized by an anti-histidine antibody.  SDS-PAGE of 12% acrylamide gels followed by: left, 
Coomassie staining; right, immunoblot against histidine (mouse α-His6 (abcam® ab6196 (1:2500 (v/v)))).  
IB, immunoblot.  I inoculated 25 mL cultures of LB Kan with overnight cultures of alphacat in pT71myc in 
Rosetta™(DE3).  When the OD600 was predicted to reach 1.0, I added IPTG to 0.5 mM and shook the 
cultures overnight at 16°C, then pelleted the cells and resuspended in lysis buffer (50 mM Tris, pH 8.0, 300 
mM NaCl, 10 mM imidazole, 1 mM CaCl2, 0.5% (v/v) NP-40, 1x PIC, 25 U per µL lysozyme, 0.1% B-
PER Bacterial Protein Extraction Reagent (Thermo Scientific 78243)).  I loaded 24 µL per lane onto the 
Coomassie, and 5 µL onto the immunoblot.  This figure has been modified from Petro and Raben1 and is 
used under CC BY-NC 2.5. 
When I assayed the DGK activity, Rosetta™(DE3) lysates that had been 
transformed with alphacat in pT71myc and induced with IPTG showed greater enzymatic 
activity than either untransformed BL21(DE3) lysates or lysates that had not been 
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induced with IPTG (Figure 7), suggesting not only that the construct was successfully 
expressing, but also that at least some of the expressed protein was catalytically 
competent, consistent with previous reports that expressed the catalytic domain in COS-7 
cells45. 
 
Figure 7.  Lysates of Rosetta™(DE3) transformed with alphacat in pT71myc have DGK activity.  I 
inoculated 25 mL LB Kan cultures with overnight cultures of either alphacat in pT71myc in 
Rosetta™(DE3) or else untransformed BL21(DE3).  When the OD600 was predicted to reach 1.0, I added 
IPTG to 0.5 mM and shook the cultures overnight (~21 hours) at 16°C, then pelleted the cells by 
centrifugation and resuspended in lysis buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 
mM CaCl2, 0.5% NP-40, 1x PIC, 1 mM DTT, 1 mg per mL lysozyme) and incubated on ice for thirty 
minutes.  I lysed the cells by probe-sonicating six times on ice for ten seconds each, resting on ice for ten 
seconds between each burst.   DGK activity assay, in 7.5 mM liposomes (53:22:17:8::PE:PC:PS:DOG), 
48.4 mM HEPES, 4.84 mM MgCl2, 0.968 mM CaCl2, 2 mM DTT, 1 mM ATP, 60.5 mCi/mmol [γ-32P]-
ATP; 15 minutes at 30°C.  I used 1 µL of lysate (or buffer) in each 50 µL reaction. 
 In order to determine whether alphacat was soluble, I first needed to make sure 
the cells actually lysed.  Bath sonication for five minutes in the presence of 0.5% NP-40 
was insufficient to completely lyse the cells, as evidenced by the fact that most of the 
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cellular proteins visible in the lysate by Coomassie were not visible in the supernatant 
(Figure 8A).  Probe sonicating for six fifteen-second bursts, followed by a thirty-minute 
incubation at 4°C with an old aliquot of lysozyme, is likewise insufficient to lyse the cells 
(Figure 8B). 
 
Figure 8.  Bath sonication, or probe-sonication with an old aliquot of lysozyme, is inadequate to lyse 
BL21(DE3) cells.  SDS-PAGE of 15% acrylamide gels followed by Coomassie staining.  (A) I inoculated a 
4 mL culture of LB Kan with overnight cultures of alphacat in pT71myc in Rosetta™(DE3), or a 4 mL 
culture of LB with overnight cultures of BL21(DE3).  When the OD600 was predicted to reach 1.0, I added 
IPTG to 0.5 mM and shook the cultures overnight at 16°C, then pelleted the cells and resuspended in lysis 
buffer (55 mM Tris, pH 8.0, 5.5 mM MgCl2, 1 mM CaCl2, 0.5% (v/v) NP-40, 1x PIC).  I bath-sonicated for 
five minutes, adding ice to the water to keep it cool, and separated the supernatant from the pellet by 
microfuging at maximum speed for ten minutes at 4°C.  I loaded 10 µL per lane.  (B) The same samples as 
shown in Figure 6.  I lysed by probe-sonicating (on setting 2.5) six times for fifteen seconds each, resting 
on ice for fifteen seconds between each burst, and inverting to mix.  I then added (old) lysozyme to 25 U 
per mL, and rotated for thirty minutes at 4°C.  I loaded 4 µL per lane.  
 When I replaced the old lysozyme with fresh egg white lysozyme, six ten-second 
bursts from the probe sonicator were sufficient to lyse the cells (Figure 9).  After lysis, 
however, although almost all of the Coomassie-staining cellular proteins were in the 
supernatant after centrifugation, the band corresponding to alphacat remained in the 
pellet, suggesting that it was insoluble.  When washed with 2 M urea and 2% (v/v) Triton 
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X-100, the vast majority of alphacat remained in the pellet rather than the supernatant 
(Figure 9A), leading me to conclude that the expressed protein went into inclusion 
bodies91.  Washing the pellet of insoluble protein with 4 M urea (instead of 2 M) and 2% 
(v/v) Triton X-100 solubilized some, but not all, of the alphacat (Figure 9B). 
 
Figure 9.  Alphacat in pT71myc goes into inclusion bodies.  SDS-PAGE of 12% acrylamide gels 
followed by Coomassie staining.  I inoculated 25 mL cultures of LB Kan with overnight cultures of 
alphacat in pT71myc in Rosetta™(DE3).  When the OD600 was predicted to reach 1.0, I added IPTG to 0.5 
mM and shook the cultures overnight (~21.5 hours) at 16-20°C, then pelleted the cells and resuspended in 4 
mL per gram wet cell pellet lysis buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 5 mM 
MgCl2, 1 mM CaCl2, 0.5% (v/v) NP-40, 1x PIC, 1 mM DTT, 1 mg per mL egg white lysozyme, 10 U per 
mL DNAse I).  I incubated on ice for thirty minutes, then probe-sonicated with six ten-second bursts, 
resting on ice for ten seconds between each burst.  I separated the supernatant from the pellet by 
centrifuging at 14,500 x g for one hour at 4°C.  I washed the pellet three times either in (A) 2M urea wash 
buffer (50 mM Tris, 300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 1 mM DTT, 2 M urea, 2% (v/v) 
Triton X-100), or (B) 4 M urea wash buffer (the same as 2 M urea wash buffer, but urea increased to 4 M).  
I loaded 0.5 µL per lane.  This figure has been modified from Petro and Raben1 and is used under CC BY-
NC 2.5. 
 I could solubilize some, but not all, of the alphacat from inclusion bodies using 
guanidine hydrochloride, a chaotropic agent that unfolds proteins (Figure 10).  After 
diluting into buffer (which, by reducing the guanidine concentration, is predicted to cause 
the protein to refold), I could enrich alphacat by nickel-nitrilotriacetic acid (Ni-NTA) 
chromatography.  NTA is a tridendate molecule that, when attached to agarose beads, 
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chelates Ni.  The His6 tag on alphacat is also predicted to chelate Ni, and thus Ni-NTA 
chromatography is predicted to be able to enrich alphacat. After enrichment, some of the 
alphacat remained in the pellet with the resin, which could be because the alphacat-Ni-
NTA interaction was too strong to be eluted with 250 mM imidazole, but was more likely 
because the alphacat was precipitating and coming down in the pellet as insoluble 
protein. 
 
Figure 10.  Alphacat can be partially solubilized from inclusion bodies, and enriched on Ni-NTA.  
SDS-PAGE of 12% acrylamide gels followed by Coomassie staining.  These are the same samples that are 
shown in Figure 9A.  I resuspended the washed pellets (that had been previously washed with 2 M urea) in 
extraction buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 1 mM DTT, 6.7 M 
guanidine chloride) and sonicated until the pellet vanished and the solution appeared clear.  I removed the 
insoluble fraction by centrifuging at 110,000 x g for one hour at 4°C.  I then refolded the extracted 
supernatant by diluting 63.5-fold into loading buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM 
imidazole, 1 mM CaCl2, 1 mM DTT), and once again removed the insoluble fraction by centrifuging at 
110,000 x g for one hour at 4°C.  I added Ni-NTA agarose (QIAGEN 30210) 1:200 (v/v) and incubated for 
one hour, rocking at 4°C.  I washed the resin with wash buffer (same as loading buffer, but DTT reduced to 
0.5 mM) and eluted with elution buffer (same as loading buffer, but imidazole increased to 250 mM).  I 
loaded 0.5 µL of the lysates and extracted samples, and 22.5 µL of the other samples. 
Because monodispersity is considered a valuable quality of proteins expressed for 
structural studies, I subjected the affinity-purified fraction (Figure 11) to analytical gel 
filtration.  If a protein is monodisperse, it is predicted elute as a single peak at the 
appropriate molecular weight: for alphacat in pT71myc, this would be at 49.8 kD 
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(between the 29 kD carbonic anhydrase and the 66 kD albumin molecular weight 
standards) if it is a monomer, at 99.6 kD (between albumin and the 150 kD alcohol 
dehydrogenase) if it is a dimer, etc.  After analytical gel filtration on Sephadex® G-100 
resin (Sigma-Aldrich®), any alphacat that eluted from the resin was undetectable by 
Coomassie staining (Figure 12A).  I tried to transfer the proteins from the Coomassie-
stained gel to nitrocellulose for immunoblotting, to see whether I could detect the 
analytical gel filtration fractions by the more sensitive method, but even though the 
alphacat lysate was easily detectable by Coomassie staining, apparently Coomassie-
stained proteins either do not transfer well or are not detected by immunoblot, because I 
was unable to detect even the alphacat lysate on the immunoblot (Figure 12B).  When I 
ran the gel filtration fractions on a new, fresh immunoblot, the alphacat that had eluted 
from the Ni-NTA resin was clearly detectable by an anti-DGK-alpha antibody (Figure 
12C) but not an anti-His antibody (Figure 12D) (note that this is a different anti-His 
antibody than the one that detected alphacat in pT71myc lysate in Figure 6).  In either 
blot, none of the gel filtration fractions were detectable, nor were they detectable by 
silver staining (Figure 12E).  (The band that migrates between the 60 kD and 70 kD 
molecular weight markers is probably albumin (66 kD) that had not been completely 
washed off the column following calibration.  Alphacat is the predominant band in the 
fraction that eluted from the Ni-NTA resin, which migrated between 50 and 60 kD on this 
gel.)  I concentrated the gel filtration fractions by ethanol-precipitating the protein, and 
still could not detect any alphacat eluting from the column by silver stain (Figure 12F). 
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Figure 11.  Expression of alphacat in pT71myc, extraction from the pellet, and purification on Ni-
NTA.  I inoculated 25 mL cultures of LB Kan with overnight cultures of alphacat in pT71myc in 
Rosetta™(DE3).  When the OD600 was predicted to reach 1.0, I added IPTG to 0.5 mM and shook the 
cultures overnight 16°C, then pelleted the cells and resuspended in 4 mL per gram wet cell pellet lysis 
buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.5% (v/v) NP-
40, 1x PIC, 1 mM DTT, 1 mg per mL egg white lysozyme, 20 U per mL DNAse I).  I incubated on ice for 
five hours.  I separated the supernatant from the pellet by centrifuging at 22,000 x g for one hour at 4°C.  I 
extracted the pellets with extraction buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mM 
CaCl2, 0.5 mM DTT, 6.7 M guanidine chloride) and vortexed and pipetted until the pellet had mostly 
vanished.  I removed the insoluble fraction by centrifuging at 22,000 x g for one hour at 4°C.  I then 
refolded the extracted supernatant by diluting 56.6-fold into loading buffer (50 mM Tris, pH 8.0, 300 mM 
NaCl, 10 mM imidazole, 1 mM CaCl2, 0.5 mM DTT), and removed the insoluble fraction by centrifuging 
at 110,000 x g for one hour at 4°C.  I added Ni-NTA agarose 1:200 (v/v) and incubated for two hours, 
rocking at 4°C.  I washed the resin with wash buffer (same as loading buffer, but imidazole increased to 20 
mM) and eluted with elution buffer (same as loading buffer, but imidazole increased to 250 mM).  (A) 
SDS-PAGE of a 12% acrylamide gel followed by Coomassie staining.  I loaded 0.5 µg of each lysate and 
equivalent volumes (see Equation 1) of the other samples.  (B) SDS-PAGE of a 12% acrylamide gel 




Figure 12.  Analytical gel filtration chromatography without first blocking the column results in 
undetectable gel filtration fractions. I loaded 130 µL of the elution shown in Figure 11 onto a 
Sephadex® G-100 column that I had previously calibrated with blue dextran, alcohol dehydrogenase, 
carbonic anhydrase, and albumin, eluting by gravity in gel filtration buffer (55 mM HEPES, 55 mM MgCl2, 
1.1 mM CaCl2, pH 8.0) and collected fractions every five minutes.  (A) SDS-PAGE of a 12% acrylamide 
gel followed by Coomassie staining.  I loaded 4 µL of eluate and 18 µL per lane of fractions 14-26 
(corresponding to predicted molecular weights of 206 kD to 16.5 kD).  (B) The same gel shown in (A) 
transferred to nitrocellulose and immunoblotted against DGK-alpha (rabbit antibody from the Sakane lab 
(1:5000 (v/v))).  (C) SDS-PAGE of a 12% acrylamide gel followed by immunoblotting against DGK-alpha 
(rabbit antibody from the Sakane lab (1:5000 (v/v))).  I tore the gel while assembling the transfer apparatus, 
causing the lanes to shift partway down the membrane.  The labeling of the lanes coincides with bottom 
region of the membrane, where alphacat is predicted to migrate.  (D) The same membrane shown in (C), 
immunoblotted against His6 (Clontech Laboratories, Inc. 631212 (1:2500 (v/v))).  (E) SDS-PAGE of a 12% 
acrylamide gel followed by silver staining.  (F) SDS-PAGE of a 12% acrylamide gel followed by silver 
staining.  I ethanol-precipitated 180 µL of each gel filtration fraction and loaded 83%, and I loaded 1 µL of 
eluate. 
One potential reason for why I could not detect alphacat eluting from the 
Sephadex® G-100 column could have been that the alphacat had adsorbed to the resin 
and never eluted off.  I therefore blocked the analytical gel filtration column with 
albumin and washed extensively (more than ten column volumes) with buffer.  I also 
ultracentrifuged the alphacat eluted from Ni-NTA (from the same preparation shown in 
Figure 12) to remove any insoluble material immediately before loading onto the 
analytical gel filtration column.  This time, I could clearly detect alphacat by 
immunoblotting in gel filtration fractions corresponding to the void volume of the column 
(Figure 13).  In fact, the alphacat eluted a little earlier than the blue dextran: this result 
could be explained by compression of the Sephadex® G-100 resin in the thirty-one days 
that elapsed between when I ran the blue dextran and when I ran the alphacat.  The 
calibration of the Sephadex® G-100 column gave a good linear fit (Figure 13C), 
suggesting that the analytical gel filtration column was working properly.  I therefore 
concluded that the alphacat was aggregating, which would explain why it eluted in the 
void volume. 
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Figure 13.  Previously blocking the column improves detection of alphacat eluting from a Sephadex® 
G-100 analytical gel filtration column, from which it elutes in the void volume.  I loaded 200 µL of the 
same elution that I used in Figure 12, except that I had added glycerol to 50% and stored it for seventeen 
days at -80°C, onto the same Sephadex® G-100 column shown in Figure 12, eluting by gravity in gel 
filtration buffer (55 mM HEPES, 5.5 mM MgCl2, 1.1 mM CaCl2, pH 7.0), and collected fractions every 
five minutes.  (A) SDS-PAGE of a 12% acrylamide gel followed by immunoblotting against DGK-alpha 
(rabbit antibody from the Sakane lab (1:5000 (v/v))).  (B) The elution of molecular weight markers as a 
function of elution volume.  I detected the elution of the proteins standards by measuring the absorbance at 
280 nm (A280) of the gel filtration fractions.  I detected the elution of the blue dextran visually: the vertical 
line marks the volume of the fraction that appeared the bluest.  To measure the elution volume of alphacat, 
I performed densitometry three times on the film shown in (A).  Mean ± SD.  (C) Calibration of the 
Sephadex® G-100 column: elution volume (presented as a ratio of the void volume) of the molecular 
weight standards as a function of logarithm molecular weight.  I calculated the linear regression using 
Microsoft® Excel®. 
In case the reason that alphacat was eluting in the void was because the fraction 
that had eluted from Ni-NTA had been frozen and thawed before I had loaded it onto the 
analytical gel filtration column, and the freeze-thaw cycles were causing the protein to 
aggregate, I repeated the Sephadex® G-100 analytical gel filtration chromatography with 
alphacat I had freshly expressed and purified.  This time, I could easily detect alphacat in 
the gel filtration fractions, but it once again eluted in the void volume (Figure 14). 
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Figure 14.  Freshly expressed and purified alphacat in pT71myc elutes from Sephadex® G-100 in the 
void volume.  I inoculated a 50 mL culture of LB Kan with an overnight culture of alphacat in pT71myc in 
Rosetta™(DE3).  When the OD600 was predicted to reach 1.0, I added IPTG to 0.5 mM and shook the 
cultures for 21 hours at 15°C, then pelleted the cells and resuspended in 4 mL per gram wet cell pellet lysis 
buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.5% (v/v) NP-
40, 1x PIC, 1 mM DTT, 1 mg per mL egg white lysozyme).  I incubated on ice for two hours.  I separated 
the supernatant from the pellet by centrifuging at 43,000 x g for ninety minutes at 4°C.  I extracted the 
pellets with extraction buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 0.5 
mM DTT, 6.7 M guanidine chloride) and probe-sonicated until the pellet had vanished and the solution was 
clear.  I removed the insoluble fraction by centrifuging at 17,900 x g for two hours at 4°C.  I then refolded 
the extracted supernatant by diluting fifty-fold into loading buffer (50 mM HEPES, pH 7.0, 300 mM NaCl, 
10 mM imidazole, 1 mM CaCl2, 0.5 mM DTT), and removed the insoluble fraction by centrifuging at 
30,000 x g for ninety minutes at 4°C.  I added Ni-NTA agarose 1:240 (v/v) and incubated for one hour, 
rocking at 4°C.  I washed the resin with wash buffer (same as loading buffer, but imidazole increased to 20 
mM) and eluted with elution buffer (same as loading buffer, but imidazole increased to 250 mM).  I 
removed the insoluble fraction by centrifuging at 43,000 x g for ninety minutes at 4°C, and loaded 200 µL 
of the eluate’s supernatant onto the same Sephadex® G-100 column shown in Figure 12 and Figure 13, 
and collected fractions every five minutes, eluting by gravity in gel filtration buffer (50 mM HEPES, 5 mM 
MgCl2, 1 mM CaCl2, pH 7.0).  (A) SDS-PAGE of 12% acrylamide gels followed by immunoblotting 
against DGK-alpha (rabbit antibody from the Sakane lab (1:5000 (v/v))).  I loaded 24 µL per lane of the gel 
filtration fractions of elution volumes corresponding to molecular weights of 270 to 2.4 kD.  (B) To 
quantify the alphacat in the gel filtration fractions, I performed densitometry, using a shorter exposure of 
the first membrane shown in (A), three times on the same film.  Mean ± SD.   
Even though the vast majority of alphacat was in the pellet after cell lysis, I also 
recovered a small amount in the supernatant.  I wondered whether this small amount of 
soluble protein could be sufficiently enriched to detect its elution from an analytical gel 
filtration column, and whether that soluble protein would be monodisperse.  I therefore 
purified the supernatant from alphacat-expressing Rosetta™(DE3) on Ni-NTA and found 
that, indeed, alphacat could be enriched from the supernatant (Figure 15A and B).  When 
I loaded this enriched fraction onto the Sephadex® G-100 analytical gel filtration 




Figure 15.  Soluble alphacat in pT1myc can be enriched by Ni-NTA chromatography, but it elutes 
from Sephadex® G-100 in the void volume.  I inoculated a 50 mL culture of LB Kan with an overnight 
culture of alphacat in pT71myc in Rosetta™(DE3).  When the OD600 was predicted to reach 1.0, I added 
IPTG to 0.5 mM and shook the cultures for 21 hours at 15°C, then pelleted the cells and resuspended in 4 
mL per gram wet cell pellet lysis buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 5 mM 
MgCl2, 1 mM CaCl2, 0.5% (v/v) NP-40, 1x PIC, 0.5 mM DTT, 1 mg per mL egg white lysozyme, 20 U per 
mL DNAse I).  I incubated on ice for one hour.  I removed the insoluble fraction by centrifuging at 43,000 
x g for ninety minutes at 4°C.  I added Ni-NTA agarose 1:12 (v/v) and incubated for 135 minutes, rocking 
at 4°C.  I washed the resin with wash buffer 1 (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 
mM CaCl2, 0.5 mM DTT) followed by wash buffer 2 (same as wash buffer 1, but imidazole increased to 20 
mM), and eluted with elution buffer (same as the wash buffers, but imidazole increased to 250 mM).  I 
removed the insoluble fraction by centrifuging at 43,000 x g for ninety minutes at 4°C, and loaded 200 µL 
of the eluate’s supernatant onto the same Sephadex® G-100 column shown in Figure 12 - Figure 14, and 
collected fractions every seven minutes, eluting by gravity in gel filtration buffer (55 mM HEPES, 5.5 mM 
MgCl2, 1.1 mM CaCl2, pH 8.0).  (A) SDS-PAGE of a 12% acrylamide gel followed by Coomassie staining.  
(B) SDS-PAGE of 12% acrylamide gels followed by immunoblotting against DGK-alpha (rabbit antibody 
from the Sakane lab (1:5000 (v/v))).  I loaded 24 µL per lane of the gel filtration fractions of elution 
volumes corresponding to molecular weights of 274 to 38 kD.  (C) To quantify the alphacat in the gel 
filtration fractions, I performed densitometry, using a shorter exposure of the first membrane shown in (B), 
three times on the same film.  Mean ± SD. 
Oligomerization of LCB5 family proteins is not unprecedented: purified 
Salmonella typhimurium YegS recombinantly expressed in E. coli elutes as a dimer from 
a Superdex G200 resin92, E. coli YegS93 and Staphylococcus aureus DgkB94 
recombinantly expressed in E. coli each crystallize as dimers, and H. sapiens DGK-
epsilon recombinantly expressed in COS-7 cells has been reported to dimerize based on 
its migration in perfluorooctanoic acid (PFO)-PAGE43.  (PFO is weaker detergent than 
SDS, and hence some protein-protein interactions are maintained during electrophoresis 
with PFO95: however, because this result was observed with DGK-epsilon-
overexpressing COS-7 lysates43 and not purified protein, the possibility cannot be ruled 
out that DGK-epsilon was not dimerizing but rather interacting with another cellular 
protein of approximately the same size as itself.)  If alphacat dimerized, however, the 
predicted size of the dimer would be 99.6 kD, which could be difficult to distinguish 
from the void volume on a Sephadex® G-100 resin.  I therefore tested where refolded 
alphacat in pT71myc eluted from Sephadex® G-150 resin, a resin with a larger exclusion 
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volume and hence able to resolve differences in molecular weight among larger 
macromolecules.  When I loaded refolded alphacat in pT71myc onto a Sephadex® G-150 
column, however, alphacat continued to elute in the void volume (Figure 16). 
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Figure 16.  Refolded alphacat elutes from Sephadex® G-150 in the void volume.  I inoculated a 72.5 
mL culture of LB Kan with an overnight culture of alphacat in pT71myc in Rosetta™(DE3).  When the 
OD600 was predicted to reach 1.0, I added IPTG to 0.5 mM and shook the cultures for 21 hours at 14°C, 
then pelleted the cells and resuspended in 4 mL per gram wet cell pellet lysis buffer (50 mM Tris, pH 8.0, 
300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 0.5% (v/v) NP-40, 1x PIC, 0.5 mM DTT, 1 mg per mL egg 
white lysozyme, 20 U per mL DNAse I).  I incubated on ice for one hour, then added DNAseI to 27 U per 
mL, then incubated on ice for another thirty minutes, then added MgCl2 to 5 mM, then incubated on ice for 
another thirty minutes, then drew through a 22-gauge needle five times.  I separated the supernatant from 
the pellet by centrifuging at 43,000 x g for twenty minutes at 4°C.  I extracted the pellets with 2.5 mL per 
gram original cell pellet extraction buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mM 
CaCl2, 0.5 mM DTT, 6.7 M guanidinium chloride) and probe-sonicated until completely clear.  I removed 
the insoluble fraction by centrifuging at 19,700 x g for thirty minutes at 4°C.  I then refolded the extracted 
supernatant by diluting fifty-fold into loading buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM 
imidazole, 1 mM CaCl2, 0.5 mM DTT), and removed the insoluble fraction by centrifuging at 18,000 x g 
for thirty minutes at 4°C.  I added Ni-NTA agarose 1:600 (v/v) and incubated for two hours, rocking at 
4°C.  I washed the resin with loading buffer, followed by wash buffer (same as loading buffer, but 
imidazole increased to 20 mM), and eluted with elution buffer (same as wash buffer, but imidazole 
increased to 250 mM).  I removed the insoluble fraction by centrifuging at 43,000 x g for ninety minutes at 
4°C, and loaded 200 µL of the eluate’s supernatant onto a Sephadex® G-150 column that had been 
previously calibrated with blue dextran, alcohol dehydrogenase, carbonic anhydrase, and albumin, and 
collected fractions every 3.5 minutes, eluting by gravity in gel filtration buffer (55 mM HEPES, 5.5 mM 
MgCl2, 1.1 mM CaCl2, pH 8.0).  (A) SDS-PAGE of 12% acrylamide gels followed by immunoblotting 
against DGK-alpha (rabbit antibody from the Sakane lab (1:5000 (v/v))).  I loaded 24 µL per lane of the gel 
filtration fractions of elution volumes corresponding to molecular weights of 305 to 8.6 kD.  (B) To 
quantify the alphacat in the gel filtration fractions, I performed densitometry, using a shorter exposure of 
the first membrane shown in (A), three times on the same film.  Mean ± SD.  (C) Calibration of the 
Sephadex® G-150 column: elution volume (presented as a ratio of the void volume) of the molecular 
weight standards as a function of logarithm molecular weight.  I calculated the linear regression using 
Microsoft® Excel®. 
 Chelating agents such as imidazole have been reported to reverse the aggregation 
of histidine-tagged proteins96.  However, when I included 250 mM imidazole in the gel 




Figure 17.  In the presence of 250 mM imidazole, refolded alphacat in pT71myc continues to elute in 
the void volume from a Sephadex® G-150 analytical gel filtration column.  I inoculated a 62.5 mL 
culture of LB Kan with an overnight culture of alphacat in pT71myc in Rosetta™(DE3).  When the OD600 
was predicted to reach 1.0, I added IPTG to 0.5 mM and shook the cultures for 21 hours at 15°C, then 
pelleted the cells and froze the pellets at -80°C for a bit over seven months.   I thawed the cell pellets by 
gently shaking the tube in room-temperature until just thawed, and resuspended in 4 mL per gram wet cell 
pellet lysis buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 
0.5% (v/v) NP-40, 1x PIC, 1 mg per mL egg white lysozyme, 20 U per mL DNAse I).  I incubated on ice 
for thirty minutes, then separated the supernatant from the pellet by centrifuging at 43,000 x g for ninety 
minutes at 4°C.  I extracted the pellets with 2 mL per gram original cell pellet extraction buffer (50 mM 
Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 0.5 mM DTT, 6.7 M guanidine chloride) and 
probe-sonicated until completely clear.  I then refolded the extracted alphacat by diluting fifty-fold into 
loading buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 0.5 mM DTT), and 
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removed the insoluble fraction by centrifuging at 110,000 x g for one hour at 4°C.  I added Ni-NTA 
agarose 1:500 (v/v) and incubated for one hour, rocking at 4°C.  I stored the flowthrough (flowthrough 1) at 
-80°C for one week, then thawed by gently shaking the tube in room-temperature until just thawed, and 
removed the insoluble fraction by centrifuging at 110,000 x g for one hour at 4°C.  I repurified the 
flowthrough by adding Ni-NTA agarose 1:500 (v/v) and incubating overnight, rocking at 4°C.   I washed 
the resin with loading buffer, followed by wash buffer (same as loading buffer, but imidazole increased to 
20 mM), and eluted with elution buffer (same as wash buffer, but imidazole increased to 250 mM).  I 
removed the insoluble fraction by microfuging, and loaded 200 µL of the eluate’s supernatant onto a 
Sephadex® G-150 column that had been previously calibrated with blue dextran, albumin, alcohol 
dehydrogenase, carbonic anhydrase, and blocked with albumin, and I collected fractions every two minutes, 
eluting by gravity in gel filtration buffer (55 mM HEPES, 5.5 mM MgCl2, 1.1 mM CaCl2, 250 mM 
imidazole, pH 8.0).  (A) SDS-PAGE of 12% acrylamide gels followed by immunoblotting against DGK-
alpha (rabbit antibody from the Sakane lab (1:5000 (v/v))).  I loaded 24 µL per lane of the gel filtration 
fractions of elution volumes corresponding to molecular weights of 231 to 17 kD.  (B) Elution profile of 
molecular weight standards and alphacat.  I measured the A280 of the protein molecular weight standards.  
I observed blue dextran elution visually: the elution volume of the bluest fraction is represented by a 
vertical line.  In order to quantify the alphacat in the gel filtration fractions, I performed densitometry on 
the films shown in (A), three times on the same film.  In order to compare the two immunoblots, I 
calculated the signal as a proportion of the signal from the eluate on the same blot.  Mean ± SD. 
 Proteins have been reported to aggregate at pHs around their pI97.  After 
sequencing the DNA of the alphacat in pT71myc construct I later learned that the pI of 
this construct is 6.99, but at the time of these experiments I was under the mistaken 
impression that the pI of the construct was 8.4.  (Not realizing that the fusion tag added 
by pT71myc included more than just the histidine tag, I had calculated the pI from the 
sequence of alphacat, plus six histidines.  I later sequenced the alphacat in pT71myc 
construct using the T7 primer: it is on this sequence that the schematic in Figure 5 is 
based.)  I had conducted the previous purifications and analytical gel filtration 
chromatography at pH 8.0.  Concerned that being too close to the pI was contributing to 
alphacat’s aggregation (at pH 8.0, approximately 40% of a protein whose pI is 8.4 would 
be uncharged), I dropped the pH of lysis, purification, and analytical gel filtration to 6.4 
(so that only 1% of a protein whose pI is 8.4 would be uncharged), in the hopes that 
doing so would increase the proportion of alphacat that eluted from the analytical gel 
filtration column in a volume corresponding to that predicted for a dimer.  (However, I 
was still using Tris to buffer the pH, even though 6.4 is well outside the buffering range 
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of Tris98, so the actual pH is uncertain.)  Under these conditions for analytical gel 
filtration, although some of the alphacat continued to elute in the void volume, some also 
eluted at a volume corresponding to about 79 kD, somewhat later than the predicted 
elution volume of a dimer (predicted size 99.6 kD) (Figure 18).  Any quantitative 
comparison of the immunoblot signal of two peaks would require that the two 




Figure 18.  In the presence of 250 mM imidazole at pH 6.4, refolded alphacat in pT71myc elutes from 
a Sephadex® G-150 analytical gel filtration column in two peaks.   The protein used in this experiment 
was purified from the same cell pellets used in Figure 17.   I thawed the cell pellets by gently shaking the 
tube in room-temperature until just thawed, and resuspended in 4 mL per gram wet cell pellet lysis buffer 
(50 mM Tris, pH 6.4, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.5% (v/v) NP-40, 1x 
PIC, 0.5 mM DTT, 1 mg per mL egg white lysozyme, 20 U per mL DNAse I).  I incubated on ice for one 
hour, vortexing halfway through, then separated the supernatant from the pellet by centrifuging at 43,000 x 
g for ninety minutes at 4°C.  I extracted the pellets with 2 mL per gram original cell pellet extraction buffer 
(50 mM Tris, pH 6.4, 300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 0.5 mM DTT, 6.7 M guanidine 
chloride) and probe-sonicated until completely clear.  I then refolded the extracted alphacat by diluting 
fifty-fold into loading buffer (50 mM Tris, pH 6.4, 300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 0.5 mM 
DTT), and removed the insoluble fraction by centrifuging at 110,000 x g for one hour at 4°C.  I added Ni-
NTA agarose 1:500 (v/v) and incubated overnight, rocking at 4°C.  I washed the resin with loading buffer, 
followed by wash buffer (same as loading buffer, but imidazole increased to 20 mM), and eluted with 
elution buffer (same as wash buffer, but imidazole increased to 250 mM).  I removed the insoluble fraction 
by microfuging, and loaded 200 µL of the eluate’s supernatant onto the same Sephadex® G-150 column 
shown in Figure 17, freshly reblocked with albumin, and I collected fractions every two minutes, eluting 
by gravity in gel filtration buffer (55 mM HEPES, 5.5 mM MgCl2, 1.1 mM CaCl2, 250 mM imidazole, pH 
6.4).  (A) SDS-PAGE of 12% acrylamide gels followed by immunoblotting against DGK-alpha (rabbit 
antibody from the Sakane lab (1:5000 (v/v))).  I loaded 24 µL per lane of the gel filtration fractions of 
elution volumes corresponding to molecular weights of 301 to 18 kD.  (B) The elution of molecular weight 
markers as a function of elution volume.  I detected the elution of the proteins standards by measuring the 
absorbance at 280 nm (A280) of the gel filtration fractions.  I detected the elution of the blue dextran 
visually: the vertical line marks the volume of the fraction that appeared the bluest.  To quantify the 
alphacat in the gel filtration fractions, I performed densitometry, using a shorter exposure of the middle 
membrane shown in (A), three times on the same film.  Mean ± SD.  (C) Calibration of the Sephadex® G-
150 column: elution volume (presented as a ratio of the void volume) of the molecular weight standards as 
a function of logarithm molecular weight.  I calculated the linear regression using Microsoft® Excel®.  The 
elution volume of the second peak of alphacat (as measured by densitometry from the blot shown in (A)), 
plotted onto the linear fit of the protein molecular weight standards, gives a predicted molecular weight of 
79 kD. 
 In order to make sure these results were reproducible, I repeated with a fresh and 
larger-scale expression of alphacat in pT71myc.  Once again, when lysed and purified at 
pH 6.4 (Figure 19A), and when loaded onto the analytical gel filtration column in 250 
mM imidazole, alphacat eluted in two distinct peaks, one corresponding to the void 
volume, and one eluting somewhat later (Figure 19B-C).  This time the predicted 
molecular weight of the second peak is 127 kD: one possible explanation for the change 
in predicted molecular weight could be that the gel filtration resin compressed in volume 
during the nearly six weeks that elapsed between calibration and the chromatography 
shown in Figure 19.  However, when I replotted alphacat’s elution onto a fresh 
calibration of the same column, the predicted molecular weight of the second peak was 
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nearly the same, at 128 kD (Figure 20).  The discrepancy in the elution volumes in the 
experiments shown in Figure 18 and Figure 19 is therefore unlikely to be a result of 
compression of the Sephadex® G-150 resin.  Another possible explanation for the 
difference in elution volumes could be that in the later experiment, alphacat was purified 
in the presence of 5 mM MgCl2.  Other LCB5 family proteins have Mg2+ binding 
sites92,94, so it is possible that the presence of Mg2+ affects alphacat’s conformation, 
which could influence its elution profile from an analytical gel filtration column.  Yet 
another possible explanation is that alphacat’s conformation is pH-dependent, and the pH 
varied between these experiments because of Tris’s poor buffering capacity at 6.4.  127 
kD is considerably larger than the predicted mass of a dimer (99.6 kD), but also smaller 




Figure 19.  In the presence of 250 mM imidazole at pH 6.4, refolded alphacat in pT71myc 
reproducibly elutes from a Sephadex® G-150 analytical gel filtration column in two peaks.  I 
inoculated three 62.5 mL cultures of LB Kan with an overnight culture of alphacat in pT71myc in 
Rosetta™(DE3).  When the OD600 was predicted to reach 1.0, I added IPTG to 0.5 mM and shook the 
cultures for 20.5 hours at 22°C, then pelleted the cells and resuspended in 4 mL per gram wet cell pellet 
lysis buffer (50 mM Tris, pH 6.4, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.5% (v/v) 
NP-40, 0.5 mM DTT, 1x PIC, 1 mg per mL egg white lysozyme, 20 U per mL DNAse I).  I incubated on 
ice for thirty minutes, vortexing occasionally to mix, then separated the supernatant from the pellet by 
centrifuging at 43,000 x g for ninety minutes at 4°C.  I extracted the pellets with extraction buffer (50 mM 
Tris, pH 6.4, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.5 mM DTT, 6.7 M guanidine 
chloride) and probe-sonicated until completely clear.  I removed the insoluble fraction by centrifuging at 
43,000 x g for ninety minutes at 4°C.  I then refolded the extracted alphacat by diluting fifty-fold into 
loading buffer (50 mM Tris, pH 6.4, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.5 
mM DTT), and removed the insoluble fraction by centrifuging at 110,000 x g for one hour at 4°C.  I added 
Ni-NTA agarose 1:500 (v/v) and incubated overnight, rocking at 4°C.  I washed the resin with loading 
buffer, followed by wash buffer (same as loading buffer, but imidazole increased to 20 mM), and eluted 
with elution buffer (same as wash buffer, but imidazole increased to 250 mM).  I removed the insoluble 
fraction by centrifuging at 43,000 x g for ninety minutes at 4°C, and loaded 200 µL of the eluate’s  
supernatant onto the same Sephadex® G-150 column shown in Figure 17 and Figure 18, freshly reblocked 
with albumin, and I collected fractions every two minutes, eluting by gravity in gel filtration buffer (55 mM 
HEPES, 5.5 mM MgCl2, 1.1 mM CaCl2, 250 mM imidazole, pH 6.4).  (A) SDS-PAGE of a 12% 
acrylamide gel followed by silver staining.  (B) SDS-PAGE of 12% acrylamide gels followed by 
immunoblotting against DGK-alpha (rabbit antibody from the Sakane lab (1:5000 (v/v))).  I loaded 24 µL 
per lane of the gel filtration fractions of elution volumes corresponding to molecular weights of 287 to 27 
kD.  (C) Elution profile of molecular weight standards and alphacat. In order to quantify the alphacat in the 
gel filtration fractions, I performed densitometry on the films shown in (B), three times on the same film.  
In order to compare the two immunoblots, I calculated the signal as a proportion of the signal from the 
eluate supernatant on the same blot.  Mean ± SD.  
 
 
Figure 20.  The second peak of refolded alphacat in pT71myc in 250 mM imidazole, pH 6.4 (Tris) 
elutes from a freshly recalibrated Sephadex® G-150 analytical gel filtration column at a volume 
consistent with a molecular weight of 128 kD.  The same column shown in Figure 17 - Figure 19, but 
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recalibrated.  Elution profile of molecular weight standards and alphacat.  I measured the A280 of the 
protein molecular weight standards, and A620 of the blue dextran fractions.  The alphacat data is the same 
shown in Figure 19C, but replotted onto the fresh calibration. 
 When I scaled the expression up to 4 L of culture, alphacat remained insoluble, 
but I was once again able to extract some alphacat from protein pellets using guanidine 
chloride, and could purify the refolded protein on Ni-NTA resin (Figure 21A).  Most of 
the purified protein either remained bound to the Ni-NTA resin or else precipitated and 
thus pelleted with the Ni-NTA resin.  The yield of eluted protein was very low, even after 
eluting overnight (eluate 3 E), suggesting that the low yield was not a result of the 
elutions’ being too short.  When I loaded the purified protein onto the Sephadex® G-150 
analytical gel filtration column, alphacat once again eluted in two distinct peaks (Figure 
21B-C).  The predicted molecular weight of the second peak, based on the calibration, 
was 122 kD, once again considerably larger than the predicted mass of a dimer (99.6 kD), 
but also smaller than the predicted mass of a trimer (149.4 kD), and consistent with the 
previously observed elution volumes consistent with molecular weights of 127-128 kD 
(Figure 19 and Figure 20). 
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Figure 21.  The second peak of refolded alphacat in pT71myc in 250 mM imidazole, pH 6.4 (Tris) 
from a scaled-up expression elutes from a Sephadex® G-150 analytical gel filtration column at a 
volume consistent with a molecular weight of 122 kD.  I inoculated four 1 L cultures of LB Kan with an 
overnight culture of alphacat in pT71myc in Rosetta™(DE3).  When the OD600 was predicted to reach 1.0, 
I added IPTG to 0.38 mM and shook the cultures overnight at 16°C, then pelleted the cells and resuspended 
in 0.8 mL per gram wet cell pellet lysis buffer (50 mM HEPES, pH 6.0, 300 mM NaCl, 10 mM imidazole, 
5 mM MgCl2, 1 mM CaCl2, 0.5 mM DTT), and stored overnight at -80°C.  I thawed the frozen lysates by 
shaking the tubes gently in room-temperature water.  I added lysis buffer to 10 mL per gram wet cell pellet.  
I lysed the cells by microfluidizing them twice at > 10,000 pounds per square inch (psi).  The supernatant 
was separated from the pellet by centrifuging at 23,500 x g for thirty minutes.  I extracted the pellets with 2 
mL per gram original cell pellet extraction buffer (50 mM HEPES, pH 6.4, 300 mM NaCl, 10 mM 
imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.5 mM DTT, 6.7 M guanidine chloride) and probe-sonicated and 
vortexed until the pellet mostly went into solution.  I removed the insoluble fraction by centrifuging at 
110,000 x g for one hour at 4°C.  I then refolded the extracted alphacat by diluting twenty-fold into loading 
buffer (50 mM HEPES, pH 6.4, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2), and 
removed the insoluble fraction by centrifuging at 23,500 x g for thirty minutes.  I added Ni-NTA agarose 
1:3040 (v/v) and incubated overnight, rocking at 4°C.  I washed the resin with loading buffer, followed by 
wash buffer (same as loading buffer, but imidazole increased to 20 mM).  I eluted in three steps, with 
elution buffer 1 (same as wash buffer, but imidazole increased to 100 mM), elution buffer 2 (200 mM 
imidazole), and elution buffer 3 (250 mM imidazole).  Because the second elution appeared the most pure, 
I selected that fraction for analytical gel filtration chromatography.  I removed the insoluble fraction by 
centrifuging at 43,000 x g for ninety minutes at 4°C, and loaded 200 µL of the eluate’s supernatant onto the 
same Sephadex® G-150 column shown in Figure 20, freshly blocked with 670 µL of 10 mg per mL 
cytochrome c, and I collected fractions every 2.5 minutes, eluting by gravity in gel filtration buffer (55 mM 
HEPES, 5.5 mM MgCl2, 1.1 mM CaCl2, 250 mM imidazole, pH 6.4).  (A) SDS-PAGE of 12% acrylamide 
gels followed by Coomassie staining.  (B) SDS-PAGE of 12% acrylamide gels followed by 
immunoblotting against DGK-alpha-C-term (Abgent AP8128b (1:300 (v/v))).  (C) Elution profile of 
molecular weight standards and alphacat from the same column shown in Figure 20.  In order to quantify 
the alphacat in the gel filtration fractions, I performed densitometry three times on the film shown in (B).  
Mean ± SD. 
 In an effort to get more concentrated alphacat so that I could measure its 
concentration with confidence in order to measure its specific activity with confidence, I 
repurified the flowthrough shown in Figure 21, this time eluting with each elution buffer 
until the Bio-Rad Protein Assay reading at 595 nm dropped below 0.010 (Figure 23A).  
Two factors seemed to contribute to the concentration of alphacat in pT71myc eluted 
from Ni-NTA.  The first is that alphacat in pT71myc appeared to be more concentrated 
after longer elution times, as expected, although this effect appeared to be more dramatic 
in elution buffer containing 250 mM imidazole than in 70 mM imidazole (Figure 23B).  
The second factor is that of buffer composition: freshly made elution buffer dramatically 
increased the concentration of alphacat eluted from the resin, in some cases.  Although 
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the reducing agent I used, tris(chloroethyl)phosphate (TCEP), has been reported to 
remain more than 80% reduced after three weeks at room temperature in a variety of 
buffers99, I took the precaution of adding fresh TCEP to elutions following elution 4 Z, in 
case that was the key buffer component.  Another issue could be the pH: 6.4 is outside 
the range of HEPES’s buffering capacity as well, so a freshly made buffer might have a 
different pH than the previous buffer.   
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Figure 22.  Alphacat in pT71myc’s elution from Ni-NTA agarose depends on the time of the elution 
and on the batch of elution buffer.  I removed the insoluble fraction from the flowthrough shown in 
Figure 21, which had been stored for thirteen days at 4°C, by centrifuging at 21,000 x g for thirty minutes 
at 4°C.  I added Ni-NTA agarose 1:2700 and rocked for ~36 hours at 4°C.  I washed with wash buffer (50 
mM HEPES, pH 6.4, 20 mM imidazole, 300 mM NaCl, 1 mM CaCl2, 5 mM MgCl2, 0.1 mM TCEP), and 
eluted with elution buffer 1 (same as wash buffer, but with imidazole increased to 50 mM), elution buffer 2 
(70 mM imidazole), elution buffer 3 (100 mM imidazole), elution buffer 4 (250 mM imidazole), and 
elution buffer 5 (500 mM imidazole), continuing to elute until the A595 as measured by the Bio-Rad 
Protein Assay was less than 0.010.  Starting with elution 4 Z, I also added TCEP fresh to the previously 
made buffers.  (A) SDS-PAGE of 12% acrylamide gels followed by Coomassie staining.  I ethanol-
precipitated the flowthrough 1, flowthrough 1 supernatant, and flowthrough 2 to remove the guanidine 
prior to loading onto the gel.  I loaded 25 µL into each lane.  (B) Blanked A595 of the Bio-Rad Protein 
Assay of eluates, plotted as a function of time and color-coded by elution buffer.  Vertical lines mark those 
eluate fractions that coincided with a change in buffer or temperature.   
I loaded the thus purified alphacat onto the Sephadex® G-150 analytical gel 
filtration column, but even after concentrating the gel filtration fractions by TCA 
precipitation, the protein concentration remained undetectable by the Bio-Rad Protein 
Assay, a method that, unlike immunoblotting, should be able to quantitatively compare 
the concentration of different populations of alphacat.  An alternative method for 
concentrating protein is to dialyze against a buffer with a high concentration of a solute 
that is too large to pass through the pores: by osmosis, water will leave the dialysis 
tubing, which concentrates the protein inside the dialysis tubing.  I therefore concentrated 
the purified alphacat by dialyzing against 15% polyethylene glycol (PEG) 17.5kD in the 
hopes that would improve the detection of the subsequent analytical gel filtration 
chromatography fractions, but dropped the tubing and thereby contaminated the purified 
protein with PEG.  PEG-SDS interactions have been reported100, and I confirmed that 
PEG disrupts the electrophoresis of alphacat (Figure 23).  I was therefore unable to 
interpret the Coomassie staining or immunoblots of analytical gel filtration fractions from 
the contaminated protein. 
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Figure 23.  PEG contamination disrupts the electrophoresis of alphacat.  I pooled the fourth elution 
(250 mM imidazole) from Figure 22 (“pooled”), which had been stored at 4°C for two weeks, and removed 
the insoluble fraction by centrifuging at 118,000 x g for one hour at 4°C.  I dialyzed the supernatant 
(“pooled supernatant”) against dialysis buffer (55 mM HEPES, 5 mM MgCl2, 1 mM CaCl2, 250 mM 
imidazole, 15% (w/v) 17.5kD PEG) using 3500 molecular weight cut-off (MWCO) dialysis tubing 
(Thermo Scientific 68035) at 4°C for ten total hours.  While I was putting the protein sample into the 
dialysis tubing, I dropped the tubing and thereby contaminated the protein with PEG.  I removed the 
insoluble fraction from the dialyzed sample by centrifuging at 54,900 x g for ninety minutes at 4°C.  I 
loaded 200 µL of the supernatant onto a Sephadex® G-150 column, freshly blocked with 1.19 mL of 10 mg 
per mL BSA, and I collected fractions every 2.5 minutes, eluting by gravity in gel filtration buffer (55 mM 
HEPES, 5.5 mM MgCl2, 1.1 mM CaCl2, 250 mM imidazole, pH 6.4).  I loaded 48 µL of each gel filtration 
fraction, and tested whether PEG disrupts PAGE by adding PEG to 7.5% to the pooled supernatant sample.  
SDS-PAGE of a 12% acrylamide SDS-PAG followed by Coomassie staining.  The sample with the added 
PEG shows distinctly more streaking in the stacking region of the gel than the sample without, showing 
that PEG is disrupting electrophoresis and staining. 
I went back and purified leftover cell pellets from the expression shown in Figure 
19, with the hopes of purifying enough alphacat to be able to concentrate with PEG 
before loading onto the column (this time without contaminating it), but the yield (as 
measured by the Bio-Rad Protein Assay) was only 0.177 mg, which was not enough for 
200 µL of a 1-2 mg per mL solution, which would be necessary to be able to reliably 
detect the eluting protein. 
 78 
With a fresh, one-liter expression, I once again extracted alphacat from protein 
pellets in buffer adjusted to pH 6.4 using HEPES as a buffer (the pH was later measured 
to be 6.0, consistent with being outside HEPES’s buffering range), and purified on Ni-
NTA (Figure 24).  By re-extracting the insoluble pellets and purifying those as well, and 
combining the washes and the eluates, and by dialyzing against 15% PEG 17.5kD, I was 
eventually able to concentrate alphacat to a concentration of 1.2 mg per mL in a volume 
of 40 uL.  After removing the insoluble, I loaded it onto a Sephadex® G-200 analytical 
gel filtration column (in the hopes of being able to distinguish a 199.2 kD dimer from the 
void volume), but alphacat eluted in the void volume (Figure 25).  I therefore concluded 




Figure 24.  Alphacat in pT71myc, expressed in a one-liter culture of Rosetta™(DE3), extracted from 
the pellet, and purified on Ni-NTA.   I inoculated two 500 mL cultures of LB Kan with an overnight 
culture of alphacat in pT71myc in Rosetta™(DE3).  When the OD600 was predicted to reach 1.0, I added 
IPTG to 0.5 mM and shook the cultures for 17 hours at 16°C, then pelleted the cells and resuspended in 4 
mL per gram wet cell pellet lysis buffer (50 mM HEPES, pH 6.4, 300 mM NaCl, 10 mM imidazole, 5 mM 
MgCl2, 1 mM CaCl2, 0.5% (v/v) NP-40, 0.5 mM DTT, 1x PIC), and froze at -80°C.  I thawed the 
resuspended cells, shaking gently in room-temperature water, and added egg white lysozyme to 1 mg per 
mL.  I incubated on ice for thirty minutes, then probe-sonicated eleven times for ten seconds each, resting 
on ice between each pulse.  I separated the supernatant from the pellet by centrifuging at 118,000 x g for 65 
minutes at 4°C.  I extracted the pellets with extraction buffer (50 mM HEPES, pH 6.4, 300 mM NaCl, 10 
mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 6.8 M guanidine chloride) and probe-sonicated until mostly 
clear.  I removed the insoluble fraction by centrifuging at 118,000 x g for 65 minutes at 4°C.  I then 
refolded the extracted alphacat by diluting fifty-fold into loading buffer (50 mM HEPES, pH 6.4, 300 mM 
NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.5 mM DTT), and removed the insoluble fraction by 
centrifuging at 20,000 x g for thirty minutes at 4°C.  I added Ni-NTA agarose 1:4000 (v/v) and incubated 
for three days, rocking at 4°C.  I washed the resin with wash buffer (50 mM HEPES, pH 6.4, 300 mM 
NaCl, 70 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.1 mM TCEP), and eluted with elution buffer (same 
as wash buffer, but imidazole increased to 250 mM).  The yield was low, so I re-extracted the same pellets, 
which had been stored for nine days at -80°C, with extraction buffer, pipetting until all of the pellets had 
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been resuspended, and probe-sonicating eleven times for 15 seconds each, resting on ice between each 
pulse.   I refolded the extracted alphacat by diluting fifty-fold into loading buffer, and removed the 
insoluble fraction by centrifuging at 20,000 x g for thirty minutes at 4°C.  I added Ni-NTA agarose 1:4000 
(v/v) and incubated for four days, rocking at 4°C.  I washed the resin with wash buffer, and eluted with 
elution buffer.  (A) SDS-PAGE of 12% acrylamide gels followed by: left, Coomassie staining; right, 
immunoblotting against DGK alpha C-terminus (Abgent AP8128b (1:300 (v/v))).  (B) SDS-PAGE of a 
12% acrylamide gel followed by Coomassie staining.  After centrifuging the Ni-NTA agarose following 
purification, I removed the top layer (predicting that it would contain more Ni-NTA agarose and less 
precipitated protein), and then vortexed it to mix.  This figure has been modified from Petro and Raben1 
and is used under CC BY-NC 2.5. 
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Figure 25.  Purified alphacat in pT71myc elutes from a Sephadex® G-200 column in the void volume.  
I pooled all the eluates from both extractions shown in Figure 24, and removed the insoluble fraction by 
centrifuging at 29,400 x g for 2.5 hours at 4°C.  The yield was still lower than I would have liked to load 
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onto the gel filtration column, so I also added all of the washes, and removed the insoluble fraction by 
centrifuging at 54,900 x g for ninety minutes at 4°C.  I dialyzed the supernatant against dialysis buffer (55 
mM HEPES, 5 mM MgCl2, 1 mM CaCl2, 250 mM imidazole, 15% (w/v) 17.5kD PEG, pH 6.4) using 3500 
MWCO dialysis tubing at 4°C for ~twenty total hours, followed by using a 10,000 MWCO dialysis cassette 
(Thermo Scientific 66383) at 4°C for ~eight hours, until the protein concentration was ~1.2 mg/mL.  I 
removed the insoluble fraction by centrifuging at 43,000 x g for ninety minutes at 4°C, and loaded 200 µL 
of the supernatant onto a Sephadex® G-200 column that had been freshly blocked with 0.9 mL of 10 
mg/mL albumin, and had been previously calibrated with blue dextran, alcohol dehydrogenase, carbonic 
anhydrase, β-amylase, and albumin, and I collected fractions every 110 seconds, eluting by gravity in gel 
filtration buffer (55 mM HEPES, 5.5 mM MgCl2, 1.1 mM CaCl2, 250 mM imidazole, pH 6.4).  (A) Elution 
volumes of molecular weight standards and of purified alphacat from a Sephadex® G-200 column. Left 
vertical axis, A280 of the protein molecular weight standards, and A620 of the blue dextran fractions.  
Right vertical axis, protein concentration of eluted alphacat, as measured by the Bio-Rad Protein Assay.  
(B) Calibration of the Sephadex® G-200 column: elution volume (presented as a ratio of the void volume) 
of the molecular weight standards as a function of logarithm molecular weight.  I calculated the linear 
regression using Microsoft® Excel®.  This figure has been modified from Petro and Raben1 and is used 
under CC BY-NC 2.5. 
Discussion 
An alternative explanation is that the alphacat oligomerizes into a complex large 
enough to elute in the void volume of the Sephadex® G-200 resin.  As previously 
mentioned, other LCB5 proteins have been shown to oligomerize.  The smallest of the 
constructs studied in this report is alphacat in pT71myc, with a molecular weight of 49.8 
kD.  In order for oligomerized alphacat in pT71myc to be larger than β-amylase (200 
kD), in front of which we observe it to elute from the Sephadex® G-200 resin, its 
oligomerization state would have to be at least that of a pentamer (249 kD).  Because the 
most plausible oligomerization states of alphacat would be either a dimer or else a dimer 
of dimers, I find the microscopic aggregate hypothesis more convincing. 
It was not entirely clear which conditions led to the appearance of a second peak 
in the analytical gel filtration fractions detectable by immunoblot.  6.4 is below the 
buffering range of both Tris and HEPES, so it could very well be a pH reproducibility 
issue.  Alternatively, the second peak could have a much higher affinity for the antibody 
than the peak eluting in the void volume: if the population in the second peak were much 
smaller than that in the void volume peak, then that would explain why a second peak 
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would be detectable by immunoblot (Figure 18 - Figure 21), but not by the Bio-Rad 
Protein Assay (Figure 25). 
Conclusions 
In conclusion, I was able to express alphacat in pT71myc, but it was mostly 
insoluble.  I was able to extract it from the pellet and purify it by Ni-NTA 
chromatography, or purify the small amount that was soluble, but in either case it eluted 
in the void volume on an analytical gel filtration column.  Adding imidazole to 250 mM 
and dropping the pH to 6.4 led to the appearance of a second peak that eluted from the 
analytical gel filtration column at an elution volume consistent with a molecular weight 
of ~120-130 kD, which is between the size predicted for a dimer and a trimer.  This 
second peak, while detectable by immunoblotting, was undetectable by the Bio-Rad 
Protein Assay, suggesting that this population was small compared to that eluting in the 
void volume.  I therefore concluded that the vast majority of the expressed alphacat in 
pT71myc was forming large aggregates unsuitable for pursuit for x-ray crystallography.  
Furthermore, the yield of soluble alphacat extracted from inclusion bodies even to load 
onto the analytical gel filtration column was very low, even though alphacat was 
expressed in large amounts.  I therefore considered strategies to improve the solubility of 
alphacat. 
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Cloning, Expression, Purification, and Analytical Gel Filtration of Alphacat in 
pT71myc Coexpressed with Bacterial Chaperones 
Introduction 
Coexpression with bacterial chaperones is a commonly used strategy to improve 
the yield and solubility of recombinantly expressed proteins in E. coli101–103.  In an 
attempt to improve the solubility of alphacat, I therefore coexpressed it with each of five 
sets of bacterial chaperones: GroEL/ES, Trigger Factor (TF), GroEL/ES/TF, 
DnaK/DnaJ/GrpE, and DnaK/DnaJ/GrpE/ClpB.   
Results 
The chaperone-containing plasmids were provided by Professor Philip Cole’s 
laboratory (Pharmacology and Molecular Sciences, The Johns Hopkins University School 
of Medicine).  In order to verify the identity, insertion of the chaperones into the provided 
plasmids, and sequence of the shorter chaperones (GroES and GrpE), I designed DNA 
sequencing primers.  The plasmids were unknown, so I designed sequencing primers 
from within the purported genes.  I looked up the genes in E. coli on the National Center 
for Biotechnology Information (NCBI)’s web site104, went to “Genomic regions, 
transcripts, and products”, and looked up the sequence (in FASTA format) of the 
Reference Sequence (RefSeq).  I then designed sequencing primers with an appropriate 
length, guanine-cytosine (GC) content, melting temperature (Tm), low predicted tendency 
to hairpin or self-dimerize, and good site-specificity with the sequence of that chaperone 
and the other chaperone genes in the same plasmid.  For GroEL, the sequencing primers 
were CCAACGAGGACCAGAACCA and GACTTCCTTGACCATCTGCG; for GroES, 
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they were GCCGCTGGATGTGAAAGT and CGATGGCTACGGTGTGAAA; for TF, 
they were TTATCCGCACCAACGAGC and TGCTGCTGGGCGAAGTTA; for DnaJ, 
they were AGGGTGATTTGCTGTGCC and ATGCCACCTTGCTCAAACG; for DnaK, 
they were AAGAAGCAGGCGACAAACT and TTTGCGGGTTCGTCACTG; for ClpB, 
they were TGAACAGCACATTGCCTCG and AATAAAGGACTAACCGAACCCC; 
and for GrpE, they were CGATGCTGGATGTTGTGCG and 
TTCACGGGTCTGGGCTTCA.  Of these sequencing primers, all except the GroEL 
forward primer successfully sequenced their chaperone gene targets. 
  From the generated sequences, I performed a protein-protein Basic Local 
Alignment Search Tool (BLAST) search105 to identify GroEL to be from either 
Plesiomonas shigelloides (GenBank: BAE95977.1) or E. coli (NCBI Reference 
Sequence: YP_006093740.1) with at least two nonsynonymous point mutations.  (This 
turned out to be a different GroEL sequence from the one that I had used to design the 
sequencing primers, which may explain why the forward primer did not successfully 
sequence.)  I likewise identified GroES, TF, DnaK, GrpE, and ClpB to be from E. coli 
(NCBI Reference Sequences NP_290775.1, NP_286178.1, NP_285706.1, NP_417104.1, 
and NP_289147.1, respectively), and DnaJ to be from either E. coli (NCBI Reference 
Sequence: NP_414556.1) or from Shigella flexneri (NCBI Reference Sequence: 
NP_835756.1).  TF had an extra codon in the GroEL/ES plasmid.  The molecular weights 
of the bacterial chaperones are as follows: GroEL = 57.4 kD; GroES, = 10.4 kD; TF = 
48.1 kD (or 48.3 kD when in the GroEL/ES plasmid); DnaK = 69.1 kD; DnaJ = 41.1 kD; 
GrpE = 21.8 kD; ClpB = 95.9 kD.  Each chaperone plasmid included a chloramphenicol 
resistance gene, a T7 promoter, and the lac operator (LacO).  In a single set, all the 
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chaperones are encoded in the plasmid in series (but each with their own stop codon) 
behind a single promoter, with the exception of GroEL/ES/TF, in which case TF follows 
a second copy of T7/LacO. 
The Rosetta™(DE3) strain of E. coli, which had been used to express the alphacat 
in pT71myc above, contains pRARE, a plasmid encoding the tRNAs for codons that are 
commonly used by eukaryotes but rarely used by E. coli.  pRARE, however, contains the 
same antibiotic resistance gene as the plasmid encoding the chaperones; therefore, to be 
able to select for expression of the chaperones, I switched to the BL21(DE3) strain of E. 
coli.  I transformed the alphacat in pT71myc plasmid into BL21(DE3) cells that had been 
previously transformed with each of the sets of chaperones.  Alphacat coexpressed with 
GroEL, GroES, TF, and DnaK robustly expressed when induced with IPTG, as detected 
by Coomassie staining after SDS-PAGE (Figure 26).  DnaJ, GrpE, and ClpB expression 
were not detectable by Coomassie staining.  To identify which chaperone constructs 
enhanced solubility of alphacat, they were coexpressed either at 37°C for three hours, or 
at 16°C overnight. Coexpression of either GroEL/ES or GroEL/ES/TF at 16°C overnight, 
and to a lesser extent, coexpression of GroEL/ES/TF at 37°C for three hours, resulted in 




Figure 26.  Apparent solubility of alphacat in pT71myc increases when coexpressed with bacterial 
chaperones.  I inoculated 4 mL LB Kan cultures with overnight cultures of alphacat in pT71myc in 
Rosetta™(DE3), and 4 mL LB Kan Cam cultures with overnight cultures of alphacat in pT71myc 
cotransformed with each of the sets of chaperones in BL21(DE3).  When the OD600 was predicted to reach 
0.3, I added IPTG to 0.1 mM and shook the cultures for either three hours at 37°C (top) or 21 hours at 16°C 
(bottom), then pelleted the cells and resuspended in either 42.7 (for 37°C expression) or 32.3 (for 16°C 
expression) mL per gram wet cell pellet lysis buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM 
imidazole, 1 mM CaCl2, 0.25% (v/v) TX-100, 0.5 mM DTT, 1x PIC), and froze at -80°C.  I thawed the 
cells by gently shaking the tube in room temperature water, added egg white lysozyme to 1 mg per mL, and 
incubated on ice for thirty minutes.  I lysed the cells by probe-sonicating ten times for ten seconds each, 
resting on ice for fifteen seconds between each pulse.  I removed the insoluble fraction by centrifuging at 
45,900 x g for ninety minutes at 4°C.  SDS-PAGE of 12% acrylamide gels followed by: left, Coomassie 
staining; right, immunoblot against DGK alpha C-terminus; top, induced at 37°C for three hours; bottom, 
induced at 16°C overnight.  U, uninduced; L, lysate; S, supernatant (after removing insoluble from lysate).  
I loaded 5 µg total protein per lane in the Coomassie-stained gels, and 0.2 µg per lane in the immunoblots.  
The molecular weights of the bacterial chaperones are as follows: GroEL = 57.4 kD; GroES, = 10.4 kD; TF 
= 48.1 kD (or 48.3 kD when in the GroEL/ES plasmid); DnaK = 69.1 kD; DnaJ = 41.1 kD; GrpE = 21.8 
kD; ClpB = 95.9 kD.  This figure has been modified from Petro and Raben1 and is used under CC BY-NC 
2.5. 
As can be seen in Figure 26, in addition to the alphacat band, the anti-DGK-alpha 
antibody recognizes higher-molecular weight bands in the GroEL-containing lanes of the 
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immunoblots.  Because the anti-DGK-alpha antibody recognizes GroEL (Figure 27), I 
concluded that the 60 kD bands in the immunoblot in Figure 26 are GroEL. 
 
Figure 27.  The anti-DGK-alpha C-terminus antibody also recognizes GroEL.  SDS-PAGE of an 8% 
acrylamide gel followed by immunoblotting against DGK alpha C-terminus (Abgent AP8128b (1:300 
(v/v))).  I loaded 0.2 µg of the lysate, and an equivalent volume of the supernatant.  This figure has been 
modified from Petro and Raben1 and is used under CC BY-NC 2.5. 
I partially purified alphacat coexpressed with GroEL/ES at 16°C overnight by Ni-
NTA chromatography.  As above, I purified it at pH 6.4, but this time I used sodium 
citrate to buffer; 6.4 is well within sodium citrate’s buffering range, so the pH of these 
experiments was actually 6.4.  GroEL (the upper band) coeluted with alphacat (the lower 
band) from the Ni-NTA resin (Figure 28).  As above, the ~60 kD band is GroEL, and the 
~50 kD band is alphacat. 
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Figure 28.  GroEL copurifies with alphacat in pT71myc on Ni-NTA.  I inoculated two 500 mL LB Kan 
Cam cultures with a freshly growing culture of alphacat in pT71myc + GroEL/ES in BL21(DE3).  When 
the OD600 was predicted to reach 0.3, I added IPTG to 0.1 mM and shook the cultures for 14.5 hours at 
16°C, then pelleted the cells and resuspended in 4 mL per gram wet cell pellet lysis buffer (50 mM Tris, pH 
8.0, 300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 0.25% (v/v) TX-100, 0.5 mM DTT, 1x PIC), and froze 
at -80°C.  I thawed the cells by gently shaking the tube in room temperature water, added egg white 
lysozyme to 1 mg per mL, and incubated on ice for thirty minutes, vortexing occasionally to mix.  I lysed 
the cells by probe-sonicating in ten second bursts until no longer viscous.  I removed the insoluble fraction 
by centrifuging at 118,000 x g for 65 minutes at 4°C.  I added Ni-NTA agarose 1:170 (v/v) to the 
supernatant and incubated for two hours, rotating at 4°C.  I washed the resin with wash buffer 1 (50 mM 
Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 0.5 mM DTT), wash buffer 2 (same as wash 
buffer 1, but replacing the Tris with 55 mM sodium citrate and buffered to pH 6.4), and wash buffer 3 
(same as wash buffer 2, but imidazole increased to 70 mM), and eluted with elution buffer 1 (250 mM 
imidazole) and elution buffer 2 (500 mM imidazole).  SDS-PAGE of a 10% acrylamide gel followed by 
Coomassie staining.  I loaded 5 µg of the lysate, equivalent volumes of the supernatant and flowthrough, 5 
µg of wash 1 (pH 8.0) and the first wash 3 (70 mM imidazole), and 24 µL of the other washes and eluates.  
This figure has been modified from Petro and Raben1 and is used under CC BY-NC 2.5. 
When I subjected the Ni-NTA eluate to Sephadex® G-200 size-exclusion 
chromatography, also buffered to pH 6.4 with sodium citrate, and in the presence of 250 
mM imidazole, alphacat and GroEL coeluted in the void volume (Figure 29).  Once 
again, the ~60 kD band is GroEL, and the ~50 kD band is alphacat. 
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Figure 29.  Purified alphacat in pT71myc coexpressed with GroEL/ES elutes from an analytical gel 
filtration column in the void volume.  I pooled the 250 mM imidazole eluates shown in Figure 28 and 
removed the insoluble fraction by centrifuging at 43,000 x g for ninety minutes at 4°C.  I loaded 200 µL of 
the resulting supernatant onto a Sephadex® G-200 column that had been freshly blocked with 1.07 mL of 
10 mg/mL fresh albumin, and had been previously calibrated with blue dextran and albumin, and I 
collected fractions every 158 seconds, eluting by gravity in gel filtration buffer (55 mM sodium citrate, 5 
mM MgCl2, 1 mM CaCl2, 250 mM imidazole, pH 6.4).  (A) SDS-PAGE of a 10% acrylamide gel followed 
by immunoblotting against DGK alpha C-terminus (Abgent AP8128b (1:300 (v/v))).  I loaded 24 µL per 
lane of the analytical gel filtration fractions.  (B) Elution volumes of molecular weight standards and of 
purified alphacat from a Sephadex® G-200 column.  Left vertical axis, A620 of blue dextran elution and 
A280 of protein standard elutions.  Right vertical axis, quantification of the immunoblot signal from the 
blot shown in (A), mean ± SD.  Densitometry of the ~50 kD band was measured three times from the same 
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film using ImageJ.  This figure has been modified from Petro and Raben1 and is used under CC BY-NC 
2.5. 
When the partially purified alphacat was subjected to native PAGE as an alternate 
method to measure monodispersity, it presented a smear (Figure 30), possibly suggesting 
a population of heterogeneous aggregates, even when coexpressed with chaperones.  
Adding different detergents to the partially purified protein did not cause it to migrate as 
a single well-resolved band, but did appear to improve recognition by the antibody.  
Seeing as the anti-DGK alpha antibody recognizes both alphacat and GroEL, it is unclear 
of which protein the detergent improved antibody recognition. 
 
Figure 30.  Partially purified alphacat coexpressed with GroEL/ES migrates on native PAGE as a 
heterogeneous population.  I pooled the 250 mM imidazole eluates shown in Figure 28, which had been 
stored for 79 days at 4°C.  Native PAGE of a 3-12% acrylamide gradient native gel (Invitrogen™) at 4°C 
followed by immunoblotting against DGK-alpha (Abgent AP8128b (1:300 (v/v))).  DDM: dodecyl-β-D-
maltoside. 
If the GroEL/ES complex had never released alphacat, it would be predicted to 
form a complex made of fourteen GroEL monomers and seven GroES monomers, plus 
the alphacat.  This complex would be at least 920 kD in size, which is indeed larger than 
the ~200-kD void volume of the Sephadex® G-200 resin.  1 mM ATP has been reported 
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to be sufficient to cause GroEL to release its substrates106.  To test whether 1 mM ATP 
would cause GroEL to release alphacat, I lysed and purified alphacat from the co-
expressing lysates in the presence of 1 mM ATP.  1 mM ATP has no effect on the Ni-
NTA purification of alphacat and GroEL/ES, and GroEL continued to coelute with 
alphacat from the Ni-NTA resin (Figure 31). 
 
Figure 31.  1 mM ATP has no effect on the purification of alphacat in pT71myc coexpressed with 
GroEL/ES.  I inoculated a 500 mL LB Kan Cam culture with a freshly growing culture of alphacat in 
pT71myc + GroEL/ES in BL21(DE3).  When the OD600 was predicted to reach 0.3, I added IPTG to 0.3 
mM and shook the cultures for 17 hours at 16°C, then pelleted the cells and resuspended in 4 mL per gram 
wet cell pellet lysis buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 0.25% 
(v/v) TX-100, 0.5 mM DTT, 1x PIC, with or without 1 mM ATP), and froze at -80°C for 19 days.  I thawed 
the cells by gently shaking the tube in room temperature water, added egg white lysozyme to 1 mg per mL, 
and incubated on ice for thirty minutes, vortexing occasionally to mix.  I lysed the cells by probe-sonicating 
ten times for ten seconds each, resting on ice for fifteen seconds between each pulse.  I removed the 
insoluble fraction by centrifuging at 118,000 x g for 65 minutes at 4°C.  I added Ni-NTA agarose 1:13 (v/v) 
to the supernatant without ATP and 1:15 to the supernatant with ATP, and incubated for two hours, rotating 
at 4°C.  I washed the resin with wash buffer 1 (50 mM sodium citrate, pH 6.4, 300 mM NaCl, 10 mM 
imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.5 mM DTT, with or without 1 mM DTT), wash buffer 2 (same as 
wash buffer 1, but imidazole increased to 50 mM), wash buffer 3 (70 mM imidazole), and wash buffer 4 
(100 mM imidazole), and eluted with elution buffer 1 (250 mM imidazole) and elution buffer 2 (500 mM 
imidazole).  SDS-PAGE of a 10% acrylamide gel followed by Coomassie staining.  The lanes marked “+” 
were purified in the presence of 1 mM ATP.  This figure has been modified from Petro and Raben1 and is 
used under CC BY-NC 2.5. 
 I loaded partially purified alphacat onto the Sephadex® G-200 analytical gel 
filtration column, but when I immunoblotted the analytical gel filtration fractions to 
determine the elution volume of alphacat, the anti-histidine antibody recognized a ~50 
immunoreactive band in the GroEL/ES lysate in addition to the alphacat and analytical 
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gel filtration columns (Figure 32), suggesting that while casting the gel, the interface 
between the stacking and separating phases and dried out and the wells’ contents had 
leaked into adjacent wells.  As such, the immunoblot is inconclusive (because what may 
appear to be a preponderance of alphacat in the void volume may just be contamination 
from the eluate’s supernatant lane). 
 
Figure 32.  The presence of the 50 kD immunoreactive band in the GroEL/ES lane suggests interwell 
contamination of the immunoblot of Sephadex® G-200 analytical gel filtration chromatography of 
partially purified alphacat in pT71myc + GroEL/ES in the presence of 1 mM ATP.  I pooled the 250 
mM imidazole eluate in the presence of 1 mM ATP, shown in Figure 31, and removed the insoluble 
fraction by centrifuging at 61,400 x g for one hour at 4°C.  I loaded 200 µL of the resulting supernatant 
onto a Sephadex® G-200 column that had been freshly blocked with 0.91 mL of 10 mg/mL fresh albumin, 
and had been previously calibrated with blue dextran, albumin, and β-amylase, and I collected fractions 
every 260 seconds, eluting by gravity in gel filtration buffer (50 mM Tris, 300 mM NaCl, 5 mM MgCl2, 1 
mM CaCl2, 250 mM imidazole, pH 8.0).  SDS-PAGE of a 10% acrylamide gel, followed by 
immunoblotting against DGK-alpha (Abgent AP8128b (1:300 (v/v))) (red) and histidine (BD Biosciences 
631212 (1:5000 (v/v))) (green).  Yellow indicates red/green overlay. The ~60 kD band is GroEL; the ~50 
kD band is alphacat.  The boxes and numbers were produced by the Odyssey® v3.0 software. 
Discussion and Conclusions 
To summarize, coexpressing alphacat in pT71myc with bacterial chaperones 
increased its yield in the soluble fraction (Figure 26), which is promising for large-scale 
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expressions for crystallography.  Unfortunately, alphacat in this soluble fraction still 
eluted in the void volume during analytical gel filtration chromatography (Figure 29).  
One reason that alphacat coexpressed with GroEL/ES eluted in the void volume could be 
explained by its being complexed to the GroEL, based on our evidence that the two 
proteins copurify on Ni-NTA (Figure 28 and Figure 31), and they coelute from the 
analytical gel filtration column (Figure 29).  If the alphacat is in fact complexed with 
GroEL/ES, the predicted molecular weight of the complex would be greater than 900 kD, 
and thus would indeed be predicted to elute in the void on the Sephadex® G-200 column.  
Lysis and purification in the presence of 1 mM ATP was apparently insufficient to cause 
the GroEL to release alphacat (Figure 31).  Another possibility is that while coexpressing 
alphacat with bacterial chaperones was sufficient to increase its yield in the supernatant, 
alphacat still remained in microscopic aggregates.  As such, I decided to pursue other 
constructs for expressing soluble alphacat for the purpose of x-ray crystallography. 
Cloning and Expression of Full-Length DGK-Alpha in pT71myc 
Introduction 
In order to know whether bacterially expressed alphacat was properly folded, I 
needed to demonstrate that it had calcium-independent enzymatic activity49.  As a 
positive control, I needed a source of full-length DGK-alpha that demonstrated calcium-
dependent enzymatic activity.  I therefore set out to express full-length DGK-alpha.  
Because the pT71myc construct robustly expressed alphacat, I tested whether I could use 
the pT71myc plasmid to express full-length S. scrofa DGK-alpha in E. coli.  
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Results 
In order to clone full-length S. scrofa DGK-alpha into pT71myc, I designed 
primers to add restriction digest sites, via the polymerase chain reaction (PCR), on either 
side of DGK-alpha.  PCR is a method used to amplify a short section of DNA107: by 
adding desired features via the primers, the amplified DNA will include those features.  I 
designed the forward primer, GTAAGTCGACATCCAAGGAGAGGGGG, to add a SalI 
restriction site just N-terminal to DGK-alpha.  SalI is an enzyme from Streptomyces albus 
that cuts DNA at a particular sequence (GTCGAC)108: if that site has been added, the 
enzyme will cut the DNA at that sequence on both strands (because the site is 
palindromic), leaving a sticky end, which can be ligated to another sticky end left at 
another digested SalI site.  By digesting and ligating, therefore, pieces of DNA can be cut 
and pasted together at particular places.  Following the SalI site, the primer included a 
single nucleotide to make sure that DGK-alpha would be in the appropriate reading frame 
in pT71myc.  I included a four-nucleotide overhang in front of the restriction site to 
improve the efficiency of the digestion of the PCR product109, and I chose the nucleotide 
content of the overhang both to provide a GC anchor to the end of the PCR product, as 
well as to keep the overall GC content of the primer below 60%.  I designed the reverse 
primer, GCAGCGGCCGCTCAGCACAAGAAGCCAAAGAAATTG, to add a NotI (a 
restriction enzyme from Nocardia otitidis-caviarum110) site immediately C-terminal to 
DGK-alpha’s stop codon, along with a three-nucleotide overhang including a GC anchor.  
The PCR product from using these primers, however, produced only a short insert, not 
the entire S. scrofa DGK-alpha gene. 
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 To improve PCR product quality, I therefore designed a new forward primer, 
GTAAGTCGACATCCAAGGAGAGGGGGCTGATAAG, which increased the length of 
the homologous region of the primer from fifteen to twenty-three nucleotides, increased 
the predicted melting temperature (Tm) of the primer from 61.9°C to 64.3°C (so that it 
was now within 5°C of the Tm of the reverse primer, 68.9°C), and decreased the GC 
content from 57.7% to 52.9%.  This primer, in conjunction with the same reverse primer, 
successfully generated the proper PCR product, and incorporation of the DGK-alpha 
insert in the PCR product was confirmed by DNA sequencing. 
 The pT71myc vector added the same N-terminal fusion tag to DGK-alpha as 
described above for the alphacat construct, consisting of a hexahistidine, a thrombin 
proteolytic site, a myc tag, and a TEV protease site (Figure 33).  The total mass of this 
protein construct (including the fusion tag) and the pI are predicted to be 87.5 kD and 
6.10 respectively. 
 
Figure 33.  Schematic of the full-length DGK-alpha in pT71myc construct.  Top, schematic of full-
length S. scrofa DGK alpha in pT71myc.  Bottom, a magnification of the epitope tag region of alpha in 
pT71myc.  pT71myc adds to the N-terminus of the protein a fusion tag consisting of a hexahistidine, a 
thrombin proteolytic site, a myc tag, and a TEV protease site.  The total mass of this protein construct 
(including the fusion tag) and pI are predicted to be 87.5 kD and 6.10, respectively.  The epitope-tagged 
region of the construct is magnified for clarity.  This figure has been modified from Petro and Raben1 and 
is used under CC BY-NC 2.5. 
When I transformed full-length DGK alpha in pT71myc into the BL21(DE3) 
strain of E. coli, it expressed readily following induction with IPTG, producing a band, 
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easily detectable by Coomassie staining following SDS-PAGE, that migrated between the 
70 kD and 100 kD molecular weight markers, consistent with the predicted size of 87.5 
kD, and was recognized by an anti-histidine antibody on immunoblots (Figure 34), 
consistent with its expressing the epitope tag, as expected.  This construct, however, as 
alphacat in pT71myc did, also produced insoluble protein: when the bacterial lysate was 
centrifuged, the protein remained in the pellet.   
 
Figure 34.  Full-length DGK alpha in pT71myc expressed a band of the correct size that was 
recognized by the anti-histidine antibody, and its apparent solubility increases when coexpressed 
with bacterial chaperones.  I inoculated two 4 mL LB Kan cultures with a freshly growing culture of full-
length DGK-alpha in pT71myc in BL21(DE3), and two 4 mL LB Kan Cam cultures each with freshly 
growing culture of full-length DGK-alpha in pT71myc transformed into BL21(DE3) previously 
transformed with each of the sets of chaperones.  When the OD600 was predicted to reach 0.4, I added 
IPTG to 0.5 mM and shook the cultures either for three hours at 37°C or 15.5 hours at 16°C, then pelleted 
the cells and stored at -80°C overnight.  I resuspended each cell pellet in 1 mL lysis buffer (50 mM Tris, pH 
8.0, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.25% (v/v) TX-100, 0.5 mM DTT, 1x 
PIC), and added egg white lysozyme to 1 mg per mL, and incubated on ice for thirty minutes, vortexing 
occasionally to mix.  I lysed the cells by probe-sonicating ten times for ten seconds each, resting on ice for 
fifteen seconds between each pulse.  I removed the insoluble fraction by centrifuging at 54,900 x g for 65 
minutes at 4°C.  SDS-PAGE of 8% acrylamide gels followed by: left, Coomassie staining; right, 
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immunoblotting against hexahistidine (BD Biosciences 631212 (1:5000 (v/v))); top, induced at 37°C for 
three hours; bottom, induced at 16°C overnight.  L, lysate; S, supernatant (following removal of the 
insoluble fraction from the lysate).  This figure has been modified from Petro and Raben1 and is used under 
CC BY-NC 2.5. 
In order to determine whether any of the sets of chaperones could improve this 
construct’s solubility, I coexpressed DGK-alpha in pT71myc and each of the sets of 
chaperones either at 37°C for three hours or at 16°C overnight.  At 16°C, coexpression of 
each of the sets of plasmids increased the amount DGK-alpha detected in the supernatant 
following centrifugation (Figure 34).  The set that increased the amount to the greatest 
extent was GroEL/ES/TF, but even in this case, most of the protein remained in the pellet 
(Figure 34). 
In order to determine the best induction conditions for full-length DGK-alpha 
coexpressed with GroEL/ES/TF, and in order to produce fresh enzyme with which to test 
its enzymatic activity, I grew a single culture of DGK-alpha in pT71myc coexpressed 
with GroEL/ES/TF, and removed aliquots at different OD600s and added IPTG to 
different concentrations, and induced at 16°C overnight.  The induction conditions that 
produced the most soluble DGK-alpha appeared to be inducing at OD600 of 0.5 and an 
IPTG concentration of 0.5 mM (Figure 35). 
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Figure 35.  Induction test of full-length DGK-alpha in pT71myc coexpressed with GroEL/ES/TF.  I 
inoculated a 78.5 mL LB Kan Cam cultures each with freshly growing culture of full-length DGK-alpha in 
pT71myc plus GroEL/ES/TF in BL21(DE3).  When the OD600 was predicted to reach the indicated values, 
I removed 4 mL aliquots, added IPTG to the indicated concentration, and shook the cultures overnight at 
16°C, then pelleted the cells and froze at -80°C.  I resuspended each cell pellet in 666 µL lysis buffer (50 
mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.25% (v/v) TX-100, 0.5 
mM DTT, 1x PIC), and added egg white lysozyme to 1 mg per mL, and incubated on ice for thirty minutes, 
vortexing occasionally to mix.  I lysed the cells by probe-sonicating ten times for ten seconds each, resting 
on ice for fifteen seconds between each pulse.  I removed the insoluble fraction by centrifuging at 71,700 x 
g for 90 minutes at 4°C.  SDS-PAGE followed by (A) Coomassie staining and (B) immunoblotting against 
histidine (BD Biosciences 631212 (1:5000 (v/v))).  The membranes had been previously probed with an 
older aliquot of primary antibody, then stripped using NewBlot™ PVDF Stripping Buffer.  I redeveloped 
the membranes to check that the signal from the primary decreased, then reblocked and proceeded with a 
fresh aliquot of primary antibody. 
 When I tried to assay the activity of these lysates, however, the liposomes I 
produced for the assay were bad, for reasons that I never clearly identified.  By the time 
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the liposome situation had resolved itself (possibly in part due to a retuned bath 
sonicator), I had used up the aliquots of DGK-alpha in pT71myc coexpressed with 
GroEL/ES/TF induced at OD600 of 0.5 and an IPTG concentration of 0.5 mM (the 
conditions that appeared to produce the most soluble DGK-alpha (Figure 35)) that had 
been stored in 50% glycerol at -80°C.  When I assayed the supernatant that had been 
induced at OD600 of 0.5 and an IPTG concentration of 1 mM, although the sample did 
show greater DGK activity than the uninduced supernatant, and although this activity was 
EGTA-dependent (as would be predicted for full-length DGK-alpha), the additional 
measured DGK activity was very low. 
 
Figure 36.  Full-length DGK-alpha in pT71myc has low but measurable and Ca2+-dependent DGK 
activity.  DGK activity assay of the supernatant of full-length DGK-alpha coexpressed with GroEL/ES/TF, 
induced at an OD600 of 0.5 with 1 mM IPTG, shown in Figure 35.  The uninduced sample was aliquoted 
and moved to the 16°C shaker at an OD600 of 0.4 (because I had used up the aliquots of the uninduced at 
an OD600 of 0.5 while troubleshooting the liposomes).  I stored the samples in 50% glycerol (v/v) at -80°C 
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for twenty days prior to assaying.  The reaction included 40 ng per µL protein (as measured by the Bio-Rad 
Protein Assay), 5 mM liposomes (53:22:17:8::POPE:POPC:POPS:DOG), 2.5 mM Tris, 102.5 mM NaCl, 
0.5 mM imidazole, 2.35 mM MgCl2, 0.225 mM CaCl2, 0.0125% (v/v) Triton X-100, 0.05x PIC, 1 mM 
DTT, 5% (v/v) glycerol, 43.75 mM 3-(N-morpholino)propanesulfonic acid (MOPS), pH 7.1, 1 mM ATP, 
and 52.3 Ci per mmol [γ-32P]-ATP.  The sample marked “EGTA” also included 0.875 mM EGTA, and 
MgCl2 increased to 2.46, for a predicted concentration of 0.9 mM MgATP and 0.2 µM free Ca2+111.  The 
reaction proceeded for 15 minutes at 30°C.  In triplicate, mean ± SD. 
Discussion and Conclusions 
At this point, my strategy was to compare the properties of alphacat and full-
length DGK-alpha, which meant that I needed “good” full-length DGK-alpha.  My 
criterion for determining whether DGK-alpha was “good” was whether it showed Ca2+-
dependent activation36.  Because the enzymatic activity of full-length DGK-alpha in 
pT71myc was so low, I decided to pursue other constructs that might improve the 
expression of soluble full-length DGK-alpha. 
Expressing and Purifying Epsiloncat in pT71myc 
Introduction 
I thought perhaps the catalytic domain of another eukaryotic DGK might express 
more solubly than alphacat, and therefore decided to try to express the catalytic domain 
of H. sapiens DGK-epsilon in pT71myc, the same plasmid that had robustly expressed 
alphacat. 
Results 
The epsiloncat construct consists of residues 201-567 of H. sapiens DGK-epsilon.  
This construct was cloned into the plasmid pT71myc, which adds to the N-terminus of 
the protein a fusion tag consisting of hexahistidine, a thrombin proteolytic site, a myc tag, 
and a TEV protease site.  The total mass of this protein construct (including the fusion 
tag) and pI are predicted to be 45.2 kD and 5.97, respectively.  I could induce the 
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expression of epsiloncat in Rosetta™(DE3) by adding IPTG to the growth medium.  
When compared to uninduced control, the induced lysate expressed an additional band, 
easily detectable by Coomassie staining, that migrated between the 35 kD and 55 kD 
molecular weight standards during SDS-PAGE, consistent with the predicted size of the 
fusion protein of 45.2 kD (Figure 37A).  This band was also recognized by an anti-
histidine antibody (Figure 37B), an anti-DGK-epsilon antibody (Figure 37C), and an 
anti-myc antibody (Figure 37D) on immunoblots, consistent with its expressing in frame 
and with the proper epitope tags.  In fact, the anti-DGK-epsilon antibody and the anti-
myc antibody recognized multiple bands in the induced, but not the uninduced lysate.  
These multiple bands might be a result of ribosome pausing, frameshifts, deletions, 
mistranslations, or aborted translation products.  Rosetta™(DE3) contains the pRARE 
plasmid, but it may not have been maintained during this expression, because the bacteria 
were cultured in the absence of Cam.  The cDNA of epsiloncat does in fact include a 
number of rare codons: three AGG, three AGA, seven CTA, five ATA, five CGA, three 
CCC, and seventeen GGA. 
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Figure 37.  Epsiloncat in pT71myc expresses when induced by IPTG, is of the appropriate size, and is 
recognized by anti-histidine, DGK-epsilon, and myc antibodies.  I inoculated two 50 mL LB Kan 
cultures each with an overnight culture of epsiloncat in pT71myc in Rosetta™(DE3).  When the OD600 
was predicted to reach 1.0, I added IPTG to 0.5 mM, and shook the cultures for 21 hours at 15°C, then 
pelleted the cells.  I resuspended each cell pellet in 4 mL per gram wet cell pellet lysis buffer (50 mM Tris, 
pH 8.0, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 0. 5% (v/v) NP-40, 0.5 mM DTT, 
1x PIC, 10 U per mL DNAse I, and 1 mg per mL egg white lysozyme), and incubated on ice for thirty 
minutes.  I lysed the cells by probe-sonicating three times for ten seconds each, resting on ice for ten 
seconds between each pulse.  I removed the insoluble fraction by centrifuging at 115,000 x g for 90 
minutes at 4°C.  SDS-PAGE of 12% acrylamide gels followed by (A) Coomassie staining, (B) 
immunoblotting against His6 (abcam® ab6196 (1:2500 (v/v))), (C) immunoblotting against DGK-epsilon 
(1:2000 (v/v)), and (D) immunoblotting against myc (abcam® ab9106 (1:250 (v/v))). 
Because the bacteria had appeared to not entirely lyse, I re-lysed the pellets and 
purified the supernatant on Ni-NTA (Figure 38).  Even when the cells are entirely lysed, 
most of the epsiloncat remains in the pellet.  However, the small amount of epsiloncat 
that partitions into the supernatant can be enriched on Ni-NTA. 
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Figure 38.  Epsiloncat in pT71myc is mostly insoluble, but the small portion that is soluble can be 
enriched on Ni-NTA.  I re-lysed the pellets shown in Figure 37, which had been stored at -80°C for eleven 
days, by adding another 4 mL per gram original cell pellet lysis buffer, incubating on ice for thirty minutes, 
and probe-sonicating in ten-second bursts, resting on ice for ten seconds between each burst, until no longer 
viscous.  I removed the insoluble fraction by centrifuging at 43,000 x g for ninety minutes at 4°C.  I added 
Ni-NTA agarose 1:4 (v/v) to the supernatant and incubated overnight, rotating at 4°C.  I washed the resin 
with wash buffer 1 (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 0.5 mM DTT) 
and wash buffer 2 (same as wash buffer 1, but imidazole increased to 20 mM), and eluted with elution 
buffer (250 mM imidazole).  SDS-PAGE followed by Coomassie staining.  I tore the gel following 
electrophoresis such that most of the rightmost lane (induced eluate 2) was missing.  U, uninduced; I, 
induced. 
Although the epsiloncat was soluble after purification on Ni-NTA in that it 
remained in the supernatant after ultracentrifugation, it eluted in the void volume when 
loaded onto a Sephadex® G-150 column (Figure 39).  (I am uncertain why the uninduced 
eluate 1 supernatant shows immunoreactivity to the anti-DGK-epsilon antibody in this 
immunoblot while the uninduced lysate shows no immunoreactivity in Figure 37.  This 
immunoblot used a dilution of the same antibody aliquot (which means the antibody was 
older), and a shorter incubation time for the secondary antibody, which should produce 
less, not more, sensitivity.  If the interface between the stacking and separating phases 
dried out and caused interwell contamination from the induced eluate 1 supernatant lane, 
I would expect immunoreactivity in the lane to the right as well, when there is none.  One 
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possibility is that the immunoreactive band is a background band from E. coli that also 
migrates between the 40 and 50 kD molecular weight standards that was enriched by Ni-
NTA and therefore not seen in the lysate, in which case the protein that elutes in the void 
volume could be this background band and not epsiloncat after all.  However, because a 
band of the right size was seen differentially in the induced vs. uninduced samples in 
Figure 38 (suggesting that epsiloncat is indeed present and enriching in Ni-NTA), and 
because the induced lysate was recognized by the antibody differentially in Figure 37 
(suggesting that the anti-DGK-epsilon antibody recognizes epsiloncat), the appearance of 
a background band of the correct size dominating antibody recognition seems unlikely.  
The most likely explanation is that some of the induced eluate 1 supernatant overflowed 
from the well into the well to the left (and not to the right) while I loaded the gel.  If that 
is the case, that should not impact the interpretation that the enriched epsiloncat eluted 
from the analytical gel filtration column in the void volume.)  I therefore deemed 
epsiloncat in pT71myc unsuitable for pursuit for x-ray crystallography. 
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Figure 39.  Soluble epsiloncat elutes from Sephadex® G-150 in the void volume.  I loaded 200 µL of 
eluate 1’s supernatant (shown in Figure 38) onto the same Sephadex® G-150 column shown in Figure 16, 
and collected fractions every 260 seconds, eluting by gravity in gel filtration buffer (55 mM HEPES, 5.5 
mM MgCl2, 1.1 mM CaCl2, pH 8.0).  (A) SDS-PAGE followed by immunoblotting against DGK-epsilon 
(1:4000 (v/v)).  I loaded the gel filtration fractions of elution volumes corresponding to molecular weights 
of 336 to 3.9 kD.  (B) The elution of molecular weight markers as a function of elution volume.  I detected 
the elution of the proteins standards by measuring the A280 of the gel filtration fractions.  A vertical line 
marks the volume of the fraction that appeared bluest during blue dextran elution: this is the void volume.  
A vertical line also marks the volume of the fraction with the greatest anti-DGK-epsilon detection from the 
immunoblot shown in (A). 
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Conclusions 
Because the enriched epsiloncat in pT71myc eluted from the Sephadex® G-150 
column in the void volume, I concluded that epsiloncat in pT71myc was unsuitable for 
pursuit for x-ray crystallography. 
Cloning, Expression, Purification, and Analytical Gel Filtration of Alphacat in pGEX-
4T2 Coexpressed with Bacterial Chaperones 
Introduction  
Translational folding partners have been reported to improve the solubility of 
proteins expressed in E. coli112–115.  In addition to being a useful epitope tag for affinity 
purification116, the protein glutathione-S-transferase (GST) is one such fusion tag that has 
been reported to improve the solubility of target proteins to which it has been fused117.  In 
fact, GST fusion tags have been successfully used to express the EF-hands of DGK-alpha 
and gamma (although not beta) in E. coli54.  In an attempt to improve the solubility of 
recombinantly expressed alphacat, alphacat was therefore cloned into a GST-containing 
plasmid. 
Results 
The pGEX-4T2 vector (Figure 40) introduces GST from Schistosoma japonicum, 
followed by a thrombin proteolytic site, at the N-terminus of the protein.  The total mass 
of this protein construct (including the fusion tag) and pI are predicted to be 71.6 kD and 
6.97, respectively.   
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Figure 40.  Schematic of alphacat in pGEX-4T2 construct.  “Alphacat” consists of residues 333-733 of 
S. scrofa DGK alpha. pGEX-4T2 adds to the N-terminus of the protein a fusion tag consisting of S. 
japonicum GST followed by a thrombin proteolytic site.  The total mass of this protein construct (including 
the fusion tag) and pI are predicted to be 71.6 kD and 6.97, respectively.  This figure has been modified 
from Petro and Raben1 and is used under CC BY-NC 2.5. 
I transformed alphacat in pGEX-4T2 into BL21(DE3) strain of E. coli, as well as 
into BL21(DE3) competent cells that had already been transformed with each of the sets 
of bacterial chaperones.  I tested the expression in LB and in Minimal Media.  The 
cultures in Minimal Media started to grow until they reached an OD600 of ~0.02, at 
which point they stopped growing.  As can be seen in Figure 41, alphacat in pGEX-4T2 
expressed readily after induction with IPTG, producing a band, easily detectable by 
Coomassie staining following SDS-PAGE, that ran between the 60 kD and 70 kD 
molecular weight markers, slightly faster than its predicted size of 71.6 kD, and was 
recognized by an α-DGK-alpha antibody, but not an anti-histidine antibody, by 
immunoblot.  As I observed with alphacat in pT71myc, the alphacat in pGEX-4T2 
construct produced insoluble protein, as measured by detection in the supernatant either 
by Coomassie staining or immunoblot following SDS-PAGE following centrifugation of 
the bacterial lysate.  As I also observed with alphacat in pT71myc, coexpressing 
GroEL/ES increased the amount of GST-tagged alphacat detected (either by Coomassie 
or immunoblot) in the supernatant following centrifugation.  As above, GroEL is 
recognized by the α-DGK-alpha antibody; in this case, GroEL is the lower band, and 
alphacat is the upper band. 
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Figure 41.  Alphacat in pGEX-4T2 expresses that runs slightly faster than predicted that is 
recognized by the anti-DGK-alpha antibody, and its apparent solubility increases when coexpressed 
with GroEL/ES.   I inoculated two 4 mL LB Carb cultures and two 4 mL M9 Minimal Media (12.8 g per L 
Na2HPO47H2O, 3 g per L KH2PO4, 0.5 g per L NaCl, 1 g per L NH4Cl, 0.4% (w/v) glucose) Carb cultures 
each with an overnight culture of alphacat in pGEX-4T2 in BL21(DE3), and two LB Carb Cam cultures 
and two M9 Minimal Media Carb Cam cultures each with overnight cultures of alphacat in pGEX-4T2 
coexpressing with each of the sets of chaperones in BL21(DE3).  When the OD600 of the LB cultures was 
predicted to reach 0.3, I added IPTG to 0.1 mM, and shook the cultures for 21 hours at 16°C.   I pelleted the 
cells and froze at -80°C overnight.  I resuspended each cell pellet in 40 mL per gram wet cell pellet lysis 
buffer (50 mM HEPES, pH 6.4, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.5% (v/v) 
NP-40, 0.5 mM DTT, 1x PIC), and added egg white lysozyme to 1 mg per mL and DNAse I to 20 U per 
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mL, and incubated on ice for thirty minutes.  I lysed the cells by probe-sonicating three times for ten 
seconds each, resting on ice for fifteen seconds between each pulse.  I removed the insoluble fraction by 
centrifuging at 54,900 x g for 20 minutes at 4°C.  SDS-PAGE of 12% acrylamide gels followed by: (A) 
Coomassie staining, (B) immunoblotting against DGK-alpha C-terminus (Abgent AP8128b (1:300 (v/v))), 
or (C) immunoblotting against His6 (abcam® ab6196 (1:2500 (v/v))).  I, induced; U, uninduced; L, lysate; 
S, supernatant (after removing insoluble from lysate).  This figure has been modified from Petro and 
Raben1 and is used under CC BY-NC 2.5. 
 Because coexpressing with GroEL/ES/TF appeared to increase the solubility of 
alphacat in pGEX-4T2, I expressed it fresh in order to assay its enzymatic activity 
(Figure 42A).  Activity in micelles was noisy (Figure 42B); the detergent may have 
solubilized endogenous E. coli DGKA, which is an integral membrane protein, allowing 
it to access the DOG in the micelles and contribute to the observed enzymatic activity.  
As such, I also assayed the DGK activity using liposomes as a substrate (Figure 42C).  I 
was able to detect greater activity in the lysate and especially in the supernatant of the 
alphacat in pGEX-4T2 coexpressed with GroEL/ES/TF, suggesting that the bacterial 
chaperones allowed more of the alphacat in a catalytically competent way, but the 
magnitude of the increase was small, especially when considering the large amount of 
alphacat expressed detected by Coomassie. 
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Figure 42.  Coexpression with GroEL/ES/TF increases the DGK activity of alphacat in pGEX-4T2 in 
BL21(DE3) lysates.  I inoculated two 125 mL LB Carb cultures with an overnight culture of alphacat in 
pGEX-4T2 in BL21(DE3), and two 125 mL LB Carb Cam cultures with an overnight culture of alphacat in 
pGEX-4T2 + GroEL/ES/TF in BL21(DE3).  When the OD600 reached 0.5, I added IPTG to 0.1 mM (or 
not) and shook the cultures for 21 hours at 16°C, then pelleted the cells.  I resuspended each cell pellet in 1 
mL lysis buffer (50 mM HEPES, pH 6.4, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 
0.5% (v/v) NP-40, 0.5 mM DTT, 1x PIC), and added DNAse I to 20 U per mL and egg white lysozyme to 1 
mg per mL, and incubated on ice for thirty minutes.  I lysed the cells by probe-sonicating three times for 
ten seconds each, resting on ice for fifteen seconds between each pulse.  I removed the insoluble fraction by 
centrifuging at 54,900 x g for 65 minutes at 4°C.  (A) SDS-PAGE followed by Coomassie staining.  I 
loaded 2 µg per well, as measured by the Bio-Rad Protein Assay.  (B) DGK activity assay in Triton X-100 
detergent micelles.  I stored the samples in 50% glycerol (v/v) at -80°C overnight prior to assaying.  The 
reaction included 40 ng per µL protein (as measured by the Bio-Rad Protein Assay), 7.3 mM Triton X-100 
micelles (6.3 mol% DOG, 18.8% mol% POPS), 5 mM HEPES, 110 mM NaCl, 1 mM imidazole, 8.5 mM 
MgCl2, 0.26 mM CaCl2, 0.05% (v/v) NP-40, 0.1x PIC, 1.3 mM DTT, 5% (v/v) glycerol, 40 mM MOPS, pH 
7.4, 1 mM ATP, and 119 Ci per mmol [γ-32P]-ATP.  The reaction proceeded for 15 minutes at 30°C.  In 
triplicate, mean ± SD.  (C) DGK activity assay in liposomes.  I stored the samples in 50% glycerol (v/v) at 
-80°C for seven days prior to assaying.  The reaction included 40 ng per µL protein (as measured by the 
Bio-Rad Protein Assay), 7.5 mM liposomes (53:22:17:8::POPE:POPC:POPS:DOG), 5 mM HEPES, 110 
mM NaCl, 1 mM imidazole, 8.5 mM MgCl2, 0.26 mM CaCl2, 0.05% (v/v) NP-40, 0.1x PIC, 1 mM DTT, 
5% (v/v) glycerol, 40 mM MOPS, pH 7.4, 1 mM ATP, and 41.7 Ci per mmol [γ-32P]-ATP.  The reaction 
proceeded for 15 minutes at 30°C.  In triplicate, mean ± SD. 
 In order to optimize expression before purification, I tested the effects of 
temperature and pH on the expression of alphacat in pGEX-4T2, coexpressed with 
GroEL/ES.  Because the pI is predicted to be 6.97, I tested the solubility of lysis at either 
pH 5 (buffered with sodium succinate) or pH 9 (buffered with glycine), in order to be at 
least two pH units away from the pI (so that only 1% of the protein would be uncharged).  
I also tested the effect of the temperature of induction: I tested expression at 37°C, and 
meant to test the expression at 16°C, but the shaking incubator had been moved to a new 
cold room, and the temperature setting that had been 16°C in the previous cold room was 
now only 6°C.  Once again, alphacat is the upper band, and GroEL is the lower band.  
More alphacat was expressed, and, as a result, more alphacat remained in the soluble 
fraction, in the 6°C expression than in the 37°C expression (Figure 43).  Under the 
conditions tested, alphacat remained mostly insoluble: the yield of alphacat is less than 
the supernatant than in the lysate as detected by Coomassie staining (Figure 43A), and is 
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not even detectable by immunoblotting, even though the alphacat in the lysate is easily 
detectable (Figure 43B). 
 
Figure 43.  Testing the effect of pH and induction temperature on the expression of alphacat in 
pGEX-4T2 coexpressed with GroEL/ES.  I inoculated two 12.5 mL LB Carb Cam cultures with an 
overnight culture of alphacat in pGEX-4T2 + GroEL/ES in BL21(DE3).  When the OD600 was predicted 
to reach 0.3, I added IPTG to 0.1 mM (or not) and shook the cultures either for three hours at 37°C or else 
for 21.5 hours at 6°C, then pelleted the cells.  I resuspended each cell pellet in either 17.4 mL per gram wet 
cell pellet (for 37°C expression) or else 450 µL (for 16°C expression) pH 5 lysis buffer (50 mM sodium 
succinate, pH 5.0, 100 mM NaCl, 20 mM NaF, 10 mM MgCl2, 0.2 mM CaCl2, 0.5% (v/v) NP-40, 1 mM 
DTT, 1x PIC) or pH 9 lysis buffer (same as pH 5 lysis buffer, except buffered with 50 mM glycine, instead 
of sodium succinate, to pH 9.0), and added egg white lysozyme to 1 mg per mL, and incubated on ice for 
thirty minutes, vortexing occasionally to mix.  I lysed the cells by probe-sonicating ten times for ten 
seconds each, resting on ice for fifteen seconds between each pulse.  I removed the insoluble fraction by 
centrifuging at 40,300 x g for ninety minutes at 4°C.  SDS-PAGE of 10% acrylamide gels followed by (A) 
Coomassie staining, or (B) immunoblotting against DGK-alpha C-terminus (Abgent AP8128b (1:300 
(v/v))).  L, lysate; S, supernatant. 
 In an effort to determine as soon as possible whether the alphacat in pGEX-4T2 
coexpressed with GroEL/ES was a promising construct to pursue for x-ray 
crystallography studies, I loaded the soluble fraction of a fresh expression directly onto a 
freshly blocked Sephadex® G-200 analytical gel filtration column, with no additional 
prior purification steps.  However, I was unable to detect alphacat in any of the gel 
filtration fractions, by Coomassie staining (Figure 44A) or by immunoblotting against 
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either DGK-alpha (Figure 44B) or GST (Figure 44C).  Clearly I needed to enrich 
alphacat in pGEX-4T2 before loading it onto the analytical gel filtration column. 
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Figure 44.  When the supernatant of alphacat in pGEX-4T2 coexpressed with GroEL/ES in 
BL21(DE3) is loaded directly onto a Sephadex® G-200 analytical gel filtration column, alphacat is 
undetectable in the eluate.  I inoculated a 100 mL LB Carb Cam culture with an overnight culture of 
alphacat in pGEX-4T2 + GroEL/ES in BL21(DE3).  When the OD600 was predicted to reach 0.3, I added 
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IPTG to 0.1 mM and shook the cultures for 22 hours at 16°C, then pelleted the cells.  I resuspended the cell 
pellet in 4 mL lysis buffer (50 mM glycine, pH 9.0, 100 mM NaCl, 20 mM NaF, 10 mM MgCl2, 0.2 mM 
CaCl2, 0.5% (v/v) NP-40, 1 mM DTT, 1x PIC) and added egg white lysozyme to 1 mg per mL, and 
incubated on ice for 45 minutes.  I lysed the cells by probe-sonicating ten times for ten seconds each, 
resting on ice for fifteen seconds between each pulse.  I removed the insoluble fraction by centrifuging at 
40,300 x g for ninety minutes at 4°C.  I loaded 200 µL of the resulting supernatant onto a Sephadex® G-
200 column that had been freshly blocked with 240 µL of 10 mg/mL fresh albumin, and I collected 
fractions every three minutes, eluting by gravity in gel filtration buffer (50 mM glycine, 100 mM NaCl, 20 
mM NaF, 10 mM MgCl2, 0.2 mM CaCl2, pH 9.0).  SDS-PAGE of 10% acrylamide gels followed by (A) 
Coomassie staining (I loaded 5 µg of the lysate, an equivalent volume of the supernatant, and 24 µL of each 
of gel filtration fraction), (B) immunoblotting against DGK-alpha C-terminus (Abgent AP8128b (1:300 
(v/v))), and (C) immunoblotting (using the same membranes shown in (B)) against GST (1:50,000(v/v)). 
 I chose to use MagneGST™ glutathione particles (Promega V8611) to affinity 
purify alphacat via its N-terminal GST tag.  Although I had tested the solubility of 
alphacat in pGEX-4T2 coexpressed with GroEL/ES at pH 5 and at pH 9, the 
manufacturer’s guide warned that buffers with pHs above 8.0 may inhibit binding of the 
GST epitope tag to the MagneGST™ glutathione particles.  Furthermore, alphacat 
coexpressed with GroEL/ES appeared more soluble at pH the solubility looks better at 
pH 6.4 (Figure 41 (although, to be fair, that lysis buffer was buffered with HEPES, whose 
buffering capacity does not extend to 6.4, so I am uncertain what the actual pH was)) than 
at pH 9.0 (Figure 43).  I therefore lysed a fresh expression of alphacat in pGEX-4T2 plus 
GroEL/ES at pH 8.0, and tested its solubility under different expression conditions.  More 
alphacat appeared to be in the supernatant following centrifugation when induced at 16°C 
overnight than when induced at 37°C for three hours (Figure 45). 
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Figure 45.  When lysed at pH 8, more alphacat coexpressed with GroEL/ES is soluble when induced 
at 16°C overnight than at 37°C for three hours.  I inoculated two 100 mL LB Carb Cam cultures with an 
overnight culture of alphacat in pGEX-4T2 + GroEL/ES in BL21(DE3).  When the OD600 was predicted 
to reach 0.3, I removed an aliquot as uninduced, and added IPTG to 0.1 mM to the remaining culture and 
shook either at 37°C for three hours or else at 16°C overnight, then pelleted the cells.  I resuspended the 
cell pellet in 4 mL per gram wet cell pellet lysis buffer (50 mM Tris, pH 8.0, 1 mM CaCl2, 0.25% (v/v) TX-
100, 5 mM DTT, 1x PIC), froze at -80°C for three hours, then thawed by shaking the tube in water gently.   
I added egg white lysozyme to 1 mg per mL, and incubated on ice for thirty minutes, vortexing 
occasionally to mix.  I lysed the cells by probe-sonicating ten times for ten seconds each, resting on ice 
between each pulse.  I removed the insoluble fraction by centrifuging at 110,000 x g for one hour at 4°C.  
SDS-PAGE of 10% acrylamide SDS-PAGs followed by (A) Coomassie staining (I loaded 5 µg in each 
lane) and (B) immunoblotting against DGK-alpha C-terminus (Abgent AP8128b (1:300 (v/v))) (left) or 
GST (1:50,000(v/v)) (right).  I loaded 0.2 µg in each lane of the immunoblots.  U, uninduced; L, induced 
lysate; S, induced supernatant. 
 I purified the supernatant of alphacat in pGEX-4T2 coexpressed with GroEL/ES 
using MagneGST™ glutathione particles according to the manufacturer’s instructions.  
Most of the protein flowed through, never adhering to the MagneGST™ glutathione 
particles in the first place, and the rest eluted off at very low concentrations glutathione 
(Figure 46), suggesting that alphacat in pGEX-4T2 had a lower than predicted affinity for 
the glutathione particles. 
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Figure 46.  Alphacat in pGEX-4T2 coexpressed with GroEL/ES has lower than expected affinity for 
MagneGST™ glutathione particles.  I thawed the 16°C supernatant (shown in Figure 45), which had 
been stored at -80°C in 20% glycerol for six days, by gently shaking the tube in water.  I removed the 
insoluble fraction by centrifuging at 110,000 x g for 65 minutes at 4°C.  I added MagneGST™ glutathione 
particles 1:24 (v/v) and rotated at 4°C for thirty minutes.  I washed the particles with wash buffer (50 mM 
Tris, pH 8.0, 140 mM NaCl, 10 mM KCl, 1 mM CaCl2, 0.1% (v/v) TX-100, 5 mM DTT), and eluted with 
elution buffer 1 (same as wash buffer, but with glutathione added to 10 mM), elution buffer 2 (30 mM 
glutathione), elution buffer 3 (50 mM glutathione), elution buffer 4 (75 mM glutathione), elution buffer 5 
(100 mM glutathione), and elution buffer 6 (same as elution buffer 5, but NaCl increased to 490 mM and 
TX-100 increased to 1%).  SDS-PAGE of 10% acrylamide gels followed by (A) Coomassie staining, (B) 
immunoblotting against DGK-alpha C-terminus (Abgent AP8128b (1:300 (v/v))), and (C) immunoblotting 
against GST (1:50,000(v/v)) (same membrane as shown in (B)).  GSH, glutathione. 
 In an effort to enrich enough alphacat to be able to detect its elution from an 
analytical gel filtration column, I therefore repurified the flowthrough on MagneGST™ 
glutathione particles, eluting with lower concentrations of glutathione.  Because I was 
unsure whether MagneGST™ glutathione particles could be reused, I repurified on both 
the previously used particles as well as fresh particles, at two different concentrations, to 
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compare (Figure 47A).  Perhaps slightly more alphacat flowed through the previously 
used resin, and perhaps slightly more adhered to and then eluted from the fresh resin, but 
overall Figure 47A shows that MagneGST™ glutathione particles can be reused to purify 
alphacat.  As observed previously with alphacat in pT71myc purification on Ni-NTA, 
longer elution times produced more concentrated eluted protein (E4 eluted over the 
weekend, whereas the other elution steps were fifteen minutes) (Figure 47).  As in Figure 
46, most of the alphacat eluted at the lowest concentration of glutathione. 
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Figure 47.  MagneGST™ glutathione particles can be reused to purify alphacat in pGEX-4T2 
coexpressed with GroEL/ES.  I had stored the flowthrough from Figure 46 frozen for nine days, and 
thawed it by shaking the tube in water gently.  I removed the insoluble fraction by centrifuging at 110,000 x 
g for 65 minutes at 4°C.  I then divided the resulting supernatant into fifths.  To one-fifth, I added the 
previously used MagneGST™ glutathione particles (Figure 46) 1:6 (v/v).  To another fifth, I added fresh 
MagneGST™ glutathione particles 1:6 (v/v), in order to determine whether the particles could be reused.  
To the remaining three-fifths, I added fresh MagneGST™ glutathione particles 1:3 (v/v).  I rotated the 
samples at 4°C for one hour, washed the particles with wash buffer (50 mM Tris, pH 8.0, 140 mM NaCl, 10 
mM KCl, 1 mM CaCl2, 0.1% (v/v) TX-100, 5 mM DTT), and eluted with elution buffer 1 (same as wash 
buffer, but with glutathione added to 2.5 mM), elution buffer 2 (5 mM glutathione), elution buffer 3 (10 
mM glutathione), elution buffer 4 (16.7 mM glutathione), elution buffer 5 (23.3 mM glutathione), elution 
buffer 6 (30 mM glutathione), and elution buffer 7 (75 mM glutathione).  SDS PAGE of 10% acrylamide 
gels followed by Coomassie staining.  (A) Comparison of 1:6 (v/v) reused vs. fresh MagneGST™ 
glutathione particles.  R, reused; F, fresh.  (B) 1:3 (v/v) fresh glutathione particles. 
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 Elution E1A from the elution on fresh MagneGST™ glutathione particles using 
the higher ratio of protein to particles (Figure 47B) was sufficiently concentrated (1 mg 
per mL by the Bio-Rad Protein Assay) to load directly onto the Sephadex® G-200 
analytical gel filtration column.  In order to match the MagneGST™ elution buffer, prior 
to loading the partially purified alphacat, I first washed the column with a new gel 
filtration buffer (50 mM Tris, 140 mM NaCl, 10 mM KCl, 1 mM CaCl2, 0.1% Triton X-
100, 5 mM DTT, pH 8.0), then blocked the column with cytochrome c.  Instead of a 
small pink band traveling down the white column, which was what I expected to observe, 
the entire column turned pink.  When the top of the column turned white again, I loaded 
the partially purified alphacat.  I was unable to detect alphacat in any of the eluting gel 
filtration fractions by immunoblotting against DGK-alpha C-terminus (Figure 48). 
 
Figure 48.  When partially purified alphacat in pGEX-4T2 coexpressed with GroEL/ES in 
BL21(DE3) is loaded onto a Sephadex® G-200 analytical gel filtration column using a gel filtration 
buffer that includes 0.1% TX-100, alphacat is undetectable in the eluate.  Eluate 1A from the 
purification using 1:3 (v/v) fresh glutathione particles (Figure 47B) was stored at 4°C for four days before I 
removed the insoluble fraction by centrifuging at 54,900 x g for ninety minutes at 4°C.  I loaded 200 µL of 
the resulting supernatant onto a Sephadex® G-200 column that had been freshly blocked with 220 µL of 10 
mg/mL cytochrome c, and I collected fractions every 5.5 minutes, eluting by gravity in gel filtration buffer 
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(50 mM Tris, 140 mM NaCl, 10 mM KCl, 1 mM CaCl2, 0.1% Triton X-100, 5 mM DTT, pH 8.0).  SDS-
PAGE followed by immunoblotting against DGK-alpha C-terminus (Abgent AP8128b (1:300 (v/v))). 
After running the partially purified alphacat on the column, I set out to calibrate 
the column in the new gel filtration buffer.  Unlike previous calibrations, loading blue 
dextran on the column did not produce any visibly blue fractions.  I poured a fresh 
Sephadex® G-200 column, but once again the blue dextran diffused into the column 
during calibration rather than producing a discrete blue band.  Dropping the Triton X-100 
concentration in the gel filtration buffer from 0.1% to 0.01% produced a wide blue peak 
for blue dextran, and removing Triton X-100 altogether from the gel filtration buffer 
returned the blue dextran peak to its normal narrow size (Figure 49).  I therefore 
concluded that the Sephadex® G-200 resin was incompatible with Triton X-100 
concentrations as low as 0.01%, and that it was the Triton X-100 in the sample that 
prevented detection of alphacat in pGEX-4T2 in the immunoblots in Figure 48. 
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Figure 49.  Sephadex® G-200 resin was incompatible with TX-100 concentrations as low as 0.01%.  
The elution of blue dextran (as monitored by A620) from a Sephadex® G-200 column in gel filtration 
buffer with differing concentrations of TX-100. 
I therefore expressed more alphacat in pGEX-4T2 plus GroEL/ES, and this time 
purified on MagneGST™ without Triton X-100, seeing as the detergent appeared to be 
incompatible with the analytical gel filtration resin that I was eventually going to use to 
determine whether alphacat in pGEX-4T2 was monodisperse.  I also eluted in even lower 
concentrations of glutathione, seeing as most of the alphacat eluted from the glutathione 
particles at the lowest concentration of glutathione in the previous purification (Figure 
47).  Although I was able to enrich alphacat using the MagneGST™, once again much of 
the alphacat flowed through the particles, and the rest eluted at the lowest concentration 
of glutathione (Figure 50A).  The partially purified alphacat was not sufficiently 
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concentrated to load onto the analytical gel filtration column, so I repurified the 
flowthrough on MagneGST™, and eluted in even lower concentrations of glutathione 
(Figure 50B).  I could enrich for alphacat, but, once again, as with alphacat in pT71myc, 
GroEL coeluted with alphacat from the glutathione particles. 
 
Figure 50.  Alphacat in pGEX-4T2 coexpressed with GroEL/ES can be enriched on MagneGST™.  I 
inoculated two 500 mL LB Carb Cam cultures with a freshly growing culture of alphacat in pGEX-
4T2 + GroEL/ES in BL21(DE3).  When the OD600 reached 0.4, I added IPTG to 0.1 mM and shook at 
16°C for fourteen hours, then pelleted the cells.  I resuspended the cell pellet in 4 mL per gram wet cell 
pellet lysis buffer (50 mM Tris, pH 8.0, 1 mM CaCl2, 0.25% (v/v) TX-100, 5 mM DTT, 1x PIC), froze at -
80°C overnight, then thawed by shaking the tube in water gently.   I added egg white lysozyme to 1 mg per 
mL, and incubated on ice for thirty minutes, vortexing occasionally to mix.  I lysed the cells by probe-
sonicating in ten-second bursts until no longer viscous.  I removed the insoluble fraction by centrifuging at 
110,000 x g for 65 minutes at 4°C.  I added the previously used MagneGST™ glutathione particles (Figure 
47) 1:92 (v/v), and rotated at 4°C for 110 minutes.  I washed the particles with wash buffer (50 mM Tris, 
pH 8.0, 140 mM NaCl, 10 mM KCl, 1 mM CaCl2, 5 mM DTT), and eluted with elution buffer 1A (same as 
wash buffer, but with glutathione added to 0.5 mM), elution buffer 2A (1.5 mM glutathione), elution buffer 
3A (2.5 mM glutathione), and elution buffer 4A (100 mM glutathione).  I forgot to pH the 200 mM 
glutathione stock that I used to make the elution buffers, so the pH of elution buffer 4 was probably 
considerably less than 8.0, especially considering that the gel-loading buffer turned yellow for the eluate 4 
samples.  I stored the flowthrough at -80°C in 20% glycerol for two days, then thawed in water shaking in 
order to repurify.  I added back the previously used MagneGST™ glutathione particles, and rotated at 4°C 
for 75 minutes.  I washed the particles with wash buffer and eluted with elution buffer 1B (same as wash 
buffer, but with glutathione added to 0.1 mM), elution buffer 2B (0.3 mM glutathione), elution buffer 3B 
(0.5 mM glutathione), elution buffer 4B (1.5 mM glutathione), and elution buffer 5B (100 mM glutathione, 
this time using a 200 mM glutathione stock whose pH had been adjusted to 8.0 using NaOH).  SDS-PAGE 
of 10% acrylamide gels.  (A) First purification.  I added NaOH to the eluate 4 and MagneGST™ samples 
prior to loading into the SDS-PAGs.  (B) Repurification of the flowthrough shown in (A).  This figure has 
been modified from Petro and Raben1 and is used under CC BY-NC 2.5. 
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I pooled the eluates of both purifications and concentrated alphacat by dialyzing 
against 15% PEG 17.5 kD.  I also took that opportunity to change the buffer from elution 
buffer to the gel filtration buffer recommended by the manufacturer of the molecular 
weight standards, plus calcium in case it was required for the proper conformation of 
alphacat (50 mM Tris, 100 mM KCl, 1 mM CaCl2, pH 8.0).  When I loaded the 
concentrated partially purified alphacat onto the Sephadex® G-200 analytical gel 
filtration column, alphacat and GroEL coeluted in the void volume (Figure 51).  I 
therefore concluded that the GST-tagged alphacat also formed aggregates unsuitable for 
pursuit for structural studies. 
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Figure 51.  Partially purified alphacat in pGEX-4T2 coexpressed with GroEL/ES elutes from a 
Sephadex® G-200 analytical gel filtration column in the void volume.  I pooled all the eluates of the 
repurification (Figure 50B) and eluates 1 and 2 of the original purification (Figure 50A) and removed the 
insoluble fraction by centrifuging at 43,000 x g for ninety minutes at 4°C.  I dialyzed the resulting 
supernatant against dialysis buffer (50 mM Tris, 100 mM KCl, 1 mM CaCl2, pH 8.0, 15% (w/v) PEG-
17.5kD) using 3.5 kD MWCO dialysis tubing at 4°C to concentrate the protein.  I removed the insoluble 
fraction by centrifuging at 43,000 x g for ninety minutes at 4°C, and loaded 200 µL of the resulting 
supernatant onto a Sephadex® G-200 column that had been freshly blocked with 610 µL of 10 mg/mL 
albumin and previously calibrated with alcohol dehydrogenase, carbonic anhydrase, albumin, and β-
amylase.  I collected fractions every 124 seconds, eluting by gravity in gel filtration buffer (50 mM Tris, 
100 mM KCl, pH 8.0).  (A) SDS-PAGE of an 8% acrylamide gel followed by immunoblotting against 
DGK-alpha C-terminus (Abgent AP8128b (1:300 (v/v))).  Because the gel filtration buffer included 
potassium, and because potassium precipitates SDS, I ethanol-precipitated 32 µL of each of the gel 
filtration fractions of elution volumes corresponding to molecular weights of 441 kD to 28.8 kD, and 
resuspended in gel-loading buffer before loading onto the gel.  (B) Elution volumes of molecular weight 
standards and of purified alphacat from a Sephadex® G-200 column. Left vertical axis, A280 of the protein 
molecular weight standards, and A620 of the blue dextran fractions.  Right vertical axis, densitometry of 
the ~70 kD band using a shorter exposure of the membrane shown in (A).  (C) Calibration of the 
Sephadex® G-200 column: elution volume (presented as a ratio of the void volume) of the molecular 
weight standards as a function of logarithm molecular weight.  I calculated the linear regression using 
Microsoft® Excel®.  A good linear fit suggests a good calibration.  This figure has been modified from 
Petro and Raben1 and is used under CC BY-NC 2.5. 
 Because alphacat in pGEX-4T2 migrated faster on SDS-PAGE than would be 
predicted by its supposed molecular weight (Figure 40-Figure 47 and Figure 50), and 
because alphacat in pGEX-4T2 exhibited a lower than predicted affinity for glutathione 
particles (Figure 46, Figure 47, and Figure 50), I wondered whether the entire GST 
epitope tag was actually present in the clone.  When I sent the construct to have its DNA 
sequenced, however, the proper leader sequence, including the entire GST gene and the 
thrombin proteolytic site, was clearly present, and alphacat was inserted in the proper 
location.  The protein sequence of alphacat in pGEX-4T2 contains several methionines: 
perhaps translation starts at a later methionine, thus expressing only part of the GST tag, 
which would explain the aberrant size and reduced affinity. 
Conclusions 
Because the concentrated partially purified alphacat in pGEX-4T2 eluted from the 
Sephadex® G-200 analytical gel filtration column in the void volume (Figure 51), I 
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concluded that the GST-tagged alphacat also formed aggregates unsuitable for pursuit for 
structural studies. 
Cloning, Expression, and Purification of Alphacat and Full-Length DGK-Alpha in 
pET32a Coexpressed with Bacterial Chaperones 
Introduction 
In another attempt to improve the solubility of alphacat and full-length DGK 
alpha, I decided to clone each of these proteins into a plasmid that would add a fusion tag 
consisting of E. coli thioredoxin (TRX), which has been reported to improve the 
solubility of target proteins112,118. 
Results 
 The pET32a plasmid adds to the N-terminus of the protein not only TRX, but 
also hexahistidine, which can be used to facilitate affinity purification by Ni-NTA 
chromatography (Figure 52).   
 
Figure 52.  Schematic of alphacat and full-length alpha in pET32a constructs.  Top: schematic of 
alphacat TEV in pET32a construct.  “Alphacat” consists of residues 333-733 of S. scrofa DGK alpha; for 
this construct, the 734th residue of S. scrofa DGK alpha, cysteine, was added back.  pET32a adds to the N-
terminus of the protein a fusion tag consisting of E. coli TRX followed by a hexahistidine tag.  For alphacat 
TEV, I added a TEV protease site between the fusion tag and alphacat.  The total mass of this protein 
construct (including the fusion tag) and pI are predicted to be 64.4 kD and 6.19, respectively.  Middle: 
schematic of alphacat PP in pET32a construct.  Instead of a TEV protease site, I added a PreScission 
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Protease site between the fusion tag and alphacat.  The total mass of this protein construct (including the 
fusion tag) and pI are predicted to be 64.4 kD and 6.19, respectively.  Bottom: schematic of full-length S. 
scrofa DGK alpha TEV in pET32a construct.  I added a TEV protease site between the fusion tag and DGK 
alpha, and I removed the initial methionine from DGK alpha.  The total mass of this protein construct 
(including the fusion tag) and pI are predicted to be 102.0 kD and 5.84, respectively.  This figure has been 
modified from Petro and Raben1 and is used under CC BY-NC 2.5. 




GG.  Both begin with a GC anchor, to promote efficient priming during the PCR reaction.  
The GC anchor is followed by a two-nucleotide spacer: that, plus the GC anchor, 
provides a four nucleotide overhang adjacent to the restriction site to promote efficient 
digestion.  I chose the two-nucleotide spacer to be AA in order to keep the total GC 
content of the primer low.  The restriction site is followed by another two-nucleotide 
spacer in order to ensure that the protease consensus sequence as well as the alphacat are 
in the same reading frame as the start codon encoded in the plasmid.  The second two-
nucleotide spacer is followed by either a TEV protease site or a PreScission Protease (PP) 
site, which is immediately followed by the first nineteen nucleotides of alphacat, ending 
in a GG anchor to promote efficient priming.  




They are identical to the alphacat primers with the exception of instead of ending with the 
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first nineteen nucleotides of alphacat, they encode the beginning of DGK-alpha, except 
for the initial methionine (in order to remove competing start sites for translation). 
For the reverse primer, I used 
GCAGCGGCCGCTCAGCACAAGAAGCCAAAGAAATTG, the same reverse primer I 
used to add a NotI site downstream of full-length DGK-alpha for cloning into pT71myc.  
This primer adds a NotI site immediately downstream of DGK-alpha or alphacat.  As 
such, it also restores to alphacat the terminal cysteine. 
The total mass of the alphacat construct (including the fusion tag, and with either 
protease site) is predicted to be 64.4 kD, and the pI is predicted to be 6.19.  The total 
mass and pI of the full-length DGK alpha construct are predicted to be 102.0 kD and 
5.84, respectively.  While the cloning strategy worked for both alphacat constructs and 
for the alpha TEV construct, I was unable to produce the alpha PP construct.  Before 
working on optimizing PCR conditions to produce the alpha PP construct, I checked the 
pET32a constructs I did have to see whether the TRX-tagged DGK was any more soluble 
than the other constructs. 
When I transformed these pET32a constructs into the BL21(DE3) strain of E. 
coli, they each expressed readily after induction with IPTG and were easily detectable by 
Coomassie staining following SDS-PAGE (Figure 53).  For each of the alphacat 
constructs, the predominant band migrated between the 55 and 70 kD molecular weight 
markers, consistent with its predicted molecular weight of 64.4 kD.  For the alpha TEV 
construct, the predominant band migrated evenly with the 100 kD molecular weight 
marker, consistent with its predicted molecular weight of 102.0 kD.  The full-length alpha 
band was less robust than the alphacat constructs, but was still easily detectable.  
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Although all of these constructs robustly expressed in the lysates, following 
centrifugation, the constructs were undetectable in the supernatant by Coomassie 
staining.  The cells appeared to lyse well, because all of the cellular proteins except the 
recombinant constructs appear in the supernatant at approximately the same intensity at 
which they appear in the lysate, so I concluded that these constructs were insoluble, not 
merely left behind in unlysed cells, and that the TRX fusion tag did not improve the 
solubility of these DGK alpha constructs. 
 
Figure 53.  Alphacat and full-length alpha each robustly express a band of the correct size in the 
pET32a construct, but this band remains insoluble after centrifugation.  I inoculated 4 mL LB Carb 
cultures with overnight cultures of the constructs shown, which I had previously transformed into 
BL21(DE3).  When the OD600 reached 0.3, I added IPTG to 0.1 mM (or not) and shook at 16°C for 22.5 
hours, then pelleted the cells.  I resuspended the cell pellet in 40 mL per gram wet cell pellet lysis buffer 
(50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.25% (v/v) TX-100, 
0.5 mM DTT, 1x PIC), added egg white lysozyme to 1 mg per mL, and incubated on ice for thirty minutes, 
vortexing occasionally to mix.  I lysed the cells by probe-sonicating ten times for ten seconds each, resting 
on ice for fifteen seconds between each burst.  I removed the insoluble fraction by centrifuging at 43,000 x 
g for ninety minutes at 4°C.  SDS-PAGE of a 10% acrylamide gel followed by Coomassie staining.  L, 
lysate; S, supernatant (after removing insoluble from lysate).  Uninduced: alphacat TEV.  This figure has 
been modified from Petro and Raben1 and is used under CC BY-NC 2.5. 
 Because GroEL/ES appeared to be the most promising bacterial chaperone for 
improving the solubility of alphacat in pT71myc and alphacat in pGEX-4T2, I likewise 
tested whether coexpression with GroEL/ES improved the solubility of each of the 
pET32a constructs.  Alpha TEV in pET32a remained undetectable in the supernatant by 
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Coomassie (Figure 54).  A small amount of either alphacat construct was visible in the 
supernatant by Coomassie (Figure 54), suggesting that coexpression with GroEL did 
improve their solubility, seeing as none was detectable when expressed without also 
overexpressing GroEL/ES (Figure 53), but the vast majority of the alphacat expressed 
remained in the pellet. 
 
Figure 54.  Coexpression with GroEL/ES does not greatly improve the solubility of DGK constructs 
in pET32a.  I inoculated 4 mL LB Carb cultures with overnight cultures of the constructs shown, which I 
had previously transformed into BL21(DE3).  When the OD600 was predicted to reach 0.3, I added IPTG 
to 1 mM and shook at 16°C overnight, then pelleted the cells.  I resuspended the cell pellet in 40 mL per 
gram wet cell pellet lysis buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 
mM CaCl2, 0.25% (v/v) TX-100, 0.5 mM DTT, 1x PIC), added egg white lysozyme to 1 mg per mL, and 
incubated on ice for thirty minutes.  I lysed the cells by probe-sonicating ten times for ten seconds each, 
resting on ice for fifteen seconds between each burst.  I removed the insoluble fraction by centrifuging at 
43,000 x g for ninety minutes at 4°C.  SDS-PAGE of a 10% acrylamide gel followed by Coomassie 
staining.  L, lysate; S, supernatant (after removing insoluble from lysate).  This figure has been modified 
from Petro and Raben1 and is used under CC BY-NC 2.5. 
 Because alphacat expressed to a greater degree than full-length alpha, I decided to 
pursue alphacat for trying to maximize the production of soluble protein.  I tested the 
coexpression of each of the sets of chaperones with alphacat TEV to see whether any of 
the other chaperones besides GroEL/ES improved its solubility.  Coexpression with 
GroEL/ES and, to a lesser extent, TF increased by a small amount the quantity of 
alphacat TEV visible in the supernatant by Coomassie (Figure 55A), but alphacat TEV in 
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the supernatant remained undetectable by immunoblot (Figure 55B).  Once again, GroEL 
was recognized by the α-DGK-alpha antibody; in this case, GroEL is the lower band, and 
alphacat is the upper band.  GroEL is soluble after centrifugation, whereas alphacat TEV 
in pET32a is not.  I concluded that coexpression with bacterial chaperones improved the 
solubility of TRX-tagged DGK constructs less than it did of alphacat in pT71myc or 
pGEX-4T2. 
 
Figure 55.  Coexpression with bacterial chaperones does not greatly improve the solubility of 
alphacat TEV in pET32a.  I inoculated one 4 mL LB Carb culture with alphacat TEV in pET32a, and 4 
mL LB Carb Cam cultures with overnight cultures of the constructs shown, all in BL21(DE3).  When the 
OD600 was predicted to reach 0.3, I added IPTG to 0.1 mM and shook at 16°C for seventeen hours, then 
pelleted the cells.  I resuspended the cell pellet in 40 mL per gram wet cell pellet lysis buffer (50 mM Tris, 
pH 8.0, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.25% (v/v) TX-100, 0.5 mM DTT, 
1x PIC), added egg white lysozyme to 1 mg per mL, and incubated on ice for 2.5 hours.  I lysed the cells by 
probe-sonicating ten times for ten seconds each, resting on ice for fifteen seconds between each burst.  I 
removed the insoluble fraction by centrifuging at 43,000 x g for ninety minutes at 4°C.  SDS-PAGE of 10% 
acrylamide gels followed by (A) Coomassie staining and (B) immunoblotting against DGK alpha C-
terminus (Abgent AP8128b (1:300 (v/v))).  L, lysate; S, supernatant (after removing insoluble from lysate).  
Uninduced: alphacat TEV in pET32a + GroEL/ES.  This figure has been modified from Petro and Raben1 
and is used under CC BY-NC 2.5. 
 I had previously observed that alphacat in pT71myc could be enriched from the 
supernatant by Ni-NTA even though the vast majority of alphacat in pT71myc is in the 
pellet, not the supernatant (Figure 15).  I therefore wondered whether the DGK constructs 
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in pET32a could likewise be enriched from the supernatant, even though the vast 
majority of the protein was insoluble.  I thus purified each of alphacat TEV and full-
length DGK-alpha TEV in pET32a on Ni-NTA agarose.  Alphacat TEV could clearly be 
enriched on Ni-NTA agarose (Figure 56).  During the course of enrichment, a second, 
lower band, migrating between the alphacat band and the 60 kD molecular weight 
standard, appeared, which was also immunoreactive to the anti-DGK-alpha antibody 
(Figure 56B).  This band could be a proteolytic fragment of alphacat, but is also the 
correct size to be endogenous GroEL, which also recognizes the DGK-alpha antibody 
(Figure 27), and could be associating to the overexpressed and possibly misfolded 
alphacat.  Although I was able to enrich alphacat, the enriched alphacat was insufficiently 
concentrated to load onto the analytical gel filtration column.  Full-length DGK-alpha 
TEV, as before (Figure 53), did not express as robustly as alphacat, and could not even be 
detected in the lysate by immunoblot (Figure 56D).  Although it appeared slightly 
enriched by Coomassie (Figure 56C), full-length alpha TEV remained undetectable by 
immunoblot even following enrichment (Figure 56D). 
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Figure 56.  Alphacat TEV, but not full-length DGK-alpha TEV, in pET32a can be enriched on Ni-
NTA, but the yield is low.  I inoculated one 500 mL LB Carb culture with a freshly growing culture of 
either alphacat TEV or else full-length DGK-alpha TEV in pET32a in BL21(DE3).  When the OD600 was 
predicted to reach 0.4, I added IPTG to 0.3 mM and shook at 16°C for 18 hours, then pelleted the cells.  I 
resuspended the cell pellet in 24 mL lysis buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 5 
mM MgCl2, 1 mM CaCl2, 0.25% (v/v) TX-100, 0.5 mM DTT, 1x PIC), divided into three tubes, and froze 
at -80°C.  I thawed one tube of each by shaking the tube gently in water.  I added egg white lysozyme to 1 
mg per mL, and incubated on ice for thirty minutes, vortexing occasionally to mix.  I lysed the cells by 
probe-sonicating ten times for ten seconds each, resting on ice for fifteen seconds between each burst.  I 
removed the insoluble fraction by centrifuging at 110,000 x g for 65 minutes at 4°C.  I added Ni-NTA 
agarose 1:15 (v/v) and incubated for two hours, rotating at 4°C.  I washed the resin with wash buffer 1 (50 
mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.5 mM DTT), wash 
buffer 2 (same as wash buffer 1, but imidazole increased to 20 mM), and wash buffer 3 (70 mM imidazole), 
and eluted with elution buffer 1 (250 mM imidazole), and elution buffer 2 (500 mM imidazole).  (A), (B): 
enrichment of alphacat TEV.  (C), (D): enrichment of full-length DGK-alpha TEV.  SDS-PAGE of 10% 
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acrylamide gels followed by (A), (C): Coomassie staining; (B), (D): immunoblotting against DGK-alpha C-
terminus (Abgent AP8128b (1:300 (v/v))). 
Conclusions 
 I concluded that the TRX tag did not improve the solubility of our DGK 
constructs as we had hoped, and decided to pursue another solubility tag. 
Cloning, Expression, Purification, and Analytical Gel Filtration of Alphacat and Full-
Length DGK-Alpha in pET28-HisMBP-FLAGpp 
Introduction 
Maltose binding protein (MBP) has been reported to improve the solubility of 
target proteins to which it has been fused113,119,120.  I therefore cloned both alphacat and 
full-length DGK-alpha into an MBP-containing plasmid. 
Results 
The pET28-HisMBP-FLAGpp plasmid adds to the N-terminus of the protein a 
fusion tag that includes hexahistidine, Pyrococcus furiosus MBP, a FLAG tag, and a 
PreScission Protease site (Figure 57).  In order to clone alphacat and full-length DGK-
alpha into pET28-HisMBP-FLAGpp, I designed the forward PCR primer 
GCAAGTCGACAAATCTATCCCAGTGTCCTGG for alphacat and 
GCAAGTCGACAATCCAAGGAGAGGGGG for full-length DGK-alpha.   Both these 
primers begin with a GC anchor to promote more efficient priming during the PCR 
reaction.  The GC anchor is followed by two spacer nucleotides: the four nucleotides in 
total provide an overhang to promote more efficient digestion by the restriction enzyme 
SalI.  I chose these two spacer nucleotides to be AA in order to keep the GC content of 
the primer low.  Following the spacer is a SalI restriction site: following digestion with 
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SalI, the digested PCR product could then be ligated into the SalI site of the pET28-
HisMBP-FLAGpp plasmid that had been likewise digested.  Following the SalI site is 
another two-nucleotide spacer, to ensure that the DGK insert is translated in the same 
reading frame as the start codon encoded in the pET28-HisMBP-FLAGpp plasmid.  Once 
again, I chose these two spacer nucleotides to be AA in order to keep the GC content of 
the primer low.  For full-length DGK-alpha, this forward primer removes the initial 
methionine, to prevent the production of untagged DGK-alpha at the second start site.  
For the reverse primer, I used 
GCAGCGGCCGCTCAGCACAAGAAGCCAAAGAAATTG, the same reverse primer I 
used to add a NotI site downstream of full-length DGK-alpha for cloning into pT71myc, 
and of both full-length DGK-alpha and alphacat for cloning into pET32a.  As in the 
pET32a cloning, this reverse primer restores the terminal cysteine to alphacat. 
 
Figure 57.  Schematic of alphacat and full-length DGK alpha in pET28-HisMBP-FLAGpp construct.  
Top, schematic of alphacat in HisMBP-FLAGpp construct.  “Alphacat” consists of residues 333-733 of 
S. scrofa DGK alpha; for this construct, the 734th residue of S. scrofa DGK alpha, cysteine, was added 
back.  pET28-HisMBP-FLAGpp adds to the N-terminus of the protein a fusion tag consisting of a 
hexahistidine tag, followed by P. furiosus maltose-binding protein (MBP) fusion tag, followed by a FLAG 
tag, followed by a PreScission Protease site.  The total mass of the protein construct (including the fusion 
tag) and pI are predicted to be 92.8 kD and 5.51, respectively.  Bottom, schematic of full-length S. scrofa 
DGK alpha construct. The total mass of the protein construct (including the fusion tag) and pI are predicted 
to be 130.6 kD and 5.45, respectively.  This figure has been modified from Petro and Raben1 and is used 
under CC BY-NC 2.5. 
When I transformed MBP-tagged alphacat or full-length DGK alpha into the 
BL21(DE3) strain of E. coli, they each expressed readily after induction with IPTG, 
producing a band, easily detectable by Coomassie staining following SDS-PAGE, that 
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was recognized by the anti-DGK-alpha antibody (Figure 58).  For alphacat, the 
predominant band migrated between the 80 and 100 kD molecular weight markers, 
consistent with its predicted molecular weight of 92.8 kD.  For full-length DGK-alpha, 
the predominant band migrated between the 120 and 130 kD molecular weight markers, 
slightly faster than its predicted molecular weight of 130.6 kD.  Both constructs also 
produced lower-molecular weight bands not seen in the uninduced cells, some of which 
were also immunoreactive to the anti-DGK-alpha antibody.  The MBP tag did not appear 
to improve DGK-alpha’s solubility: the fusion-tagged protein, either alphacat or full-
length DGK-alpha, while easily detectable in the lysate, remained undetectable by 
immunoblotting the supernatant following centrifugation (Figure 58C). 
 
Figure 58.  Both alphacat and full-length alpha in pET28-HisMBP-FLAGpp express a band of the 
correct size that is recognized by the DGK-alpha antibody, but both protein constructs remain in the 
pellet after centrifugation.  I inoculated two 25 mL LB Kan cultures with overnight cultures of alphacat in 
pET28-HisMBP-FLAGpp in Bl21(DE3), and two 50 mL LB Kan cultures with overnight cultures of full-
length DGK-alpha in pET28-HisMBP-FLAGpp in BL21(DE3).  When the OD600 was predicted to reach 
0.3, I added IPTG to 0.1 mM (or not) and shook overnight (18 hours for alphacat, and 19 hours for full-
length DGK-alpha) at 16°C, then pelleted the cells.  I resuspended the cell pellet in 4 mL per gram wet cell 
pellet lysis buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 0.25% (v/v) TX-
100, 0.5 mM DTT, 1x PIC), added egg white lysozyme to 1 mg per mL, and incubated on ice for thirty 
minutes, vortexing occasionally to mix.  I lysed the cells by probe-sonicating ten times for ten seconds 
each, resting on ice for fifteen seconds between each burst.  I removed the insoluble fraction by 
centrifuging at 43,000 x g for ninety minutes at 4°C.  SDS-PAGE of 8% acrylamide gels followed by: (A) 
and (B) Coomassie staining; (C) immunoblotting against DGK-alpha C-terminus (Abgent AP8128b (1:300 
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(v/v))).  U, uninduced; I, induced; L, lysate; S, supernatant (after removing insoluble from lysate).  This 
figure has been modified from Petro and Raben1 and is used under CC BY-NC 2.5. 
 I had been under the impression that MBP fusion tags targeted the attached 
protein to the periplasmic space, and that the subsequent isolation from making 
inappropriate contacts from other cellular proteins was part of the mechanism by which 
MBP’s solubilization worked.  It turns out that the targeting to the periplasmic space 
came from a signal peptide contained in another MBP-containing plasmid I had 
previously worked with, and MBP itself has no such properties, but at the time I tested 
whether the MBP-tagged constructs went to the periplasmic space.  Following New 
England BioLabs® Inc.’s Protein Expression & Analysis instruction manual “pMAL™ 
Protein Fusion & Purification System” (New England BioLabs® Inc. #E8200S), I 
extracted the periplasmic space from fresh expressions of alphacat and of full-length 
DGK-alpha in pET28-HisMBP-FLAGpp.  Horizontal streaking in the Coomassie-stained 
gels suggests that the interface between the stacking and separating phases dried out 
during casting, and caused the wells to leak during electrophoresis (Figure 59A). For 
each construct, a predominant, lower-molecular weight immunoreactive band is seen in 
the first resuspension (R1) but not the second (R2) (a more precise estimate of the 
molecular weight of these bands is complicated by the fact that the two sets of molecular 
weight standards migrate differently on the immunoblot): the fate of these proteins is 
unclear.  Because the periplasmic extraction did not include protease inhibitors, one 
possibility is that these bands were proteolytically digested during the periplasmic 
extraction, although this interpretation seems unlikely, seeing as the samples were stored 
at 4C overnight prior to electrophoresis (and hence, any proteases present in R2 during 
the periplasmic extraction were also present in the R1 samples waiting for 
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electrophoresis: one possible explanation could be that endogenous protease inhibitors 
were removed in the supernatant (S1)).  The immunoreactive bands are clearly in the 
resuspended periplasm but not the supernatant (Figure 59B), showing that the MBP-
tagged DGK-alpha constructs did not travel to the periplasmic space.   
 
Figure 59.  Alphacat and full-length DGK-alpha in pET28-HisMBP-FLAGpp in Bl21(DE3) are not in 
the periplasmic space.  I inoculated two 50 mL LB Kan cultures each with overnight cultures of alphacat 
in pET28-HisMBP-FLAGpp or full-length DGK-alpha in pET28-HisMBP-FLAGpp in BL21(DE3).  When 
the OD600 was predicted to reach 0.5, I added IPTG to 0.3 mM (or not) and shook for seventeen hours at 
16°C, then pelleted the cells.  To extract the periplasmic space, I resuspended the cell pellet in 80 mL per 
gram wet cell pellet resuspension buffer 1 (30 mM Tris, 20% sucrose (w/v), pH 8.0), and removed an 
aliquot as resuspended 1 (R1).  I then added EDTA to 1 mM, and shook at room temperature for five 
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minutes.  I removed the insoluble fraction by centrifuging at 8,000 x g for twenty minutes at 4°C, and 
removed an aliquot of the resulting supernatant as supernatant 1 (S1).  I resuspended the pellet in 80 mL 
per gram ice cold 5 mM MgSO4, and removed an aliquot as resuspended 2 (R2).  I shook in an ice bath for 
five minutes, then removed the insoluble fraction by centrifuging at 8,000 x g for twenty minutes at 4°C, 
and removed an aliquot of the resulting supernatant as supernatant 2 (S2), the osmotic shock fluid.  SDS-
PAGE of 8% acrylamide gels followed by (A) Coomassie staining, and (B) immunoblotting against DGK-
alpha C-terminus (Abgent AP8128b (1:300 (v/v))).  The reason for the discrepancy in the migration 
patterns between the two sets of molecular weight standards in the immunoblot is unclear. 
I had previously observed that alphacat in pT71myc could be enriched from the 
supernatant by Ni-NTA even though the vast majority of alphacat in pT71myc was in the 
pellet, not the supernatant (Figure 15).  I therefore wondered whether the DGK constructs 
in pET28-HisMBP-FLAGpp could likewise be enriched from the supernatant, even 
though the vast majority of the protein was insoluble, as I had done with the pET32a 
constructs.  I thus purified the supernatants of both alphacat in pET28-HisMBP-FLAGpp 
expressions (both the expression test shown in Figure 58 and the periplasmic expression 
test shown in Figure 59) on Ni-NTA agarose.  Even though alphacat was undetectable in 
the supernatant in Figure 58, I could indeed enrich alphacat in pET28-HisMBP-FLAGpp 
on Ni-NTA agarose (Figure 60A and B).  The concentration in alphacat in the 
supernatant from the periplasmic extraction, however, was so low that even after Ni-NTA 
agarose enrichment, it was undetectable by immunoblotting (Figure 60C and D). 
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Figure 60.  Alphacat in pET28-HisMBP-FLAGpp can be enriched from BL21(DE3) supernatant, but 
not osmotic shock fluid, by Ni-NTA chromatography.  I stored the supernatant from Figure 58 for two 
weeks and the osmotic shock fluid (S2) from Figure 59 for eleven days at -80°C (in 20% glycerol, plus 1.6 
mL per gram 1 M Tris, pH 8.0), then thawed by gently shaking the tubes in water.  I removed the insoluble 
fraction by centrifuging at 110,000 x g for one hour at 4°C.  I added Ni-NTA agarose 1:14 (v/v) to the 
supernatant (from Figure 58) and 1:408 (v/v) to the osmotic shock fluid (from Figure 59) and incubated 
for 4.5 hours, rotating or rocking at 4°C.  I washed the resin with wash buffer 1 (50 mM Tris, pH 8.0, 300 
mM NaCl, 10 mM imidazole, 5 mM MgCl2, 1 mM CaCl2, 0.5 mM DTT) and wash buffer 2 (same as wash 
buffer 1, but imidazole increased to 70 mM), and eluted with elution buffer 1 (250 mM imidazole) and 
elution buffer 2 (500 mM imidazole).  SDS-PAGE followed by: (A), (C), Coomassie staining; (B), (D), 
immunoblotting against DGK-alpha C-terminus (Abgent AP8128b (1:300 (v/v))).  (A) and (B) show the 
purification from the supernatant shown in Figure 58. (C) and (D) show the purification from the osmotic 
shock fluid (S2) shown in Figure 59.  I loaded a larger volume of S2 into the immunoblot shown in (D) 
than I did into the immunoblot shown in Figure 59, which may explain why the antibody was able to detect 
it in this blot but not in the previous one.  This figure has been modified from Petro and Raben1 and is used 
under CC BY-NC 2.5. 
Although the enriched alphacat was clearly not purified to homogeneity (Figure 
60), the yield was sufficient that I could load it onto the Sephadex® G-200 analytical gel 
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filtration column, after first concentrating it by dialyzing against 15% PEG 17.5k.  The 
eluting MBP-tagged alphacat was clearly detectable by immunoblotting, along with 
several other immunoreactive bands (consistent with the presence of other 
immunoreactive bands in the partially purified fraction (Figure 60)) (Figure 61).  The 
predominant immunoreactive band migrates between 60 and 70 kD, so could very well be 
endogenous GroEL (which also recognizes the anti-DGK-alpha antibody (Figure 27)) 
associating with the overexpressed and possibly recombinant protein, similarly to what I 
observed with partially purified alphacat in pET32a (Figure 56B).  Alphacat in pET28-
HisMBP-FLAGpp’s predicted molecular weight is consistent with the top, ~90 kD band, 
and it is on this band that I performed densitometry.  Alphacat was not monodisperse, but 
rather eluted in two populations, one in the void volume, and one at an elution volume 
corresponding to a molecular weight of 124 kD (Figure 61), between the predicted 
molecular weights of a monomer and of a dimer.  Because alphacat in pET28-HisMBP-
FLAGpp was not monodisperse, I therefore concluded that the MBP-tagged alphacat also 
formed aggregates unsuitable for pursuit for structural studies. 
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Figure 61.  Partially purified alphacat in pET28-HisMBP-FLAGpp is not monodisperse a Sephadex® 
G-200 analytical gel filtration column.  The second wash (70 mM) of the supernatant (shown in Figure 
60A and B appeared to have the highest yield of alphacat, so, after storing for two days at 4°C, I removed 
the insoluble fraction by centrifuging at 43,000 x g for ninety minutes at 4°C, and then dialyzed the 
resulting supernatant against dialysis buffer (50 mM tris, 100 mM KCl, 1 mM CaCl2, pH 8.0, 15% (w/v) 
PEG 17.5 kD) for two hours at 4°C using a 10,000 MWCO cassette to concentrate it.  I stored the sample 
overnight at 4°C, then removed the insoluble fraction by centrifuging at 43,000 x g for ninety minutes at 
4°C.  I loaded 200 µL of the resulting supernatant onto a Sephadex® G-200 column that had been freshly 
blocked with 930 µL of 10 mg/mL albumin and previously calibrated with albumin and β-amylase.  I 
collected fractions every four minutes, eluting by gravity in gel filtration buffer (50 mM Tris, 300 mM 
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NaCl, 5 mM MgCl2, 1 mM CaCl2, 250 mM imidazole, pH 8.0).  (A) SDS-PAGE followed by 
immunoblotting against DGK-alpha C-terminus (Abgent AP8128b (1:300 (v/v))) of gel filtration fractions 
of elution volumes corresponding to molecular weights of 549 to 19.2 kD.  (B) Elution volumes of 
molecular weight standards and of purified alphacat from a Sephadex® G-200 column. Left vertical axis, 
A280 of the protein molecular weight standards, and A620 of the blue dextran fractions.  Right vertical 
axis, densitometry performed three times on the ~90 kD band using the film shown in (A), mean ± SD.  
This figure has been modified from Petro and Raben1 and is used under CC BY-NC 2.5. 
In another attempt to improve the protein constructs’ solubility, after inducing 
expression in E. coli with IPTG I added chloramphenicol to arrest translation, which has 
been reported in to improve the solubility of other proteins prone to aggregation121.  
Treating the cells with chloramphenicol did not appear to improve the recovery of MBP-
tagged alphacat or full-length DGK alpha in the supernatant following centrifugation, as 




Figure 62.  Arresting protein translation with chloramphenicol during expression does not improve 
the solubility following centrifugation of either alphacat or full-length DGK-alpha in pET28-
HisMBP-FLAGpp.  I inoculated four 4 mL LB Kan cultures with an overnight culture of either alphacat or 
else full-length DGK-alpha in pET28-HisMBP-FLAGpp.  When the OD600 was predicted to reach 0.8, I 
added IPTG to 0.1 mM (or not), and shook for fifteen hours at 20°C, then pelleted the cells.  I resuspended 
the uninduced cell pellets in the same volume as original cell culture in either LB Kan Cam (to control for 
the effects of translation arrest in BL21(DE3) not overexpressing a recombinant protein) or LB Kan plus 
ethanol (to control for the addition of ethanol, since that is the solvent in which our concentrated 
chloramphenicol stocks are stored), and I resuspended the induced cell pellets in either LB Kan Cam (to 
test whether translation arrest improved the solubility of the recombinant proteins) or else LB Kan plus 
ethanol plus 0.1 mM IPTG.  I returned the resuspended cells to culture tubes and continued to shake at 
20°C for two more hours, then pelleted the cells and froze at -80°C for two hours.  I thawed the cells by 
gently shaking the tubes in water, then resuspended the cells in 20 mL per gram wet cell pellet lysis buffer 
(50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 0.25% (v/v) TX-100, 0.5 mM DTT, 
1x PIC), added egg white lysozyme to 1 mg per mL, and incubated on ice for thirty minutes, vortexing 
occasionally to mix.  I lysed the cells by probe-sonicating ten times for ten seconds each, resting on ice for 
between each burst.  I removed the insoluble fraction by centrifuging at 43,000 x g for ninety minutes at 
4°C.  SDS-PAGE of 8% acrylamide gels followed by: (A), Coomassie staining; (B), immunoblotting 
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against DGK-alpha C-terminus (Abgent AP8128b (1:300 (v/v))).  U, uninduced; I, induced; L, lysate; S, 
supernatant (after removing insoluble from lysate).  Cam, chloramphenicol. 
Conclusions 
 I concluded that the MBP tag did not improve the solubility of the DGK 
constructs as I had hoped. 
Bacterial Expression Discussion and Conclusions 
Solubility challenges with expressing eukaryotic DGKs recombinantly in E. coli 
have been previously reported.  In one case S. scrofa DGK alpha purified from inclusion 
bodies had no detectable DGK activity49 (even though E. coli lysate overexpressing the 
same protein does have DGK activity36); in another, AtDGK2 from the plant Arabidopsis 
thaliana required a NusA tag in order to express in E. coli51.  Takahashi et al. report that 
they were unable to express the C-terminal domain of S. scrofa DGK alpha in E. coli 
because the cysteine-rich C1 domain rendered it insoluble39.  Recombinantly expressing 
LCB5 family proteins in E. coli has generally been more successful when those family 
members are prokaryotic92–94. 
One possible explanation for why recombinant expression of prokaryotic LCB5 
family proteins has been more successful than eukaryotic is that prokaryotes have 
different codon abundances than eukaryotes.  Insufficient availability of the appropriate 
tRNA can lead to ribosome pausing, frameshifts, deletions, mistranslations, aborted 
translation products, and decreased expression of the target protein, even in response to 
only a single rare codon122,123.  The cDNA of alphacat does in fact have a number of rare 
codons: two AGG, five AGA, eight CTA, one ATA, four CGA, twelve CCC, eight GGA, 
and three CGG.  Alphacat TEV in pET32a, when coexpressed with the 
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DnaK/DnaJ/GrpE/ClpB set of chaperones, produces, in addition to the predominant band 
of the predicted size, an additional, lower band that is recognized by the anti-DGK-alpha-
C-terminus antibody (Figure 55B); alphacat in pET28-HisMBP-FLAGpp (Figure 58C, 
Figure 59B, and Figure 60B) and alphacat in pT71myc (Figure 6B and Figure 16A) 
likewise produce several recognized bands.  These additional bands could indeed be 
truncations produced by aborted translation or by frameshifting during translation.   
Size may be another factor limiting the success of recombinantly expressing 
eukaryotic DGKs in prokaryotic systems.  S. typhimurium YegS and S. aureus DgkB are 
32 and 35 kD, respectively, smaller than any of the eukaryotic DGKs.  Although no 
absolute upper limit has been reported for the size of proteins that can be recombinantly 
expressed in E. coli, in general, larger proteins express less well.  My own observations 
are consistent with this rule of thumb: the smallest construct tested, alphacat in pT71myc, 
expresses the most robustly, and the alphacat constructs always express at higher levels 
than their full-length DGK alpha counterparts. 
Translational folding partners are frequently used to improve the solubility of 
proteins expressed in E. coli112–115.  However, my work has demonstrated that adding 
GST, TRX, or MBP as a fusion tag did not improve the solubility of either full-length 
DGK-alpha or alphacat.  All of the constructs in the bacterial expression studies are 
tagged on the N-terminus.  The position of a fusion tag can greatly affect a protein’s 
expression and function124,125; perhaps exposure of the N-terminus of full-length DGK 
alpha is required for stability, and a C-terminally tagged construct would express better or 
be more stable.  Alternatively, as discussed above, even the smallest constructs used in 
this study is large by prokaryotic standards, and perhaps any additional solubility 
 149 
conferred by the fusion tag was counteracted by the fact that the tagged protein was 
larger in size. 
Progress is being made in the ability to predict the ideal fusion tag to solubilize 
target proteins; however, much work remains to be done.  Protein solubility prediction 
servers126,127 are invaluable tools, but they sometimes disagree in their predictions.  For 
example, PROSO127 predicts our full-length DGK alpha in pT71myc construct to be 
soluble with a probability of 0.520, whereas SOLpro126 predicts it to be insoluble with a 
probability of 0.550540.  Their predictions may not be always accurate, either: 
SOLpro126, for example, predicts the alphacat in pET28-HisMBP-FLAGpp construct to 
be soluble with a probability of 0.771506, which is contrary to the data shown in Figure 
58.  Given the difficulty in predicting which solubility tags will work, it is entirely 
possible that alternative solubility tags could help increase the soluble yield of 
mammalian DGKs, and perhaps even cause them to elute as a monodisperse population 
from an analytical gel filtration column.  As mentioned above, the NusA tag proved 
helpful for expressing A. thaliana AtDGK2 in E. coli51; however, this report does not 
mention whether the purified AtDGK2 was monodisperse.  Solubility predictions by 
SOLpro126 for NusA-tagged alphacat and full-length DGK alpha are very optimistic, 
predicting them to be soluble with probabilities of 0.922228 and 0.870324, respectively, 
whereas predictions by PROSO127 are more measured: 0.561 and 0.532, respectively, 
possibly owing to the large size of these constructs (110 and 148 kD, respectively). Tags 
specifically engineered to improve the solubility of target proteins have been successfully 
developed in some systems115, and could be useful for DGK studies; however, at this 
 150 
juncture, improving the solubility of eukaryotic DGKs remains a process of trial-and-
error. 
Coexpressing alphacat with bacterial chaperones, especially GroEL/ES, increases 
the yield of some, but not all, of the tested constructs in the soluble fraction, which is 
promising for large-scale expressions for crystallography.  Unfortunately, alphacat in this 
soluble fraction still elutes in the void volume during analytical gel filtration 
chromatography.  One reason that alphacat coexpressed with GroEL/ES elutes in the void 
volume could be explained by its being complexed to the GroEL, based on the evidence 
that the two proteins copurify on Ni-NTA (Figure 28, Figure 31, Figure 46, Figure 47, 
and Figure 50), and they coelute from the analytical gel filtration column (Figure 29 and 
Figure 51).  If the alphacat is in fact complexed with GroEL/ES, the predicted molecular 
weight of the complex would be greater than 900 kD, and thus would indeed be predicted 
to elute in the void on the Sephadex® G-200 column.  Another possibility is that while 
coexpressing alphacat with bacterial chaperones is sufficient to increase its yield in the 
supernatant, it still remains in microscopic aggregates. 
The maximum size of a protein to fit in the cis-cavity of GroEL has been reported 
to be 57 kD128; on the other hand, GroEL has also been reported to help fold substrates as 
large as 150 kD129.  Therefore, it is not entirely surprising that the GroEL/ES sets of 
chaperones did not improve the solubility of any of the full-length DGK alpha constructs, 
or of the alphacat in pET32a constructs, although coexpression with GroEL/ES clearly 
improved the yield of alphacat in pGEX-4T2 in the supernatant after centrifugation, even 
though the size of the GST-tagged alphacat construct is 71.6 kD. 
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Analysis of the chaperone data is further complicated by the fact that GroEL is 
recognized by the α-DGK-alpha antibody (Figure 27).  Endogenous GroEL could thus be 
the identity of the predominant 60 kD immunoreactive band seen in the partially purified 
alphacat in pET32a (Figure 56) and in the partially purified alphacat in pET28-HisMBP-
FLAGpp (Figure 60 and Figure 61), in which case, GroEL’s failing to release alphacat 
could once again explain why alphacat in pET28-HisMBP-FLAGpp elutes in the void 
volume from the analytical gel filtration column (Figure 61), even though GroEL was not 
overexpressed in this preparation. 
It is not surprising that the DnaK/DnaJ/GrpE and DnaK/DnaJ/GrpE/ClpB sets of 
chaperones did not improve the solubility of either alphacat or full-length DGK alpha in 
any of the constructs tested, seeing as only DnaK appeared to overexpress (Figure 26A, 
Figure 34, Figure 41, and Figure 55), and its cochaperones DnaJ (which stimulates 
DnaK’s ATPase activity130) and GrpE (which acts as a nucleotide exchange factor for 
DnaK130) are not expressed proportionately.  DnaK has also been reported to induce 
proteolysis in response to overproduction of a recombinant protein131, which may be the 
reason we observe new, smaller, immunoreactive bands in alphacat TEV in pET32a 
lysates when coexpressed with the DnaK set of chaperones (Figure 55).     
It is entirely possible that coexpression with alternative sets of chaperones could 
also enhance the solubility of these proteins, but the process of choosing a set of 
chaperones to coexpress with a given protein remains largely empirical.  Other proteins 
reported to have chaperone activity, and thus potential candidates for coexpression to 
improve the solubility of eukaryotic DGKs, include Hsp90132, α-crystallins133, and 
dehydrins134.   DnaK itself indeed would also be a candidate for consideration, as long as 
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its cochaperones DnaJ and GrpE are also appropriately expressed, and could even be 
coexpressed with GroEL/ES, given that these chaperones can work in parallel135, thereby 
delivering the driving force needed to solubilize DGK-alpha. 
Detergents have often been reported to improve the solubility of recalcitrant 
proteins136–138.  Our method for determining monodispersity, analytical gel filtration 
using a Sephadex® G-200 resin, however, is incompatible with Triton X-100 
concentrations as low as 0.01% (v/v) because the detergent causes an unacceptable loss 
of resolution in the molecular weight standards (Figure 49).  Future studies wishing to 
monitor the monodispersity of eukaryotic DGKs may wish to consider alternative 
resin/detergent combinations. 
Given the challenges of expressing DGKs in prokaryotic hosts, I also tried to 
express and purify DGKs from eukaryotic expression systems. 
Expressing and Purifying Dictyostelium discoideum FLAG-DGKA from D. 
discoideum 
Introduction 
 A partially finished collaboration started previously in the laboratory sought to 
answer the question of whether four synthetic diglyceride analogs produced by the 
laboratory of Professor Glenn Prestwich (Department of Medicinal Chemistry, University 
of Utah), whose structures are shown in Figure 120, activated, inhibited, or could serve as 
substrates for eukaryotic DGKs.  This work was begun by Ms. Michele Ostroski using 
FLAG-DGKA expressed and purified from D. discoideum as the eukaryotic DGK.  In 
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order to continue the project, I therefore also needed to express and purify FLAG-DGKA 
from Dictyostelium discoideum. 
Results 
When I followed Ostroski et al.47’s methods for purifying FLAG-DGKA from the 
eukaryote and slime mold D. discoideum, the recombinant protein was enriched on the 
anti-FLAG agarose, but did not elute from the resin (Figure 63).  One important 
difference between my approach and that of Ostroski et al.47 was that while they grew 
their D. discoideum cultures in suspension in liter quantities, I maintained the D. 
discoideum as an adherent culture on tissue culture plates and therefore expressed much 
smaller quantities of protein.  I was unable to maintain D. discoideum as a suspension 
culture. 
 
Figure 63.  Following protocol Ostroski et al47 to purify FLAG-DGKA from D. discoideum gives low 
yield.  I resuspended FLAG-DGKA-expressing D. discoideum cells in their own medium.  I pelleted 
the cells and washed with cell wash buffer (50 mM N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic 
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acid (TES), 3x PIC, pH 7.3), then resuspended the cells in lysis buffer (50 mM TES, 200 mM NaCl, 10 
mM EDTA, 1 mM DTT, 3x PIC, pH 7.3), and filtered the cells through a 5 µm membrane.  I removed the 
insoluble fraction by centrifuging at 115,000 x g for one hour at 4°C.  I precleared the resulting supernatant 
with packed 1:20 (v/v) sepharose 4B and rotated at 4°C for 45 minutes.  I then added anti-FLAG agarose 
(which I had previously washed with anti-FLAG agarose wash buffer (50 mM TES, 400 mM NaCl, 1 mM 
EDTA, 1 mM DTT, 3x PIC, pH 7.0) 1:45 (v/v) and rotated at 4°C for two hours.  I washed the resin with 
wash buffer and eluted with 200 µg per mL FLAG peptide, and postcleared the eluate with 1:45 (v/v) 
DEAE Sephadex.  SDS PAGE of 8% acrylamide gels, followed by (A) silver staining, and (B) 
immunoblotting against FLAG (1:500 (v/v)). 
Following the manufacturer’s protocol was more productive for using anti-FLAG 
agarose to purify FLAG-DGKA from adherent cultures.  After initial success from a 
single 15-cm plate expression (Figure 64), I scaled up the expression to five 15-cm plates 
and removed the insoluble fraction before purifying on anti-FLAG agarose (Figure 65).  
Recognition by the anti-FLAG antibody in the immunoblot (Figure 64B and Figure 65B) 
was consistent with the major band detected in the silver stain’s being, in fact, FLAG-
DGKA.  I could readily detect DGK enzymatic activity of purified FLAG-DGKA (Figure 
66), both in micelles and in liposomes, but only in the presence of activators, as has been 
previously shown for its mammalian homolog DGK-theta3.   
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Figure 64.  FLAG-DGKA can be purified from D. discoideum following the FLAG-agarose 
manufacturer’s protocol.  I rinsed one 15 cm plate of FLAG-DGKA-expressing D. discoideum cells with 
PBS, added lysis buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% TX-100, 5x PIC, pH 7.4), and 
rocked at room temperature for 15 minutes.  I resuspended the cells in the lysis buffer, then removed the 
insoluble fraction by centrifuging at 115,000 x g for one hour at 4°C.  I added anti-FLAG agarose (which I 
had previously washed with agarose wash buffer (Tris-buffered saline (TBS) (50 mM Tris, 150 mM NaCl, 
pH 7.4), 5x PIC)) 1:25 (v/v) and rotated at 4°C for two hours.  I washed the resin with TBS and with wash 
buffer 2 (50 mM TES, 5x PIC, pH 7.3), and eluted with elution buffer (50 mM TES, pH 7.3, 200 µg per mL 
FLAG peptide).  SDS-PAGE of 8% acrylamide gels, followed by (A) silver staining, and (B) 
immunoblotting against FLAG (1:500 (v/v)). 
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Figure 65.  Scaled-up purification of FLAG-DGKA from D. discoideum.  I rinsed five 15 cm plate of 
FLAG-DGKA-expressing D. discoideum cells with PBS, added lysis buffer (50 mM Tris, 150 mM 
NaCl, 1 mM EDTA, 1% TX-100, 5x PIC, pH 7.4), and rocked at room temperature for 15 minutes.  I 
resuspended the cells in the lysis buffer, then removed the insoluble fraction by centrifuging at 115,000 x g 
for one hour at 4°C.  I froze the resulting supernatant overnight at -80°C.  I added anti-FLAG agarose 
(which I had previously washed with wash buffer 1 (TBS, 5x PIC)) 1:25 (v/v) and rotated at 4°C for two 
hours.  I washed the resin with wash buffer 1 and with wash buffer 2 (50 mM TES, 5x PIC, pH 7.3), and 
eluted with elution buffer (50 mM TES, pH 7.4, 200 µg per mL FLAG peptide, 5x PIC).  SDS-PAGE of 
8% acrylamide gels followed by (A) silver staining, and (B) immunoblotting against FLAG (1:500 (v/v)). 
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Figure 66.  Purified FLAG-DGKA’s enzymatic activity depends on the presence of an activator.  (A) 
DGK activity in Triton-X micelles. The reaction included micelles of the composition shown, 47 mM Tris, 
pH 7.4, 4.7 mM MgCl2, 0.7 ng per µL purified DGKA (as estimated from the silver stain in Figure 65A), 2 
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mM TES, 0.2x PIC, 8 µg per µL FLAG peptide, 2% (v/v) glycerol, 1 mM ATP, and 114 Ci per mmol [γ-
32P]-ATP, and proceeded for 7.5 minutes at 37°C.  Where indicated, 3 µL of concentrated casein stock 
solution was included per 50 µL reaction.  In duplicate: mean ± SD.  The DGKA had been stored at -80°C 
in 50% glycerol for six weeks prior to assaying.  (B) DGK activity in liposomes.  The reaction included 2 
mM liposomes (40:40:12:8::POPE:POPS:PI:DOG), 42 mM Tris, pH 7.0, 8.4 mM MgCl2, 8.4 mM NaF, 0.7 
ng per µL purified DGKA (as estimated from the silver stain in Figure 65A), 2 mM TES, 0.2x PIC, 8 µg 
per µL FLAG peptide, 2% (v/v) glycerol, 1 mM ATP, and 114 Ci per mmol [γ-32P]-ATP, and proceeded for 
7.5 minutes at 37°C.  1 µL of concentrated stock solutions of the indicated activators was included per 50 
µL reaction, where indicated.  In triplicate: mean ± SD.  The DGKA had been stored at -80°C in 50% 
glycerol for six weeks prior to assaying.   
Discussion and Conclusions 
By following the manufacturer’s protocol, I was able to express and purify 
FLAG-DGKA.  This purified fraction was recognized by an anti-FLAG antibody, and 
gave detectable enzymatic activity, but only in the presence of an activator.  The antibody 
recognition and the detectable DGK activity not only support the interpretation that the 
major band was, in fact, FLAG-DGKA, but also suggests that the recombinant enzyme 
was properly folded and had experienced any post-translational processing necessary for 
activity. 
Expressing and Purifying DGK Constructs from Insect Cells 
Insect Cell Expression Introduction 
 While prokaryotic expression systems can produce recombinant protein 
abundantly, which can be useful for producing the highly concentrated protein required 
for x-ray crystallography, eukaryotic expression systems have a number of advantages 
over prokaryotic expression systems for expressing eukaryotic proteins, including the 
proper codon preference, the proper machinery for expressing large proteins, and the 
proper post-translational modifications, which might be important for solubility.  
Eukaryotic expression systems generally produce less protein than prokaryotic expression 
systems, but insect cell lines have nonetheless been successfully used to express proteins 
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for x-ray crystallography.  I therefore set out to express and purify eukaryotic DGK 
constructs in two different insect cell lines in an effort to produce enough protein for 
structural studies. 
Cloning, Expressing, and Purifying Rattus norvegicus DGK-Alpha from Sf9 Cells 
Cloning R. norvegicus DGK-Alpha into the Bacmid 
The pENTR™11X vector was made by removing a SalI site from the 
pENTR™11 vector (Invitrogen™), in order to produce the proper reading frame for a 
previous cloning project.  R. norvegicus DGK-alpha in GFPC2 and pENTR™11X were 
previously digested with the restriction endonuclease EcoRI, electrophoresed, and 
excised from the agarose gel.  After extracting the DNA from the agarose, I treated the 
digested pENTR™11X vector with calf intestinal alkaline phosphatase (CIP) to remove 
the 5’ phosphoryl termini to prevent self-ligation139, electrophoresed, excised from the 
agarose gel, and extracted the DNA from the gel.  I then estimated the concentration of 
the DNA by comparing to molecular weight standards in agarose gel electrophoresis, 
ligated the DGK-alpha insert into the pENTR™11X plasmid, transformed the construct 
into the TOP10 strain of E. coli, and selected for kanamycin resistance (conferred by the 
pENTR™11X plasmid).  I extracted the DNA from successful transformants and 
confirmed successful insertion of DGK-alpha into pENTR™11X by diagnostic digest 
with EcoRI and SalI, and with EcoRV and HindIII. 
I used LR Clonase™ II to recombine DGK-alpha from pENTR™11X via its 
attL1 and attL2 sites into pDEST™10 (Invitrogen™) via its attR1 and attR2 sites.  After 
terminating the reaction with Proteinase K, I transformed the construct into the TOP10 
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strain of E. coli, and selected for carbenicillin resistance (conferred by the ampicillin 
resistance gene in pDEST™10).  I extracted the DNA from successful transformants and 
confirmed successful insertion of DGK-alpha into pDEST™10 by diagnostic digest with 
EcoRI. 
I then transformed the construct (R. norvegicus DGK-alpha in pDEST™10) into 
the DH10Bac™ strain of E. coli (Invitrogen), and selected for the parent bacmid 
bMON14272 with kanamycin, for the helper plasmid pMON7124 with tetracycline, and 
for pDEST™10 with gentamycin.  I selected recombinant bacmids as white colonies (not 
blue) in the presence of IPTG (to induce expression of β-galactosidase) and 5-bromo-4-
chloro-3-indolyl β-D-galactopyranoside (X-Gal) (a chromogenic substrate of β-
galactosidase), because successful insertion of DGK-alpha into pDEST™10 was 
predicted to disrupt the β-galactosidase gene.  I extracted the (large) bacmid DNA, and 
confirmed successful insertion of DGK-alpha by diagnostic PCR using the M13 universal 
primer to complement the bacmid and another primer to complement the insert. 
Expressing and Purifying R. norvegicus DGK-Alpha from Sf9 Cells 
 With the help of Dr. Becky Tu-Sekine, I first cloned R. norvegicus DGK-alpha 
from the GFPC2 plasmid into pENTR™11X, a variant of the pENTR™11 vector, to 
provide donor recombination sites in the proper frame around DGK-alpha.  I then 
recombined DGK-alpha from pENTR™11X into the pDEST10™ baculoviral vector, 
which produces a protein with an N-terminal hexahistidine fusion tag followed by a TEV 
protease site, and confirmed successful incorporation of the insert by diagnostic PCR.  I 
transfected the baculoviral vector into Sf9 Spodoptera frugiperda cells, which then 
produced baculovirus from the baculoviral vector. 
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 After infecting Sf9 cells with baculovirus encoding DGK-alpha in pDEST10™, 
the infected Sf9 cell lysates expressed a band easily detectable by silver staining that 
migrated between 80 and 90 kD, consistent with the predicted molecular weight of the 
fusion protein of 88.8 kD, and whose intensity increased with increasing multiplicity of 
infection (MOI) and increasing time of infection (Figure 67A).  A band migrating 
between 80 and 100 kD in the infected lysate but not the uninfected lysate was 
recognized by antibodies against DGK-alpha (Figure 67B) and DGK-alpha C-terminus 
(Figure 69), but not by antibodies against DGK-alpha N-terminus or histidine (Figure 
67B).  By DGK enzymatic activity assay, I measured greater DGK activity in Sf9 lysates 
that had been infected with the baculovirus than uninfected lysates, with greater activity 
in detergent micelles than in liposomes (Figure 68), consistent with the expressed bands’ 
identity being that of DGK-alpha. 
 
Figure 67.  Sf9 cells infected with DGK-alpha in pDEST10™ express a band whose migration pattern 
consistent with the predicted molecular weight and whose intensity increases with increasing MOI 
and increasing time of infection, and which is recognized by antibodies against DGK-alpha, but not 
by antibodies against DGK-alpha N-terminus or histidine.  (A) I infected a freshly fed 12-well plate of 
Sf9 cells with DGK-alpha in pDEST10™ at the indicated MOIs.  At the indicated timepoints, I removed 
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the medium by aspiration, resuspended the cells in lysis buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 
mM imidazole, 1 mM CaCl2, 0.5% NP-40, 1x PIC, 0.5 mM DTT), and stored at -20°C.  SDS-PAGE of an 
8% acrylamide gel followed by silver staining.  (B) I infected a 15 cm plate of Sf9 cells with 105 plaque-
forming units (pfu) per mL DGK-alpha in pDEST10™ for two days, then removed the medium by 
aspiration.  I added cold lysis buffer to the cells and allowed them to sit on ice for a few minutes before 
scraping and homogenizing twenty times with a glass cell homogenizer.  SDS-PAGE followed by 
immunoblotting against DGK-alpha N-terminus (Abgent AP8128a (1:200 (v/v)) (left), against His6 
(abcam® ab6196 (1:2500 (v/v)) (middle), and against DGK-alpha (Sakane (1:5000 (v/v)) (right).  I loaded 
0.5 µg protein (as measured by the Bio-Rad Protein Assay) per well. 
 
Figure 68.  The lysates of Sf9 cells infected with DGK-alpha in pDEST10™ have greater DGK 
activity than uninfected lysates.  The sample used is that shown in Figure 67, and had been stored 
overnight in 50% glycerol at -80°C prior to assaying.  Detergent micelles were 5 mM Triton X-100 
micelles with 6 mol% DOG and 9 mol% PS.  Liposomes were 7.5 mM, 53:22:17:8::PE:PC:PS:DOG.  The 
reaction included 47 mM HEPES, pH 8.0, 4.7 mM MgCl2, 1 mM CaCl2, 1 mM ATP, 2 mM Tris, 12 mM 
NaCl, 0.4 mM imidazole, 0.02% NP-40, 0.2x PIC, 40 ng per µL total protein (as measured by the Bio-Rad 
Protein Assay), and 29.3 Ci per mmol [γ-32P]-ATP, and proceeded for 15 minutes at 30°C.  In duplicate: 
mean ± SD. 
 I estimated my maximum yield of fusion protein to be 5 ng DGK-alpha per 0.5 µg 
total protein (Figure 67A), or 1% by weight, or approximately 0.46 µg per square 
centimeter of adherent Sf9 culture.  However, while total fusion protein yield increased 
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as a function of time after expression (Figure 67), fusion protein solubility decreased 
(Figure 69), so the maximum yield of soluble fusion protein would be quite a bit less. 
 
Figure 69.   The solubility of DGK-alpha in pDEST10™ decreases with decreasing time of infection.  
I infected one ten cm plate of Sf9 cells with DGK-alpha in pDEST10™ at a MOI of ~5.  At the 
indicated timepoints, I removed the medium by aspiration, added cold lysis buffer (50 mM Tris, pH 8.0, 
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300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 0.5% NP-40, 1x PIC) to the cells, and allowed them to sit 
on ice for a few minutes before scraping and homogenizing twenty times with a glass cell homogenizer.  
For the 96-hour infection, the lysis buffer also included 0.5 mM DTT.  I removed the insoluble fraction by 
centrifuging at maximum speed in a tabletop centrifuge for 15 minutes.  SDS-PAGE of 8% acrylamide gels 
followed by (A) Coomassie staining (of the 72-hour infection), (B) immunoblotting against DGK-alpha C-
terminus (Abgent AP8128b (1:300 (v/v))) (of the 72-hour infection), (C) Coomassie (of the 96-hour 
infection), and (D) immunoblotting against DGK-alpha (left: Sakane (1:5000 (v/v)); right: DGK-alpha C-
terminus Abgent AP8128b (1:200 (v/v)).  L, lysate; S, supernatant; U, uninfected; I, infected with DGK-
alpha in pDEST10™. 
After ultracentrifugation for one hour at 115,000 x g, some of the DGK-alpha 
fusion protein remained in the soluble fraction (Figure 70).  When I tried to enrich the 
DGK-alpha in that soluble fraction on Ni-NTA agarose, however, the protein flowed 
through the resin.  One possible explanation for why the DGK-alpha had no apparent 
affinity for the Ni-NTA resin could be that DGK-alpha might require calcium to fold in 
such a way that the hexahistidine tag is exposed and competent for binding to Ni-NTA.  
Another possible explanation is that the histidine tag might be occluded or indeed not 
even present in the protein, which would also explain why the anti-histidine antibody did 
not recognize the fusion protein (Figure 67).  The incorporation of the fusion protein into 
the plasmid was confirmed by diagnostic PCR, but not by sequencing: it is entirely 
possible that the hexahistidine tag was truncated or missing altogether because of a 
deletion or frameshift.  Any such genetic modification, however, would have to be small 
in magnitude, because the expressed protein was still between 80 and 90 kD in size, was 
recognized by the anti-DGK-alpha antibody, and showed detectable DGK enzymatic 
activity (Figure 67 - Figure 70). 
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Figure 70.  DGK-alpha in pDEST10™ expressed in Sf9 cells has very low affinity for Ni-NTA 
agarose.  I infected one ten cm plate of Sf9 cells with DGK-alpha in pDEST10™ 1:10 (v/v).   
After 48 hours, I removed the medium by aspiration, gently washed the cells with PBS, resuspended in 
lysis buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 0.1% TX-100, 1x PIC), and 
homogenized ten times with a glass cell homogenizer.  I froze the lysates at -80°C for four days, then 
thawed and removed the insoluble fraction by centrifuging 115,000 x g for one hour.  I added Ni-NTA 
agarose 1:10 (v/v) to the resulting supernatant, and rotated for two hours at 4°C.  I washed the resin with 
loading buffer (50 mM Tris, 300 mM NaCl, 10 mM imidazole, 1x PIC, 1 mM DTT) and wash buffer (same 
as loading buffer, but imidazole increased to 50 mM imidazole), and eluted in elution buffer (250 mM 
imidazole).  SDS-PAGE of an 8% acrylamide gel followed by immunoblotting against DGK-alpha (Sakane 
(1:5000 (v/v))). 
Discussion and Conclusions 
 I was able to express in Sf9 cells a band that was between 80 and 90 kD in size, 
was recognized by the anti-DGK-alpha antibody, and showed detectable DGK enzymatic 
activity (Figure 67 - Figure 70).  This protein, however, did not recognize an anti-
histidine antibody (Figure 67) and had no apparent affinity for a Ni-NTA resin (Figure 
70), suggesting that while at least most of the DGK was present, the histidine tag may 
have been improperly folded, occluded, or not even present.  Because I was unable to 
purify this protein, and because its solubility was poor to begin with, I therefore decided 
to pursue another construct for expression in insect cells for structural studies. 
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Expressing and Purifying Homo sapiens DGK-Theta from High Five™ Cells 
Introduction 
 H. sapiens DGK-theta is currently the best-studied DGK in our laboratory3,140,141.  
Although H. sapiens DGK-theta can be expressed and purified from mammalian cells, 
insect cells have the potential to produce larger amounts of protein, which would be 
amenable for structural studies requiring large amounts of protein.  We were interested in 
learning more about the structure of DGK-theta, and therefore set out to express H. 
sapiens DGK-theta in insect cells. 
Results 
After I infected High Five™ Trichoplusia ni ovary cells with baculovirus 
encoding H. sapiens DGK-theta in pDEST10™, infected lysates expressed a band easily 
detectable by Coomassie staining, not seen in the uninfected cell lysate, that migrated 
between the 130 and 160 kD molecular weight markers, a bit higher than its predicted 
molecular weight of 110.0 kD (Figure 71).  Less prominent new bands, one between 35 
and 55 kD in size, and one between 55 and 70 kD in size, also appeared.  I was also able 
to detect much greater DGK enzymatic activity in the infected lysates than in the 
uninfected lysates, using either detergent micelles or liposomes as a substrate (Figure 72).  
I therefore concluded that the infected lysates were successfully expressing DGK-theta. 
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Figure 71. High Five™ cells infected with DGK-theta in pDEST10™ express a band whose migration 
pattern is slightly slower than that of the predicted molecular weight: three representative 
expressions.   (A) I infected one of two fifteen cm plates of High Five™ cells with DGK-theta in 
pDEST10™ 1:100 (v/v).  After 23 hours, I replaced the medium on the cells.  The next day, I removed the 
medium by aspiration, washed the cells with PBS, resuspended the cells in cold lysis buffer (100 mM 
NaH2PO4, pH 8.0, 10 mM Tris, 0.5% NP-40, 1 mM DTT, 1x PIC), and homogenized ten times with a glass 
cell homogenizer.  SDS-PAGE of an 8% acrylamide gel followed by silver staining.  (B) I infected one of 
two fifteen cm plates of High Five™ cells with 300 µL DGK-theta in pDEST10™.  After two days, I 
removed the medium by aspiration, washed the cells with cold fractionation buffer (FB) (10 mM HEPES, 
pH 7.4, 1 mM EDTA, 0.5 mM EGTA), added cold lysis buffer (FB, 100 mM NaCl, 1x PIC, 30 mM NAG, 
1 mM NaVO4, 0.5% NP-40) to the cells, and allowed them to sit on ice for ~20 minutes before scraping 
and homogenizing twenty times with a glass cell homogenizer.  SDS-PAGE of an 8% acrylamide gel 
followed by Coomassie staining.  (C) I infected one of two fifteen cm plates of High Five™ cells with 300 
µL DGK-theta in pDEST10™.  After two days, I washed the cells with cold FB, added cold lysis buffer, 
and allowed them to sit on ice for ten minutes before scraping and homogenizing twenty times with a glass 
cell homogenizer.  SDS-PAGE of an 8% acrylamide gel followed by Coomassie staining.   
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Figure 72.  High Five™ cells infected with DGK-theta in pDEST10™ have higher DGK activity than 
uninfected lysates.  DGK activity assays.  (A) In detergent micelles.  I stored the lysates shown in Figure 
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71B in 50% glycerol at -80°C for eleven days prior to assaying.  The reaction included 7 mM TX-100 
micelles (9 mol% POPS, 6 mol% DOG), 44 mM Tris, pH 7.4, 4.4 mM MgCl2, 1 mM ATP, 0.5 mM 
HEPES, 47 µM EDTA, 23 µM EGTA, 5 mM NaCl, 1.5 mM NAG, 50 µM NaVO4, 0.025% (v/v) NP-40, 
0.05x PIC, 2.5% (v/v) glycerol, 2.5 µL original lysate (prior to adding glycerol per 50 µL reaction, and 43.1 
Ci per mmol [γ-32P]-ATP, and proceeded for 15 minutes at 37°C.  In duplicate: mean ± SD.  (B) In 
liposomes.  I stored the lysates shown in Figure 71C in 50% glycerol at -80°C for two days prior to 
assaying.  The reaction included 5.25 mM liposomes (53:22:17:8::POPE:POPC:POPS:DOG), 44 mM 
HEPES, pH 7.5, 4.4 mM MgCl2, 1 mM ATP, 0.5 mM HEPES, 47 µM EDTA, 23 µM EGTA, 85 mM NaCl, 
1.5 mM NAG, 50 µM NaVO4, 0.025% (v/v) NP-40, 0.05x PIC, 2.5% (v/v) glycerol, 2.5 µL original lysate 
(prior to adding glycerol) per 50 µL reaction, and 66.7 Ci per mmol [γ-32P]-ATP, and proceeded for 15 
minutes at 37°C.  In duplicate: mean ± SD.   
 An antibody against DGK-theta was able to recognize bands in the infected lysate 
not detected in the uninfected lysate immunoblotting, consistent with the infected lysate’s 
successfully expressing DGK-theta.  However, frequently the antibody detected many 
bands of different sizes, or else bands that ran much higher than the predicted molecular 
weight (Figure 73).  The cells from which the lysate with the high-running bands was 
derived were infected were lysed in a different buffer and more lysate was loaded onto 
the gel: it is not entirely clear which of these differences is responsible for the difference 
in antibody detection.  More puzzlingly, these high-running bands were detected in the 
very same samples in which the predominant band by silver staining ran at a lower 
molecular weight (Figure 71A): perhaps the antibody-recognizing bands were resistant to 
silver staining, or perhaps the silver-staining bands were resistant to recognition by the 
antibody.  Following sonication, an antibody-recognizing band of the appropriate size 
appeared (Figure 73B).  Denaturation by urea greatly enhanced antibody recognition (less 
protein was loaded into the urea pellet lane than in the lysate or supernatant lane, yet far 
more protein was recognized by the antibody), and also increased the number of 
recognized bands.  Following gradual renaturation by serially dialyzing into buffers with 
lower urea concentrations, the band of the correct size was enriched relative to the 
higher-running band, but the higher-running band never completely disappeared. 
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Figure 73.  An anti-DGK-theta antibody recognizes bands in lysates infected with DGK-theta that 
are not present in uninfected lysates, but migration in SDS-PAGE varies among expressions.  (A) I 
infected one of two 15 cm plates of High Five™ cells with 464 µL DGK-theta in pDEST10™.  The 
following day, I replaced the medium on the cells.  The day after that, I removed the medium by aspiration, 
washed the cells with PBS, resuspended the cells in cold lysis buffer (FB, 1x PIC), and homogenized ten 
times with a glass cell homogenizer.  SDS-PAGE of an 8% acrylamide gel followed by immunoblotting 
against DGK-theta (1:350 (v/v)).  (B) I collected the aggregates from the lysates shown in Figure 71A by 
centrifugation, resuspended them in lysis buffer (100 mM NaH2PO4, pH 8.0, 10 mM Tris, 0.5% NP-40, 1 
mM DTT, 1x PIC), and probe-sonicated eight times for fifteen seconds each, resting on ice for fifteen 
seconds between each burst.  I microfuged to collect the pellet, and resuspended the pellet in Buffer B (8 M 
urea, 100 mM NaH2PO4, 10 mM Tris, pH 8.0, 1x PIC, 1 mM DTT).  I added Ni-NTA agarose 1:5 (v/v) to 
the resuspended pellet, then washed the resin with wash buffer (same as Buffer B, but pH reduced to 6.3) 
and eluted with elution buffer (pH 4.5).  I dialyzed the eluate overnight against dialysis buffer 1 (4 M urea, 
100 mM NaH2PO4, 10 mM Tris, pH 7.4) at 4°C using 3500 MWCO dialysis tubing.  The next day, I 
gradually dripped in dialysis buffer 2 (10% (w/v) sucrose, 100 mM NaH2PO4, 10 mM Tris, pH 7.4), such 
that the final buffer composition was 5% sucrose and 2 M urea.  Two days later, I removed half the dialysis 
buffer, and dripped in more dialysis buffer 2, such that the final buffer composition was 7.5% sucrose and 1 
M urea.  The next day, I transferred the dialysis tubing to dialysis buffer 3 (same as dialysis buffer 2, but 
urea increased to 500 mM).  After four hours, I transferred the dialysis tubing to dialysis buffer 2.  The next 
day, I transferred the dialysis tubing to dialysis buffer 4 (same as dialysis buffer 2, but with 50 µM ZnCl2).  
SDS-PAGE of an 8% acrylamide gel followed by immunoblotting against DGK-theta (1:350 (v/v)).   
 The fraction of DGK-theta expressed in High Five™ cells that remained in the 
pellet after low-speed centrifugation gave a much higher immunoblot signal than that in 
the supernatant (Figure 74).  Any quantitative comparison by immunoblot requires 
assuming that the antibody has equal affinity for the soluble and insoluble populations of 
DGK-theta, but given that it seems unlikely the antibody would have considerably higher 
affinity for the insoluble population than for the soluble population, it seems reasonable 
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to conclude that DGK-theta expressed in High Five™ cells is mostly insoluble.  I could 
solubilize some DGK-theta from these pellets by washing with salt (Figure 75).  MgCl2 
was more effective than NaCl for salting in DGK-theta, but not because of its higher 
ionic strength.  When I removed the salt from these samples by dialysis and assayed their 
DGK activity in micelles, however, their activity was so low that the radiolabeled lipids 
extracted from the assay did not even produce spots when exposed to film. 
 
Figure 74.  DGK-theta expressed in High Five™ cells is mostly insoluble.  I stored the lysates shown in 
Figure 73A at -80°C overnight, the thawed and collected the aggregates by centrifugation, resuspended in 
lysis buffer (FB, 10 mM DTT, 1x PIC), and probe-sonicated eight times for fifteen seconds each, resting on 
ice for thirty seconds between each burst.  I added NaCl to 1 M and deoxycholate (DOC) to 2% (w/v), 
rotated at 4°C for thirty minutes, and microfuged to remove the insoluble fraction.  SDS-PAGE of an 8% 
acrylamide gel followed by immunoblotting against DGK-theta (1:350 (v/v)).   
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Figure 75.  DGK-theta expressed in High Five™ cells can be partially solubilized by salting in.  I 
resuspended the pellets from High Five™ cells infected with DGK-theta in pDEST10™ in DNAseI buffer, 
then probe-sonicated five times for five seconds each, resting on ice for fifteen seconds between each burst.  
I collected the pellet by centrifugation, then resuspended in DNAse I buffer.  I added DNAse I to 0.1 U per 
µL and incubated at 37°C for fifteen minutes.  I divided into three equal portions, then collected the pellet 
by centrifugation.  The first pellet I resuspended in alkaline phosphatase buffer, added alkaline phosphatase 
to 0.5 U per µL, and incubated at 37°C for fifteen minutes.  The second pellet I washed with 1 M NaCl (in 
DNAse I buffer), then 2 M NaCl, then 3 M NaCl, then 6 M urea in FP buffer.  The third pellet I 
resuspended in 333 mM MgCl2 (in DNAse I buffer), then 667 M MgCl2, then 1 M MgCl2, then 6 M urea in 
FP buffer.  SDS-PAGE of an 8% acrylamide gel followed by immunoblotting against DGK-theta (1:350 
(v/v)).   
I could also solubilize DGK-theta from pellets using urea.  After slowly removing 
the urea by dialysis, however, the protein precipitated when transferred to dialysis buffer 
that contained 50 µM ZnCl2 at pH 7.2.  Adding EDTA to 1.5 mM in the dialysis buffer 
was insufficient to resolubilize the protein, but I could resolubilize the protein by 
dialyzing against buffer that included 4 M urea at pH 9.5.  The protein remained soluble 
as the urea was dialyzed out, and as ZnCl2 was dialyzed in to 50 µM at pH 9.5.  Despite 
reports that insoluble pellets from DGK-theta-overexpressing High Five™ cells were so 
enriched for DGK-theta that additional purification steps were unnecessary, the final 
dialyzed DGK-theta contained, in addition to the predominant band between 100 and 120 
kD, many other bands detectable by silver staining (Figure 76A).  In another expression, 
washing the pelleted protein with 1 M NaCl and 2% deoxycholate (DOC) before 
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solubilizing it into a buffer containing 8 M urea, pH 12.5 was insufficient to produce 
purified dialyzed DGK-theta after the urea was removed (Figure 76B).  In fact, adding 
DOC caused protein to crash out of solution and thereby increased, not decreased, the 
contents of the pellet.  In order to produce purified protein, then, I needed additional 
enrichment steps. 
 
Figure 76.  Insoluble pellets from two different expressions of DGK-theta-overexpressing High 
Five™ cells require additional enrichment steps in order to produce purified DGK-theta.  (A) I 
resuspended the pellets from High Five™ cells infected with DGK-theta in pDEST10™ in extraction 
buffer (9.89 M urea, 1.1 mM TCEP, 1.24 mM EDTA, pH 12.2), then removed the insoluble fraction by 
microfuging at maximum speed for ten minutes at room temperature.  I dialyzed overnight into dialysis 
buffer 1 (3 M urea, 1 mM TCEP, 50 mM Tris, 10% sucrose, pH 9.5) at 4°C using 3500 MWCO dialysis 
tubing.  The next day, I poured out about a third of the dialysis buffer, then gradually dripped in dialysis 
buffer 2 (same as dialysis buffer 1, but urea reduced to 2 M).  The next day, I poured out about a third of 
the dialysis buffer, then gradually dripped in dialysis buffer 3 (1 M urea).  At the end of the day, I poured 
out about two-thirds of the dialysis buffer, then gradually dripped in dialysis buffer 4 (500 mM urea).  The 
next day, I gradually dripped in dialysis buffer 5 (0 mM urea, plus 50 µM ZnCl2).  The next day, I 
transferred the dialysis tubing to dialysis buffer 5, adjusted the pH to 7.2, and, after 3.5 hours, the protein 
precipitated.  I added EDTA to the dialysis buffer to 1.5 mM, but after an hour the protein still had not gone 
into solution.  I transferred the dialysis tubing to dialysis buffer 6 (same as dialysis buffer 1, but urea 
increased to 4 M), which did cause the protein go back into solution.  I gradually dripped in dialysis buffer 
7 (0 mM urea), such that the final concentration of urea was 2 M.  The next day, I removed half the dialysis 
buffer, and gradually dripped in dialysis buffer 7, such that the final concentration of urea was 1 M.   The 
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next day, I removed half the dialysis buffer, and gradually dripped in dialysis buffer 7, such that the final 
concentration of urea was 500 mM.  The next day, I removed half the dialysis buffer, and gradually dripped 
in dialysis buffer 7, such that the final concentration of urea was 250 mM.  The next day, I transferred the 
dialysis tubing to dialysis buffer 8 (100 mM urea), and after three hours, I transferred the dialysis tubing to 
dialysis buffer 7.  I gradually dripped in buffer 5, such that the final concentration of ZnCl2 was 25 µM.  
SDS-PAGE followed by silver staining.  (B) SDS-PAGE of the same samples shown in Figure 74 on an 
8% acrylamide gel, followed by silver staining. 
I was able to enrich DGK-theta overexpressed in High Five™ cells by non-native 
affinity chromatography against the hexahistidine epitope tag conferred by the 
pDEST10™ expression vector using Ni-NTA affinity chromatography (Figure 77).  
Although DGK-theta was clearly enriched, although the purified DGK-theta was 
recognized by the anti-DGK-theta antibody (Figure 73B), and although the 
overexpressing lysates had much greater DGK enzymatic activity than the uninfected 
lysates, by the time the DGK-theta was purified, it was no longer any more active than 
protein that had been similarly isolated from uninfected cells (Figure 78).  Adding tau to 
the reaction, which has been shown to activate DGK-theta purified from mammalian 
cells3, did not increase the activity of purified DGK-theta.  This loss of activity over the 
course of purification was not simply due to the time it had spent at 4°C, because lysate 
stored at 4°C lost only a fraction of its activity as compared to lysate stored at -80°C in 
50% glycerol.  Although by immunoblot more DGK-theta appeared to be in the pellet 
than in the supernatant (Figure 74 and Figure 77), most of the activity was retained in the 
supernatant (Figure 78), suggesting that the DGK-theta in the insoluble fraction is not 
very active to begin with, which might explain why enriching that insoluble protein does 
not give a very active fraction. 
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Figure 77.  DGK-theta in pDEST10™ can be enriched from High Five™ cells by Ni-NTA affinity 
chromatography. Purification of DGK-theta from High Five™ cells on Ni-NTA.  The band presumed 
to be DGK-theta, because it is clearly detectable in infected but not uninfected lysates, has been circled.  
The accompanying immunoblot for this purification may be seen in Figure 73B. 
 
Figure 78. DGK-theta purified from High Five™ cells has no more DGK activity than uninfected 
High Five™ cells that had been mock-purified.  I stored the samples shown in Figure 77 in 50% 
glycerol at -80°C for five days prior to assaying.  The reaction included 5 mM liposomes 
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(53:22:17:8::POPE:POPC:POPS:DOG), 44 mM Tris, pH 7.4, 4.4 mM MgCl2, 8 mM NaF, 1 mM ATP, 4 
mM NaH2PO4, 1 mM DTT, 2 µM ZnCl2, 2% (v/v) glycerol, 2 µL original lysate (prior to adding glycerol) 
per 50 µL reaction, and 125 Ci per mmol [γ-32P]-ATP, and proceeded for 15 minutes at 37°C.  In duplicate: 
mean ± SD. 
 I attempted, multiple times, to reproduce efforts in the lab reported to solubilize 
enzymatically active DGK-theta from the insoluble fraction from High Five™ cells.  One 
representative attempt is shown in Figure 79.  After washing the pellet with B-PER, I 
could solubilize the pellet in 25 mM glycine, 10 mM BME, 1 mM OG, pH 13.7.  Because 
DGK-theta was reported to be in an “SDS-resistant network of enzyme” at this stage (as 
in Figure 73B), I then denatured the protein by adding urea to 8 M, after first dropping 
the pH to 9.0, which had been reported to cause DGK to migrate appropriately on SDS-
PAGE.  After dropping the pH to 9.0, some, but not all, of the DGK had been solubilized 
(Figure 79A).  After slowly dialyzing out the urea, however, no DGK activity remained 
(Figure 79B).  In fact, the activity had been lost even before denaturation by urea (Figure 
79C).  As before, adding activators such as β-casein, protamine, or histone H1 were 
unable to increase the activity of purified DGK-theta to detectable levels. 
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Figure 79.  Some of the DGK-theta from the insoluble fraction of infected High Five™ cells can be 
solubilized, but this solubilized protein has no more DGK activity than protein similarly isolated 
from uninfected cells.  I infected one of two 15 cm plates of High Five™ cells with 300 µL DGK-theta in 
pDEST10™.  After two days, I washed the cells with cold FB, added cold lysis buffer (FB, 100 mM NaCl, 
1x PIC, 1 mM NaVO4, 0.5% NP-40) to the cells, and allowed them to sit on ice for ~30 minutes before 
scraping and homogenizing ten times with a glass cell homogenizer.  I stored the lysates at -80°C for six 
days, then thawed by shaking the tubes gently in water.  I collected the aggregates by centrifugation and 
washed with B-PER (Thermo Scientific), wash buffer 1 (10 mM NaH2PO4, pH 8.0), and wash buffer 2 (10 
mM HEPES, pH 8.0).  I solubilized the pellet by incubating with extraction buffer (25 mM glycine, 10 mM 
BME, 1 mM OG, pH 13.7) for ten minutes at 37°C, and removed the insoluble fraction by microfuging at 
maximum speed for five minutes at room temperature.  I diluted the resulting supernatant fivefold into 
dilution buffer 1 (100 mM HEPES, pH 9.0), then removed the insoluble fraction by centrifuging at 46,000 
x g for one hour at 25°C.  I diluted the resulting supernatant into dilution buffer 2 (8 M urea, 25 mM 
glycine, 1 mM EDTA, 10 mM BME, pH 9.0), then dialyzed overnight into dialysis buffer 1 (same as 
dilution buffer 2, but without EDTA).  I gradually dripped in dialysis buffer 2 (3 M urea, 10% sucrose, 25 
mM HEPES, 10 mM BME, pH 9.0), such that the final concentration of urea was 3.6 M, and then I 
gradually dripped in dialysis buffer 3 (same as dialysis buffer 2, except that the urea was reduced to 2 M), 
such that the final concentration of urea was 2.9 M.  The next day, I poured out most of the buffer and 
gradually dripped in dialysis buffer 4 (1 M urea), such that the final concentration of urea was 1.9 M, and 
then I gradually dripped in dialysis buffer 5 (500 mM urea), such that the final concentration of urea was 
1.3 M.  The next day, I poured out most of the buffer and gradually dripped in dialysis buffer 6 (0 M urea), 
such that the final concentration of urea was 330 mM.  The next day, I poured out about half of the buffer 
and gradually dripped in dialysis buffer 7 (same as dialysis buffer 6, plus 50 µM ZnCl2), such that the final 
concentration was 170 mM urea and 25 µM ZnCl2.  The next day, I transferred the dialysis tubing to 
dialysis buffer 8 (25 µM ZnCl2), and dialyzed all day.  (A) SDS-PAGE of 8% acrylamide gels followed by 
Coomassie staining.  I, infected; U, uninfected.  (B) DGK activity assay, in detergent micelles.  The 
reaction included 5 mM TX-100 micelles (9 mol% POPS, 6 mol% DOG), 44 mM Tris, pH 7.4, 4.4 mM 
MgCl2, 8 mM NaF, 1 mM ATP, 0.8% (w/v) sucrose, 2 mM HEPES, 0.8 mM BME, 2 µM ZnCl2, 4 µL 
dialyzed sample per 50 µL reaction, and 66.7 Ci per mmol [γ-32P]-ATP, and proceeded for 15 minutes at 
37°C.  In duplicate: mean ± SD.  One of the two replicates of the uninfected dialyzed sample appeared to 
have been contaminated by the sample in the adjacent lane (this was before I included the 0.2 mm buffer 
zone between lanes on aluminum plates), so that replicate has been omitted and, as such, no SD is shown.  
(C) DGK activity assay, in liposomes.  The samples were stored at 4°C for five days prior to assaying.  The 
reaction included 5 mM liposomes (53:22:17:8::POPE:POPC:POPS:DOG), 44 mM Tris, pH 7.4, 4.4 mM 
MgCl2, 8 mM NaF, 1 mM ATP, 0.4 mM glycine, 0.4 mM BME, 6 mM HEPES, 20 µM OG, 0.8 mM BME, 
4 µL dialyzed sample per 50 µL reaction, and 47.5 Ci per mmol [γ-32P]-ATP, and proceeded for 15 minutes 
at 37°C.  In duplicate: mean ± SD.     
In an effort to pinpoint precisely when the activity was lost, I tried again with a 
fresh expression of DGK-theta, with only small changes in the solubilization protocol 
(the lysis buffer included NAG; the cell pellet was not frozen before lysis; the cells were 
homogenized twenty times instead of ten; the protein pellets were washed in a larger 
volume; after the B-PER wash the pellets were washed with a HEPES buffer instead of a 
phosphate buffer; and I incubated the pellet for a longer time in the high-pH, OG-
containing buffer to solubilize it), but this time collected aliquots at each step of the 
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process, and stored them at -80°C in 50% glycerol in order to later assay the enzymatic 
activity.  Although the vast majority of the DGK-theta was in the pellet, not the 
supernatant (Figure 80A and Figure 81B), only about half of the DGK activity was 
recovered in the supernatant (Figure 80B).  As the protein pellet was washed, it quickly 
lost all of its DGK activity (consistent with some small amount of soluble, active DGK 
having been trapped within the protein pellet, and then removed upon washing, even 
though the vast majority of the DGK remained in the insoluble pellet), leaving no 
detectable activity even before the solubilization at pH 13.7.  I could detect no activity in 
the DGK that had been solubilized at pH 13.7, in either micelles (Figure 80B) or 
liposomes (Figure 81B), even in the presence of activators such as casein (Figure 80B), 
protamine, or the lysates of uninfected High Five™ cells (Figure 81B) in multiple 
attempts with multiple expressions, in contrast to what had previously been reported. 
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Figure 80. DGK-theta solubilized from High Five™ cells has no detectable DGK activity in detergent 
micelles.  The same expression as shown in Figure 71B.   I collected the aggregates by centrifugation, and 
washed with B-PER and wash buffer (10 mM HEPES, pH 8.0), vortexing for one minute for each wash.  I 
solubilized the aggregates by resuspending them in solubilization buffer (25 mM glycine, 1 mM OG, pH 
13.7), removed the insoluble fraction by microfuging at maximum speed for five minutes at room 
temperature, and diluted the resulting supernatant 1:4.2 in resuspension buffer (100 mM HEPES, pH 9.0).  
(A) SDS-PAGE of an 8% acrylamide gel followed by Coomassie staining.  U, uninfected; I, infected; R, 
resuspended; S, supernatant; P, pellet.  (B) I stored the lysates shown in Figure 71B in 50% glycerol at -
80°C for eleven days prior to assaying.  The reaction included 7 mM TX-100 micelles (9 mol% POPS, 6 
mol% DOG), 44 mM Tris, pH 7.4, 4.4 mM MgCl2, 1 mM ATP, 2.5% (v/v) glycerol, 2.5 µL protein sample 
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(prior to adding glycerol) per 50 µL reaction, and 43.1 Ci per mmol [γ-32P]-ATP, and proceeded for 15 
minutes at 37°C.  In duplicate: mean ± SD.   
 
Figure 81.  DGK-theta solubilized from High Five™ cells has no detectable DGK activity in 
liposomes.  The same expression as shown in Figure 71C.  I collected the aggregates by centrifugation, 
and washed with B-PER and wash buffer (10 mM HEPES, pH 8.0), vortexing for one minute for each 
wash.  I solubilized the aggregates by resuspending them in solubilization buffer (25 mM glycine, pH 
13.7), removed the insoluble fraction by microfuging at maximum speed for five minutes at room 
temperature, and diluted the resulting supernatant 1:5 in resuspension buffer (100 mM HEPES, pH 9.0), 
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then diluted that 1:6.25 into 8 M urea.  (A) SDS-PAGE of 8% acrylamide gels followed by Coomassie 
staining.  (B) DGK activity assay.  I stored the samples in 50% glycerol at -80°C overnight prior to 
assaying.  The reaction included 7 mM liposomes (53:22:17:8::POPE:POPC:POPS:DOG), 44 mM Tris, pH 
7.5, 4.4 mM MgCl2, 1 mM ATP, 2.5% (v/v) glycerol, 2.5 µL protein sample (prior to adding glycerol) per 
50 µL reaction, and 66.7 Ci per mmol [γ-32P]-ATP, and proceeded for 15 minutes at 37°C.  In duplicate: 
mean ± SD. 
I lowered the temperature of expression from 27°C to room temperature 
(approximately 24°C) to see whether a lower temperature would improve protein quality 
and hence enzymatic activity of solubilized protein.  The vast majority to DGK-theta 
remained insoluble (Figure 82).  I could, as with the higher-temperature expressions, 
solubilize DGK-theta from this insoluble fraction, but, also as before, the solubilized 
DGK-theta had no detectable DGK activity. 
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Figure 82. DGK-theta solubilized from High Five™ cells grown at a lower temperature has no 
detectable DGK activity in liposomes.  I infected one of two 15 cm plates of High Five™ cells with 300 
µL DGK-theta in pDEST10™.  Two days later, I washed the cells with FB, added lysis buffer (FB, 1x PIC, 
30 mM NAG, 1 mM NaVO4, 0.5% NP-40), and incubated on ice for fifteen minutes before scraping and 
homogenizing ten times with a glass cell homogenizer.  I collected the aggregates by centrifugation, and 
washed them with B-PER and with wash buffer (10 mM HEPES, pH 8.0).  I solubilized the aggregates by 
resuspending in solubilization buffer (25 mM glycine, 10 mM fresh BME, 1 mM OG, pH 13.7).  I removed 
the insoluble fraction by microfuging at maximum speed for five minutes at room temperature, diluted the 
resulting supernatant 1:5 into 8 M urea.  I then refolded the protein by diluting an additional 1:40 into wash 
buffer, such that the final concentration was 4 mM urea.  SDS-PAGE of 8% acrylamide gels followed by 
(A) Coomassie staining, (B) silver staining, and (C) immunoblotting against DGK-theta (1:350 (v/v)).  U, 
uninfected; I, infected; R, resuspended; S, supernatant; P, pellet.  (D) DGK activity assay.  I stored the 
samples in 50% glycerol at -80°C for 18 days prior to assaying.  The reaction included 7.5 mM liposomes 
(53:22:17:8::POPE:POPC:POPS:DOG), 44 mM Tris, pH 7.5, 4.4 mM MgCl2, 80 mM NaCl, 1 mM ATP, 
2% (v/v) glycerol, 2.5 µL protein sample (prior to adding glycerol) per 50 µL reaction, and 125 Ci per 
mmol [γ-32P]-ATP, and proceeded for 15 minutes at 37°C.  In duplicate: mean ± SD. 
Conclusions 
Because the DGK-theta expressed in High Five™ cells was inactive, it was 
deemed unsuitable for structural studies (since it would be unclear whether any structural 
information derived from inactive enzyme would be relevant to the turnover-competent 
molecule). 
Insect Cell Expression Conclusions 
 Although eukaryotic expression systems are predicted to have several advantages 
over prokaryotic expression systems, the eukaryotic DGK constructs tested expressed in 
insect cells with poor quality.  R. norvegicus DGK-alpha in pDEST10™ in Sf9 cells did 
not properly express the histidine tag and therefore could not be enriched by Ni-NTA 
chromatography, and H. sapiens DGK-theta in pDEST10™ in High Five™ cells was 
enzymatically inactive.  Insect cell expression therefore proved no more useful than 
bacterial expression did. 
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Expressing and Purifying Homo sapiens DGK-Theta from 293FT Human 
Embryonic Kidney Cells 
Introduction 
 Although mammalian cell lines produce less protein than other expression 
systems, they also include all of the proper machinery for expressing mammalian proteins 
such as mammalian DGKs.  The very fact that less protein is produced may also 
contribute to higher protein quality: it is possible that eukaryotic DGKs have exposed 
hydrophobic patches to help facilitate lipid binding, and while at endogenous levels of 
protein the exposed hydrophobic patches might not impair DGK function, when too 
much DGK is produced in too small a space the exposed hydrophobic patches at a high 
density might promote aggregation.  Although the lower levels of protein produced make 
mammalian cells an unlikely source for producing protein for x-ray crystallography, the 
higher quality of produced protein make them an ideal candidate for expressing protein 
for enzymological studies.  For the enzymological studies to answer questions about 
eukaryotic DGK chemistry, therefore, I set out to express and purify DGKs from 
mammalian cells. 
Results 
The Fc-FLAG-DGK-theta in pCDNA3.1 (+) construct begins with an N-terminal 
fusion tag of H. sapiens Ig heavy chain (Fc), followed by a TEV protease site, followed 
by a FLAG tag (Figure 83).  The MW and pI of this construct are predicted to be 129.5 
kD and 7.22, respectively. 
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Figure 83.  Schematic of Fc-FLAG-DGK-theta in pCDNA 3.1 (+) construct. 
I was able to express Fc-FLAG-DGK-theta in 293FT human embryonic kidney 
(HEK) cells via transient transfection.  After fractionating the cells, I was able to use the 
Fc tag to batch-purify DGK-theta from either cytosol or non-nuclear membranes by 
affinity chromatography using sepharose conjugated to Protein A, a bacterial protein with 
high affinity for immunoglobulins.  After batch purification, I was able to enrich a band 
that migrated between the 120 and 160 kD molecular weight markers, consistent with the 
predicted molecular weight of Fc-FLAG-DGK-theta, that recognized the anti-DGK-theta 
antibody (Figure 84): I concluded that this band was Fc-FLAG-DGK-theta.  While 
Protein A sepharose could enrich Fc-FLAG-DGK-theta, it was not purified to 
homogeneity.  Small changes in the purification protocol did not greatly affect purity or 
yield (Figure 84).  Fc-FLAG-DGK-theta enriched on protein A sepharose beads had 
detectable DGK enzymatic activity using either micelles or liposomes as a substrate and 




Figure 84.  Fc-FLAG-DGK-theta in pCDNA3.1 (+) can be enriched from HEK293FT via protein A 
sepharose affinity chromatography.  I transfected five 15 cm 293FT flasks, which had been grown in 
293FT growth medium 1, with Fc-FLAG-DGK-theta in pCDNA3.1 (+) for four hours.  Three days later, I 
washed the cells with FB.  I added cold lysis buffer (18 mM HEPES, pH 7.4, 92 mM NaCl, 0.5 mM EGTA, 
0.9 mM EDTA, 4 µg per mL quinacrine, 1x PIC, 100 mM NAG, 5 mM NaVO4, 10 mM NaF, 5 mM DTT, 
0.25% (v/v) NP-40), scraped the plates, and allowed to sit on ice for seven minutes before homogenizing 
seven times with a glass cell homogenizer.  I removed the insoluble fraction by centrifugation.  I 
fractionated the resulting supernatant by centrifuging at 115,000 x g for 65 minutes: the resulting 
supernatant was the cytosol, and the resulting pellet was the non-nuclear membranes (NNM).  I stored the 
cytosol in 20% glycerol at -80°C for two weeks, then thawed by shaking the tube gently in water.  I 
removed the insoluble fraction by centrifugation, then added protein A sepharose 1:125 (v/v) and rotated at 
4°C for two hours.  I washed the resin with wash buffer 1 (20 mM HEPES, pH 7.4, 150 mM NaCl, 0.5% 
NP-40), wash buffer 2 (same as wash buffer 1, but NaCl increased to 500 mM), and TB (20 mM HEPES, 
pH 8.4, 1 mM DTT).  SDS-PAGE followed by (A) silver staining, and (B) immunoblotting against DGK-
theta (1:350 (v/v)).  From the same expression shown in (A) and (B), I resuspended the NNM in lysis 
buffer and probe-sonicated three times for tens seconds each, and stored in 20% glycerol at -80°C 
overnight.  I thawed by shaking the tube gently in water, removed the insoluble fraction by centrifugation, 
then added protein A sepharose 1:50 (v/v) and rotated at 4°C for three hours.  I washed the resin with wash 
buffer 3 (20 mM HEPES, pH 7.4, 5 mM DTT, 250 mM NaCl, 1% (v/v) TX-100), wash buffer 4 (same as 
wash buffer 3, but TX-100 replaced with 0.5% (v/v) NP-40), and TB.  SDS-PAGE followed by (C) silver 
staining, and (D) immunoblotting against DGK-theta (1:350 (v/v)).  I transfected five 15 cm 293FT plates, 
which had been grown in 293FT growth medium 2, with Fc-FLAG-DGK-theta in pCDNA3.1 (+).  Two 
days later, I replaced the medium, and the next day, washed the cells with FB.  I added cold lysis buffer, 
scraped the plates, and homogenized twelve times with a glass cell homogenizer.  I removed the insoluble 
fraction by centrifugation, and fractionated the resulting supernatant into cytosol and NNM by centrifuging 
at 115,000 x g for 65 minutes.  I resuspended the NNM in lysis buffer and probe-sonicated five times for 
tens seconds each, and stored in 20% glycerol at -80°C for one month.  I thawed by shaking the tube gently 
in water, removed the insoluble fraction by centrifugation, then added protein A sepharose 1:50 (v/v) and 
rotated at 4°C for three hours.  I washed the resin with wash buffer 5 (same as wash buffer 3, but NP-40 
increased to 1% (v/v)), wash buffer 6 (same as wash buffer 5, but NaCl increased to 250 mM), and 
thrombin buffer (10 mM HEPES, pH 7.5, 10 mM Tris, 100 mM NaCl, 0.1% (w/v) PEG-8000).  SDS-
PAGE of 8% acrylamide gels followed by (E) silver staining, and (F) immunoblotting against DGK-theta 




Figure 85. Fc-FLAG-DGK-theta enriched from 293FT non-nuclear membranes has detectable DGK 
activity.  (A) The samples shown in Figure 84(C-D) were stored in 50% glycerol at -80°C for six weeks 
prior to assaying.  The reaction included 5 mM TX-100 micelles (9 mol% POPS, 6 mol% DOG), 49 mM 
HEPES, pH 7.0, 4.8 mM MgCl2, 132 mM NaCl, 1 mM ATP, 0.5% (v/v) glycerol, 23 pg protein sample per 
50 µL reaction, and 98.3 Ci per mmol [γ-32P]-ATP, and proceeded for 15 minutes at 37°C.  In duplicate: 
mean ± SD.  (B) The samples shown in Figure 84(E-F) were stored in 50% glycerol at -80°C for three 
weeks prior to assaying.  The reaction included 7.5 mM liposomes (53:22:17:8::POPE:POPC:POPS:DOG), 
44 mM HEPES, pH 7.0, 4.4 mM MgCl2, 123 mM NaCl, 1 mM ATP, 0.25 mM Tris, 1% (v/v) glycerol, 1 ng 
per µL protein sample per 50 µL reaction, and 66.7 Ci per mmol [γ-32P]-ATP, and proceeded for 15 
minutes at 37°C.  In duplicate: mean ± SD. 
We were also interested in learning whether DGK expressed in a mammalian 
system, presumably with its appropriate post-translational processing, was monodisperse, 
or whether it would elute in the void volume from a Sephadex G200 analytical gel 
filtration resin.  When I loaded supernatant from 293T cells overexpressing myc-tagged 
DGK-theta onto the resin, DGK eluted slightly before the void volume, as detected by 
Western blotting against either the myc tag or DGK-theta (Figure 86).  We concluded 




Figure 86.  DGK expressed in a mammalian system elutes in the void volume from a Sephadex® G-
200 column under the conditions tested.  Two 10 cm plates of 293T cells were washed with PBS, then 
resuspended in lysis buffer (4 mM HEPES, 130 mM sucrose, pH 7.4), scraped, and homogenized 18 times 
with a glass cell homogenizer.  I removed the insoluble fraction by centrifuging at 16,000 x g for ten 
minutes at 4°C, and loaded 200 µL of the resulting supernatant onto a Sephadex® G-200 column that had 
been previously calibrated with blue dextran, albumin, and alcohol dehydrogenase, and I collected fractions 
every 7.5 minutes, eluting by gravity in lysis buffer.  SDS-PAGE of an 8% acrylamide gel followed by 
immunoblotting against (A) myc (mouse 1:1000 (v/v)), and (B) DGK-theta (rabbit 1:200 (v/v)).  I loaded 
15 µL per well of gel filtration fractions of elution volumes corresponding to molecular weights of 364 to 
70 kD.  The same membrane was incubated in both antibodies simultaneously, since their signals could be 
distinguished on the LI-COR® detection system.  (C) Elution of molecular weight standards (left vertical 
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axis, A620 for blue dextran and A280 for protein standards) and myc-DGK-theta (immunoblot signal from 
(A) and (B), quantified by LI-COR®). 
Mammalian Cell Expression Conclusions 
 I was able to express and enrich Fc-FLAG-DGK-theta in 293FT HEK cells.  
Although this protein eluted in the void volume from an analytical gel filtration column 
and thus was not promising for x-ray crystallography studies, the limited amount of 
protein produced by mammalian cells would have been a challenge for such studies 
anyway.  The enriched protein was enzymatically active, and was therefore suitable for 
enzymological studies. 
Expressing and Purifying DGKs Discussion and Conclusions 
 Recombinantly expressed eukaryotic DGKs face major solubility challenges, not 
only in bacteria but also in insect cells, a eukaryotic expression system.  The protein 
quality of the DGKs expressed in insect cells is so poor that insect cell expression 
appears to be a no more promising approach than bacterial expression, despite its 
purported advantages.  Mammalian cells, possibly because of the lower abundance of 
proteins overexpressed therein, are able to produce enzymatically active DGK, but even 
DGK recombinantly expressed in mammalian cells elutes from an analytical gel filtration 
column in the void volume under the conditions tested, suggesting that DGK expressed in 
mammalian cells likewise faces solubility challenges.  Perhaps this tendency toward 
aggregation is telling us something about how these enzymes work: they are, after all, 
lipid-handling enzymes, so it is possible that they are exposing hydrophobic patches that, 
when the concentration of DGK rises too high in a cell, such as when recombinantly 
expressed, the density of these hydrophobic patches promotes aggregation.  Future 
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studies wishing to produce large amounts of eukaryotic DGKs will face these challenges.  
It is my hope that this work will help guide future research into more productive 
directions, so that anyone wishing to express these proteins know which strategies have 
already been tried.  It is also my hope that this work will help inform future efforts to 
predict which expression strategies will be amenable for which proteins, so that not every 
method will have to be empirically tested for every protein to be expressed, but rather the 
proper method can be recommended based on the primary sequence of a protein alone. 
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Chapter 4: DGK stability 
DGK Storage Conditions 
Introduction  
Purifying and expressing DGKs takes time, and it is impractical to do all 
experiments on DGK immediately after expressing and purifying it.  Therefore, in order 
to study the activity of DGK, it became plainly apparent that it was imperative to find 
conditions under which DGK could be stored between expression and experiment that 
mitigated the loss of DGK activity. 
Results 
 I compared how alphacat in pT71myc from freshly lysed Rosetta™(DE3) cells vs. 
a lysate that had been stored at -80°C in 20% glycerol for thirteen days fractionated upon 
washing with 2 M or 4 M urea.  When monitored by SDS-PAGE followed by Coomassie 
staining, how the alphacat fractionated did not appear to depend on whether the lysate 
was fresh or had been previously frozen (Figure 87A-D).  When monitored by SDS-
PAGE followed by immunoblotting against histidine, the lysates and supernatants did not 
appear different fresh vs. frozen; however, more alphacat appeared to wash off in the first 
2 M urea wash in the freshly expressed sample, and more alphacat appeared to wash off 
in the first 4 M urea wash in the sample that had been frozen (Figure 87E), suggesting 
that freezing may transfer some of the alphacat to a population that is insoluble at 2 M 
urea but soluble at 4 M urea.  I also immunoblotted against DGK-alpha (Figure 87F), but 
the interpretation of this immunoblot is limited by the fact that the immunoreactive band 
of the appropriate size to be alphacat was also faintly detected in the uninduced lysate, 
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suggesting that the interface between the stacking and separating phases of the gel may 
have dried out during casting, causing the wells’ contents to leak and contaminate other 
lanes.  I also assayed the DGK activity of these fractionations, but interpretation of this 
activity assay is severely limited by two factors.  Firstly, the vial of lipid that had been 
labeled as “DOG” and used as substrate was not, in fact, dioleoylglycerol, but rather 
dioctanoylglycerol (DiC8), as evidenced by the fact that instead of the single spot usually 
produced at a relative front (Rf) of 0.85, this substrate produced two spots: a stronger one 
with an average Rf of 0.54, and a weaker one with an average Rf of 0.75 (Figure 88A).  
Secondly, the lysate that had been left on ice for the duration of the assay showed nearly 
as high DGK activity as the lysate that had been incubated at 30°C for 15 minutes (Figure 
88B).  Considerable activity on ice makes the results of the assay difficult to interpret 
because, due to the logistics of large assays, some of the samples spend more time than 
others in the presence of [γ-32P]-ATP on ice.  A higher readout of the DGK assay may, in 
this case, say more about the amount of time the sample spent on ice with the assay 
components before being moved into the water bath than it does about the specific 




Figure 87.  Storing at -80°C in 20% glycerol for thirteen days may transfer some of the alphacat in 
pT71myc in Rosetta™(DE3) to a population that is insoluble at 2 M urea but soluble at 4 M urea, as 
compared to a fresh lysate.  The fresh expression is the same as shown in Figure 9.  The frozen 
expression is the same as shown in Figure 7.  I stored the lysates in 20% glycerol for thirteen days at -80C 
before fractionating as described in the figure legend to Figure 9.  SDS-PAGE followed by (A)-(D) 
Coomassie staining, (E) immunoblotting against His6 (abcam® ab6196 (1:2500 (v/v))), and (F) 
immunoblotting against DGK-alpha (Sakane (1:5000 (v/v))).  (A) and (C) show the fractionation of the 
fresh lysate; (B) and (D) show the fractionation of the frozen lysate. 
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Figure 88.  Rosetta™(DE3) lysate overexpressing alphacat in pT71myc shows considerable DGK 
activity on ice using DiC8 as a substrate.  The samples (Figure 87) had been stored in 50% glycerol at -
80°C for three weeks prior to assaying their DGK activity.  The reaction included 7.5 mM liposomes 
(53:22:17:8::POPE:POPC:POPS:“DOG”), 49 mM HEPES, pH 8.0, 4.9 mM MgCl2, 1 mM CaCl2, 1 mM 
ATP, 0.25 mM Tris, 1.5 mM NaCl, 50 µM imidazole, 0.0025% (v/v) NP-40, 0.005x PIC, 0.25% (v/v) 
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glycerol, 0.5 µL protein sample per 50 µL reaction, and 37.3 Ci per mmol [γ-32P]-ATP, and proceeded for 
15 minutes at 30°C.  Forty minutes elapsed between combining the reaction mix for “fresh lysate on ice” 
and placing the “fresh lysate” tube in the 30°C water bath.  (A) Autoradiograph.  The marked line indicates 
the solvent front.  A,B: no activator.  C,D: plus heat-inactivated tau.  (B) DGK activity assay.  In duplicate: 
mean ± SD. 
 Because of the DOG/DiC8 mix-up, I thought that the alphacat in pT71myc lysates 
were losing activity when stored at -80°C, and thus became concerned about storage 
conditions, and therefore set out to test those expressly.  In these same experiments, I also 
tested a range of protein concentrations to determine the linear range of the assay.  I was 
unable to test the lysate fresh because the PE vial had been mislabeled as 25 mg/mL 
when it was in fact 10 mg/mL, meaning that the lipids dried for liposomes had too high a 
PC:PE ratio to be able to successfully extrude.  I dried down fresh lipids of the correct 
composition for liposomes, but as such I had to store the lysate overnight at 4°C before I 
was able to assay it.  These liposomes also included DiC8 instead of DOG (because of 
the mislabeled vial of lipid mentioned previously).  After one night at 4°C, the bacterial 
lysate overexpressing alphacat in pT71myc demonstrated more DGK activity toward 
DiC8 than the uninduced lysate, and this activity depended linearly on the concentration 
of the enzyme at least up through 60 ng per µL of total protein (Figure 89). 
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Figure 89.  Rosetta™(DE3) lysate overexpressing alphacat in pT71myc shows greater DGK activity 
toward DiC8 than uninduced lysate, and this activity depends linearly on the concentration of the 
enzyme at least up through 60 ng per µL of total protein.  I inoculated two 25 mL LB Kan cultures with 
an overnight culture of alphacat in pT71myc in Rosetta™(DE3).  When the OD600 was predicted to reach 
1.0, I added IPTG to 0.5 mM (or not) and shook the cultures for 21.5 hours at ~18°C, then pelleted the cells 
by centrifugation and resuspended in 6 mL each cold lysis buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 
mM imidazole, 1 mM CaCl2, 0.5% NP-40, 1x PIC, 1 mM DTT, 1 mg per mL lysozyme) and incubated on 
ice for thirty minutes.  I lysed the cells by probe-sonicating six times on ice for ten seconds each, resting on 
ice for ten seconds between each burst.   I stored the lysates overnight at 4°C prior to assaying their DGK 
activity.  The reaction included 7.5 mM liposomes (53:22:17:8::POPE:POPC:POPS:“DOG”), 49 mM 
HEPES, pH 8.0, 4.9 mM MgCl2, 1 mM CaCl2, 1 mM ATP, 98.3 Ci per mmol [γ-32P]-ATP, and, from the 
lysates, up to 0.9 mM Tris, 5.4 mM NaCl, 180 µM imidazole, 0.009% (v/v) NP-40, and 0.018x PIC, and 
proceeded for 16 minutes at 30°C.  23 minutes elapsed between combining the reaction mix for “alphacat 
in pT71myc on ice” and placing the other tubes in the 30°C water bath.  I calculated the nmol PA as the 
total of the two radiolabeled spots produced from DiC8.  In duplicate: mean ± SD. 
 After the initial storage at 4°C overnight, I stored aliquots of the lysates either at 
4°C, at -80°C in 20% (v/v) glycerol, and at -80°C in 50% glycerol.  After one week, I 
assayed the activity again in liposomes: this time DOG was used as a substrate, although 
the Rf remained lower than expected (~0.7).  Because the substrate was different, the 
specific activity cannot be compared quantitatively to the activity one week previously, 
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so I cannot conclude whether or not the alphacat lost activity during the course of the 
week, or by how much.  I can, however, conclude that for all three storage methods, the 
activity of alphacat-overexpressing lysates remained higher than that of uninduced lysates 
(Figure 90).  The activity was the highest for alphacat that had been stored at -80°C in 
50% glycerol; the activity of lysates stored at 4°C or at -80°C in 20% glycerol were 
comparable to one another.  The activity on DiC8 after one night at 4°C for the induced 
lysate was more than four times the activity of the uninduced lysate (Figure 89), but the 
activity on DOG after one week of any of the tested storage conditions was less than four 
times that of the uninduced lysate (Figure 90); however, as mentioned, any interpretation 




Figure 90.  For all three storage methods tested, the activity of alphacat-overexpressing 
Rosetta™(DE3) lysates remained higher than that of uninduced lysates.  DGK activity assay.  The 
samples used were the same as shown in Figure 89, stored for one week under the conditions shown.  The 
reaction included 7.5 mM liposomes (53:22:17:8::POPE:POPC:POPS:DOG), 49 mM HEPES, pH 8.0, 4.9 
mM MgCl2, 1 mM CaCl2, 1 mM ATP, 76.2 Ci per mmol [γ-32P]-ATP, and, from the lysates, up to 0.9 mM 
Tris, 5.4 mM NaCl, 180 µM imidazole, 0.009% (v/v) NP-40, 0.018x PIC, and 0.9% (v/v) glycerol, and 
proceeded for 15 minutes at 30°C.  Twenty minutes elapsed between combining the reaction mix for 
“alphacat -80°C 50% glycerol on ice” and placing the other tubes in the 30°C water bath.  In duplicate: 
mean ± SD. 
 After two weeks’ storage, the activity of all the samples had fallen as compared to 
their activity after one week’s storage (Figure 91) (although caution must be urged in any 
quantitative comparison between two different assays).  Once again, the induced lysates 
show higher DGK activity than their uninduced counterparts.  As opposed to storage after 
one week (Figure 90), after two weeks’ storage, the highest activity is shown by the 
alphacat that had been stored at 4°C, and the lowest is shown by that stored at -80°C in 
50% glycerol (Figure 91).  Once again, however, the interpretation of these data is 
limited by the fact that, even though this assay was relatively fast, the lysate stored on ice 
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for the time of the assay, plus twenty minutes, showed considerable activity, and the 4°C 
lysate’s high activity may merely reflect the fact that 32P-γ-ATP had been added to those 
samples first, and they spent longer sitting on ice before being moved to the 30°C water 
bath. 
 
Figure 91.  Storage test of alphacat in pT71myc in Rosetta™(DE3) lysates: two weeks.  DGK activity 
assay.  The samples used were the same as shown in Figure 89, stored for two weeks under the conditions 
shown.  The reaction included 7.5 mM liposomes (53:22:17:8::POPE:POPC:POPS:DOG), 49 mM HEPES, 
pH 8.0, 4.9 mM MgCl2, 1 mM CaCl2, 1 mM ATP, 70.0 Ci per mmol [γ-32P]-ATP, and, from the lysates, up 
to 0.9 mM Tris, 5.4 mM NaCl, 180 µM imidazole, 0.009% (v/v) NP-40, 0.018x PIC, and 0.9% (v/v) 
glycerol, and proceeded for 15 minutes at 30°C.  25.5 minutes elapsed between combining the reaction mix 
for “alphacat -80°C 50% glycerol on ice” and placing the other tubes in the 30°C water bath.  In duplicate: 
mean ± SD. 
 Because the switch in substrates caused by the mislabeled lipid limited the 
conclusions that could be drawn from the alphacat storage conditions experiment, I 
decided to repeat the experiment.  The freshly harvested induced lysate showed higher 
DGK activity on DOG-containing liposomes than the uninduced lysate did, and this 
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activity appeared to depend linearly on concentration up through at least 50 ng per µL 
total protein. 
 
Figure 92.  Rosetta™(DE3) lysate overexpressing alphacat in pT71myc shows greater DGK activity 
toward DOG than uninduced lysate, and this activity depends linearly on the concentration of the 
enzyme at least up through 50 ng per µL of total protein.  I inoculated two 25 mL LB Kan cultures with 
a freshly growing culture of alphacat in pT71myc in Rosetta™(DE3).  When the OD600 was predicted to 
reach 1.0, I added IPTG to 0.5 mM (or not) and shook the cultures for 20.5 hours at ~15°C, then pelleted 
the cells by centrifugation and resuspended in 4 mL per gram wet cell pellet lysis buffer (50 mM Tris, pH 
8.0, 300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 5 mM MgCl2, 0.5% NP-40, 1x PIC, 0.5 mM DTT, 1 
mg per mL lysozyme) and incubated on ice for ~75 minutes.  I vortexed the cells, and they were quite 
viscous, suggesting that the cells did lyse.  I added DNAse I to 10 U per mL and incubated on ice for thirty 
minutes.   I kept the lysates on ice until the DGK assay.   The reaction included 7.5 mM liposomes 
(53:22:17:8::POPE:POPC:POPS:DOG), 49 mM HEPES, pH 8.0, 4.9 mM MgCl2, 1 mM CaCl2, 1 mM 
ATP, 119 Ci per mmol [γ-32P]-ATP, and, from the lysates, up to 0.5 mM Tris, 3 mM NaCl, 100 µM 
imidazole, 0.005% (v/v) NP-40, and 0.01x PIC, and proceeded for 15 minutes at 30°C.  In duplicate: mean 
± SD. 
I once again stored aliquots of the lysates either at 4°C, at -80°C in 20% glycerol, 
or at -80°C in 50% glycerol.  After two weeks’ storage, the specific activity dropped 
dramatically, although once again caution must be urged in any quantitative comparison 
between two different assays (Figure 93).  The activity dropped so much that the induced 
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lysate that had been stored at 4°C for two weeks no longer had any more activity than the 
uninduced lysate (in contrast to the results shown in Figure 91).  The induced lysates 
stored at -80°C, in either 20% glycerol or 50% glycerol, retained greater activity than 
their uninduced counterparts, and their activity was comparable to one another (Figure 
93).  Once concern about this assay is that the activity appeared to no longer depend 
linearly on the concentration of the protein used: in fact, for nearly all the samples tested, 
the 30 ng per µL samples (1.5 µg in 50 µL) showed lower activity than the 20 ng per µL 
samples (1 µg in 50 µL). 
 
Figure 93.  Rosetta™(DE3) lysate overexpressing alphacat in pT71myc lost a considerable amount of 
DGK activity after two weeks’ storage.  DGK assay on liposomes of alphacat in pT71myc-
overexpressing BL21(DE3) lysates stored for two weeks under the conditions shown.  DGK activity assay.  
The samples used were the same as shown in Figure 92, stored for two weeks under the conditions shown.  
The reaction included 7.5 mM liposomes (53:22:17:8::POPE:POPC:POPS:DOG), 49 mM HEPES, pH 8.0, 
4.9 mM MgCl2, 1 mM CaCl2, 1 mM ATP, 60.5 Ci per mmol [γ-32P]-ATP, and, from the lysates, up to 0.5 
mM Tris, 3 mM NaCl, 100 µM imidazole, 0.005% (v/v) NP-40, 0.01x PIC and 0.5% (v/v) glycerol, and 
proceeded for 15 minutes at 30°C. In duplicate: mean ± SD. 
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 After four weeks’ storage, the activity of the alphacat lysate that had been stored 
at 4°C remained no higher than that of the uninduced lysate, and the activity of the lysate 
that had been stored at -80°C, in either 20% glycerol or 50% glycerol, still retained 
greater activity than their uninduced counterparts, and their activity remained comparable 
to one another (Figure 94A).  The activity, however, was no less than that of the aliquots 
tested two weeks previously, and, in the case of the lysate stored at -80°C in 20% 
glycerol, even higher (Figure 94B), suggesting that something might have been wrong 
with the earlier assay. 
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Figure 94.  Storage test of alphacat in pT71myc in Rosetta™(DE3) lysates: four weeks.  (A) DGK 
activity assay.  The samples used were the same as shown in Figure 92, stored for thirty days under the 
conditions shown.  The reaction included 7.5 mM liposomes (53:22:17:8::POPE:POPC:POPS:DOG), 49 
mM HEPES, pH 8.0, 4.9 mM MgCl2, 1 mM CaCl2, 1 mM ATP, 114 Ci per mmol [γ-32P]-ATP, and, from 
the lysates, up to 0.5 mM Tris, 3 mM NaCl, 100 µM imidazole, 0.005% (v/v) NP-40, 0.01x PIC, 0.5% (v/v) 
glycerol and 2 µg total protein per 50 µL reaction, and proceeded for 15 minutes at 30°C.  In duplicate: 
mean ± SD. (B) Specific activity compared to that from previous assays shown in Figure 92 and Figure 
93. 
 After eight weeks’ storage, the activity of the alphacat lysate that had been stored 
at 4°C remained no higher than that of the uninduced lysate, and the activity of the lysate 
that had been stored at -80°C, in either 20% glycerol or 50% glycerol, still retained 
greater activity than their uninduced counterparts (Figure 95A).  This time, however, the 
lysate that had been stored in 50% glycerol demonstrated greater DGK activity than the 
lysate that had been stored in 20% glycerol.  Indeed, the lysate that had been stored at -
80°C in 50% glycerol showed even greater specific activity than when the lysate had 
been fresh, eight week’s previously (Figure 95B), supporting the hypothesis that 
something had been wrong with the assay at two weeks. 
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Figure 95.  Storage test of alphacat in pT71myc in Rosetta™(DE3) lysates: eight weeks.  (A) DGK 
activity assay.  The samples used were the same as shown in Figure 92, stored for sixty-two days under the 
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conditions shown.  The reaction included 7.5 mM liposomes (53:22:17:8::POPE:POPC:POPS:DOG), 49 
mM HEPES, pH 8.0, 4.9 mM MgCl2, 1 mM CaCl2, 1 mM ATP, 89.2 Ci per mmol [γ-32P]-ATP, and, from 
the lysates, up to 0.5 mM Tris, 3 mM NaCl, 100 µM imidazole, 0.005% (v/v) NP-40, 0.01x PIC, 0.5% (v/v) 
glycerol and 2 µg total protein per 50 µL reaction, and proceeded for 15 minutes at 30°C.  In duplicate: 
mean ± SD.  (B) Specific activity compared to that from previous assays shown in Figure 92-Figure 94. 
 It remained unclear how long alphacat lysate could be stored at 4°C before losing 
its activity.  A few hours between lysis and the assay appeared fine in Figure 92, and also 
in Figure 89, although that used DiC8 and not DOG as a substrate.  Induced lysate still 
retained more activity than uninduced lysate after one week in Figure 90 and after two 
weeks in Figure 91, although as mentioned before, interpreting these results is 
complicated by the lysate’s activity on ice.  Contrariwise, in the second experiment, 
alphacat stored at 4°C had lost its activity within two weeks (Figure 93) and, even if this 
experiment is discounted because of apparent problems with this assay (Figure 95B), the 
induced lysate stored at 4°C had clearly lost its activity at four (Figure 94A) and eight 
weeks (Figure 95A).  Therefore, I tested whether storage of the lysate from a third 
expression could be stored at 4°C overnight without losing activity.  When this lysate was 
stored overnight at -80°C in 50% glycerol, it maintained higher activity than uninduced 
lysate, but not when it was stored overnight at 4°C (Figure 96).  The first expression 
(which maintained its activity at 4°C) differed from the second and third expressions 
(which did not maintain their activity at 4°C) in several ways: the first expression was 
induced at 18°C, whereas the second and third expressions were induced at lower 
temperatures; the first expression was lysed in a larger volume of lysis buffer (and 
therefore was more dilute when it was stored); and the first expression’s lysis buffer did 




Figure 96.  Rosetta™(DE3) lysates overexpressing alphacat in pT71myc lose their activity overnight 
when stored at 4°C but not when stored at -80°C in 50% glycerol.  I inoculated two 25 mL LB Kan 
cultures with an overnight culture of alphacat in pT71myc in Rosetta™(DE3).  When the OD600 was 
predicted to reach 1.0, I added IPTG to 0.5 mM (or not) and shook the cultures overnight at ~14°C, then 
pelleted the cells by centrifugation and stored the cell pellets overnight at -80°C.  I resuspended in 4 mL per 
gram wet cell pellet lysis buffer (50 mM Tris, pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mM CaCl2, 5 
mM MgCl2, 0.5% NP-40, 1x PIC, 1 mM DTT, 1 mg per mL lysozyme, 20 U per mL DNAse I) and 
incubated on ice for ~five hours, and stored the samples for the DGK assay under the conditions shown 
overnight.   The reaction included 7.5 mM liposomes (53:22:17:8::POPE:POPC:POPS:DOG), 49 mM 
HEPES, pH 8.0, 4.9 mM MgCl2, 1 mM CaCl2, 1 mM ATP, 114 Ci per mmol [γ-32P]-ATP, and, from the 
lysates, up to 0.1 mM Tris, 0.6 mM NaCl, 20 µM imidazole, 0.001% (v/v) NP-40, 0.002x PIC, and 0.1% 
glycerol, and proceeded for 15 minutes at 30°C.  In duplicate: mean ± SD. 
From the alphacat in pT71myc in Rosetta™(DE3) lysate storage experiments, I 
learned that alphacat lysate maintains its activity when stored at -80°C, in either 20% or 
50% glycerol, and that the DGK activity assay sometimes has reproducibility issues that 
mean that not too much stock can ever be put into a single assay.  Whether or not 
alphacat lysate loses its activity at 4°C may depend on the temperature induction, 
concentration of storage, and, most intriguingly, the concentration of MgCl2 during 
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storage.  Because these are lysates, and not purified protein, these effects could also 
depend on components in the lysate besides alphacat: perhaps the bacterial lysate 
includes another, Mg2+-dependent, enzyme, which is active at 4°C but not when frozen, 
that processes alphacat in such a way such that it is no longer active. 
After expressing H. sapiens DGK-theta in High Five™ cells (the expression 
shown in Figure 73A, Figure 74, and Figure 76B), I compared the activity of lysates 
stored either at -80°C or at 4°C for one week.  Storage at 4°C for one week decreased the 
DGK activity as compared to the lysate that had been frozen, but DGK activity remained 
detectable, and clearly greater than that of the uninfected High Five™ lysate. 
 
Figure 97.  Storage at 4°C, as compared to -80°C, for one week decreases the DGK enzymatic activity 
of H. sapiens DGK-theta-overexpressing High Five™ lysates.  DGK activity assay.  The samples used 
were the same as shown in Figure 73A, Figure 74, and Figure 76B, stored for one week either frozen or 
else at 4°C (“refrigerated”).  The reaction included 5 mM liposomes 
(53:22:17:8::POPE:POPC:POPS:DOG), 48 mM Tris, pH 7.4, 4.8 mM MgCl2, 8.8 mM NaF, 1 mM ATP, 
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98.3 Ci per mmol [γ-32P]-ATP, and, from the lysates, 0.2 mM Tris, 20 µM EDTA, and 10 µM EDTA, and 
proceeded for 15 minutes at 37°C.  In duplicate: mean ± SD. 
 As such, I generally stored the enzyme in 50% glycerol at -80°C for activity 
assays.  However, such storage conditions were no guarantee to maintain enzymatic 
activity.  I also observed aliquots of DGK-theta purified from HEK293T cells, having 
been stored at -80°C in glycerol and maintaining their enzymatic activity for years, that  
suddenly lost activity, even when those particular aliquots had never been thawed and 
refrozen, while sister aliquots maintained their activity (Figure 98). 
 
Figure 98.  Aliquots of DGK-theta purified from HEK293T cells, stored in 50% glycerol at -80C, can 
suddenly lose enzymatic activity even while sister aliquots retain theirs.  DGK activity assay.  The 
“aliquot used before” had been successfully thawed and refrozen without losing activity.  “From other 
strip” is from the same original sample, aliquoted into separate tubes, and unthawed since originally being 
frozen.  “601D” and “601E” are from other fractions of the purification, frozen at the same time and 
likewise unthawed.  Samples were first preincubated in 0.4% (v/v) NP-40 on ice for ten minutes.  The final 
reaction mixture included 5 mM liposomes (55.3:27.7:9:8::POPE:POPC:POPS:DOG), 50 mM HEPES, pH 
7.4, 99 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 145 Ci per mmol [γ-32P]-ATP, 0.25% (v/v) glycerol, 
0.004% (v/v) NP-40, 0.1 µM histone H1, 1 mM DTT, and 6.5 pg per µL purified DGK (as estimated from 
silver staining and interpolating from the intensity of BSA standards), and proceeded for 15 minutes at 
37°C.  In duplicate: mean ± SD. 
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Conclusions 
DGK generally maintained its activity in 50% glycerol at -80°C better than it did 
in 20% glycerol at -80°C, at -20°C, or at 4°C.  As such, I generally stored the enzyme in 
50% glycerol at -80°C for activity assays.  However, such storage conditions were no 
guarantee to maintain enzymatic activity.   
Inactivation of DGK by Incubating While Diluted on Ice or at Room Temperature, 
and Preincubation and Incubation Conditions That Can Mitigate This Inactivation 
Introduction 
 DGK activity is influenced not only by the conditions of the activity assay, and 
the conditions of its longterm storage, but also by the conditions to which is has been 
exposed acutely before the assay. 
Results 
Incubating purified DGK-theta purified from HEK293T cells on ice for less than 
two hours before the assay vastly reduced its enzymatic activity (Figure 99A).  I was 
surprised by this finding, seeing as the purification of the enzyme takes longer than two 
hours, but the results were reproducible (Figure 99B).  I therefore set out to find 




Figure 99.  Incubating purified DGK-theta purified from HEK293T cells on ice for less than two 
hours before the assay markedly reduces its enzymatic activity.   Samples were preincubated for ten 
minutes in 0.4% NP-40, then incubated on ice in incubation buffer (0.013% NP-40, 50 mM HEPES, 100 
mM NaCl, 1 mM DTT, pH 7.4).  In triplicate: mean ± SD.  (A) The samples were incubated in incubation 
buffer for either 102 (“DGK-theta on ice”) or 16 (“fresh DGK-theta on ice”) minutes prior to the start of the 
reaction.  The final reaction mixture included 2.75 mM substrate-containing liposomes 
(50:25:9:16::POPE:POPC:POPS:DOG), 2 mM filler liposomes (60.7:30.3:9::POPE:POPC:POPS), 50 mM 
HEPES, pH 7.4, 100 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 131 Ci per mmol [γ-32P]-ATP, 0.04% (v/v) 
glycerol, 0.0007% (v/v) NP-40, 0.1 µM histone H1, 1 mM DTT, and 1.1 pg per µL purified DGK (as 
estimated from silver staining and interpolating from the intensity of BSA standards), and proceeded for 16 
minutes at 37°C.  (B) The samples were incubated in incubation buffer for either 78 (“DGK-theta on ice”) 
or 18 (“fresh DGK-theta on ice”) minutes prior to the start of the reaction.  The final reaction mixture was 
the same as in (A) except that [γ-32P]-ATP was decreased to 119 Ci per mmol.  The reaction proceeded for 
15 minutes. 
 When first thawing aliquots of purified DGK-theta for activity assays, I generally 
first preincubated in 0.4% (v/v) NP-40 on ice for ten minutes before proceeding.  
Adjusting the pH of the 0.4% NP-40 preincubation from 8.5 to 7.4 had no effect on the 
enzymatic activity of DGK-theta purified from HEK293T cells, nor did adding MgCl2 to 
the preincubation to 15 mM (Figure 100). 
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Figure 100.  Modifying the pH or the MgCl2 concentration in the 0.4% NP-40 preincubation has no 
effect on the enzymatic activity of DGK-theta purified from HEK293T cells.  DGK activity assay.  
Samples were first preincubated in 0.4% (v/v) NP-40 on ice under the conditions shown for ten minutes.  
The final reaction mixture included 5 mM liposomes (55.3:27.7:9:8::POPE:POPC:POPS:DOG), 50 mM 
HEPES, pH 7.4, 99 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 145 Ci per mmol [γ-32P]-ATP, 0.004% (v/v) 
NP-40, 0.1 µM histone H1, and 1 mM DTT, and proceeded for 15 minutes at 37°C.  In duplicate: mean ± 
SD. 
 When I preincubated purified DGK-theta with DOG-containing liposomes on ice, 
the DGK activity was higher than purified DGK-theta incubated on ice without liposomes 
(Figure 101).  This observation is consistent with previously reported work showing 
DGK-theta to be a quasi-scooter140: if liposome-binding is partially rate-limiting, then 
allowing DGK-theta more time to bind the substrate-containing liposomes before 
assaying the activity would be predicted to increase the apparent activity. 
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Figure 101.  Preincubating with DOG-containing liposomes on ice increases the enzymatic activity of 
purified DGK-theta.  I first preincubated the samples in 0.4% (v/v) NP-40 on ice for ten minutes.  I then 
diluted the samples 1:1 into assay buffer (55.6 mM HEPES, pH 7.4, 111 mM NaCl), with or without 5 mM 
DOG-containing liposomes (50:25:9:16::POPE:POPC:POPS:DOG), and incubated on ice for two hours.  
The final reaction mixture included 5 mM liposomes (for “DGK-theta on ice”, 
55.3:27.7:9:8::POPE:POPC:POPS:DOG; for “DGK-theta + DOG-containing liposomes on ice”, 2.5 mM of 
the original DOG-containing liposomes plus an additional 2.5 mM of 60.7:30.3:9::POPE:POPC:POPS), 36 
mM HEPES, pH 7.4, 72 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 98.3 Ci per mmol [γ-32P]-ATP, 0.2% (v/v) 
glycerol, 0.1% (v/v) NP-40, 0.1 µM histone H1, 1 mM DTT, and 1.1 pg per µL purified DGK, and 
proceeded for 15 minutes at 37°C.  In triplicate: mean ± SD. 
Incubation at room temperature of DGK-theta purified from HEK293T cells 
vastly reduced its enzymatic activity (Figure 102).  I did this particular experiment to see 
whether the conditions of the O-GlcNAcylation assay inactivated DGK: the lower pH 
buffer partially did, but the room-temperature incubation inactivated DGK even more so. 
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Figure 102.  Incubation at room temperature of DGK-theta purified from HEK293T cells vastly 
reduces its enzymatic activity.  DGK activity assay.  I incubated purified DGK for 160 minutes in either 
10 mM HEPES buffer (10 mM HEPES, pH 7.4, 0.1% (w/v) BSA) or OGT buffer (24 mM sodium 
cacodylate, pH 6.5, 5.4x PIC, 268 mM GalNAc, 0.67 mM UDP-GlcNAc, 0.006% (w/v) BSA), either at 
room temperature or on ice.  The reaction included 5 mM TX-100 micelles (6 mol% PS, 9 mol% DOG), 
and 1 mM DTT, and proceeded for 15 minutes at 30°C.  In duplicate: mean ± SD. 
 Irradiation with a 360 nm lamp inactivated DGK time-dependently (Figure 103).   
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Figure 103.  Irradiation with a 360 nm lamp inactivates DGK-theta purified from HEK293T cells 
time-dependently.  DGK activity assay.  I first preincubated the samples in 0.4% (v/v) NP-40 on ice for 
ten minutes.  I then diluted the samples into assay buffer (55.6 mM HEPES, pH 7.4, 111 mM NaCl), and 
then added liposomes (50:25:9:16::POPE:POPC:POPS:DOG).  I then irradiated with a 360 nm lamp for the 
time shown in a water-jacketed quartz cuvette.  The final reaction mixture included 2.5 mM substrate-
containing liposomes (50:25:9:16::POPE:POPC:POPS:DOG), 2.5 mM filler liposomes 
(60.7:30.3:9::POPE:POPC:POPS), 50 mM HEPES, pH 7.4, 100 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 
73.5 Ci per mmol [γ-32P]-ATP, 0.05% (v/v) glycerol, 0.0007% (v/v) NP-40, 0.1 µM histone H1, 1 mM 
DTT, and 1.1 pg per µL purified DGK, and proceeded for 15 minutes at 37°C. 
I thought this inactivation might result from the UV lamp’s warming up the 
protein in the quartz cuvette, so I measured the temperature of buffer in the water-
jacketed quartz cuvette before and after irradiating it.  While the temperature of 100 µL 
of water in the quartz cuvette with the lamp on was only slightly higher than that 
protected by cardboard, or with no lamp on at all, it was also only slightly below room 
temperature (Table 1), and thus I suspected that DGK irradiated at 360 nm was being 
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subjected to room-temperature inactivation, since I had previously shown that incubation 
at room temperature inactivates DGK (Figure 102). 
Condition Temperature (°C) 
100 µL of buffer, in water-jacketed quartz 
cuvette, irradiated with lamp for 5 minutes 
21.1 
100 µL of buffer, in water-jacketed quartz 
cuvette, irradiated with lamp for 5 minutes 
with cardboard barrier 
20.8 
100 µL of water in water-jacketed quartz 
cuvette 
20.5 
100 uL of water in quartz cuvette (water 
not flowing in jacket) 
22.9 
Room temperature 24 
Table 1.  Temperature as measured by a steel-probed thermometer of buffer in a water-jacketed 
quartz cuvette under various conditions. 
Indeed, incubation at room temperature for 30 minutes inactivated DGK just as 
much as irradiation at 360 nm did, with or without cardboard between the lamp and the 
cuvette (Figure 104). 
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Figure 104.  Incubation at room temperature for 30 minutes inactivates DGK-theta purified from 
HEK293T cells as much as irradiation at 360 nm.  DGK activity assay.  I first preincubated the samples 
in 0.4% (v/v) NP-40 on ice for ten minutes.  I then diluted the samples 1:1 into assay buffer (55.6 mM 
HEPES, pH 7.4, 111 mM NaCl) with or 5 mM DOG-containing liposomes 
(50:25:9:16::POPE:POPC:POPS:DOG), and incubated either on ice (for the “on ice” sample) or at room 
temperature (RT) for thirty minutes.  I then irradiated the “UV” and “cardboard” samples with a 360 nm 
lamp for four minutes in a water-jacketed quartz cuvette (with a piece of cardboard between the lamp and 
the cuvette for the “cardboard” sample).  The final reaction mixture included 5 mM liposomes (2.5 mM of 
the original DOG-containing liposomes plus an additional 2.5 mM of 60.7:30.3:9::POPE:POPC:POPS), 36 
mM HEPES, pH 7.4, 72 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 98.3 Ci per mmol [γ-32P]-ATP, 0.2% (v/v) 
glycerol, 0.1% (v/v) NP-40, 0.1 µM histone H1, 1 mM DTT, and 1.1 pg per µL purified DGK, and 
proceeded for 15 minutes at 37°C.  In triplicate: mean ± SD. 
MgATP is one of the substrates of the chemical reaction that DGK catalyzes, and 
as such may be necessary for DGK to assume a reaction-competent conformation.  
Histone H1 activates purified DGK-theta3, and likewise may be necessary for DGK to 
assume a reaction-competent conformation.  These conformational changes might also, in 
theory, protect DGK from inactivation at room temperature or even on ice.  The 
laboratory has observed conflicting results regarding whether DTT, a reducing agent, has 
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any effect on DGK activity; DTT could likewise be affecting the conformation of the 
enzyme, and variable results might reflect variable time spent on ice prior to the assay.  I 
therefore tested whether preincubation with histone H1 and/or MgATP protected DGK 
from room-temperature inactivation.  DTT in the preincubation appeared to have no 
effect on DGK activity (Figure 105).  Incubation at room temperature decreased the 
activity of DGK.  Incubation with histone H1 (without MgATP) on ice decreased DGK 
activity as much as that which had been incubated at room temperature; it had no 
additional effect on the DGK that had been incubated at room temperature.  Incubation 
with MgATP, with or without histone H1, precipitously dropped DGK’s activity: 
however, this may have been due the fact that I accidentally added ATP and MgCl2 to 10 
mM and 15 mM, respectively, when I had intended to add them to 1 mM and 1.5 mM, 
and the higher concentration of Mg2+, a divalent cation, may have adversely affected the 
quality of the liposomes142. 
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Figure 105.  DTT in the preincubation has no effect on the enzymatic activity of DGK-theta purified 
from HEK293T cells.    DGK activity assay.  I preincubated purified DGK-theta in 0.4% NP-40 on ice for 
27 minutes, either with or without 1 mM DTT.  Then I diluted that preincubated DGK into 4 mM 
liposomes (55.3:27.7:9:8::POPE:POPC:POPS:DOG), with or without 0.625 µM histone H1 and/or 18.75 
mM MgCl2 and 12.5 mM ATP, and incubated at 30 minutes either on ice or at room temperature (RT).  The 
final reaction mixture included 5 mM liposomes (55.3:27.7:9:8::POPE:POPC:POPS:DOG), 47 mM 
HEPES, pH 7.4, 94 mM NaCl, 1.5 (or 15) mM MgCl2, 1 (or 10) mM ATP, 98.3 (or 49.2) Ci per mmol [γ-
32P]-ATP, 0.04% (v/v) glycerol, 0.92% (v/v) NP-40, 0.1 µM histone H1, 1 mM DTT, and 1.1 pg per µL 
purified DGK, and proceeded for 15 minutes at 37°C.  In duplicate: mean ± SD. 
 I retested the effect of histone H1 and/or MgATP preincubation on DGK-theta, 
this time with the correct MgATP concentration.  This time, I preincubated purified DGK 
with the factors tested in the presence of 0.4% NP-40 on ice for ten minutes.  Then I 
diluted the preincubated DGK into liposomes, and incubated either at room temperature 
or on ice for 30 minutes.  As seen before, a 30-minute incubation at room temperature 
partially inactivates purified DGK-theta as compared to DGK-theta that had been 
incubated on ice (Figure 106A), even in the presence of liposomes.  Preincubation with 
histone H1 (but not MgATP) increased DGK’s activity, even on ice, and room-
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temperature incubation no longer inactivated DGK.  Preincubation with MgATP (but not 
histone H1) had no effect on DGK’s activity.  Preincubation with both histone H1 and 
MgATP inactivated DGK, either incubated on ice or at room temperature. Preincubation 
with histone H1 on ice also increased the DGK activity of purified DGK-theta and 
protected against room temperature inactivation when the activity was assayed using 
Triton X-100 micelles as a substrate (Figure 106B).  The implications for possible 
conformational changes in DGK caused by MgATP, histone H1, and lipid are intriguing 
(perhaps histone H1 and MgATP pin DGK into a conformation such that the lipid 
substrate can no longer access the active site?), but the practical implications were that if 
I first preincubated DGK-theta purified from HEK293T cells on ice for ten minutes in the 




Figure 106.  Preincubation in the presence of histone H1 activates purified DGK-theta and protects 
against room-temperature inactivation when assayed in both liposomes and detergent micelles.  (A) 
DGK activity assay in liposomes.  I preincubated purified DGK-theta on ice in 0.4% NP-40 in the presence 
or absence of 4 µM histone H1, 30 mM MgCl2, and 20 mM ATP for 10 minutes, then diluted into 5 mM 
liposomes (55.3:27.7:9:8::POPE:POPC:POPS:DOG) and incubated either on ice or at room temperature for 
30 minutes before assaying the activity.  The final concentration of histone H1 and MgATP in the assay 
was the same for all samples.  The final reaction mixture included 5 mM liposomes, 50 mM HEPES, pH 
7.4, 99 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 66.7 (or 33.3) Ci per mmol [γ-32P]-ATP, 0.06% (v/v) 
glycerol, 0.01% (v/v) NP-40, 0.1 µM histone H1, 1 mM DTT, and 1.1 pg per µL purified DGK, and 
proceeded for 15 minutes at 37°C.  In duplicate: mean ± SD.  (B) DGK activity assay in Triton X-100 
micelles.  I preincubated purified DGK-theta on ice in 0.4% NP-40 and 1 mM DTT in the presence or 
absence of 4 µM histone H1 for 10 minutes, then diluted into 2 mM TX-100 micelles (9 mol% POPS) and 
incubated either on ice or at room temperature for 30 minutes before assaying the activity.  The final 
concentration of histone H1 in the assay was the same for all samples.  The final reaction mixture included 
2 mM TX-100 micelles (1.5 mM (9 mol% POPS), and 0.5 mM (9 mol% POPS, 32 mol% DOG)), 50 mM 
HEPES, pH 7.4, 99 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 60.5 Ci per mmol [γ-32P]-ATP, 0.04% (v/v) 
glycerol, 0.01% (v/v) NP-40, 0.1 µM histone H1, 1 mM DTT, and 1.1 pg per µL purified DGK, and 
proceeded for 15 minutes at 37°C.   
 Indeed, not only did the histone H1 preincubation prevent inactivation by 
incubating at room temperature, but it also at least partially prevented inactivation caused 
by irradiating with 360 nm light (Figure 107; compare to Figure 104). 
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Figure 107.  Preincubation in the presence of histone H1 partially prevents inactivation by 
irradiation with 360 nm light of purified DGK-theta.  DGK activity assay.  I preincubated purified 
DGK-theta on ice in preincubation buffer (21 mM HEPES, pH 7.4, 41 mM NaCl, 0.005% (v/v) dodecyl-β-
D-maltoside (DDM), 4 µM histone H1, 1 mM DTT) for 10 minutes, then diluted into 1.9 mM liposomes 
(55.3:27.7:9:8::POPE:POPC:POPS:DOG).  I then irradiated the “UV” and “cardboard” samples with a 360 
nm lamp for ten minutes in a water-jacketed quartz cuvette.  The final reaction mixture included 2 mM 
liposomes, 50 mM HEPES, pH 7.4, 100 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 53.1 Ci per mmol [γ-32P]-
ATP, 0.04% (v/v) glycerol, 0.0001% (v/v) DDM, 0.1 µM histone H1, 1 mM DTT, and 1.1 pg per µL 
purified DGK, and proceeded for 15 minutes at 37°C.  I calibrated the scintillation counts to a measured 
amount of [γ-32P]-ATP.  In triplicate: mean ± SD. 
 However, while preincubation with histone H1 on ice protected against room-
temperature inactivation in the presence of 1.9 mM liposomes, when the liposome 
concentration was dropped to 17.5 µM, DGK continued to be inactivated by incubation in 
the water-jacketed quartz cuvette without irradiation, even when preincubated with 
histone H1 on ice (Figure 108). 
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Figure 108.  Preincubation with histone H1 is insufficient to protect against room-temperature 
inactivation of purified DGK-theta in the presence of dilute liposomes.  DGK activity assay.  I 
preincubated purified DGK-theta on ice in preincubation buffer (21 mM HEPES, pH 7.4, 41 mM NaCl, 
0.005% (v/v) DDM, 4 µM histone H1, 1 mM DTT) for 10 minutes, then diluted into 17.5 µM liposomes 
(55.3:27.7:9:8::POPE:POPC:POPS:DOG).  I then irradiated the “UV” sample with a 360 nm lamp for ten 
minutes in a water-jacketed quartz cuvette.  The “unirradiated” sample was incubated in the cuvette with 
the lamp turned off.  The final reaction mixture included 1 mM liposomes, 50 mM HEPES, pH 7.4, 100 
mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 43.8 Ci per mmol [γ-32P]-ATP, 0.04% (v/v) glycerol, 0.0001% 
(v/v) DDM, 0.1 µM histone H1, 1 mM DTT, and 1.1 pg per µL purified DGK, and proceeded for 15 
minutes at 37°C.  I calibrated the scintillation counts to a measured amount of [γ-32P]-ATP.  In triplicate: 
mean ± SD. 
 I then tested whether DGK required an interface in order for preincubation in 
histone H1 to protect against room-temperature inactivation (Figure 109).  Preincubation 
in the presence of 2 mM liposomes and histone H1 once again prevented room-
temperature inactivation.  DGK incubated with 17.5 µM liposomes was less active than 
DGK incubated with 2 mM liposomes, at either temperature.  Adding glycerol activated 
DGK when incubated with 17.5 µM liposomes on ice, but did not protect against room-
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temperature inactivation.  Incubating in detergent micelles inactivated DGK; they may 
have disrupted the substrate-containing liposomes in the assay.  But the treatment that 
activated DGK the most, at either temperature, was incubation with ovalbumin, which 
may have prevented DGK from adhering to the sides of the tube. 
 
Figure 109.  Interface test for room-temperature inactivation of purified DGK-theta.  DGK activity 
assay.  Following preincubation with histone H1 on ice, DGK was combined with the components shown 
and incubated on ice for one hour, prior to being incubated at the temperature indicated for 30 minutes.  
Detergent micelles included 9 mol% POPS; liposomes were (60.7:30.3:9::POPE:POPC:POPS).  The final 
reaction mixture included 2 mM substrate-containing liposomes (55.3:27.8:9:8:POPE:POPC:POPS:DOG), 
1 mM filler liposomes (60.7:30.3:9::POPE:POPC:POPS), 50 mM HEPES, pH 7.4, 100 mM NaCl, 1.5 mM 
MgCl2, 1 mM ATP, 36.1 Ci per mmol [γ-32P]-ATP, 0.04% (v/v) glycerol, 0.0001% (v/v) DDM, 0.1 µM 
histone H1, 1 mM DTT, and 1.1 pg per µL purified DGK, and proceeded for 15 minutes at 37°C.  I 
calibrated the scintillation counts to a measured amount of [γ-32P]-ATP.  In duplicate: mean ± SD. 
 I tested that hypothesis by measuring room-temperature inactivation in Eppendorf 
LoBind tubes, which purport to improve sample recovery as compared to regular 
Eppendorfs.  However, in this experiment, I also included 0.005% (v/v) dodecyl-β-D-
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maltoside (DDM) with the DGK at all times, which rescued room-temperature 
inactivation, beyond which incubation in LoBind tubes or ovalbumin had no additional 
benefit.  As before, the implications for possible conformational changes in DGK caused 
by detergent are intriguing, but the practical implications were that if I kept DDM at 
0.005% at all times, I could protect against room-temperature inactivation of DGK, even 
in the presence of only dilute liposomes.   
 
Figure 110.  Keeping DDM at 0.005% (v/v) protects against room-temperature inactivation of 
purified DGK-theta, beyond which incubation in LoBind tubes or ovalbumin had no additional 
benefit.  DGK activity assay.  Following preincubation on ice with histone H1, DGK was incubated with 
each of the following components in the presence of 17.5 µM liposomes 
(55.3:27.8:9:8:POPE:POPC:POPS:DOG) for one hour on ice, followed by 30 minutes at each of the 
temperatures shown.  DDM was kept at 0.005% at all times.  The final reaction mixture included 2 mM 
liposomes, 50 mM HEPES, pH 7.4, 100 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 31.2 Ci per mmol [γ-32P]-
ATP, 0.04% (v/v) glycerol, 0.005% (v/v) DDM, 0.1 µM histone H1, 1 mM DTT, and 1.1 pg per µL 
purified DGK, and proceeded for 15 minutes at 37°C.  In duplicate: mean ± SD. 
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 However, even when 0.005% DDM was present at all times, DGK still was 
inactivated when incubated in the water-jacketed quartz cuvette, even without radiation 
(Figure 111), and even though, as previously mentioned (Table 1), the temperature was 
even cooler than room temperature. 
 
Figure 111.  Even with 0.005% (v/v) present at all times, and even with histone H1 preincubation, 
purified DGK-theta still was inactivated when incubated in the water-jacketed quartz cuvette.  DGK 
activity assay.  Following preincubation on ice with histone H1, DGK was incubated with 17.5 µM 
liposomes (55.3:27.8:9:8:POPE:POPC:POPS:DOG) on ice for 30 minutes, followed by 30 minutes under 
each of the conditions shown.  DDM was kept at 0.005% at all times.  The final reaction mixture included 2 
mM liposomes, 50 mM HEPES, pH 7.4, 100 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 49.9 Ci per mmol [γ-
32P]-ATP, 0.04% (v/v) glycerol, 0.005% (v/v) DDM, 0.1 µM histone H1, 1 mM DTT, and 1.1 pg per µL 
purified DGK, and proceeded for 15 minutes at 37°C.  In triplicate: mean ± SD. 
 I wondered whether incubation in the water-jacketed quartz cuvette was uniquely 
stressful to DGK-theta, more so than the mere rise in temperature.  (Caution, however, 
must always be urged when comparing assays: note for example the difference between 
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inactivation of DGK incubated with 17.5 µM liposomes in the water-jacketed quartz 
cuvette in Figure 108 and at room temperature in an Eppendorf in Figure 109.)  As such, 
I compared the activity of DGK-theta in a plastic Eppendorf, either on ice or at room 
temperature, and in quartz, either in the water-jacketed quartz cuvette with the stir bar, or 
just a plain quartz cuvette, in case the stirring was what was disturbing DGK.  In order to 
test whether adhesion to the quartz was an issue, I also tested whether adding ovalbumin 
could improve DGK’s tolerance of any of these conditions.  I continued to preincubate 
DGK in 0.1 µM histone H1 on ice for ten minutes before diluting into any liposomes, and 
I continued to include 0.005% DDM at all times, because I had previously shown those 
conditions to stabilize DGK (Figure 106 and Figure 110).  I found that while 
preincubation with histone H1 and including 0.005% DDM continued to prevent DGK 
from room-temperature inactivation in a plastic Eppendorf in the presence of 17.5 µM 
liposomes, as expected, DGK lost activity when incubated in the quartz cuvette at 4°C, 
and lost even more activity when incubated in the water-jacketed quartz cuvette with 
stirring (Figure 112).  The inactivation in the quartz cuvette was rescued by including 0.1 
mg per mL ovalbumin, suggesting that part of the problem was that DGK was sticking to 
the quartz.  However, the inactivation in the water-jacketed quartz cuvette was only 
partially rescued by the ovalbumin; that, and the fact that incubation in the water-jacketed 
quartz cuvette inactivated DGK more than incubation in the plain quartz cuvette did, 
suggested that in addition to the adhesion problem, there was also a problem with the 
water-jacketed quartz cuvette, perhaps the shear forces from stirring.  Speculating on the 
nature of the physical basis for the inactivation of DGK by quartz (affinity for electrical 
charges on the surface of the crystal?) and shear forces (a particularly mechanosensitive 
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structure?) is tempting, but in practicality, if I wanted to use UV irradiation to study 
DGK, I needed another vessel for irradiation. 
 
Figure 112.  Purified DGK-theta is sensitive to quartz, and is particularly sensitive to the water-
jacketed quartz cuvette with stirring.  DGK activity assay.  DGK + ovalbumin in Eppendorf samples 
were omitted in the interest of limiting the size of the experiment: compare to Figure 110.  Following 
preincubation on ice with histone H1, DGK was incubated with 17.5 µM liposomes 
(55.3:27.8:9:8:POPE:POPC:POPS:DOG) on ice for 30 minutes, followed by 30 minutes under each of the 
conditions shown.  DDM was kept at 0.005% at all times.  The final reaction mixture included 2 mM 
liposomes, 50 mM HEPES, pH 7.4, 100 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 39.1 Ci per mmol [γ-32P]-
ATP, 0.04% (v/v) glycerol, 0.005% (v/v) DDM, 0.1 µM histone H1, 1 mM DTT, and 1.1 pg per µL 
purified DGK, and proceeded for 15 minutes at 37°C.  In triplicate: mean ± SD. 
My next candidate for an irradiation vessel was a 96-well plastic plate.  I likewise 
wanted to test whether UV itself inactivated DGK more than room-temperature 
incubation itself did, and, anticipating that DGK might stick to the plastic 96-well plate, I 
decided to also test whether ovalbumin could mitigate any such inactivation.  I found that 
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UV irradiation in the 96-well plate did indeed inactivate DGK, but this inactivation was 
at least partially rescued by including 0.1 mg per mL ovalbumin (Figure 113).   
 
Figure 113.  Irradiation with a 360 nm lamp inactivates purified DGK-theta, but incubation in the 
presence of ovalbumin at least partially prevents this inactivation.  DGK activity assay.  DGK + 
ovalbumin in Eppendorf on ice samples were omitted in the interest of limiting the size of the experiment.  
Following preincubation on ice with histone H1, DGK was incubated with 17.5 µM liposomes 
(55.3:27.8:9:8:POPE:POPC:POPS:DOG) on ice for 30 minutes, followed by 30 minutes under each of the 
conditions shown.  DDM was kept at 0.005% at all times.  The final reaction mixture included 2 mM 
liposomes, 50 mM HEPES, pH 7.4, 100 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 35.5 Ci per mmol [γ-32P]-
ATP, 0.04% (v/v) glycerol, 0.005% (v/v) DDM, 0.1 µM histone H1, 1 mM DTT, and 1.1 pg per µL 
purified DGK, and proceeded for 15 minutes at 37°C.  In triplicate: mean ± SD. 
However, even among experiments done on an ice bucket, in the same cold room, 
under the same lamp, for the same amount of time, with the same concentration of 
ovalbumin, the degree of inactivation from irradiation varied among experiments (Figure 
114A-E).  The concentration of DGK in the well, and, consequently, the concentration of 
glycerol in the well (since the glycerol came from the purified DGK, which had been 
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stored in glycerol at 80°C), also varied among experiments, but the experiments shown in 
Figure 114A, Figure 114B, and Figure 114C all used the same concentration of DGK 
(and therefore glycerol) in the incubation.  Because these experiments showed different 
degrees of inactivation by irradiation, it seems unlikely that the key variable determining 
susceptibility to inactivation by irradiation is concentration of either DGK or glycerol.  
The other variables that varied among these experiments were the distance between the 
lens of the lamp and the 96-well plate (by a few centimeters at most), the angle of the 
lamp (by several degrees at most), the volume of sample in the well (although I measured 
the volumes before and after irradiation, and I took the concentration caused by 
evaporation into account when calculating the specific activity of the enzyme), the time 
that DGK was thawed before it was irradiated, and the time that elapsed between the 
DGK was irradiated and the time it was assayed.  Any one or combination of these 
factors might contribute to the degree of inactivation of DGK by irradiating with the 360 
nm lamp, protected or not with aluminum foil. 
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Figure 114.  The degree of inactivation under foil during irradiation as compared to incubation on 
ice varies among experiments.  DGK activity assays.  (A) I incubated purified DGK-theta in 
preincubation buffer (75 pg per µL DGK-theta, 1.9% (v/v) glycerol, 0.005% (v/v) DDM, 1 mM DTT, 2.5 
µM histone H1, 50 mM HEPES, pH 7.4) on ice for ten minutes.  I then diluted into irradiation buffer (15 pg 
per µL DGK-theta, 0.4% (v/v) glycerol, 0.005% (v/v) DDM, 1 mM DTT, 0.5 µM histone H1, 50 mM 
HEPES, pH 7.4, 100 mM NaCl, 0.1 mg per mL ovalbumin, 1 mM ATP, 1.5 mM MgCl2, 7.5 mM liposomes 
(53.3:26.7:20::POPE:POPC:POPS)), rocked at room temperature for thirty minutes, then incubated under 
the conditions shown for another thirty minutes.  The final reaction mixture included 5 mM substrate-
containing liposomes (56.7:28.3:9:6::POPE:POPC:POPS:DOG), 1.5 mM incubation liposomes, 1.5 mM 
filler liposomes (49.3:24.7:20:6::POPE:POPC:POPS:compound 3, 50 mM HEPES, pH 7.4, 100 mM NaCl, 
1.5 mM MgCl2, 1 mM ATP, 70.9 Ci per mmol [γ-32P]-ATP, 0.1% (v/v) glycerol, 0.005% (v/v) DDM, 0.1 
µM histone H1, 0.02 mg per mL ovalbumin, 1 mM DTT, and 3.0 pg per µL purified DGK, and proceeded 
for 30 minutes at 37°C.  In triplicate: mean ± SD.  (B) The experiment was the same as that shown in (A) 
with the exception timepoints were taken at the times shown, I increased [γ-32P]-ATP to 158 Ci per mmol, 
and the reaction proceeded for 20 minutes at 37°C.  In triplicate: mean ± SD.  (C) The experiment was the 
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same as that shown in (A) and (B) with the exception that the composition of the filler liposomes was 
(49.1:24.5:10:6.4::POPE:POPC:POPS:compound 4, [γ-32P]-ATP was 117 Ci per mmol, and the reaction 
proceeded for 30 minutes at 37°C.  (D) I incubated purified DGK-theta in preincubation buffer 2 (996 pg 
per µL DGK-theta, 16.5% (v/v) glycerol, 0.005% (v/v) DDM, 1 mM DTT, 0.32 µM histone H1, 50 mM 
HEPES, pH 7.4) on ice for ten minutes.  I then diluted into irradiation buffer 2 (307 pg per µL DGK-theta, 
5.1% (v/v) glycerol, 0.005% (v/v) DDM, 1 mM DTT, 0.1 µM histone H1, 50 mM HEPES, pH 7.4, 100 mM 
NaCl, 0.1 mg per mL ovalbumin, 1 mM ATP, 1.5 mM MgCl2, 7.5 mM incubation liposomes), rocked at 
room temperature for thirty minutes, then incubated under the conditions shown for another thirty minutes.  
The final reaction mixture included 5 mM substrate-containing liposomes, 43 µM incubation liposomes, 43 
µM filler liposomes (compound 4), 50 mM HEPES, pH 7.4, 100 mM NaCl, 1.5 mM MgCl2, 0.8 mM ATP, 
35.7 Ci per mmol [γ-32P]-ATP, 0.04% (v/v) glycerol, 0.005% (v/v) DDM, 0.1 µM histone H1, 0.6 µg per 
mL ovalbumin, 1 mM DTT, and 1.8 pg per µL purified DGK-theta, and proceeded for 30 minutes at 37°C.  
In triplicate: mean ± SD.  (E) 227B and 323 are two different batches of purified DGK-theta.  I incubated 
purified DGK-theta in preincubation buffer (for 227B, 48 pg per µL purified DGK and 1.2% (v/v) glycerol; 
for 323, 120 pg per µL purified DGK and 2.0% (v/v) glycerol) on ice for ten minutes.  I then diluted into 
irradiation buffer, rocked at room temperature for thirty minutes, then incubated under the conditions 
shown for another thirty minutes.  The final reaction mixture was the same as in (B) except that [γ-32P]-
ATP was reduced to 20.9 Ci per mmol.  The reaction proceeded for 30 minutes at 37°C.  In triplicate: mean 
± SD. 
 One possible explanation for why the time that DGK was thawed before it was 
irradiated could be an issue is that the DTT might have been breaking down and losing its 
power as a reducing agent, and that the effect could therefore be perhaps mitigated by 
using BME as a reducing agent instead.  However, when I tested the reducing agent 
requirement explicitly, while incubating purified DGK-theta with a reducing agent 
increased its enzymatic activity, the identity of the reducing agent did not seem to matter 
(Figure 115).  It therefore seems unlikely that DTT breakdown could explain the 
irreproducibility seen in foil inactivation of purified DGK-theta, although out of an 
abundance of caution, I did replace 1 mM DTT with 3 mM BME in future experiments. 
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Figure 115.  Incubation in the presence of a reducing agent increases purified DGK-theta’s 
enzymatic activity under the conditions tested, but the identity of the reducing agent does not seem to 
matter.  DGK activity assay.  I incubated purified DGK-theta in preincubation buffer (67 pg per µL DGK-
theta, 1.9% (v/v) glycerol, 0.005% (v/v) DDM, 0.5 µM histone H1, 50 mM HEPES, pH 7.4, and the 
indicated concentrations of reducing agent) on ice for ten minutes.  I then diluted into irradiation buffer (13 
pg per µL DGK-theta, 0.4% (v/v) glycerol, 0.005% (v/v) DDM, 0.1 µM histone H1, 50 mM HEPES, pH 
7.4, 100 mM NaCl, 0.1 mg per mL ovalbumin, 1 mM ATP, 1.5 mM MgCl2, 7.5 mM liposomes 
(53.3:26.7:20::POPE:POPC:POPS), and the indicated concentrations of reducing agent), rocked at room 
temperature for thirty minutes.  I then placed the samples either on ice or in a 96-well plate with aluminum 
foil between the samples and the lamp, and irradiated the samples with a 360 nm lamp for thirty minutes at 
room temperature.  After irradiation, I returned the samples to Eppendorfs, and measured the volume to 
account for concentration of DGK due to evaporation.  The final reaction mixture included 5 mM substrate-
containing liposomes (56.7:28.3:9:6::POPE:POPC:POPS:DOG), 1.5 mM incubation liposomes, 50 mM 
HEPES, pH 7.4, 100 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 28.4 Ci per mmol [γ-32P]-ATP, 0.08% (v/v) 
glycerol, 0.005% (v/v) DDM, 0.1 µM histone H1, 0.02 mg per mL ovalbumin, 2.7 pg per µL purified DGK, 
and the indicated concentrations of reducing agent, and proceeded for 30 minutes at 37°C.  In triplicate: 
mean ± SD.   
A relatively recent technological development is the UV light-emitting diode 
(LED), which produces less heat than the 360 nm lamp I had been using.  Indeed, a UV 
LED flashlight with a peak wavelength of 365 nm did not inactivate purified DGK-theta, 
even when it was irradiated as long as sixty minutes (Figure 116).  Whether the UV LED 
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flashlight will solve the problem of foil inactivation of purified DGK-theta will therefore 
depend on whether the UV LED flashlight provides sufficient photon flux to produce 
probe-, UV-dependent enzymatic inactivation, as the 360 nm UV lamp did. 
 
Figure 116.  Irradiation with the 365 nm LED for up to sixty minutes does not inactivate purified 
DGK-theta.  DGK activity assay.  I incubated purified DGK-theta in preincubation buffer (125 pg per µL 
DGK-theta, 3.6% (v/v) glycerol, 0.005% (v/v) DDM, 0.5 µM histone H1, 50 mM HEPES, pH 7.4, 3 mM 
BME) on ice for ten minutes.  I then diluted into irradiation buffer (25 pg per µL DGK-theta, 0.7% (v/v) 
glycerol, 0.005% (v/v) DDM, 0.1 µM histone H1, 50 mM HEPES, pH 7.4, 100 mM NaCl, 0.1 mg per mL 
ovalbumin, 1 mM ATP, 1.5 mM MgCl2, 7.5 mM liposomes (53.3:26.7:20::POPE:POPC:POPS), and 3 mM 
BME), rocked at room temperature for thirty minutes.  I then placed the samples either on ice or in a 96-
well plate, and irradiated the samples with a 365 nm peak wavelength LED flashlight for either thirty 
minutes (at which point the samples were returned to ice for the remaining thirty minutes) or sixty minutes 
at room temperature (“foil” samples had aluminum foil between the samples and the flashlight).  After 
irradiation, I returned the samples to Eppendorfs, and measured the volume to account for concentration of 
DGK due to evaporation.  The final reaction mixture included 5 mM substrate-containing liposomes 
(56.7:28.3:9:6::POPE:POPC:POPS:DOG), 1.5 mM incubation liposomes, 50 mM HEPES, pH 7.4, 100 mM 
NaCl, 1.5 mM MgCl2, 1 mM ATP, 15.1 Ci per mmol [γ-32P]-ATP, 0.2% (v/v) glycerol, 0.005% (v/v) 
DDM, 0.1 µM histone H1, 0.02 mg per mL ovalbumin, 5.0 pg per µL purified DGK, and 3 mM BME, and 
proceeded for 43.5 minutes at ~33°C.  In triplicate: mean ± SD.   
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Conclusions 
 The maintenance of purified DGK activity is very sensitive to temperature.  
Incubation at room temperature can greatly decrease the activity of purified DGK, as can 
incubation on ice.  Measures that help protect against this inactivation include keeping 
detergents such as NP-40 and DDM around at all times, preincubating purified DGK in 
the presence of histone H1 but not MgATP, and adding ovalbumin to prevent DGK from 
being lost to adhesion to surfaces.  Although raising the temperature may be necessary 
for an experiment (such as allowing DGK the thermal flexibility that might be required to 
bind a substrate analog), keeping the temperature as low as possible, by keeping the 
protein on ice or by using a UV LED instead of a UV lamp, will help preserve the 
activity of DGK long enough that it can be assayed. 
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Chapter 5: DGK Activation, Inhibition, and Substrate Specificity 
Introduction 
 In addition to learning about the structure of eukaryotic DGKs, I was also 
interested in learning about their chemistry.  Studying activators and inhibitors of DGKs 
can give insight into their chemistry as well as their regulation.  Studying the substrate 
specificity requirements can give insight into the structure, topography, and chemical 
features of the active site.  Finding activators of DGKs also has the extremely practical 
benefit of increasing the observed DGK enzymatic activity: including an activator in an 
assay can thus make studying the enzymology of DGKs much easier.  I was therefore 
very interested to learn more about activation, inhibition, and substrate specificity of 
eukaryotic DGKs. 
Polybasic Activators and DGKs  
Polybasic Activator Introduction 
Polybasic proteins such as casein, tau, and histone H1 have been shown to 
activate H. sapiens DGK-theta expressed and purified from HEK293T cells3.  The 
question remained whether these proteins likewise activated other eukaryotic DGK 
isoforms and constructs. 
Casein and Alphacat in pT71myc Expressed and Purified from E. coli 
Introduction  
Polybasic proteins such as casein, tau, and histone HI have been shown to activate 
H. sapiens DGK-theta expressed and purified from HEK293T cells3.  I therefore tested 
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whether alphacat in pT71myc expressed in E. coli and purified on Ni-NTA (which I 
showed to elute from the Sephadex® G-100 analytical gel filtration resin in the void in 
Figure 15) could likewise be activated by casein.   
Results 
Alphacat clearly had more DGK activity than assay buffer, when assayed either in 
detergent micelles or in liposomes (Figure 117).  However, unlike the reported effect on 
full-length H. sapiens DGK-theta, the addition of casein to the assay buffer decreased the 
DGK activity of alphacat (Figure 117). 
 
 
Figure 117.  The addition of casein appears to decrease the enzymatic activity of purified alphacat in 
pT71myc.  I stored the samples for four weeks at -80°C in 50% glycerol prior to assaying.  The final 
reaction mixture included either 6.1 mM containing liposomes (53:22:17:8::POPE:POPC:POPS:DOG) or 
4.3 mM TX-100 micelles (18.2% POPS, 6 mol% DOG), 44 mM HEPES, pH 8.0, 4.4 mM MgCl2, 0.93 mM 
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CaCl2, 1 mM ATP, 103 Ci per mmol [γ-32P]-ATP, 2.5 mM Tris, 12.5 mM imidazole, 15 mM NaCl, 5% 
(v/v) glycerol, 0.1 mg per mL each of α- and β-casein (or not), and either 3.7 ng per µL eluate or 1.8 ng per 
µL eluate supernatant (as measured by the Bio-Rad Protein Assay), and proceeded for 15 minutes at 30°C.  
In duplicate: mean ± SD. 
Conclusions 
 Whereas casein activates H. sapiens DGK-theta expressed and purified from 
HEK293T cells3, it decreases the activity of alphacat in pT71myc expressed in E. coli and 
purified on Ni-NTA.  If casein’s mechanism of action were on the membrane, making 
diglyceride a better substrate for DGK, one would predict that casein would exert the 
same effect on alphacat, but it does not, suggesting that the site of casein’s action is on 
DGK itself.  Were it that casein had no effect on alphacat, one might conclude that its 
binding site on DGK-theta might be outside the catalytic domain.  The fact that it 
decreases alphacat’s activity, however, is intriguing.  One possible interpretation could be 
that casein is promoting a conformational change in the catalytic domain that, in the 
presence of the accessory domains, promotes catalytic turnover, but in their absence, 
makes turnover more difficult.  Another possible explanation is that casein exerts one 
effect on DGK-theta and another on DGK-alpha.  In order to resolve these two possible 
explanations, the effect of casein on full-length DGK-alpha could be tested. 
Polybasic Activators and FLAG-DGKA expressed and purified from D. discoideum 
Introduction 
 Getting at the question of whether polybasic activators affect different eukaryotic 
isoforms differently, I likewise tested whether casein activated FLAG-DGKA expressed 
and purified from D. discoideum.   
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Results 
The purified FLAG-DGKA was not contaminated with diglyceride, because 
FLAG-DGKA incubated with micelles without diglyceride showed no detectable DGK 
activity (Figure 118A).  The casein was not contaminated with DGK, because casein 
incubated with substrate-containing micelles likewise showed no detectable DGK activity 
(Figure 118A).  When FLAG-DGKA and casein were combined in the presence of 
substrate-containing micelles, however, together they showed much greater DGK activity 
than DGKA without casein (Figure 118A), suggesting that casein activates FLAG-
DGKA, as it does DGK-theta3.  Activation of purified FLAG-DGKA by casein was 
reproducible among assays as well as between batches of purified FLAG-DGKA (Figure 
66A and Figure 118B). 
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Figure 118.  Casein activates purified FLAG-DGKA in detergent micelles.  DGK activity assays.  (A) I 
stored purified DGKA (shown in Figure 65) in 50% glycerol at -80°C for three months prior to assaying.  
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The reaction included 10 mM TX-100 micelles (9 mol% POPS, with or without 6 mol% DOG), 40 mM 
Tris, pH 7.0, 4 mM MgCl2, 8 mM NaF, 0.7 ng per µL purified FLAG-DGKA (as estimated from the silver 
stain in Figure 65A), 2 mM TES, 0.2x PIC, 8 µg per µL FLAG peptide, 2% (v/v) glycerol, 1 mM DTT, 1 
mM ATP, and 89.1 Ci per mmol [γ-32P]-ATP, and proceeded for 15 minutes at 37°C.  I included 3 µL of 
concentrated stock solutions of casein per 50 µL reaction, where indicated.  In duplicate: mean ± SD.  (B) I 
stored purified DGKA (shown in Figure 64) in 50% glycerol at -80°C for nine days prior to assaying.  The 
reaction included 7 mM TX-100 micelles (9 mol% POPS, 6 mol% DOG), 40 mM Tris, pH 7.0, 4 mM 
MgCl2, 8 mM NaF, 5 µL purified FLAG-DGKA per 100 µL reaction, 2.5 mM TES, 0.25x PIC, 10 µg per 
µL FLAG peptide, 2.5% (v/v) glycerol, 1 mM ATP, and 108 Ci per mmol [γ-32P]-ATP, and proceeded for 
15 minutes at 30°C.  I included 3 µL of concentrated stock solutions of casein per 50 µL reaction, where 
indicated.  In duplicate: mean ± SD.   
 I also tested the effect of other activators on the activity of FLAG-DGKA in 
detergent micelles.  BL21 has, in its lysate, at least one component that activates DGK-
theta, such that when bacterial lysate is added to DGK-theta, its DGK activity is 
increased.  I therefore tested whether the supernatant from BL21 cells likewise activated 
FLAG-DGKA.  I also tested tau, which had been purified from BL21 cells and stored at 
either -20 or -80°C, as well as BL21 lysate that had been mock-purified, to see whether 
the effect (if any) could be attributed to tau or to some other bacterial component that co-
purified with tau.  All of the tested activators increased the DGK activity of FLAG-
DGKA, but they also demonstrated greater DGK activity themselves than FLAG-DGKA 
did (Figure 119).  Therefore, while all four activators appeared to activate FLAG-DGKA 
(as in they demonstrated greater activity than either DGKA or activator alone), it was 
unclear how to determine quantitatively how much of the DGK activity was resulting 
from the activated FLAG-DGKA, and how much was resulting from the activator 




Figure 119.  Polybasic activators give high DGK activity in detergent micelles.  DGK activity assay. I 
stored purified DGKA (shown in Figure 65) in 50% (v/v) glycerol at -80°C for three months prior to 
assaying.  The reaction included 10 mM TX-100 micelles (9 mol% POPS, 6 mol% DOG), 44 mM Tris, pH 
7.4, 4.4 mM MgCl2, 1 mM DTT, 1 mM ATP, 80.1 Ci per mmol [γ-32P]-ATP, and, from the purified 
DGKA, up to 1.4 ng per µL purified DGKA (as estimated from the silver stain in Figure 65A), 4 mM TES, 
0.4x PIC, 16 µg per µL FLAG peptide, and 4% (v/v) glycerol, and proceeded for 15 minutes at 37°C.  I 
included 1 µL of concentrated stock solutions of each activator per 50 µL reaction, where indicated.  In 
duplicate: mean ± SD. 
Discussion and Conclusions 
 While all four activators appeared to activate FLAG-DGKA (as in they 
demonstrated greater activity than either DGKA or activator alone), it was unclear how to 
determine quantitatively how much of the DGK activity was resulting from the activated 
FLAG-DGKA, and how much was resulting from the activator (indeed, FLAG-DGKA 
could possibly have activated the activators, rather than the other way around). 
  If the DGK activity of the activators was a result of contaminating E. coli DGK, I would 
predict that the DGK activity of the activators would decrease when assayed in liposomes 
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as compared to detergent micelles, because E. coli DGK is an integral membrane protein, 
and while it could incorporate into detergent micelles and access the substrates therein, it 
would remain mostly excluded from substrate-containing liposomes.  I therefore tested 
whether these activators activated DGKA in liposomes.  Indeed, the activity of each of 
the activators in the absence of DGKA but in the presence of substrate was lower in 
liposomes than in micelles, suggesting that previous source of contamination could 
indeed have been E. coli DGK (Figure 66).  Casein, as in detergent micelles (Figure 118), 
activated DGKA in liposomes, as did the other tested activators (Figure 66). 
Polybasic Activator Discussion and Conclusions 
One reason that these activators may activate D. discoideum DGKA (Figure 118 
and Figure 66) but not alphacat in pT71myc (Figure 117) could be that DGKA has 
greater primary sequence homology to DGK-theta than DGK-alpha does46.  Another 
possible explanation is that the region of the protein required for activation by casein is 
found in the N-terminus and not in the catalytic domain included in alphacat.  Yet another 
possible explanation is that post-translational modifications or other processing of DGK 
provided by a eukaryotic expression host such as HEK293T cells (in the case of DGK-
theta3) or D. discoideum (in the case of DGKA) is required in order for casein to activate 
the enzyme.  The practical implications, however, were that in order to do enzymological 
studies of purified DGKA, I would need to add an activator to ensure that its DGK 
activity was detectable. 
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JG compounds and D. discoideum DGKA 
Introduction 
 The laboratory of Professor Glenn Prestwich (Department of Medicinal 
Chemistry, University of Utah) produced four synthetic diglyceride analogs (named for 
the person who synthesized them, Dr. Joanna Gajewiak), whose structures are shown in 
Figure 120. 
 
Figure 120.  Structures of the JG compounds synthesized by Dr. Joanna Gajewiak of Professor 
Glenn Prestwich’s laboratory (Department of Medicinal Chemistry, University of Utah).  The JG 
compounds are DAG analogs.  JG21 and JG22 include an aminooxy group instead of a hydroxyl group, and 
JG29 and JG30 include a hydroxylamino group.  JG21 and 29 include palmitoyl fatty acid chains, and JG22 
and JG30 include oleoyl fatty acid chains. 
 Continuing work started by Ms. Michele Ostroski, I tested whether these DAG 
analogs activated, inhibited, or could serve as substrates for FLAG-DGKA expressed and 
purified from D. discoideum. 
Results 
 When I included casein, which I had previously shown to activate purified FLAG-
DGKA in liposomes (Figure 66), in the reaction, none of the tested JG compounds 
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appeared to either activate or inhibit DGKA when included in the liposomes at 8 mol%, 
along with 8 mol% DOG (Figure 121).  When DGKA was incubated with liposomes 
containing 8 mol% JG29 in the absence of DOG, however, I did detect greater DGK 
activity than DGKA incubated without any liposomes (Figure 121).  I therefore 
concluded that JG29 was able to serve as a substrate for DGKA, albeit at a much lower 
affinity than DOG.  JG30, contrariwise, did not appear to be a substrate for DGKA 
(Figure 121), even though it has the same head group as JG29, and the two DAG analogs 
differ only by their fatty acid constituents.  
 
Figure 121.  The JG compounds do not appear to affect the activity of purified FLAG-DGKA in the 
presence of DOG, but JG29 may serve as a substrate.  DGK activity assay. I stored purified FLAG-
DGKA (shown in Figure 65) in 50% (v/v) glycerol at -80°C for three months prior to assaying.  The 
reaction included 5 mM liposomes of the composition shown (for the “DOG only” or “JG only” liposomes, 
the composition was (40:40:12:8::POPS:POPE:PI:(DOG or JG)), and for the liposomes that contained both 
DOG and either POPG or one of the JG compounds, the composition was 
(40:32:12:8:8::POPS:POPE:PI:DOG:(POPG or JG)), 41 mM Tris, pH 7.0, 8.2 mM MgCl2, 8.2 mM NaF, 1 
µL of concentrated stock casein per 50 µL reaction, 1 mM DTT, 1 mM ATP, 91.7 Ci per mmol [γ-32P]-
ATP, and, from the purified FLAG-DGKA, up to 1.3 ng per µL purified FLAG-DGKA (as estimated from 
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the silver stain in Figure 65A), 3 mM TES, 0.3x PIC, 12 µg per µL FLAG peptide, and 3% (v/v) glycerol, 
and proceeded for 7.5 minutes at 37°C.  In triplicate: mean ± SD. 
Discussion and Conclusions 
JG29 appeared to be able to serve as a substrate for FLAG-DGKA expressed and 
purified from D. discoideum, whereas JG30 did not, even though it has the same head 
group as JG29, and the two DAG analogs differ only by their fatty acid constituents. This 
substrate specificity resulting from different fatty acid chains is consistent with previous 
reports of DGKA’s substrate specificity with regard to the fatty acid chains of different 
DAGs47, although palmitoyl and oleoyl side chains of DAG substrates have not been 
compared explicitly.  If JG29 is, indeed, a substrate for DGKA, I would predict it to be a 
competitive inhibitor of DGKA when DOG is used as a substrate, but, as can be seen in 
Figure 121, JG29’s affinity for DGKA is too low for any such inhibition to be apparent 
when assayed in liposomes with 8 mol% each JG29 and DOG.  
Medium-Chain Diglycerides as Substrates for DGK 
Introduction 
 The substrate specificity of interfacial enzymes such as eukaryotic DGKs includes 
two components: not only is affinity for the substrate itself important, but so too is the 
enzyme’s ability to bind to the membrane where the substrate resides.  If membrane-
binding is impaired for some reason, enzymatic activity will be impaired even if the 
active site is still able to recognize and turn over the lipid substrate. 
 One way to resolve the question of substrate recognition from that of membrane 
binding is by using a short-chain substrate analog that is soluble in the aqueous phase 
without a membrane present.  Such soluble substrates can therefore be used to answer the 
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question of, for example, whether membrane binding causes a conformational change in 
the enzyme that is required for catalytic turnover (in that case, an enzyme will not be able 
to use a soluble substrate analog).  I wondered whether these eukaryotic DGK constructs 
could use short-chain diglycerides as substrates. 
Results 
 1,2-dioctanoyl-sn-glycerol (DiC8) is a medium-chain diglyceride that has been 
previously shown to be a substrate for D. discoideum DGKA47.  In that report, 4 mM 
DiC8 was solubilized by adding OG to 10 mM, below its CMC.  When I added 10 mM 
OG to 4 mM DiC8, however, the mixture remained cloudy.  The buffers were similar, but 
not identical: the buffer reported in Ostroski et al. was 50 mM Tris, 10 mM MgCl2, 1 mM 
DTT, pH 7.4, and the one I used was 55 mM Tris, 5.5 mM MgCl2, pH 7.4.  Perhaps the 
additional MgCl2 and/or the DTT was necessary for solubilizing the DiC8. I did not 
include DiC8 with 10 mM OG, with or without casein, as a negative control, but the 
activity of FLAG-DGKA in the presence of 4 mM DiC8 and 10 mM OG is no greater 
than the DGK activity measured from DOG micelles (without DGKA), with or without 
casein.  As such, I was unable to demonstrate that purified FLAG-DGKA had measurable 
DGK activity using DiC8 as a substrate (Figure 122), but that could easily have been 
because of inadequately solubilized lipid substrate.   
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Figure 122.  The DGK activity of purified FLAG-DGKA using DiC8 as a substrate is no greater than 
background activity in DOG micelles.  I stored purified FLAG-DGKA (shown in Figure 64) in 50% 
glycerol at -80°C for nine days prior to assaying.  The reaction included either 7 mM TX-100 micelles (9 
mol% POPS, 6 mol% DOG) or else 4 mM DiC8 plus 10 mM OG, 40 mM Tris, pH 7.0, 4 mM MgCl2, 8 
mM NaF, 1 mM ATP, and 108 Ci per mmol [γ-32P]-ATP, and, from the purified FLAG-DGKA, up to 5 µL 
purified FLAG-DGKA per 100 µL reaction, 2.5 mM TES, 0.25x PIC, 10 µg per µL FLAG peptide, and 
2.5% (v/v) glycerol, and proceeded for 15 minutes at 30°C.  I included 3 µL of concentrated stock solutions 
of casein per 50 µL reaction, where indicated.  In duplicate: mean ± SD.  
 I was similarly unable to demonstrate that purified H. sapiens DGK-theta had 
measurable DGK activity on DiC8 (Figure 123).  In fact, DGK-theta in the presence of 
casein in 4 mM DiC8 and 10 mM OG had even less DGK activity than casein in DOG 
micelles, without DGK-theta.  Once again, the lack of activity might be due to 
insufficiently solubilized lipid substrate. 
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Figure 123.  The DGK activity of purified H. sapiens DGK-theta using DiC8 as a substrate is no 
greater than background activity in DOG micelles.  The reaction included either 7 mM TX-100 micelles 
(9 mol% POPS, 6 mol% DOG) or else 4 mM DiC8 plus 10 mM OG, 41 mM Tris, pH 7.0, 4.1 mM MgCl2, 
8.3 mM NaF, 1 mM ATP, and 108 Ci per mmol [γ-32P]-ATP, and proceeded for 15 minutes at 30°C.  I 
included 3 µL of concentrated stock solutions of casein per 50 µL reaction, where indicated.  In duplicate: 
mean ± SD. 
 Because a vial of DiC8 had been labeled as DOG, I also inadvertently tested the 
DGK activity of alphacat in pT71myc expressed in E. coli using DiC8 incorporated into 
liposomes as a substrate.  Induced lysate reproducibly had greater DGK activity than 
uninduced lysate when using DiC8 as a substrate (Figure 124 and Figure 89).  I therefore 
concluded that alphacat was able to use DiC8 as a substrate.  Because the DiC8 was 
incorporated into liposomes, however, the question of whether alphacat required an 
interface in order to catalyze the reaction remains unresolved. 
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Figure 124.  Rosetta™(DE3) lysate overexpressing alphacat in pT71myc is able to use DiC8 
incorporated into liposomes as a substrate.    DGK activity assay.  The samples (Figure 87B and F) had 
been stored in 50% glycerol at -80°C for three weeks prior to assaying their DGK activity.  The reaction 
included 7.5 mM liposomes (53:22:17:8::POPE:POPC:POPS:“DOG”), 49 mM HEPES, pH 8.0, 4.9 mM 
MgCl2, 1 mM CaCl2, 1 mM ATP, 0.25 mM Tris, 1.5 mM NaCl, 50 µM imidazole, 0.0025% (v/v) NP-40, 
0.005x PIC, 0.25% (v/v) glycerol, 0.5 µL protein sample per 50 µL reaction, and 37.3 Ci per mmol [γ-32P]-
ATP, and proceeded for 15 minutes at 30°C.  In duplicate: mean ± SD. 
Conclusions 
 FLAG-DGKA purified from D. discoideum and purified H. sapiens DGK-theta 
were unable to use DiC8 as a substrate, but the lack of activity might have been due to 
insufficiently solubilized lipid substrate rather than a fundamental inability to use DiC8 
as a substrate.  E. coli lysate overexpressing alphacat in pT71myc was able to use DiC8 
as a substrate, but because the DiC8 was incorporated into liposomes, however, the 
question of whether alphacat required an interface in order to catalyze the reaction 
remains unresolved. 
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Buffers and H. sapiens DGK-theta expressed and purified from HEK293T cells 
Introduction 
 Studying the effects of different buffer components, such as salts or metal ions, 
can be of enormous practical value: if I find conditions that optimize DGK’s enzymatic 
activity, I can use less enzyme in the assay, and it will be easier to study its enzymology.  
Buffer requirements can also lend insight into the chemistry of how DGK catalyzes the 
reaction.  If an increase in salt decreases enzymatic activity, for example, it could be that 
an internal salt bridge or an ionic interaction between the protein and the substrate is 
important for catalysis.  If metal chelators decrease enzymatic activity, for example, a 
metal ion might be important for properly positioning the substrate.  I therefore studied 
how different buffer components affected enzymatic activity of purified eukaryotic 
DGKs. 
Results 
In order to test the effect of PIP2 on DGK-theta activity, I needed to find extrusion 
conditions that could produce PIP2 liposomes.  I did eventually find a buffer that could be 
used to produce PIP2 liposomes, but this buffer included 150 mM NaCl.  Before testing 
the effect of PIP2 on DGK, I therefore first tested the effect of NaCl in the assay buffer.  
Concentrations of NaCl up to 150 mM did not adversely affect the activity of DGK-theta 
purified from HEK293T cells, and at 200 mM, appeared to somewhat enhance DGK 
activity (Figure 125).  The molecular basis for this effect could be that the salt ions 
neutralized charged regions of the enzyme, or destabilized exposed hydrophobic regions 
which the influenced the fold of the protein, but the practical implications were that I 
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could assay DGK-theta in the presence of the 150 mM NaCl required to produce PIP2-
containing liposomes. 
 
Figure 125.  DGK activity of purified H. sapiens DGK-theta as a function of NaCl concentration.  
DGK activity assay.  I first incubated purified DGK-theta for four hours on ice in 34% (w/v) sucrose, 1 
mg/mL BSA.  The reaction included in 7 mM Triton X-100 micelles (9 mol% POPS, 6 mol% DOG), 42 
mM Tris, pH 8.2, 4.5 mM MgCl2, 1 mM ATP, 5% (w/v) sucrose, 0.1 mg per mL BSA, 5 ng per µL purified 
DGK-theta, and 43.1 Ci per mmol [γ-32P]-ATP, and proceeded for 15 minutes.  In duplicate: mean ± SD.   
 The ADP Quest™ kinase assay kit uses propriety buffers, but its protocol warns 
that at least one of these proprietary reagents is incompatible with HEPES because of its 
sulfonic acid moiety.  I therefore tested the effects of different non-sulfonic-acid-
containing buffers whose buffering range include pH 7.5 on the activity of DGK-theta 
purified from HEK293T cells.  Using HEPES at either 50 mM or 5 mM or using 
triethanolamine or tricine to buffer the assay buffer to pH 7.5, had no effect on DGK 
activity (Figure 126), as would be expected for reagents whose only role is buffering the 
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pH of the reaction.  Sodium pyrophosphate reduced the DGK activity to undetectable 
levels (Figure 126), consistent with the pyrophosphate’s precipitating out the magnesium 
so that none was left to coordinate the ATP in the reaction.  Imidazole appeared to 
enhance DGK’s activity somewhat (Figure 126).  In addition to buffering the pH, 
imidazole could also be chelating ions such as nickel, zinc, or cobalt: if any of these 
metals ions inhibit DGK activity, then removing them from the protein by increasing the 
concentration of imidazole in the buffer would be predicted to increase DGK’s activity.  
The primary sequence of DGK-theta, unlike the other mammalian isoforms, includes four 
consecutive histidines, which could be a site of chelating such metal ions. 
 
Figure 126.  DGK-theta buffer test.  DGK activity assay.  I incubated purified DGK-theta in 
preincubation buffer (30 pg per µL DGK-theta, 0.5% (v/v) glycerol, 0.006% (v/v) DDM, 1.1 mM DTT, 
0.11 µM histone H1, 1.1 mM liposomes (48:24:20:8::POPE:POPC:POPS:DOG), 111 mM NaCl, 0.11 mg 
per mL ovalbumin, 55.6 (or 5.6) mM of the buffer in question) on ice for ten minutes.  The final reaction 
mixture included 1 mM liposomes, 100 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 70.9 Ci per mmol [γ-32P]-
ATP, 0.1% (v/v) glycerol, 0.005% (v/v) DDM, 0.1 µM histone H1, 0.02 mg per mL ovalbumin, 1 mM 
 260 
DTT, and 3.0 pg per µL purified DGK, and proceeded for 30 minutes at 37°C.  In triplicate: mean ± SD.    
NaPPi, sodium pyrophosphate. 
Discussion and Conclusions 
Concentrations of NaCl up to 150 mM did not adversely affect the activity of 
DGK-theta purified from HEK293T cells, and at 200 mM, appeared to somewhat 
enhance DGK activity (Figure 125).  The molecular basis for this effect could be that the 
salt ions neutralized charged regions of the enzyme, or destabilized exposed hydrophobic 
regions which the influenced the fold of the protein, but the practical implications were 
that I could assay DGK-theta in the presence of the 150 mM NaCl required to produce 
PIP2-containing liposomes.  Imidazole appeared to enhance purified DGK-theta’s activity 
somewhat (Figure 126).  In addition to buffering the pH, imidazole could also be 
chelating ions such as nickel, zinc, or cobalt: if any of these metals ions inhibit DGK 
activity, then removing them from the protein by increasing the concentration of 
imidazole in the buffer would be predicted to increase DGK’s activity.  The primary 
sequence of DGK-theta, unlike the other mammalian isoforms, includes four consecutive 
histidines, which could be a site of chelating such metal ions. 
Hirudin and H. sapiens DGK-Theta 
Introduction 
 Hirudin is a thrombin inhibitor found in the salivary glands of the leech Hirudo 
medicinalis143.  When conducting proteolysis studies on purified H. sapiens DGK-theta 
using thrombin as a protease, I observed that purified Fc-FLAG-DGK-theta bound to 
Protein A sepharose via an Fc epitope tag that had been digested with thrombin 
demonstrated higher DGK activity than DGK-theta bound to beads that had been digested 
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with thrombin in the presence of hirudin (Figure 127).  I was surprised because I 
expected the beads with hirudin to show much higher DGK activity, because the DGK 
was still bound to the beads, whereas the DGK successfully digested by thrombin 
(without hirudin to inhibit it) was mostly detached and in the supernatant, not the beads 
(Figure 127A).  I therefore wondered whether hirudin inhibits DGK in addition to 
thrombin (even though the Protein A sepharose beads had been extensively washed and 
only ~12 nU hirudin per µL would be predicted to remain in the samples assayed). 
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Figure 127.  Purified Fc-FLAG-DGK-theta bound to Protein A sepharose via an Fc epitope tag that 
had been digested with thrombin demonstrates higher DGK activity than DGK-theta bound to beads 
that had been digested with thrombin in the presence of hirudin.  I stored purified Fc-FLAG-DGK-
theta bound to Protein A sepharose (shown in Figure 84E and F) in 50% glycerol at -80°C for four days 
before thawing and washing with thrombin buffer 1 (10 mM HEPES, 10 mM Tris, 100 mM NaCl, 0.1% 
(w/v) PEG-8000, pH 8.5).  I then incubated 15% (v/v) of the purified Fc-FLAG-DGK-theta bound to 
Protein A sepharose with 10 mU per µL thrombin (Calbiochem (now EMD Millipore) 605195) in thrombin 
buffer 1 with or without 15 mU per µL hirudin (Sigma H7380) rotating at 4°C for 22 hours.  I washed the 
 263 
beads with thrombin buffer 1 and thrombin buffer 2 (same as thrombin buffer 2 except pH 10.0 instead of 
8.5).  (A) SDS-PAGE followed by silver staining.  R+S, resin plus supernatant; S, supernatant; WR, 
washed resin.  (B) DGK activity assay.  The samples had been stored in 50% glycerol at -80°C for six 
weeks prior to assaying.  The final reaction included 7.5 mM liposomes 
(53:22:17:8::POPE:POPC:POPS:DOG), 45 mM HEPES, pH 7.0, 130 mM NaCl, 4.4 mM MgCl2, 1 mM 
Tris, 0.01% (w/v) PEG-8000, 1 mM ATP, 63.5 Ci per mmol [γ-32P]-ATP, 1 mM DTT, 1.5 ng per µL LMW 
polylysine, up to 0.7% (v/v) glycerol, and up to 35 pg per µL purified DGK (as estimated from the silver 
stain in (A)), and proceeded for 15 minutes at 37°C.  In duplicate: mean ± SD.      
Results 
 When I tested the effects of increasing concentrations of hirudin on the activity of 
DGK-theta in liposomes, I was quite surprised to find that only the lowest concentration 
of hirudin tested inhibited the DGK activity of the non-nuclear membrane fraction of 
HEK293T cells transiently transfected with DGK-theta (Figure 128A).  I repeated the 
experiment with even lower concentrations of hirudin, and confirmed that low, but not 
too low, concentrations of hirudin inhibit DGK-theta (Figure 128B).  These 
concentrations are much lower than the concentrations that are effective for inhibiting 




Figure 128.  Low, but not too low, concentrations of hirudin inhibit the DGK activity of NNM from 
293FT cells overexpressing Fc-FLAG-DGK-theta.  DGK activity assays.  (A) I stored the NNM of 
293FT cells overexpressing Fc-FLAG-DGK-theta (the same expression shown in Figure 84E and F) in 
50% glycerol at -80°C for seven weeks prior to assaying.  The reaction included 7.5 mM liposomes 
(53:22:17:8::POPE:POPC:POPS:DOG), 49 mM HEPES, pH 7.0, 134 mM NaCl, 4.9 mM MgCl2, 1 mM 
ATP, 98.3 Ci per mmol [γ-32P]-ATP, 1 mM DTT, and, from the NNM, 6 µM EGTA, 11 µM EDTA, 50 ng 
per mL quinacrine, 0.01x PIC, 1 mM NAG, 60 µM NaVO4, 120 µM NaF, 0.003% (v/v) NP-40, 0.6% (v/v) 
glycerol, and 40 ng per µL total protein (as measured by the Bio-Rad Protein Assay), and proceeded for 15 
minutes at 37°C.  In duplicate: mean ± SD.  (B) I assayed aliquots of the same NNM samples three days 
later.  The reaction conditions were the same as in (A) with the exception that [γ-32P]-ATP was reduced to 
43.1 Ci per mmol.  In duplicate: mean ± SD.   
Discussion and Conclusions 
 Low, but not too low, concentrations of hirudin inhibit the DGK activity of NNM 
from 293FT cells overexpressing Fc-FLAG-DGK-theta.  One possible explanation for 
bell-shaped inhibition (low inhibition at low and high concentrations of inhibitor, and 
high inhibition at medium concentrations) could be that the hirudin aggregated, such that 
at high concentrations, the hirudin oligomerized into a form that did not inhibit DGK.  
The practical implications were that if I wanted to inhibit thrombin digestion of DGK and 
measure the effects on DGK activity, I would need to find another thrombin inhibitor. 
PMSF and H. sapiens DGK-Theta 
Introduction 
 Phenylmethylsulfonyl fluoride (PMSF) is another thrombin inhibitor.  Before 
using it in the proteolysis studies, I wanted to first check whether PMSF inhibited DGK, 
as hirudin did.   
Results 
I first checked whether PMSF inhibited the DGK activity of lysates of HEK293T 
cells transiently transfected with Fc-FLAG-DGK-theta.  When the concentrations of 
PMSF tested did not appear to inhibit the NNM of Fc-FLAG-DGK-theta-overexpressing 
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293FT cells (Figure 129A), I then tested whether PMSF, in the same range of 
concentrations, inhibited purified Fc-FLAG-DGK-theta on Protein A sepharose beads 
(the sample that would be used in the proteolysis study).  The concentrations of PMSF 
tested did not appear to inhibit purified DGK-theta (Figure 129B), although the 
uncertainty of this experiment is admittedly large. 
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Figure 129.  PMSF does not inhibit Fc-FLAG-DGK-theta at the concentrations tested.  DGK activity 
assays.  (A) I assayed aliquots of the same NNM samples shown in Figure 128B ten days later.  The 
 268 
reaction included 7.5 mM liposomes (53:22:17:8::POPE:POPC:POPS:DOG), 49 mM HEPES, pH 7.0, 135 
mM NaCl, 4.9 mM MgCl2, 1 mM ATP, 70.0 Ci per mmol [γ-32P]-ATP, 1 mM DTT, and, from the NNM, 3 
µM EGTA, 6 µM EDTA, 25 ng per mL quinacrine, 0.006x PIC, 0.6 mM NAG, 30 µM NaVO4, 60 µM 
NaF, 0.002% (v/v) NP-40, 0.3% (v/v) glycerol, and 20 ng per µL total protein (as measured by the Bio-Rad 
Protein Assay), and proceeded for 15 minutes at 37°C.  In duplicate: mean ± SD.  (B) I stored purified Fc-
FLAG-DGK-theta bound to Protein A sepharose in 50% glycerol at -80°C for nine weeks since it had been 
last thawed (Figure 127) prior to assaying.  The reaction included 7.5 mM liposomes 
(53:22:17:8::POPE:POPC:POPS:DOG), 47 mM HEPES, pH 7.0, 133 mM NaCl, 4.7 mM MgCl2, 1 mM 
ATP, 60.5 Ci per mmol [γ-32P]-ATP, 1 mM DTT, 1.5 ng per µL LMW polylysine (or not), and, from the 
purified Fc-FLAG-DGK-theta, up to 0.5 mM Tris, 0.005% (v/v) glycerol, 0.8% (v/v) glycerol, and 70 pg 
per µL purified DGK-theta (as estimated from the silver stain in Figure 127A), and proceeded for 15 
minutes at 37°C.  In duplicate: mean ± SD.   
Discussion and Conclusions 
 I had meant to test PMSF concentrations that would remain following digestion of 
the beads with 1 mM PMSF followed by extensive washing, but I made an arithmetical 
error, and the concentrations tested here are much larger than would remain.  It is 
unknown whether lower, or higher, concentrations of PMSF would inhibit DGK, but the 
concentrations tested did not. 
Photoaffinity Labels and H. sapiens DGK-Theta 
Introduction 
 The laboratory of Professor Michael Best (Department of Chemistry, University 
of Tennessee) produced photoaffinity labels such that part of the molecule is diglyceride-
like, and part of the molecule includes a photoactivatable crosslinker, such as 
benzophenone.  Although these molecules were designed for photoaffinity labeling, 
because they are diglyceride analogs, I wondered whether they could serve as 
competitive inhibitors for diglyceride or even as substrates. 
Compound 1 and H. sapiens DGK-Theta 
 The structure of compound 1 is shown in Figure 130.  It includes two stearic acyl 
tails as well as the hydroxyl in the 3-position of the glycerol backbone common to 1,2-
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diacylglycerol.  It also includes benzophenone, a photoactivatable crosslinker, connected 
at the 1-position of the glycerol backbone via a linker left behind by the click chemistry 
used in its synthesis144.  
 
Figure 130.  The structure of compound 1. 
 To confirm that compound 1 was the advertised concentration, and that it 
remained a single population and had not crosslinked to itself, I ran it on a TLC plate and 
charred the plate to estimate the intensity of the spots as compared to DOG standards of a 




Figure 131.  By visualizing the intensity of compound 1 compared to known amounts of DOG on 
charred TLC plates, I estimated it to be perhaps 1/20th the advertised concentration.  (A) After 
spotting the indicated amounts onto a glass TLC plate, I ran the plate for one hour in fresh tank fluid 
(85:15:5::toluene:chloroform:methanol), which caused the solvent front to reach the top of the plate.  
“Isomerized DOG” had been stored in chloroform at room temperature for several months.  (B) After 
spotting the indicated amounts onto a glass TLC plate, I ran the plate for thirty minutes in day-old tank 
fluid and marked the solvent front with pencil before drying.  A, B, and C indicate different aliquots of 
compound 1. 
 Because compound 1 is a diglyceride analog, I wondered whether it could 
compete for DOG in a DGK activity assay.  In order to work out whether compound 1 
was competing for DOG, I first needed to get an idea of what, approximately, DGK-
theta’s Km for DOG was.  The Km(surface) of purified H. sapiens DGK-theta in the presence 
of polylysine has been reported3, but only at a single concentration of total liposomes (0.2 
mM), and DGK-theta’s affinity for DOG has been shown to depend both on the surface 
and the total concentration of diglyceride140.  I therefore thought it best to measure myself 
how DGK-theta’s activity depends on the concentration of DOG.  I was unable to extrude 
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liposomes containing 24 mol% DOG.  For the liposomes I was able to extrude, at 0.5 mM 
liposomes, 3 mol% DOG provided much less than half-maximal activity, and I concluded 
that, at least at 0.5 mM liposomes, DGK-theta’s Km(surface) for DOG is greater than 3 
mol%, the value reported for 0.2 mM liposomes3.  One possible source for the 
discrepancy is the fact that I used 9 mol% POPS, rather than the 8 mol% used for the 
reported Km(surface); on the other hand, the reported Km(surface) did not depend on whether 
the liposomes contained 0 or 8 mol% POPS, so POPS-dependence between 8 and 9 
mol% seems unlikely.  Another possible source of discrepancy is that the liposomes used 
for the reported Km(surface) used POPC, whereas I used egg PC.  (Usually I also used 
POPC, but several packages of lipid that had been labeled “POPC” were, in fact, PC with 
other fatty acid chains, which meant that the laboratory ran out of POPC without 
realizing that I needed to order more.)  The primary fatty acid chains in egg PC are 
palmitoyl and oleoyl, in roughly equal proportions, but other fatty acyls present at 
detectable levels include linoleoyl, stearoyl, arachidonoyl, palmitoleoyl, 
docosahexaenoyl, eicosatrienoyl, eicosadienoyl, and myristoyl chains145: it is a formal 
possibility that these other lipid constituents affect DGK’s affinity for DOG. 
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Figure 132.  Using 0.2 mM liposomes containing 9 mol% POPS, DGK-theta’s Km(surface) for DOG 
appears to be greater than 3 mol%.  DGK activity assay.  I first preincubated purified DGK-theta in 
preincubation buffer (43 pg per µL purified DGK-theta, 1.7% (v/v) glycerol, 0.005% (v/v) DDM, 4 µM 
histone H1, 1 mM DTT, 31 mM HEPES, pH 7.5, 62 mM NaCl) on ice for ten minutes.  The final reaction 
mixture included 0.5 mM liposomes (2:1::POPE:egg PC; 9 mol% POPS, and the indicated concentrations 
of DOG), 44 mM HEPES, pH 7.5, 87 mM NaCl, 1 mM DTT, 1.5 mM MgCl2, 1 mM ATP, 26.6 Ci per 
mmol [γ-32P]-ATP, 0.1 µM histone H1, 0.1 mg per mL ovalbumin, 1.1 pg per µL purified DGK-theta, and 
0.04% (v/v) glycerol, and proceeded for 15 minutes at 37°C.  In triplicate: mean ± SD. 
 Of course, another possible explanation was that the liposomes were just bad for 
some reason, so I confirmed by testing two surface concentrations of DOG at three total 
concentrations of liposomes.  I was also interested in learning what total concentration of 
liposomes would be required to confidently measure the activity of DGK in 3 mol% 
DOG liposomes (so that I could more accurately measure any inhibition from compound 
1), so I tested higher total liposome concentrations than in the previous experiment.  I 
confirmed that the activity of purified DGK-theta depends on both the surface and total 
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concentration of DOG, and that at 2 mM liposomes, 3 mol% DOG gives much less than 
half-maximal activity, consistent with the Km(surface) of DGK for DOG’s being greater 
than 3 mol% in 2 mM liposomes (Figure 133), as I had observed at 0.5 mM liposomes 
(Figure 132).  This experiment was performed using POPC, not egg PC, so the PC fatty 
acyl chain constituents did not appear to be the issue, and, because the results repeated, 
bad liposomes did not appear to be the issue, either.  Another possible explanation is that 
DGK’s affinity for DOG does not depend on the total concentration of DOG, but rather 
on the total concentration of another lipid constituent of the liposomes, such as POPE, 
POPC, or POPS (although, as mentioned before, the reported Km(surface) did not depend on 
whether the liposomes contained 0 or 8 mol% POPS3, and DGK-theta activity has been 
reported not to depend on PC or PE140, so that explanation also seems unlikely, 
particularly when surface dilution kinetic theory predicts that a quasi-scooter would 
indeed depend on both the surface and the total concentration of lipid substrate).  I 
therefore concluded that, under my experimental conditions, at liposome concentrations 
of 5 mM or lower, the Km(surface) of purified DGK-theta for DOG is considerably greater 
than 3 mol%. 
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Figure 133.  Purified DGK-theta’s enzymatic activity depends on both the surface and total 
concentrations of DOG, and, using liposome concentrations of 5 mM or lower with 9 mol% POPS, its 
Km(surface) for DOG is greater than 3 mol%.   DGK activity assay.  I first preincubated purified DGK-
theta in preincubation buffer (43 pg per µL purified DGK-theta, 1.7% (v/v) glycerol, 0.005% (v/v) DDM, 4 
µM histone H1, 1 mM DTT, 31 mM HEPES, pH 7.5, 62 mM NaCl) on ice for ten minutes.  The final 
reaction mixture included liposomes (2:1::POPE:POPC; 9 mol% POPS, and the indicated concentrations of 
DOG) at the concentrations shown, 44 mM HEPES, pH 7.5, 87 mM NaCl, 1 mM DTT, 1.5 mM MgCl2, 1 
mM ATP, 66.7 Ci per mmol [γ-32P]-ATP, 0.1 µM histone H1, 0.1 mg per mL ovalbumin, 1.1 pg per µL 
purified DGK-theta, and 0.04% (v/v) glycerol, and proceeded for 15 minutes at 37°C.  In triplicate: mean ± 
SD. 
 In an effort to boost the DGK activity I could detect, so that I could more reliably 
measure a decrease in activity that might be caused by compound 1, I once again tested 
the dependence of DGK-theta’s activity on the surface and total concentration of DOG, 
this time in the presence of 20 mol% POPS, a lipid that has been reported to activate 
DGK-theta140.  In the presence of 20 mol% POPS, the activity of DGK-theta once again 
depended on both the total and surface concentration of DOG, and, at the liposome 
concentrations tested, the Km(surface) for DOG was considerably greater than 3 mol%. 
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Figure 134.  In the presence of 20 mol% POPS, the activity of purified DGK-theta depends on both 
the total and surface concentration of DOG, and, at the liposome concentrations tested, the Km(surface) 
for DOG is considerably greater than 3 mol%.  DGK activity assay.  I first preincubated purified DGK-
theta in preincubation buffer (43 pg per µL purified DGK-theta, 1.7% (v/v) glycerol, 0.005% (v/v) DDM, 4 
µM histone H1, 1 mM DTT, 31 mM HEPES, pH 7.5, 62 mM NaCl) on ice for ten minutes.  The final 
reaction mixture included liposomes (2:1::POPE:POPC; 20 mol% POPS, and the indicated concentrations 
of DOG) at the concentrations shown, 44 mM HEPES, pH 7.5, 87 mM NaCl, 1 mM DTT, 1.5 mM MgCl2, 
1 mM ATP, 60.5 Ci per mmol [γ-32P]-ATP, 0.1 µM histone H1, 0.1 mg per mL ovalbumin, 1.1 pg per µL 
purified DGK-theta, and 0.04% (v/v) glycerol, and proceeded for 15 minutes at 37°C.  In triplicate: mean ± 
SD. 
 If I estimate the Km(surface) of DGK at 0.5 mM liposomes to be 6 mol%, then if an 
inhibitor is presented at the concentration equal to its Ki, then the maximum (and thus 
most easily detected) difference in activity between inhibited and uninhibited enzyme 
would be predicted to be at 8.5 mol% substrate (Figure 135).  I therefore tested the effect 
of three different concentrations of compound 1 in the presence of 8.5 mol% DOG to see 
whether compound 1 might inhibit DGK-theta.  I was quite surprised to observe that 
compound 1 activated DGK-theta, but not monotonically (Figure 136).  One possible 
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explanation for such an effect could be that compound 1 was interacting with one higher-
affinity site that helped the DGK bind the membrane (and encounter DOG) and also with 
another lower-affinity site that competed for DOG in the active site. 
 
Figure 135.  Predicted difference in activity between DGK with and without an inhibitor at the 
concentration equal to its Ki (blue), plotted as a function of mol% substrate, assuming a Km(surface) of 6 
mol%.  The red tangent marks where the derivative is equal to zero (i.e., where the local maximum is), and 
the green orthogonal indicates to which concentration of DOG that maximum corresponds (8.5 mol%). 
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Figure 136.  Compound 1 activates purified DGK-theta, but not monotonically.  DGK activity assay.  I 
first preincubated purified DGK-theta in preincubation buffer (43 pg per µL purified DGK-theta, 1.7% 
(v/v) glycerol, 0.005% (v/v) DDM, 0.5 µM histone H1, 1 mM DTT, 45 mM HEPES, pH 7.5, 91 mM NaCl) 
on ice for ten minutes.  The final reaction mixture included 0.5 mM liposomes (2:1::POPE:POPC; 20 mol% 
POPS, 8.5 mol% DOG, and the indicated concentrations of compound 1), 46 mM HEPES, pH 7.5, 91 mM 
NaCl, 1 mM DTT, 1.5 mM MgCl2, 1 mM ATP, 60.5 Ci per mmol [γ-32P]-ATP, 0.1 µM histone H1, 0.1 
mg per mL ovalbumin, 4.3 pg per µL purified DGK-theta, and 0.2% (v/v) glycerol, and proceeded for 15 
minutes at 37°C.  In triplicate: mean ± SD.  
When I repeated the experiment, the difference in DGK activity between 0 mol% 
and ~0.4 mol% (the highest concentration I could successfully extrude) compound 1 in 
the presence of 4 mol% DOG and 20% POPS was not significant (Figure 137).  
Compound 1 certainly did not appear to inhibit DGK under these conditions.  The 
concentration of compound 1 is admittedly low, especially in the context of 8.5 mol% 
DOG.  It is entirely possible that compound 1 might inhibit DGK at higher 
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concentrations, but 0.4 mol% was the highest concentration I was able to incorporate into 
liposomes. 
 
Figure 137.  Compound 1 does not inhibit purified DGK-theta under the conditions tested.  DGK 
activity assay.  I first preincubated purified DGK-theta in preincubation buffer (43 pg per µL purified 
DGK-theta, 1.7% (v/v) glycerol, 0.005% (v/v) DDM, 0.1 µM histone H1, 1 mM DTT, 53 mM HEPES, pH 
7.5, 105 mM NaCl) on ice for ten minutes.  The final reaction mixture included 0.5 mM liposomes 
(2:1::POPE:POPC; 20 mol% POPS, 8.5 mol% DOG, and the indicated concentrations of compound 1), 46 
mM HEPES, pH 7.5, 91 mM NaCl, 1 mM DTT, 1.5 mM MgCl2, 1 mM ATP, 49.9 Ci per mmol [γ-32P]-
ATP, 0.1 µM histone H1, 0.1 mg per mL ovalbumin, 17 pg per µL purified DGK-theta, and 0.6% (v/v) 
glycerol, and proceeded for 15 minutes at 37°C.  In triplicate: mean ± SD. 
Because compound 1 has a hydroxyl in the 3-position of its carbon backbone, as 
diacylglycerol does, I also wondered whether DGK-theta could use compound 1 as a 
substrate.  Compound 2 (whose structure is shown in Figure 138) is the product that 
would be produced by DGK-theta if it were to phosphorylate compound 1 on that 
hydroxyl.  When I subjected compound 2 to TLC in the same solvent system used to 




Figure 139.  Compound 2 comigrates with POPA in the PA separation TLC solvent system.  After 
spotting the indicated amounts onto a glass TLC plate, I ran the plate for one hour in fresh tank fluid and 
marked the solvent front with pencil.  I visualized the plate by charring.   
 I therefore set out to test whether purified DGK-theta could use compound 1 as a 
substrate by measuring its enzymatic activity on liposomes containing compound 1 but 
not DOG.  I could reproducibly detect greater activity in liposomes that contained ~0.4% 
compound 1 as compared to liposomes containing none (Figure 140).  I therefore 
concluded that DGK-theta was able to use compound 1 as a substrate. 
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Figure 140.  DGK-theta is able to use compound 1 as a substrate.  DGK activity assays.  (A) I first 
preincubated purified DGK-theta in preincubation buffer 1 (43 pg per µL purified DGK-theta, 1.7% (v/v) 
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glycerol, 0.005% (v/v) DDM, 1 µM histone H1, 1 mM DTT, 43 mM HEPES, pH 7.5, 85 mM NaCl) on ice 
for ten minutes.  The final reaction mixture included 0.5 mM liposomes (2:1::POPE:POPC; 20 mol% 
POPS, and the indicated concentrations of compound 1), 46 mM HEPES, pH 7.5, 92 mM NaCl, 1 mM 
DTT, 1.5 mM MgCl2, 1 mM ATP, 49.9 Ci per mmol [γ-32P]-ATP, 0.1 µM histone H1, 0.1 mg per mL 
ovalbumin, 2.2 pg per µL purified DGK-theta, and 0.08% (v/v) glycerol, and proceeded for 15 minutes at 
37°C.  In triplicate: mean ± SD.  (B) I first preincubated purified DGK-theta in preincubation buffer 2 (43 
pg per µL purified DGK-theta, 1.7% (v/v) glycerol, 0.005% (v/v) DDM, 0.1 µM histone H1, 1 mM DTT, 
53 mM HEPES, pH 7.5, 105 mM NaCl) on ice for ten minutes.  The final reaction mixture included 0.5 
mM liposomes (2:1::POPE:POPC; 20 mol% POPS, and the indicated concentrations of compound 1), 46 
mM HEPES, pH 7.5, 91 mM NaCl, 1 mM DTT, 1.5 mM MgCl2, 1 mM ATP, 49.9 Ci per mmol [γ-32P]-
ATP, 0.1 µM histone H1, 0.1 mg per mL ovalbumin, 17 pg per µL purified DGK-theta, and 0.6% (v/v) 
glycerol, and proceeded for 15 minutes at 37°C.  In triplicate: mean ± SD. 
Compound 3 and H. sapiens DGK-Theta 
 Compound 3 is, like compound 1, a diglyceride-based photoaffinity probe using 
benzophenone as the photoactivatable crosslinker (Figure 141).  Unlike compound 1, 
whose fatty acyl chains are stearic (18 carbons), compound 3’s fatty chains are palmitic 
(16 carbons).  These chains are attached to the glycerol backbone not by an acyl 
connection, as in compound 1 and diglyceride, but rather by an ether connection, which is 
predicted to lead to less chain migration. 
 
Figure 141.  The structure of compound 3. 
 Especially given my experience with compounds 1 and 2, I first wanted to 
measure the concentration of compound 3 before testing whether it was an inhibitor 
and/or a substrate of DGK.  I therefore ran it on a TLC plate and charred the plate to 
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estimate the intensity of the spots as compared to DOG standards of a known 
concentration.  Unlike compounds 1 and 2, the intensity of the charred spots 
corresponding to compound 3 was consistent with the advertised concentration (Figure 
142). 
 
Figure 142.  Compound 3’s concentration is consistent with the advertised concentration. After 
spotting the indicated amounts onto a glass TLC plate, I ran the plate for thirty minutes in tank fluid 
(85:15:5::toluene:chloroform:methanol) that had been made eleven days previously, and marked the 
solvent front with a pencil before drying.  I charred the plate to visualize the spots. 
 Because compound 3 is a diglyceride analog, I tested whether it could 
competitively inhibit DGK by measuring the enzymatic activity of purified DGK-theta in 
the presence of 4 mol% DOG and an increasing concentration of compound 3 (which 
went into liposomes much more easily than compound 1 did).  Instead of inhibiting DGK, 
compound 3 appeared to enhance DGK-theta’s enzymatic activity (Figure 143A).  As 
with compound 1 (Figure 136A), the activation appeared to not be monotonic.  
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Activation of purified DGK-theta by compound 3 was reproducible, but not nearly as 
dramatic when repeated (Figure 143B).  I therefore concluded that compound 3 activated 
DGK-theta’s enzymatic activity using DOG as a substrate, possibly by helping the 
enzyme target to the membrane. 
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Figure 143.  Compound 3 activates purified DGK-theta.  DGK activity assays.  (A) I first preincubated 
purified DGK-theta in preincubation buffer 1 (37 pg per µL purified DGK-theta, 1.4% (v/v) glycerol, 
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0.006% (v/v) DDM, 0.1 µM histone H1, 1 mM DTT, 0.1 mg per mL ovalbumin, 52 mM HEPES, pH 7.5, 
105 mM NaCl) on ice for ten minutes.  The final reaction mixture included 0.5 mM liposomes 
(2:1::POPE:POPC; 20 mol% POPS, 4 mol% DOG, and the indicated concentrations of compound 3), 51 
mM HEPES, pH 7.5, 102 mM NaCl, 1 mM DTT, 0.75 mM MgCl2, 0.5 mM ATP, 85.0 Ci per mmol [γ-
32P]-ATP, 0.05 µM histone H1, 0.05 mg per mL ovalbumin, 16 pg per µL purified DGK-theta, and 0.6% 
(v/v) glycerol, and proceeded for 25 minutes at 37°C.  In triplicate: mean ± SD.  (B) I first preincubated 
purified DGK-theta (“601E” and “227A” signify two different batches of purified DGK-theta) in 
preincubation buffer 1 (33 pg per µL purified DGK-theta, up to 1.3% (v/v) glycerol, 0.005% (v/v) DDM, 3 
mM MgCl2, 0.2 µM histone H1, 1 mM DTT, 0.1 mg per mL ovalbumin, up to 41 mM HEPES, pH 7.5, up 
to 83 mM NaCl) on ice for ~thirty minutes.  The final reaction mixture included 0.5 mM liposomes 
(2:1::POPE:POPC; 20 mol% POPS, 4 mol% DOG, and the indicated concentrations of compound 3), 28 
mM HEPES, pH 7.5, 98 mM NaCl, 1 mM DTT, 1.5 mM MgCl2, 1 mM ATP, 85.0 Ci per mmol [γ-32P]-
ATP, 0.1 µM histone H1, 0.05 mg per mL ovalbumin, 17 pg per µL purified DGK-theta, and 0.6% (v/v) 
glycerol, and proceeded for 15 minutes at 37°C.  In triplicate: mean ± SD. 
 Compound 3 includes a hydroxyl in the 3-position of the glycerol backbone, as 
diglyceride does, so I therefore tested whether DGK-theta could use compound 3 as a 
substrate.  (The migration pattern of the phosphorylated product of compound 3 in the PA 
separation TLC solvent system is unknown, so I do not know whether such radiolabeled 
spots might be contributing to the activity detected in Figure 143.)  Early experiments 
measuring the enzymatic activity of DGK-theta on liposomes containing compound 3 
without DOG were either inconclusive (Figure 144B, C) or demonstrated that DGK-
theta’s Km for compound 3 must be very high (Figure 144A), but when I increased the 
liposome concentration to 7.5 mM, the DGK-theta concentration to 60 pg per µL, and the 
time of the assay to sixty minutes, I could confidently measure DGK-theta’s activity on 
liposomes containing compound 3 to be greater than its activity on liposomes without 
compound 3 (Figure 145).  I therefore concluded that compound 3 is a substrate for 
DGK-theta, albeit one with very low affinity. 
 287  
 288 
Figure 144.  Early experiments measuring the enzymatic activity of DGK-theta on liposomes 
containing compound 3 without DOG were inconclusive.  DGK activity assays.  (A) I first preincubated 
purified DGK-theta in preincubation buffer 1 (37 pg per µL purified DGK-theta, 1.4% (v/v) glycerol, 
0.006% (v/v) DDM, 0.1 µM histone H1, 1 mM DTT, 0.1 mg per mL ovalbumin, 52 mM HEPES, pH 7.5, 
105 mM NaCl) on ice for ten minutes.  The final reaction mixture included 0.5 mM liposomes 
(2:1::POPE:POPC; 20 mol% POPS, and the indicated concentrations of compound 3), 51 mM HEPES, pH 
7.5, 102 mM NaCl, 1 mM DTT, 0.75 mM MgCl2, 0.5 mM ATP, 85.0 Ci per mmol [γ-32P]-ATP, 0.05 µM 
histone H1, 0.05 mg per mL ovalbumin, 16 pg per µL purified DGK-theta, and 0.6% (v/v) glycerol, and 
proceeded for 25 minutes at 37°C.  In triplicate: mean ± SD.  (B) I first preincubated purified DGK-theta 
(“601E” and “227A” signify two different batches of purified DGK-theta) in preincubation buffer 2 (33 pg 
per µL purified DGK-theta, up to 1.3% (v/v) glycerol, 0.005% (v/v) DDM, 3 mM MgCl2, 0.2 µM histone 
H1, 1 mM DTT, 0.1 mg per mL ovalbumin, up to 41 mM HEPES, pH 7.5, up to 83 mM NaCl) on ice for 
~thirty minutes.  The final reaction mixture included 0.5 mM liposomes (2:1::POPE:POPC; 20 mol% 
POPS, and the indicated concentrations of compound 3) at the concentrations shown, 48 mM HEPES, pH 
7.5, 95 mM NaCl, 1 mM DTT, 1.5 mM MgCl2, 1 mM ATP, 73.5 Ci per mmol [γ-32P]-ATP, 0.1 µM 
histone H1, 0.05 mg per mL ovalbumin, 17 pg per µL purified DGK-theta, and 0.6% (v/v) glycerol, and 
proceeded for 15 minutes at 37°C.  In triplicate: mean ± SD.  (C) I first preincubated purified DGK-theta in 
preincubation buffer 3 (80 pg per µL purified DGK-theta, 2% (v/v) glycerol, 0.005% (v/v) DDM, 3 mM 
MgCl2, 0.2 µM histone H1, 1 mM DTT, 0.1 mg per mL ovalbumin, 40 mM HEPES, pH 7.5, 80 mM NaCl) 
on ice for half an hour.  The final reaction mixture included liposomes (2:1::POPE:POPC; 20 mol% POPS, 
and the indicated concentrations of compound 3) at the concentrations shown, 28 mM HEPES, pH 7.5, 98 
mM NaCl, 1 mM DTT, 1.5 mM MgCl2, 1 mM ATP, 85.0 Ci per mmol [γ-32P]-ATP, 0.1 µM histone H1, 
0.05 mg per mL ovalbumin, 40 pg per µL purified DGK-theta, and 1% (v/v) glycerol, and proceeded for 
thirty minutes at 37°C.  In triplicate: mean ± SD. 
 
Figure 145.  DGK-theta can use compound 3 as a substrate.  DGK activity assay.  I first preincubated 
purified DGK-theta in preincubation buffer 1 (150 pg per µL purified DGK-theta, 6% (v/v) glycerol, 
0.006% (v/v) DDM, 0.3 µM histone H1, 1 mM DTT, 0.1 mg per mL ovalbumin, 63 mM HEPES, pH 7.5, 
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126 mM NaCl) on ice for half an hour.  The final reaction mixture included (2:1::POPE:POPC; 20 mol% 
POPS, and the indicated concentrations of compound 3), 50 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM 
DTT, 1.5 mM MgCl2, 1 mM ATP, 98.3 Ci per mmol [γ-32P]-ATP, 0.1 µM histone H1, 0.05 mg per mL 
ovalbumin, 60 pg per µL purified DGK-theta, and 2% (v/v) glycerol, and proceeded for one hour at 37°C.  
In triplicate: mean ± SD. 
Compound 4 and H. sapiens DGK-Theta 
 Compound 4 is, like compounds 1 and 3, a diglyceride-based photoaffinity probe 
using benzophenone as the photoactivatable crosslinker (Figure 146).  Like compound 3, 
its fatty chains are palmitic and attached to the glycerol backbone via an ether 
connection.  Unlike compounds 1, 2, and 3, it was not synthesized using click chemistry, 
and as a result, it has a shorter linker between its benzophenone moiety and its DAG-like 
moiety. 
 
Figure 146.  The structure of compound 4. 
Especially given my experience with compounds 1 and 2, I first wanted to 
measure the concentration of compound 4 before testing whether it was an inhibitor 
and/or a substrate of DGK.  I therefore ran it on a TLC plate and charred the plate to 
estimate the intensity of the spots as compared to DOG standards of a known 
concentration.  Unlike compounds 1 and 2, but like compound 3, the intensity of the 
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charred spots corresponding to compound 4 was consistent with the advertised 
concentration (Figure 147). 
 
Figure 147. Compound 4’s concentration is consistent with the advertised concentration.  After 
spotting the indicated amounts onto a glass TLC plate, I ran the plate for thirty minutes in fresh tank fluid 
(85:15:5::toluene:chloroform:methanol).  I charred the plate to visualize the spots. 
Because compound 4 is a diglyceride analog, I tested whether it could 
competitively inhibit DGK by measuring the enzymatic activity of purified DGK-theta in 
the presence of 5 mol% DOG and an increasing concentration of compound 4 (which 
went into liposomes much more easily than compound 1 did, but not so easily as 
compound 3).  Compound 4 did not appear to inhibit DGK-theta (Figure 148), and, 
unlike compounds 1 (Figure 136 and Figure 137) and 3 (Figure 143), it did not appear to 
activate DGK-theta, either (Figure 148). 
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Figure 148.  Compound 4 appears to neither activate nor inhibit purified DGK-theta under the 
conditions tested.  DGK activity assay.  I first preincubated purified DGK-theta in preincubation buffer 
(1.1 pg per µL purified DGK-theta, 0.02% (v/v) glycerol, 0.005% (v/v) DDM, 0.5 µM histone H1, 1 mM 
DTT, 50 mM HEPES, pH 7.5, 100 mM NaCl) on ice for half an hour.  The final reaction mixture included 
7.5 mM liposomes (2:1::POPE:POPC; 20 mol% POPS, 5 mol% DOG, and the indicated concentrations of 
compound 4), 50 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM DTT, 1.5 mM MgCl2, 1 mM ATP, 37.3 Ci 
per mmol [γ-32P]-ATP, 0.1 µM histone H1, 0.1 mg per mL ovalbumin, 0.22 pg per µL purified DGK-theta, 
and 0.006% (v/v) glycerol, and proceeded for thirty minutes at 37°C.  In triplicate: mean ± SD. 
Compound 4 includes a hydroxyl in the 3-position of the glycerol backbone, as 
diglyceride does, so I therefore tested whether DGK-theta could use compound 4 as a 
substrate.  (The migration pattern of the phosphorylated product of compound 4 is 
unknown, so I do not know whether such radiolabeled spots might be contributing to the 
activity detected in Figure 148: it is a formal possibility that compound 4 is, in fact, 
inhibiting DGK-theta to exactly the same extent that it is a substrate, so that the loss and 
gain in radiolabeled spots perfectly balance one another, but that explanation seems 
extremely unlikely.)  I measured the enzymatic activity of purified DGK-theta to be 
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greater on liposomes containing 10 mol% compound 4 than on liposomes containing 0% 
compound 4 (Figure 149).  I therefore concluded that DGK-theta is able to use compound 
4 as a substrate. 
 
Figure 149.  Purified DGK-theta is able to use compound 4 as a substrate.  DGK activity assay.  I first 
preincubated purified DGK-theta in preincubation buffer (300 pg per µL purified DGK-theta, 8% (v/v) 
glycerol, 0.005% (v/v) DDM, 0.5 µM histone H1, 1 mM DTT, 50 mM HEPES, pH 7.5, 100 mM NaCl) on 
ice for fifteen minutes.  The final reaction mixture included 7.5 mM liposomes (2:1::POPE:POPC; 20 
mol% POPS, and the indicated concentrations of compound 4), 50 mM HEPES, pH 7.5, 100 mM NaCl, 1 
mM DTT, 1.5 mM MgCl2, 1 mM ATP, 85.0 Ci per mmol [γ-32P]-ATP, 0.1 µM histone H1, 0.1 mg per mL 
ovalbumin, 60 pg per µL purified DGK-theta, and 1.5% (v/v) glycerol, and proceeded for one hour at 37°C.  
In triplicate: mean ± SD. 
Conclusions 
 Under my experimental conditions, at liposome concentrations of 5 mM or lower, 
the Km(surface) of purified DGK-theta for DOG is considerably greater than 3 mol%. 
  Compounds 1 and 3 activate purified DGK-theta, but not monotonically, possibly by 
helping the enzyme target to the membrane, and can also be used as a substrate by the 
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enzyme.  Compound 4, contrariwise, does not appear to activate DGK-theta under the 
conditions tested, but DGK-theta is also able to use it as a substrate. 
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Chapter 6: Bimolecular Fluorescence Complementation (BiFC) to Probe 
DGK-Theta’s Protein-Protein interactions 
Introduction 
Bimolecular fluorescence complementation (BiFC) is a method for observing 
protein-protein interactions146.  The basic idea is that half of a fluorescent protein is fused 
to protein A, and the other half of the fluorescent protein is fused to protein B; if and 
when proteins A and B interact, the two halves of the fluorescent protein come together 
and fluoresce.  One advantage to this method is that no exogenous staining molecules are 
required to visualize the interaction.  Another advantage is that the method provides very 
high signal to noise, because in the absence of the interaction between proteins A and B, 
the two halves of the fluorescent molecule remain separate and do not fluoresce.  The fact 
that unassociated proteins produce no signal is also a limitation to the method: with no 
signal from unassociated proteins, the kinetics of real-time association cannot be 
measured.  Another challenge is that the method requires overexpression of recombinant 
proteins, and, as always is a risk with overexpressed proteins, the observed effects might 
be more an artifact of overexpression than a result of the endogenous molecules’ 
interactions. 
Methods 
 “YN” signifies residues 1-154 (or the N-terminus) of enhanced yellow fluorescent 
protein (eYFP), a mutant of green fluorescent protein (GFP), which is a protein from the 
Northwest Pacific jellyfish Aequoria victoria, that has been engineered to have red-
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shifted excitation and emission wavelengths147 as well as a single excitation peak148.  
“YC” signifies residues 155-238 (or the C-terminus) of eYFP.   
I transformed the FLAG/YN-Smad3 and FLAG/YC-Smad4 constructs each into 
the One Shot® TOP 10 (Life Technologies™) strain of E. coli, selecting for 
transformants using the antibiotic carbenicillin, and made glycerol stocks of the 
transformed bacteria. 
 In order to use the YN-Smad3 and YC-Smad4 constructs for cloning DGK BiFC 
constructs, I needed to know the sequence of those constructs.  I therefore designed 
sequencing primers to be at least eighteen nucleotides long, ending with GC rich content, 
and homologous to regions approximately 100 nucleotides from the sequence of interest.  
For YN-Smad3, the forward sequencing primer I designed was 
GGGCGACACCCTGGTGAACCGC and the reverse sequencing primer I designed was 
CGGGCAGGAGGAGAAATGGTGCG, and for YC-Smad4, the forward sequencing 
primer I designed was CCGCCGCCGGGATCACTCTCGGC and the reverse sequencing 
primer I designed was GCATTGTGCATAGTTTGATGTGCC.  The sequences produced 
by the reverse primers were more robust than the sequences produced by the forward 
primers, and I was able to successfully sequence the YN-Smad3 and YC-Smad4 
constructs. 
 In order to generate the DGK-theta BiFC constructs, I decided to use PCR to 
amplify either YN (from YN-Smad3) or YC (from YC-Smad4) with the appropriate 
restriction digestion sites for ligating into the DGK-theta in pCDNA3.1 (+) plasmid.  For 
inserting the YFP fragments upstream of DGK-theta (to produce a fusion protein with the 
YFP fragment attached to the N-terminus of DGK-theta), I used a HindIII site upstream 
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and an EcoRI site downstream of the YFP fragments (Figure 150).  For inserting the YFP 
fragments downstream of DGK-theta (to produce a fusion protein with the YFP fragment 
attached to the C-terminus of DGK-theta), I used an XbaI site upstream and a XhoI site 
downstream of the YFP fragments (Figure 151). 
 The forward primer I designed for PCRing the YN fragment, for fusion either 
upstream or downstream of DGK-theta, was gctaCTCGAGACatggactacaaagac (Figure 
150A).  This primer begins with a four-nucleotide overhang, for improving the efficiency 
of digestion at the following XhoI restriction site (for fusing the YN fragment to the C-
terminus of DGK-theta).  The XhoI site is followed by two nucleotides, which ensure that 
the YN fragment is translated in the same reading frame as DGK-theta (for the construct 
in which YN is attached C-terminally to DGK-theta).  The primer ends with fifteen 
nucleotides homologous to the beginning of the FLAG tag in the FLAG/YN-Smad3 
template. 
 The reverse primer I designed for PCRing the YN fragment, likewise for adding 
either upstream or downstream of DGK-theta, was CGATtctagaCgaattcGGCCATGATA 
(Figure 150B).  This primer also begins with a four-nucleotide overhang, for improving 
the efficiency of digestion at the following XbaI restriction site (for fusing the YN 
fragment to the C-terminus of DGK-theta).  The XbaI site is followed by a single 
nucleotide, which ensures that DGK-theta is translated in the same reading frame as YN 
(for the construct in which YN is attached N-terminally to DGK-theta).  The single 
nucleotide is followed by an EcoRI restriction site (for fusing the YN fragment to the N-
terminus of DGK-theta).  The primer ends with ten nucleotides homologous to the 
reverse complement of the end of YN in the FLAG/YN-Smad3 template. 
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 The produced PCR fragment of YN, therefore, is predicted to begin with a four 
nucleotide overhang, followed by an XhoI restriction site, followed by a two nucleotide 
spacer, followed by FLAG-YN as it encoded in the FLAG/YN-Smad3 template, followed 
by an EcoRI site immediately C-terminal to YN, followed by a single nucleotide spacer, 
followed by an XbaI restriction site, followed by a four nucleotide overhang (Figure 
150B).  When digested by EcoRI and HindIII (whose restriction site is already present in 
the FLAG/YN-Smad3 template, between the FLAG tag and YN) and ligated into DGK-
theta in pCDNA3.1 (+) plasmid that has been likewise digested, the predicted protein 
product begins with YN, followed by a glutamate and a phenylalanine, followed by 
DGK-theta, which from the pCDNA3.1(+) also includes a five-amino-acid tail whose 
sequence is AAARV: this is the YN-DGK-theta construct (Figure 150C).  Alternatively, 
EcoRI- and HindIII-digested PCR product can be ligated into pCDNA3.1(+) empty 
vector, in order to produce free YN, which can be used as a negative control for 
spontaneous interaction between YN and YC.  When the PCR product is digested by 
XhoI and XbaI and ligated into DGK-theta in pCDNA3.1 (+) plasmid that has been 
likewise digested, the predicted protein product begins with DGK-theta, followed by a 
five-amino-acid linker whose sequence is AAARD, followed by the FLAG tag, followed 
by a single leucine, followed by YN, followed by three amino acids whose sequence is 
EFV: this is the DGK-theta-YN construct (Figure 150C).  Free YN can also be produced 




Figure 150.  Cloning strategy for generating YN DGK BiFC constructs.  (A) Primers designed for PCR 
of YN, using FLAG/YN-Smad3 as a template.  (B) Predicted PCR product.  (C) YN-DGK-theta construct 
(top) and DGK-theta-YN construct (bottom). 
 The forward primer I designed for PCRing the YC fragment to fuse to the N-
terminus of DGK-theta was GCTAaagcttATGgacaagcagaagaag (Figure 151A).  This 
primer begins with a four-nucleotide overhang, for improving the efficiency of digestion 
at the following HindIII restriction site.  The HindIII site is followed by a start codon.  
The primer ends with fifteen nucleotides homologous to beginning of YC in the 
FLAG/YC-Smad4 template. 
 The reverse primer I designed for PCRing the YC fragment to fuse to either the 
N- or C-terminus of DGK-theta was CGATtctagaCgaattcCTTGTACAGC (Figure 151A).  
This primer begins with a four-nucleotide overhang, for improving the efficiency of 
digestion at the following XbaI restriction site.  The XbaI site is followed by a single 
nucleotide, for ensuring that the stop codon in the XbaI site is in the same translational 
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reading frame as the fusion protein, such that fusion protein will end with four amino 
acids after the end of YC.  The single nucleotide spacer is followed by an EcoRI site.  
The primer ends with ten nucleotides homologous to the reverse complement of the end 
of YC in the FLAG/YC-Smad4 template. 
 The produced PCR fragment using these two primers, therefore, is predicted to 
begin with a four-nucleotide overhang, followed by a HindIII site, followed by a start 
codon, followed by YC, as it is encoded in the FLAG/YC-Smad4 template, followed by 
an EcoRI site immediately C-terminal to YC, followed by a single-nucleotide spacer, 
followed by an XbaI site, followed by a four-nucleotide overhang (Figure 151B).  When 
digested by EcoRI and HindIII and ligated into DGK-theta in pCDNA3.1 (+) plasmid 
that has been likewise digested, the predicted protein product begins with YC, followed 
by a glutamate and a phenylalanine, followed by DGK-theta, which from the 
pCDNA3.1(+) also includes a five-amino-acid tail whose sequence is AAARV: this is the 
YC-DGK-theta construct (Figure 151C). 
 
Figure 151.  Cloning strategy for generating the YC-DGK-theta BiFC construct.  (A) Primers 
designed for PCR of YC, using FLAG/YC-Smad4 as a template.  (B) Predicted PCR product.  (C) YC-
DGK-theta construct. 
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 The forward primer I designed for PCRing the YC fragment to fuse to the C-
terminus of DGK-theta was gctaCTCGAGagATGgacaagcagaag (Figure 152A).  This 
primer begins with a four-nucleotide overhang, for improving the efficiency of digestion 
at the following XhoI restriction site.  The XhoI site is followed by two nucleotides, 
which ensure that YC is translated in the same reading frame as DGK-theta.  The two 
nucleotides are followed by a start codon.  The primer ends with twelve nucleotides 
homologous to the beginning of YC in the FLAG/YC-Smad4 template. 
 The produced PCR product using this primer and the reverse primer shown in 
Figure 151A, therefore, is predicted to begin with a four-nucleotide overhang, followed 
by an XhoI site, followed by a two-nucleotide spacer, followed by a start codon, followed 
by YC, as it is encoded in the FLAG/YC-Smad4 template, followed by an EcoRI site 
immediately C-terminal to YC, followed by a spacer nucleotide (to make sure that the 
downstream stop codon is in frame), followed by an XbaI site, followed by a four-
nucleotide overhang (Figure 152B).  When digested by XhoI and XbaI and ligated into 
DGK-theta in pCDNA3.1 (+) plasmid that has been likewise digested, the predicted 
protein product begins with DGK-theta, followed by a five-amino-acid linker whose 
sequence is AAARE, followed by YC, and ending with three amino acids whose 
sequence is EFV: this is the DGK-theta-YC construct (Figure 152C). 
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Figure 152.  Cloning strategy for generating the DGK-theta-YC BiFC construct.  (A) Primers 
designed for PCR of YC, using FLAG/YC-Smad4 as a template.  (B) Predicted PCR product.  (C) DGK-
theta-YC construct. 
 After my first attempt at PCR, the YN primers produced robust PCR products of 
approximately the correct size, but the YC primers did not.  Adjusting the annealing 
temperature of the PCR reaction did not help.  Adding DMSO to the PCR reaction did 
not help.  Reducing the template concentration, reducing the initial annealing 
temperature, and increasing the time of the annealing steps produced PCR products of 
approximately the correct size faintly detectable by ethidium bromide staining following 
agarose electrophoresis for the XhoI YC PCR product, but not for the HindIII YC 
product.  Using previous PCR attempts as the template for more rounds of PCR 
eventually produced enough of a PCR product for HindIII YC that was approximately the 
correct size and faintly detectable by ethidium bromide staining following agarose 
electrophoresis, but the YC PCR products were never as robustly amplified as the YN 
PCR products.  PCR purification of the PCR products using either the QIAGEN or 
Invitrogen™ (now Life Technologies™) kits appeared to work equally well. 
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 Because of the poor yields from the attempts to PCR the YC fragment, I designed 
new primers.  The fact that increasing the primer:template ratio, decreasing the annealing 
temperature, and increasing the annealing time improved the amplification of the PCR 
product suggested that the problem with the first set of primers was that their affinity for 
the template was too low.  For the next set of primers, therefore, I increased the length of 
the primer that was homologous to the template, in order to increase its affinity.  In order 
to make room for the increased homologous region, each primer included only one 
restriction site.  I therefore designed the new set of primers such that one set of PCR 
primers would produce the YC fragment with the HindIII and EcoRI sites required for 
fusing the YC fragment upstream of DGK-theta, and a second set of PCR primers would 
produce the YC fragment with the XhoI and XbaI sites required for fusing the YC 
fragment downstream of DGK-theta. 
 The forward primer I designed for this second attempt to PCR the YC fragment to 
fuse to the N-terminus of DGK-theta was 
cgacaagcttatgGACAAGCAGAAGAAGAACGG (Figure 153A).  Similarly to the 
previous primer, it begins with a four-nucleotide overhang, including a GC anchor, for 
improving the efficiency of digestion at the following HindIII restriction site.  Following 
the HindIII site is a start codon.  The primer ends with twenty nucleotides (as opposed to 
only fifteen in the previous primer) homologous to the beginning of YC.  I hoped that the 
longer homologous region would improve PCR efficiency.  This primer is calculated to 
have a Tm of 66°C, a homologous Tm of 55°C, and a GC content of 48%. 
 The reverse primer I designed for this second attempt to PCR the YC fragment to 
fuse to the N-terminus of DGK-theta was 
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gcatGAATTCCTTGTACAGCTCGTCCATGCC (Figure 153A).  Similarly to the 
previous primer, it begins with a four-nucleotide overhang, including a GC anchor, for 
improving the efficiency of digestion at the following EcoRI restriction site.  The primer 
ends with twenty-one nucleotides (as opposed to only ten in the previous primer) 
homologous to the end of YC.  I hoped that the longer homologous region (allowed by 
removing the XbaI site) would improve PCR efficiency.  This primer is calculated to 
have a Tm of 66°C, a homologous Tm of 61°C, and a GC content of 52%. 
 The PCR product predicted to be produced by these two primers is very similar to 
that produced by the first round of primers (Figure 153B; compare to Figure 151B), and, 
because the PCR product would be inserted into DGK-theta in pCDNA3.1 (+) via 
HindIII and EcoRI sites, the final YC-DGK-theta construct would be the same (Figure 
153C; compare to Figure 151C). 
 
Figure 153.  Cloning strategy for generating the YC-DGK-theta BiFC construct, attempt 2.  (A) 
Primers designed for PCR of YC, using FLAG/YC-Smad4 as a template.  (B) Predicted PCR product.  (C) 
YC-DGK-theta construct. 
 The forward primer I designed for this second attempt to PCR the YC fragment to 
fuse to the C-terminus of DGK-theta was 
 304 
gctaCTCGAGAGGACAAGCAGAAGAAGAACGG (Figure 154A).  Similarly to the 
previous primer, it begins with a four-nucleotide overhang, including a GC anchor, for 
improving the efficiency of digestion at the following XhoI restriction site.  As before, 
the XhoI site is followed by two nucleotides, which ensure that YC is translated in the 
same reading frame as DGK-theta.  Unlike the previous primer, this time I omitted the 
start codon.  The primer ends with twenty nucleotides homologous to the beginning of 
YC (as opposed to only twelve nucleotides in the first primer).  I hoped that the longer 
homologous region would improve PCR efficiency.  This primer is calculated to have a 
Tm of 66°C, a homologous Tm of 58°C, and a GC content of 53%. 
 The reverse primer I designed for this second attempt to PCR the YC fragment to 
fuse to the C-terminus of DGK-theta was 
CGATtctagaCCTTGTACAGCTCGTCCATGCC (Figure 154A).  Similarly to the 
previous primer, it begins with a four-nucleotide overhang, including a GC anchor, for 
improving the efficiency of digestion at the following XbaI restriction site.  As before, 
the XbaI site is followed by a single nucleotide to ensure that the stop codon in the XbaI 
site is translated in the same reading frame as the fusion protein.  I omitted the EcoRI 
site, and the primer ends with twenty-one nucleotides homologous to the end of YC (as 
opposed to only ten in the first primer).   I hoped that the longer homologous region 
(allowed by removing the EcoRI site) would improve PCR efficiency.  This primer is 
calculated to have a Tm of 66°C, a homologous Tm of 59°C, and a GC content of 53%. 
 The PCR product predicted to be produced by these primers, unlike the PCR 
product predicted to be produced in the first cloning attempt, is missing the start codon 
 305 
and the EcoRI site (Figure 154B).  As such, the tail of the fusion protein, after the end of 
the YC coding sequence, is reduced to only a single valise (Figure 154C). 
 
Figure 154.  Cloning strategy for generating the DGK-theta-YC BiFC construct, attempt 2.  (A) 
Primers designed for PCR of YC, using FLAG/YC-Smad4 as a template.  (B) Predicted PCR product.  (C) 
DGK-theta-YC construct. 
With the new PCR primers, the YC PCR products were more robust than with the 
previous primers, but still not as robust as the YN PCR products. 
I isolated the DNA from glycerol stocks of One Shot® TOP 10 (Life 
Technologies™) strain of E. coli that had been labeled as transformed with pCDNA3.1 
(+) empty vector and from DGK-theta in pCDNA3.1(+).  When I digested the isolated 
DNA with either HindIII and EcoRI or with XhoI and XbaI, I discovered that the glycerol 
stock that had been labeled as pcDNA3.1 (+) empty vector was, in fact, DGK-theta in 
pCDNA3.1 (+).  The glycerol stock that had been labeled DGK-theta in pCDNA3.1 (+) 
was, in fact, DGK-theta in pCDNA3.1 (+), but that was different from the sequence that I 
had been told was DGK-theta in pCDNA3.1 (+).  The original sequence (and the one 
from the glycerol stock) included two EcoRI sites, one on either side of DGK-theta; the 
sequence that I had been working with, which had also been labeled DGK-theta in 
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pCDNA3.1(+), was the original sequence that had been digested with NotI and religated 
to remove the extra EcoRI sites.   
As a control for ligation, I always also included a reaction without insert, to assess 
the number of background colonies from incompletely digested plasmids that had 
religated without incorporating the insert.  Ligations that using XhoI and XbaI sites gave 
high background.  XhoI’s enzymatic activity has been reported to be impaired by CpG 
dinucleotide methylation149, and thus more restriction enzyme may be required for 
supercoiled plasmid than for linear DNA.  In order to assess whether XhoI was the 
culprit, I redigested the previously digested plasmid either with XhoI or XbaI.  The 
plasmid that was redigested with XbaI, when ligated and transformed into E. coli, still 
gave a large number of background colonies, suggesting that incomplete digestion by 
XbaI was not the problem.  The plasmid that was redigested with XhoI, contrariwise, 
when ligated and transformed into E. coli gave many more colonies than the originally 
digested plasmid, suggesting that at least part of the source of the high background was 
due to incomplete digestion at the XhoI site.  Subsequent digestion, first by XbaI to 
linearize the plasmid followed by XhoI, likewise gave low background, and I therefore 
used sequential rather than simultaneous digestion for the XhoI / XbaI sites. 
My early attempts at ligating the digested PCR products into the digested 
plasmids were unsuccessful, probably because I had too much insert in the ligation 
reactions.  I thought that large amounts of insert would favor ligation, but apparently too 
much insert reduced ligation efficiency.  I therefore picked colonies even when the 
number of colonies was no higher than on the background plates, in the hopes that any 
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colonies were successful transformants, and that the low number of colonies reflected 
repression from too much insert, and not from high background. 
In order to assess whether the transformants had successfully incorporated the 
insert, I performed diagnostic PCR using cultures that had been inoculated from single 
colonies from the transformed plate.  Because the YN forward primer relies on the FLAG 
tag, which would be removed after HindIII digestion, for constructs that were cloned via 
HindIII I used T7 as a forward primer instead for the diagnostic PCR.  The T7 primer is 
considerably shorter than the other primers, and failure to PCR may partially be a result 
of poor compatibility in Tm within the primer pair.  For clones that appeared promising 
by diagnostic PCR, I isolated the DNA and sent it for sequencing, using either the T7 
primer for N-terminal fusions or for the fragments ligated into the vector alone, or a 
primer I designed for sequencing the C-terminal fusions based on homology to the C-
terminal region of DGK-theta, ggccctaaggtgcacatgc.  I then discovered that the sequence 
I had been working with to design the constructs (“DGK-theta in pCDNA3.1(+)”) had yet 
another discrepancy from the actual physical sequence.  The actual sequence had one 
more nucleotide between the end of the DGK-theta coding region and the XhoI site, 
meaning that the C-terminal fusion constructs I had designed were out of frame when 
cloned into the real sequence. 
 In an attempt to solve the frame-shift problem, I digested the DGK-YC (via XhoI 
and XbaI) construct with NotI, to leave an appropriately sized sticky end such that when 
the sticky end was removed by mung bean nuclease, the resulting blunt ends, when 
ligated together, would be in the appropriate frame.  For 4 µg of construct that had been 
digested with NotI and gel-purified, however, a 15-minute digestion at 30°C with 10 U of 
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mung bean nuclease completely chewed up the construct (Figure 155).  Another possible 
explanation for the appearance of the construct in Figure 155 is that recovery from gel-
purification following NotI digestion was much worse than the recovery from gel-
purification of DGK-theta in pCDNA3.1 (+) following HindIII and EcoRI digestion. 
 
Figure 155.  Very little pCDNA3.1 (+) is left after digestion with NotI and mung bean nuclease under 
the conditions shown.  Electrophoresis of a 1% (w/v) agarose gel visualized by ethidium bromide staining.  
Left, DGK-theta in pCDNA3.1 (+) that had been digested with HindIII and EcoRI and gel-purified.  Right, 
DGK-YC (via XhoI and XbaI) in pCDNA3.1 (+) that had been digested with NotI, gel-purified, digested 
with mung bean nuclease, and PCR-purified. 
In order to solve the frame-shift problem, then, I designed yet a third set of 
primers that would produce C-terminally fused constructs that would be in the 
appropriate frame. 
 The forward primer I designed for fusing YN to the C-terminus of DGK-theta, in 
the appropriate frame, was gctaCTCGAGCatggactacaaagacg (Figure 156A).  As with the 
other primers, it begins with a four-nucleotide overhang, including a GC anchor, for 
improving the efficiency of digestion at the following XhoI restriction site.  The XhoI 
site, unlike in previous primers, is immediately followed by one, not two nucleotides, so 
that YN will be translated in the same reading frame as DGK-theta.  The primer ends 
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with sixteen nucleotides homologous to the beginning sequence of the FLAG tag, 
including the start codon.  This primer is calculated to have a Tm of 62°C and a 
homologous Tm of 45°C. The predicted PCR product (Figure 156B) is very similar to that 
produced by the first set of YN primers (Figure 150B), but because of the frame shift, the 
linker sequence between the end of the DGK-theta coding sequence and the beginning of 
the FLAG tag was now GGRSS (Figure 156C; compare to Figure 150C). 
 
Figure 156.  Cloning strategy for generating DGK-theta-YN, attempt 2.  (A) Primers designed for PCR 
of YN, using FLAG/YN-Smad3 as a template.  (B) Predicted PCR product.  (C) DGK-theta-YN construct. 
 The forward primer I designed for fusing YC to the C-terminus of DGK-theta, in 
the appropriate frame, was gctaCTCGAGGGACAAGCAGAAGAAGAACG.  This 
primer is very similar to the second forward primer I designed for fusing YC to the C-
terminus of DGK-theta, but instead of a two-nucleotide spacer between the XhoI site and 
the beginning of the YC sequence, it has a one-nucleotide spacer, so that YC will be 
translated in the same reading frame as DGK-theta.  The primer ends with nineteen 
nucleotides homologous to the beginning sequence of YC, ending with another GC 
anchor.  This primer is calculated to have a Tm of 65°C and a homologous Tm of 52°C.  
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As with the redesign of the YN primers, the predicted PCR product (Figure 157B) is very 
similar to that produced by the second set of YC primers (Figure 154B), but because of 
the frame shift, the linker sequence between the end of the DGK-theta coding sequence 
and the beginning of the YC coding sequence was now GGRSR (Figure 157C; compare 
to Figure 154C). 
 
Figure 157.  Cloning strategy for generating the DGK-theta-YC BiFC construct, attempt 3.  (A) 
Primers designed for PCR of YC, using FLAG/YC-Smad4 as a template.  (B) Predicted PCR product.  (C) 
DGK-theta-YC construct. 
 I also designed primers for diagnostic PCR to determine whether the clones 
successfully incorporated the insert.  I designed the forward primer 
GGTGAGCAAGGGCGAGGAGC to detect the presence of YN, and the forward primer  
GCAGAAGAAGAACGGCATCAAGG to detect the presence of YC.  These primers 
were designed to complement the 5’ region of the sequence, and successful PCR would 
be predicted only if the YFP fragments were incorporated.  The reverse primers that were 
used to generate the constructs could be used with these forward primers for diagnostic 
PCR. 
 PCR using this third set of primers finally gave PCR products that were robustly 
detected by ethidium bromide staining and agarose electrophoresis (Figure 158).  The 
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intensity of the recovered bands also depended strongly on which tube of template was 
used.  The new success, therefore, may have either been due to superior primer design, or 
else due to some problem with the tubes of template used previously (such as incorrect 
concentration measurement, etc.). 
 
Figure 158.  The newest sets of primers robustly produce PCR products, although the yield also 
depends on the tube of template used.  Agarose electrophoresis visualized by ethidium bromide staining 
of PCR products of YFP fragments using the third set of primers.  “HindIII and EcoRI” signify the primers 
used to amplify the BiFC constructs for fusion to the N-terminus of DGK-theta, and “XhoI and XbaI” 
signify the primers used to amplify the constructs for fusion to the C-terminus of DGK-theta.  A, B, C, and 
D signify different tubes of template.  The migration patterns of the PCR products are consistent with their 
predicted sizes (523 bp for YN using the “XhoI and XbaI” primers, 294 bp for YC using the “HindIII and 
EcoRI” primers, and 277 bp for YC using the “XhoI and XbaI” primers). 
 I PCR-purified these PCR products and then digested either with HindIII or 
EcoRI, or with XbaI and XhoI (because the PCR products are linear, subsequent 
digestion was not necessary).  I PCR-purified the digests, and assessed the DNA 
concentration by agarose electrophoresis visualized by ethidium bromide staining.  I 
ligated these digested PCR products at a 3:1 molar ratio with DGK-theta in pCDNA3.1 
(+) that had likewise been digested with either HindIII and EcoRI, or by XbaI followed 
by XhoI, and PCR-purified.  I transformed the ligations into E. coli, and the number of 
colonies on the transformed plates greatly exceeded the number of colonies on the control 
plates (digested plasmid without insert).  I inoculated cultures with single colonies from 
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these plates, and performed diagnostic PCR on the cultures using the forward primers I 
had designed for diagnostic PCR, and the reverse primers used for the original PCR to 
build the insert.  I assessed the diagnostic PCR by running the diagnostic PCR products 
on an agarose gel (Figure 159).  I isolated the DNA from clones that had produced robust 
bands of the correct size, and submitted for sequencing.  I made glycerol stocks of good 
clones confirmed by DNA sequencing. 
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Figure 159.  Diagnostic PCR of some BiFC clones.  Agarose electrophoresis visualized by ethidium 
bromide staining.  A, B, C, and D correspond to the PCR products shown in Figure 158. 
 I was therefore able to successfully generate clones of YN, YC, YN-DGK-theta, 
YC-DGK-theta, DGK-theta-YN, and DGK-theta-YC, all in pCDNA3.1 (+). 
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BiFC and H. sapiens DGK-theta dimerization in HEK293T cells 
Introduction 
 As previously mentioned, oligomerization of LCB5 family proteins is not 
unprecedented: purified Salmonella typhimurium YegS recombinantly expressed in E. 
coli elutes as a dimer from a Superdex G200 resin92, E. coli YegS93 and Staphylococcus 
aureus DgkB94 recombinantly expressed in E. coli each crystallize as dimers, and H. 
sapiens DGK-epsilon recombinantly expressed in COS-7 cells has been reported to 
dimerize based on its migration in PFO-PAGE43.  We therefore wondered whether H. 
sapiens DGK-theta was likewise dimerizing.  More traditional methods that would be 
used to measure dimerization of a protein, such as size exclusion chromatography or 
analytical ultracentrifugation require large amounts of purified protein.  (The migration 
pattern of an unpurified protein in size exclusion chromatography or PFO-PAGE could 
be followed by a sensitive assay such as Western blotting, but if the protein is unpurified, 
it is impossible to show conclusively that the protein is dimerizing and not merely 
interacting with another, similarly-sized protein.)  If DGK-theta dimerizes, it would be 
predicted that, if the fusion proteins are in the proper orientation, DGK-theta would 
produce a BiFC signal.  Advantages of this approach include the fact that it does not 
require large amounts of purified protein, and that it would reflect the dimerization state 
in vivo. 
Results 
 For positive controls, I used the FLAG/YN-Smad3 and FLAG/YC-Smad4 
constructs2.  Smad3 and Smad4 are proteins that form a heteromeric complex in response 
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to TGF-β stimulation150, and BiFC has been used to monitor their interaction151.  “YN” 
signifies residues 1-154 (or the N-terminus) of enhanced yellow fluorescent protein 
(eYFP), a mutant of green fluorescent protein (GFP), which is a protein from the 
Northwest Pacific jellyfish Aequoria victoria, that has been engineered to have red-
shifted excitation and emission wavelengths147 as well as a single excitation peak148.  
“YC” signifies residues 155-238 (or the C-terminus) of eYFP.  When I transfected 
HEK293T cells with FLAG/YN-Smad3 or FLAG/YN-Smad4 alone, I did not observe 
any fluorescence, but when I transfected the two constructs together, I observed robust 
fluorescence (Table 2), consistent with successful BiFC.  I therefore concluded that the 
YN-Smad3 and YN-Smad4 constructs were suitable positive controls for the DGK-theta 
dimerization BiFC experiment. 




YN-Smad3 alone No 
YC-Smad4 alone No 
Both YN-Smad3 and YC-Smad4 Yes 
Table 2.  The FLAG/YN-Smad3 and FLAG/YN-Smad4 constructs produce a BiFC signal when 
cotransfected, but not when transfected separately.  I transfected the DNA (2 µg per well of a 6-well 
dish) into HEK293T cells using HiFect® Reagent (Lonza) and Opti-MEM® Reduced Serum Medium (Life 
Technologies™) for 3.5 hours, and observed the cells on a fluorescent microscope three days later using a 
GFP filter, through which the eYFP signal bled.  GFP served as a positive control; the untransfected and 
mock-transfected cells served as negative controls for autofluorescence. 
 For negative controls, I cloned the YN or YC fragments alone into pCDNA3.1(+). 
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When I transfected HEK293T cells with these constructs, the cells gave no detectable 
signal when excited at 514 nm (Figure 160E), suggesting that the YN and YC fragments 
do not have high enough affinity for one another to drive BiFC of their fused proteins.  
When cells transfected with the FLAG/YN-Smad3 and FLAG/YN-Smad4 positive 
controls and excited with the same laser intensity, they gave a robust YFP signal (Figure 
160C and D), which I interpreted as successful BiFC.  I therefore concluded that the YN 
and YC constructs were a suitable control for the DGK-theta dimerization BiFC 
experiment. 
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Figure 160.  YN and YC (the negative controls) do not produce a BiFC signal, even though the 
positive controls in the same transfection do.  I transfected the DNA (2 µg per 35-mm coverslip-
bottomed dish) into HEK293T cells using HiFect® Reagent and Opti-MEM® Reduced Serum Medium for 
three and a quarter hours, and observed the cells two days later on a Zeiss laser scanning microscope 
(LSM) 510 Inverted META.  (A) and (B): two representative panels from cells transfected with GFP-C2 as 
a positive control for transfection.  The excitation wavelength was 488 nm, and the signal was observed 
through a 505-530nm filter.  (C) and (D): two representative panels from cells transfected with FLAG/YN-
Smad3 and FLAG/YN-Smad4.  The excitation wavelength was 514 nm, and the signal was observed 
through a 530-600nm filter.  (E) Cells transfected with YN and YC.  The excitation wavelength was 514 
nm, and the signal was observed through a 530-600nm filter.   
 I cloned the YN and the YC fragments to either the N-terminus or the C-terminus 
of DGK-theta to produce four constructs: YN-DGK-theta, YC-DGK-theta, DGK-theta-
YN, and DGK-theta-YC, in case the orientation of the YFP fragment limited the 
efficiency of BiFC.  In order to confirm the expression of these constructs, I 
immunoblotted lysates from HEK293T cells that had been transiently transfected with 
them.  HEK293T cells expressed a GFP-antibody-immunoreactive band between 27 and 
35 kD, which could be faintly detected in the untransfected cells (Figure 161A).  The 
anti-GFP antibody only faintly detected two bands between 15 and 27 kD in lysates 
expressing YN and YC.  The higher of these bands ran a bit faster than would be 
predicted for YN’s predicted molecular weight of 19.3 kD.  The lower of these bands ran 
quite a bit slower than would be predicted for YC’s predicted molecular weight of 11.9 
kD.  
The anti-GFP antibody recognized a smear of proteins in the lysate coexpressing 
YN-Smad3 and YC-Smad4 (Figure 161B), whose molecular weights are predicted to be 
71.5 kD and 59.2 kD respectively, and, therefore, would have been predicted to run off 
the gel. 
The anti-DGK and anti-GFP antibodies both recognize the same two bands in 
lysates coexpressing DGK-theta-YN and DGK-theta-YC (Figure 161B).  These two 
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bands, however, migrating just faster and just slower than the 130 kD molecular weight 
marker, electrophoresed a little more slowly than the predicted protein products would: 
the predicted molecular weight of DGK-theta-YN is 120.1 kD, and the predicted weight 
of DGK-theta-YC is 110.7 kD.  The anti-DGK-theta antibody recognized three bands in 
the lysates coexpressing YN-DGK-theta and YC-DGK-theta, the upper two of which 
were also recognized by the anti-GFP antibody (Figure 161B) and were presumably the 
two YFP-fragment-fused constructs.  The molecular weight of YN-DGK-theta is 
predicted to be 119.5 kD, and the molecular weight of YC-DGK-theta is predicted to be 
113.1 kD. The lowest band, which was recognized by the anti-DGK but not the anti-GFP 
antibody, was presumably DGK-theta where translation began at the start codon at DGK-
theta, whose resulting molecular weight is predicted to be 101.7 kD (from the alternative 
start site in YN-DGK-theta) or 101.9 kD (from the alternative start site in YC-DGK-
theta).  All three of these bands electrophoresed more slowly than would be predicted 
from their sequence.  The discrepancies between the predicted and the observed 
migration patterns may reflect post-translational processing.   
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Figure 161.  The BiFC constructs successfully express.  I transfected the DNA (2 µg per well of a 6-well 
plate) into HEK293T cells using HiFect® Reagent and Opti-MEM® Reduced Serum Medium for four and 
a quarter hours.  Two days late I washed the cells with FB, then added lysis buffer (FB, 0.1% (v/v) Triton 
X-100, 1x PIC) and incubated on ice.  I resuspended the cells in the lysis buffer, and loaded 10 µg total 
protein (as measured by the Bio-Rad Protein Assay) per lane.  Immunoblot following SDS-PAGE.  (A) 
15% acrylamide; immunoblot against GFP (abcam® ab6556 (1:5000 (v/v))).  (B) 6% acrylamide. Left, 
immunoblot against GFP (abcam® ab6556 (1:5000(v/v))).  Right, immunoblot against DGK-theta C-term 
(1:500 (v/v)). 
 Because the BiFC constructs were detected by the appropriate antibodies and 
were not detected in the untransfected cells, and because the constructs were of 
approximately the correct molecular weight, I concluded that they were successfully 
expressing.  The presence of untagged DGK might dilute the BiFC signal in cells 
expressing YN-DGK-theta or YC-DGK-theta.  Also, the relative amounts of each 
construct in each coexpression cannot be estimated from the immunoblot, because the 
intensity of the band might reflect the affinity of the antibody for the epitope (which 
might be enhanced by its three-dimensional context) rather than its abundance. 
 When I co-transfected the DGK-theta-YN and DGK-theta-YC constructs (the two 
constructs that appear not to produce any untagged DGK that might dilute the signal) into 
HEK293T cells, the DGK BiFC constructs gave no detectable signal, at either of the two 
ratios of transfection tested (Figure 162D and E).  Not surprisingly, the positive control 
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of FLAG/YN-Smad3 cotransfected with FLAG/YN-Smad4 gave a weaker signal when 
excited at 488 nm (Figure 162C) than it did at 514 nm (Figure 160C and D), but the 
signal was still discernible.  I confirmed the expression of DGK BiFC constructs by 
immunoblotting (Figure 162). 
 322  
 323 
Figure 162.  DGK-theta-YN / DGK-theta-YC do not produce a BiFC signal.  I transfected the DNA (2 
µg for each construct or 4 µg per well in a six-well plate) into HEK293T cells using HiFect® Reagent and 
Opti-MEM® Reduced Serum Medium for 3.5 hours, and observed the cells two days later on a Zeiss laser 
scanning microscope (LSM) 510 Inverted META.  The excitation wavelength was 488 nm, and the signal 
was observed through a 505nm+ filter.  (A) and (B): two representative panels from cells transfected with 
GFP-C2 as a positive control for transfection. (C) Cells transfected with FLAG/YN-Smad3 and FLAG/YN-
Smad4.  (D) Cells transfected with DGK-YN-theta and DGK-YC-theta in a 1:1 ratio.  (E) Cells transfected 
with DGK-YN-theta and DGK-YC-theta in a 0.9:1.1 ratio. 
 
Figure 163.  DGK-theta-YN / DGK-theta-YC express.  After imaging the cells shown in Figure 162, I 
removed the medium, added lysis buffer (FB, 0.1% (v/v) Triton X-100, 1x PIC), and incubated on ice.  I 
resuspended the cells in the lysis buffer, and loaded 15 µg total protein (as measured by the Bio-Rad 
Protein Assay) per lane.  SDS-PAGE of a 6% acrylamide gel, followed by immunoblotting against (A) 
GFP (abcam® ab6556 (1:5000 (v/v))), and (B) DGK-theta Cterm (1:500 (v/v)). 
The DGK BiFC signal could very well depend on the orientation of the YFP 
fragments relative to the DGK interface: that was the very reason that I made four DGK 
BiFC constructs and not just two.  I therefore transfected HEK293T cells with each of the 
remaining three possible combinations: YN-DGK-theta and YC-DGK-theta, YN-DGK-
theta and DGK-YC-theta, and DGK-YN-theta and YC-DGK-theta.  Although positive 
controls for transfection (Figure 164A) and BiFC (Figure 164B) gave a clearly detectable 
signal, I could not detect any BiFC signal for any of the DGK-BiFC combinations, 
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cotransfected at multiple ratios (Figure 164C-I).  Immunoblotting against DGK-theta and 
GFP confirmed the expression of all the constructs. 
 
Figure 164.  None of the tested DGK BiFC construct combinations produce a BiFC signal.  I 
transfected the DNA (2 µg for each construct or 4 µg per well in a six-well plate) into HEK293T cells using 
HiFect® Reagent and Opti-MEM® Reduced Serum Medium for 3.5 hours, and observed the cells two days 
later on a Zeiss laser scanning microscope (LSM) 510 Inverted META.  The excitation wavelength was 514 
nm, and the signal was observed through a 530-600nm filter.  Representative panels are shown.  (A) Cells 
transfected with GFP-C2 as a positive control for transfection.  (B) Cells transfected with FLAG/YN-
Smad3 and FLAG/YN-Smad4 in a 1:1 ratio as a positive control for BiFC.  (C) Cells transfected with YN-
DGK and YC in a 1:1 ratio as a negative control.  (D) Cells transfected with YN and YC-DGK in a 1:1 
ratio as a negative control.  (E) Cells transfected with YN-DGK and YC-DGK in a 1:1 ratio.  (F) Cells 
transfected with YN-DGK and DGK-YC in a 1:1 ratio.  (G) Cells transfected with YN-DGK and DGK-YC 
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in a 1.25:0.75 ratio.  (H) Cells transfected with DGK-YN and YC-DGK in a 1:1 ratio.  (I) Cells transfected 
with DGK-YN and YC-DGK in a 1:25:0.75 ratio. 
 
Figure 165.  The DGK BiFC constructs expressed.  After imaging the cells shown in Figure 164, I 
removed the medium and resuspended the cells in lysis buffer (FB, 0.1% (v/v) TX-100, 1x PIC).  I loaded 
14 µL per lane.  SDS-PAGE of a 15% acrylamide gel followed by immunoblotting against (A) GFP 
(abcam® ab6556 (1:5000 (v/v))) and (B) DGK-theta Cterm (1:350 (v/v)). 
Discussion and Conclusions 
The negative controls (YN and YC) do not produce a BiFC signal, even though 
the positive controls (YN-Smad3 and YC-Smad4) in the same transfection do.  The DGK 
BiFC constructs express, but none of the tested DGK BiFC construct combinations 
produce a BiFC signal.   
One possible explanation for the lack of BiFC signal for any of the 
cotransfections tested is that DGK-theta, unlike the other LCB5 family proteins 
mentioned, might not dimerize.  On the other hand, even if DGK-theta was dimerizing, 
the DGK BiFC signal could very well be weaker than that of the positive control, because 
its affinity for itself could be lower than the affinity between Smad3 and Smad4.  Even 
for an equal affinity, we would expect half the BiFC signal (because, if the DGK-theta 
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dimerized randomly, one-quarter would be DGK-theta-YN/DGK-theta-YN pairs, and 
give no signal, and one-quarter would be DGK-theta-YC/DGK-theta-YC pairs, and give 
no signal, leaving only half of the dimerized DGK in DGK-theta-YN/DGK-theta-YC 
pairs).  For BiFC constructs in which the DGK was fused to the C-terminus of the YFP 
fragments and included its own start codon, the signal would be even further diluted by 
competition from untagged DGK-theta.  Yet another possible explanation is that the 
DGK-theta dimerization interface might not be compatible with any of the four 
combinations tested, such that DGK-theta did dimerize but gave no BiFC signal using 
these constructs.  Thus, while I failed to find any evidence using the BiFC approach that 
DGK-theta dimerizes, I cannot conclude that DGK-theta does not dimerize, only that any 
oligomeric interaction between DGK-theta and itself is undetectable using these 
particular constructs. 
BiFC and the interaction between tau and H. sapiens DGK-theta in mammalian 
cells 
Introduction 
 Purified H. sapiens DGK-theta’s enzymatic activity is activated in vitro by 
polybasic proteins including tau3.  If DGK-theta and tau directly interact physically, they 
would be expected to produce a BiFC signal when attached to the appropriate YFP 
fragments.  Using the DGK-theta BiFC constructs described in the previous subchapter, 
we therefore decided to use a BiFC approach to see whether we could see a BiFC signal 
produced by a DGK-theta/tau interaction.  Phorbol esters such as phorbol 12-myristate 
13-acetate (PMA) have been shown to increase DGK activity and enhance the association 
 327 
of DGKs with other proteins38, so we were also curious whether any BiFC-reflected 
association between DGK-theta and tau depended on PMA.  Because PMA also activates 
protein kinase C (PKC), I also tested whether any such PMA-induced effect depended on 
pretreatment with PKC inhibitors.   
Results 
I looked at the YFP signal of two of the DGK BiFC constructs discussed 
previously (DGK-theta-YN and DGK-theta-YC) when coexpressed with two tau BiFC 
constructs, YN-tau40 and YC-tau40.   Of the combinations tested, however, only the 
positive control for BiFC (FLAG/YN-Smad3 cotransfected with FLAG/YC-Smad4, 
described in the previous subchapter) gave a BiFC signal. 
 Whenever I checked the expression of YN-tau40 by immunoblot (among four 
different expressions, in both HEK293T and COS7 cells), I never saw any anti-GFP 
antibody-immunoreactive band of the appropriate size in any of the transfected lysates, 
even though the anti-GFP antibody was able to recognize YN fused to either end of 
DGK-theta (Figure 161B, Figure 163A, and Figure 165A) and therefore would be 
predicted to recognize YN on tau40 as well.  What I did observe was a band that was 
immunoreactive to the anti-GFP antibody, but not the anti-tau antibody, that migrated 
slightly faster than GFP (whose molecular weight is 27 kD) (Figure 166). 
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Figure 166.  The anti-GFP antibody does not recognize a band of the appropriate size in YN-tau40-
transfected lysates, but does recognize a band migrating slightly faster than GFP (27 kD).  I 
transfected the DNA (0.5 µg for each construct or 1 µg per well in a twelve-well plate) into COS-7 cells 
using HiFect® Reagent and Opti-MEM® Reduced Serum Medium for four hours, and observed the cells 
on a fluorescent microscope two days later.  Seeing no BiFC signal, I removed the medium by aspiration, 
and added lysis buffer (FB, 1x PIC, 0.5% (v/v) NP-40) to the cells on ice and scraped.  I loaded 12 µL 
lysate per lane.  SDS-PAGE of a 10% acrylamide gel followed by immunoblotting against (A) tau 
(1:30,000 (v/v)), and (B) GFP (abcam® ab6556 (1:1000 (v/v))). 
 Much later, when I was finally able to access the original sequencing data for the 
YN-tau40 constructs, I found a single nucleotide insertion in the fourth amino acid of the 
tau40 sequence, such that only the first three amino acids of tau40 are expressed, 
followed by a string of thirty-six amino acids (resulting from the frame shift and thus not 
from tau40), followed by a prematurely introduced stop codon, producing a protein with 
a predicted size of 25 kD that includes all of the YN but almost none of the tau40, 
consistent with the anti-GFP-immunoreactive band I saw in Figure 166.  The “YN-tau40” 
construct, therefore, was not helpful for addressing whether DGK and tau can produce a 
BiFC signal, seeing as it did not encode tau.  Unfortunately, in two out of three 
experiments attempting to reproduce reported observations of a PMA-induced BiFC 
signal, I focused on the constructs reported to produce that result, YN-tau40 and DGK-
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theta-YC, and tried to optimize expression with varying ratios of transfected DNA.  As a 
result did not test the other combination, YC-tau40 and DGK-theta-YN in those 
experiments. 
 I observed that when HEK293T cells were treated with PMA, they released the 
plate and rounded up (Figure 167), which resulted in an increase in autofluorescence.  
This increase in autofluorescence could explain the PMA-dependent increase in “BiFC” 
signal that was reportedly observed in the “YN-tau40” and DGK-theta-YC cotransfected 
cells. 
 
Figure 167.  Treating HEK293T cells with 500 nM PMA causes them to release the plate and round 
up.  HEK293T cells that I had transfected with 1 µg each of YN and DGK-theta-YC in a 35 mm coverslip-
bottomed dish for three hours and observed two days later on an Olympus I fluorescence microscope on 
brightfield.  (A) Brightfield before PMA treatment.  (B) Brightfield five minutes after adding PMA to 500 
nM, refocused due to the z-drift caused by the cells’ motion. 
The first experiment I tried with the tau and DGK BiFC constructs did include 
YC-tau40 coexpressed with YN-DGK-theta.  Before I could conclude anything about the 
lack of BiFC signal from the coexpression, I first needed to confirm that the constructs 
expressed, which I tested by immunoblotting the lysates of the cells.  I never did access 
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the sequence of the YC-tau40 construct, but I estimated from the size of YC and the 
published sequence of tau40 that the fusion construct must be at least 91 kD.  I first 
immunoblotted against GFP, which I had previously shown to recognize both the YN and 
YC fragments when fused to target proteins (Figure 161B, Figure 163A, and Figure 
165A). In the lysates cotransfected with YN and with YC-tau40, I observed a faint 
immunoreactive band greater than 70 kD not visible in the mock-transfected lysate 
(Figure 168A), consistent with YC-tau40 expression.  However, this band was the same 
size as the immunoreactive band in the adjacent lane, and thus may have resulted from 
lane contamination, which can result from the interface between the stacking and 
separating phases of the gels’ drying out during casting.  In order to confirm the 
expression of YC-tau40, I therefore ran a fresh gel and immunoblotted against tau-5.  The 
anti-tau-5 antibody recognized three new bands in the lysates transfected with YC-tau40 
not seen in the mock-transfected lysate, but all of these bands migrated faster than the 70 
kD molecular weight marker (Figure 168B).  These bands are consistent with some sort 
of recombinant expression of tau or part of tau, but because these bands do not coincide 
with the anti-GFP-immunoreactive band, and because they are too small to be the YC-
fused protein, I therefore concluded that the “YC-tau40” construct was not properly 
expressing as a fusion protein of YC and tau40.  Whether this failure to express is due to 
some complication from this particular expression (such as proteolytic processing by the 
HEK293FT cells) or due to some problem with the construct (such as a frameshift, as 
seen in the YN-tau40 construct, or a second start codon at the beginning of the tau40 




Figure 168.  The YC-tau40 construct did not properly express in HEK293FT cells as a fusion protein 
of YC and tau40.  I transiently transfected HEK293FT cells with 0.75 µg of each DNA construct (for a 
total of 1.5 µg DNA per 35 mm glass-bottomed plate) for three hours, and observed the cells on an 
Olympus I fluorescence microscope two days later.  Seeing no BiFC signal, I removed the medium by 
aspiration, and resuspended the cells in lysis buffer (FB, 10 mM NaCl, 1x PIC, 0.1% (v/v) Triton X-100).  I 
loaded 20 µg total protein (as measured by the Bio-Rad Protein Assay) per lane.  (A) SDS-PAGE of a 15% 
acrylamide gel followed by immunoblotting against GFP (abcam® ab6556 (1:500 (v/v))).  (B) SDS-PAGE 
of an 8% acrylamide gel followed by immunoblotting against tau5 (1:5000 (v/v)). 
Discussion and Conclusions 
 Because neither the YN-tau40 construct nor the YC-tau40 construct expressed, I 
did not observe any BiFC signal between the tau and DGK BiFC constructs.  Previous 
reports of a PMA-dependent BiFC signal could be explained by the reaction of control 
cells to PMA, and did not depend on the presence of the BiFC constructs.  It remains to 
be seen whether a direct DGK-tau interaction could be observed by a BiFC approach, but 
any such approach would require cloning new tau BiFC constructs, and confirming their 
proper translational frame by DNA sequencing. 
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Chapter 7: Proteolysis to Probe Structure 
Introduction 
 We were curious as to whether the N-terminal accessory domains of mammalian 
DGK auto0inhibited the C-terminal catalytic domain, and whether activation by 
polybasic proteins and/or lipids operated via any such N-terminal auto-inhibition.  An 
obvious approach to answer this question would be to express the C-terminal catalytic 
domain by itself and compare its activity and activation to that of full-length DGK, but I 
experienced solubility challenges for recombinantly expressed truncations of DGK. 
I therefore wondered whether we could approach this problem by allowing the protein to 
fold (in the setting of a mammalian cell, for mammalian DGK) first, and then truncating 
it via proteolysis after the protein has folded. 
Results 
 I used the Peptide Cutter tool152 on the ExPASy (which originally stood for 
“Expert Protein Analysis System”), the Swiss Institute of Bioinformatics (SIB)’s 
bioinformatics resource portal153, to determine which commonly available proteases 
would digest mammalian DGK isoforms into tractable fragments.  For the sequences I 
examined, the most promising protease was thrombin, which was predicted to cut H. 
sapiens DGK-theta in two places, at position 127 (between the first and second C1 
domains), and at position 394, just before the RA domain (Figure 169).  Digestion of 
untagged DGK-theta would therefore be predicted to produce three fragments: a 13 kD 
N-terminal fragment including the first C1 domain, a 28 kD middle fragment including 
the second two C1 domains, and a 60 kD C-terminal fragment including the RA and 
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LCB5 domains.  Incomplete digestion would also produce a 41 kD N-terminal fragment 
including all three C1 domains, and an 88 kD C-terminal fragment including the second 
two C1 domains, the RA domain, and the LCB5 domain.  The predicted size of these 
fragments would be modified by the addition of any epitope tags to the N- or C-terminus 
of the DGK-theta construct used. 
 
Figure 169.  Schematic of predicted thrombin digestion sites on H. sapiens DGK-theta.  I performed a 
BLAST search of the sequence of H. sapiens DGK-theta (NP_001338), which automatically annotated the 
sequence according to the Conserved Domain Database with three C1 domains, an RA domain, and an 
LCB5 domain.  Red vertical lines indicate the location of the predicted thrombin sites relative to the 
annotated domains in the sequence. 
 In order to test whether the thrombin in the freezer was still active, I tested its 
activity on a synthetic chromogenic substrate, N-(p-Tosyl)-Gly-Pro-Arg p-nitroanilide 
acetate salt154, by measuring the absorbance at 385 nm of the substrate as a function of 
time in the presence of six different concentrations of thrombin.  For the three most 
concentrated samples of thrombin, the reaction had already gone to completion on ice in 
the time it took to mix the reaction and measure the absorbance of it, and all of the tested 
concentrations went to completion within four hours at 4°C (Figure 170).  I therefore 
concluded that the thrombin in the freezer was still active. 
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Figure 170.  The thrombin in the freezer was still active on a chromogenic substrate under the 
conditions tested.  Absorbance at 385 nm as a function of time of chromogenic substrate (16.4 µM) in the 
presence of six different concentrations of thrombin, in 10 mM HEPES, 10 mM Tris, pH 7.8, 100 mM 
NaCl, 0.1% (w/v) PEG-8000. 
 I next tested conditions for digesting purified H. sapiens DGK-theta with the 
thrombin.  The construct of DGK-theta I first used included a 25 kD C-terminal tag, such 
that the predicted sizes of the fragments would be 13 kD and 113 kD after a single cut at 
the first site, 41 kD and 85 kD after a single cut at the second site, and 28 kD after cuts at 
both sites (Figure 171).  I incubated two different samples of purified DGK-theta with 
four different concentrations of thrombin, collected timepoints, and assessed the degree 
of digestion by silver staining following SDS-PAGE.  The predominant band that 
migrated between the 120 and 160 kD molecular weight markers (Figure 172) was 
consistent in size to be full-length DGK-theta, whose molecular weight including the 25 
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kD C-terminal tag was predicted to be 126 kD.  Incubation with thrombin that had been 
diluted 312,500-fold had no obvious effect on DGK-theta’s migration pattern, even after 
16 hours at 4°C (Figure 172A).  Contrariwise, when I diluted the thrombin only 500-fold, 
the intensity of the heaviest band noticeably decreased as a function of time, and new 
bands that migrated between the 100 and 120 kD molecular weight markers emerged 
(Figure 172B), consistent with the predicted size of 113 kD after a single cut at the first 
site.  The accompanying 13 kD band that would be produced by cutting at this site would 
have run off this 8% acrylamide gel.  Cutting at the second size would be predicted to 
produce a band at 41 kD, but no new bands appeared during the timecourse that run 
between the 40 and 50 kD molecular weight markers.  New bands running between the 
30 and 40 kD molecular weight markers, between the 50 kD and 60 kD markers, and 
between the 100 kD molecular weight marker and the previously described 113 kD band 
do appear (Figure 172B); whether these fragments result from post-translational 
modification of predicted fragments, contaminating proteases in the thrombin sample, or 
cryptic thrombin sites in the epitope tag is unclear.  These fragments are not visible in the 
samples incubated without thrombin, suggesting that they are not resulting from 
nonspecific degradation or from contaminated proteases from the purified DGK-theta.  
When I tested digestion of another batch of purified DGK-theta, once again, only in the 
highest concentration of thrombin tested did the predicted band migrating between 100 
and 120 kD appear, as did the mystery band just above the 30 kD molecular weight 
marker (Figure 172C).  I concluded that while the concentrations of thrombin tested in 
Figure 170 were perfectly adequate for digesting 16.4 µM chromogenic substrate, higher 
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concentrations would be required to generate the LCB5-including protein fragment of 
DGK-theta purified from HEK293T cells. 
 
Figure 171.  Schematic of predicted thrombin digestion sites on H. sapiens DGK-theta when 25 kD of 
C-terminal epitope tags are included.  Vertical lines indicate the locations of the predicted thrombin sites. 
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Figure 172.  Higher concentrations of thrombin are required to generate the LCB5-including protein 
fragment of DGK-theta purified from HEK293T cells than to digest the chromogenic substrate.  I 
incubated DGK-theta, which had been purified from cytosol on Protein A beads and washed with thrombin 
buffer (10 mM HEPES, 10 mM Tris, pH 7.8, 100 mM NaCl, 0.1% (w/v) PEG-8000), with different 
concentrations of thrombin in thrombin buffer at 4°C and took timepoints at 0, 2, 4, 8, and 16 hours.  I 
quenched the reaction of each timepoint by adding SDS-gel-loading buffer to 1x.  SDS-PAGE of 8% 
acrylamide gels followed by silver staining.  Arrows indicate the passage of time.  (A) Left, no thrombin.  
Right, 312500x diluted thrombin.  (B) 500x diluted thrombin.  Left, no DGK-theta.  Right, DGK-theta 
cytosol purified on Protein A beads.  (C) 414A batch of purified DGK-theta.  Left, no thrombin.  Right, 
500x diluted thrombin.  (D) 414A batch of purified DGK-theta.  Left, 12,500x diluted thrombin.  Right, 
312,500x diluted thrombin. 
 I therefore incubated purified DGK-theta in the presence of undiluted thrombin at 
either 4°C, 16°C, or 37°C, collected timepoints, and once again assessed the degree of 
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digestion by silver staining following SDS-PAGE.  There was no detectable difference 
between the timepoints taken from the incubations at 37°C and 16°C (i.e., the reaction 
appeared to be complete by thirty minutes’ incubation at 37°C, and two hours’ incubation 
at 16°C, the earliest timepoints taken for each), but the reaction did appear to progress 
more slowly at 4°C than at 16°C or 37°C (Figure 173).  In the samples with thrombin, no 
detectable full-length DGK-theta remained after two hours.  In the samples incubated at 
4°C, a band between 100 and 120 kD (consistent with the 113 fragment that would be 
produced by a single cut) appeared at 2 hours, but disappeared overnight, consistent with 
cutting first at the first site, and then cutting a second time.  New bands also appeared 
between 30 and 40 kD and between 70 and 80 kD in all the completely digested samples, 
but the intensity of these bands did not appear to sum to equal the intensity of the original 
full-length DGK-theta.  It was unclear where the rest of the DGK-theta was going: as 
above, DGK-theta incubated in the absence of thrombin experienced no degradation, so it 




Figure 173.  Higher concentrations of thrombin digest purified DGK-theta, but do not produce the 
expected pattern of bands.  I stored the purified DGK-theta shown in Figure 172A and B for six days in 
50% glycerol at -80°C prior to thawing and washing with thrombin buffer (10 mM HEPES, 10 mM Tris, 
pH 7.8, 100 mM NaCl, 0.1% (w/v) PEG-8000).  Some of the purified DGK-theta I heat-inactivated at 
100°C for twenty minutes.  I incubated the DGK-theta with 3 µL thrombin per 30 µL reaction (10x diluted) 
(or not) in thrombin buffer at the indicated temperature.  I took timepoints from the 37°C reaction at 0 
minutes, 30 minutes, and two hours, and I took timepoints from the 16°C and 4°C reactions at 0 hours, two 
hours, and overnight.  I quenched the reaction of each timepoint by adding SDS-gel-loading buffer to 1x.  
SDS-PAGE of 10% acrylamide gels followed by silver staining.  1, thrombin (no DGK); 2, DGK (no 
thrombin); 3, heat-denatured DGK plus thrombin; 4, DGK plus thrombin.  Arrows indicate the passage of 
time.  (A) 37°C incubations.  (B) 16°C incubations.  (C) 4°C incubations. 
 In order to find an optimal thrombin concentration for producing the C-terminal 
fragment of DGK-theta, I incubated DGK-theta with lower concentrations of thrombin 
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(though not so low as in the experiment shown in Figure 172) at 4°C, collected 
timepoints, and once again assessed the degree of digestion by silver staining following 
SDS-PAGE.  As before, new bands appeared between 120 and 160 kD, between 100 and 
120 kD, between 60 and 70 kD, between 30 and 40 kD, and between 25 and 30 kD, some 
of which are consistent with the predicted fragments of 13 kD, 28 kD, 41 kD, 113 kD, 
and 126 kD.  As before, the sum of the intensities of these bands did not appear to equal 
the intensity of the original DGK-theta.  None of these bands were visible in the Protein 
A sepharose and thrombin samples, suggesting that they are came from the DGK-theta 
purification. 
 
Figure 174.  Incubation of purified DGK-theta with moderate amounts of thrombin produces new 
bands detectable by silver staining, some of which are consistent with the predicted size, but do not 
appear to total the intensity of the original band.  I stored the purified DGK-theta shown in Figure 173 
for four days in 50% glycerol at -80°C prior to thawing and washing with thrombin buffer (10 mM HEPES, 
10 mM Tris, pH 7.8, 100 mM NaCl, 0.1% (w/v) PEG-8000).  I incubated the DGK-theta with different 
concentrations of thrombin in thrombin buffer at 4°C, and took timepoints at 0, 2, and 20 hours.  I 
quenched the reaction of each timepoint by adding SDS-gel-loading buffer to 1x.  SDS-PAGE of 10% 
acrylamide gels followed by silver staining.  Arrows indicate the passage of time. 
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 Because of uncertainty resolving which of the produced bands was actually the C-
terminal band I was looking for, I decided to immunoblot against the Fc tag on the C-
terminus to follow thrombin digestion of DGK-theta.  However, when I immunoblotted 
against Fc, I was unable to detect any of the DGK-theta.  On the other hand, the 
secondary antibody wasn’t able to recognize the Magic Mark™ XP Western Protein 
Standard (Life Technologies™) molecular weight standards, either, so the lack of 
recognition was probably an antibody problem rather than a construct problem.  
Contrariwise, the anti-DGK-theta antibody was readily able to detect the DGK-theta 
(Figure 175).  Protein A sepharose and thrombin produced no anti-DGK-theta-antibody 
immunoreactive bands (Figure 175A).  As I had observed with the silver stains, when 
DGK-theta was incubated over time in the absence of thrombin, full-length DGK-theta 
persisted (Figure 175B), suggesting that the digested bands were not produced by 
nonspecific degradation or by proteases copurifying with DGK-theta.  Contrariwise, 
when DGK-theta was incubated with thrombin, the immunoreactive band corresponding 
with full-length DGK-theta disappeared as a function of time and was undetectable after 
22 hours, and lower immunoreactive bands appeared as time progressed (Figure 175C).  
The first band to appear, visible at 2.5 hours and even faintly at the 0 hour timepoint (and 
therefore produced in the time taken to mix the reaction), migrated between the 80 and 
100 kD molecular weight markers, and was consistent with the 85 kD fragment that 
would be predicted to be formed by thrombin’s cutting at the second thrombin site.  The 
corresponding peptide, at 41 kD, would be predicted to have run off the gel, and, 
furthermore, was unlikely to be able to be detected by the monoclonal antibody directed 
against the C-terminus of DGK-theta.  After 5.5 hours, two more immunoreactive bands 
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appeared: one that migrated between 100 and 120 kD and thus was consistent with the 
113 kD fragment produced by thrombin’s cutting at the first site, and one that migrated 
between 60 and 80 kD, whose identity was unclear.  By 22 hours, two more 
immunoreactive bands appeared: one that ran just above the mystery band, also between 
60 and 80 kD, whose identity was equally mysterious, and one that ran between the dye 
front and the 60 kD molecular weight marker.  Only three possible immunoreactive bands 
were expected (126 kD for full-length, 113 kD for the C-terminus left from cutting at the 
first site, and 88 kD for the C-terminus left from cutting at the second site), yet I observed 
five different bands.  As with the silver stain, the intensity of these bands did not appear 
to sum to the intensity of the original, full-length band (although using the immunoblot 
signal as a measure of protein abundance assumes that antibody has equal affinity for all 
the proteolyzed fragments, which it very well might not have).  Consistent with the Fc 
tag’s being on the C-terminus of the construct, the immunoreactive bands remained 




Figure 175.  Incubation of purified DGK-theta with thrombin produces new bands detectable by 
immunoblotting against DGK-theta, some of which are consistent with the predicted size.  I stored the 
purified DGK-theta shown in Figure 174 for four days in 50% glycerol at -80°C prior to thawing and 
washing with thrombin buffer (10 mM HEPES, 10 mM Tris, pH 7.8, 100 mM NaCl, 0.1% (w/v) PEG-
8000).  I incubated the DGK-theta with or without 1000x diluted thrombin in thrombin buffer at 4°C, and 
took timepoints at 0, 2.5, 5.5, and 22 hours.  For each timepoint, I microfuged the sample to separate the 
supernatant from the pellet.  I quenched the reaction of each timepoint by adding SDS-gel-loading buffer to 
1x.  SDS-PAGE of 6% acrylamide gels followed by immunoblotting against DGK-theta (1:350 (v/v)).  
Arrows indicate the passage of time.  S, supernatant; P, pellet.  (A) Protein A sepharose with thrombin.  (B) 
DGK-theta without thrombin.  (C) DGK-theta with thrombin. 
 Concerned that the old thrombin from the freezer might be contaminated with 
other proteases, which would explain the presence of unexpected bands and also why the 
intensity of those bands was less than expected, I bought some new, supposedly highly 
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purified thrombin (Calbiochem (now EMD Millipore) 605195).  I compared the digestion 
of purified DGK-theta with the old thrombin vs. the new thrombin.  The new thrombin 
digested almost all of the full-length DGK-theta such that no full-length band was 
detectable after one hour, but in this experiment the old thrombin likewise completely 
digested DGK-theta within one hour (Figure 176), although the conditions were 
supposedly the same as in Figure 175.  Also unlike previous experiments, in this 
experiment the intensity of the signal of DGK-theta incubated in the absence of thrombin 
also decreased over time (Figure 176).  At the time, I interpreted these results as 
problems of inherent irreproducibility of this approach, but in hindsight, primary 
antibody reuse may be a problem.  At the time I was in the habit of reusing dilutions of 
primary antibody, to be frugal.  However, such reuse can lead to irreproducibility among 
blots: antibodies that have been diluted longer may have weaker affinity for their epitopes 
because of degradation or denaturation, and dilutions that have been used more than once 
may have lower concentrations of antibody because antibody molecules may have been 
left adhered to previous blots.  The differences between Figure 175 and Figure 176B, 
therefore, may reflect more about antibody irreproducibility than thrombin digestion 
irreproducibility.  But, as was seen in previous experiments, the intensity of the faster-
running fragments was once again considerably lower than that of the full-length enzyme, 
making it very difficult to monitor the size and number of newly appearing bands. 
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Figure 176.  Irreproducibility in immunoblotting detection among thrombin digestions might have 
resulted from primary antibody reuse.  I stored the purified DGK-theta shown in Figure 175 for eleven 
days in 50% glycerol at -80°C prior to thawing and washing with thrombin buffer (10 mM HEPES, 10 mM 
Tris, pH 7.8, 100 mM NaCl, 0.1% (w/v) PEG-8000).  I incubated the DGK-theta with either 1000x diluted 
old thrombin or else 1 mU per µL new (Calbiochem) thrombin in thrombin buffer at 4°C, and took 
timepoints at 0, 1, 2, 4, and 18 hours.  I quenched the reaction of each timepoint by adding SDS-gel-loading 
buffer to 1x.  SDS-PAGE of 6% acrylamide gels followed by immunoblotting against DGK-theta (1:350 
(v/v)).  Arrows indicate the passage of time.  
 At this point, I ran out of purified DGK-theta and needed to purify more.  Once I 
had expressed and purified Fc-FLAG-DGK-theta from 293FT cells (Figure 84A-B), I 
tested the digestion of this new construct by thrombin.  With 28 kD of N-terminal epitope 
tags, the predicted size of the fragments produced by thrombin digestion of this construct 
are 41 kD and 88 kD after a single cut at the first thrombin site, 69 kD and 60 kD after a 
single cut at the second thrombin site, and 28 kD after cutting at both sites (Figure 177).  
The conditions that had robustly digested the previous batch of purified DGK-theta did 
not digest this batch of purified DGK-theta any more than heat-denatured thrombin did 
(Figure 178A).  Silver staining confirmed that two hours at 4°C with 1 mU per µL of the 
Calbiochem thrombin was insufficient to digest this new batch of purified DGK-theta 
(Figure 178B).  I therefore needed to work out afresh thrombin digestion conditions for 
this new batch of purified DGK-theta. 
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Figure 177.  Schematic of predicted thrombin digestion sites on the Fc-FLAG-DGK-theta construct.  
Vertical lines indicate the locations of the predicted thrombin sites. 
 
Figure 178.  Purified Fc-FLAG-DGK-theta requires different thrombin digestion conditions than the 
C-terminally tagged DGK-theta construct.  I stored the purified DGK-theta shown in Figure 84A-B for 
two days in 50% (v/v) glycerol at -80°C prior to thawing and washing with thrombin buffer (10 mM 
HEPES, 10 mM Tris, 100 mM NaCl, 0.1% (w/v) PEG-8000, pH 7.5).  I incubated the DGK-theta or protein 
A sepharose with 1 mU per µL thrombin (Calbiochem) in thrombin buffer at 4°C for two hours.  I 
quenched the reaction by adding SDS-gel-loading buffer to 1x.  (A) SDS-PAGE followed by 
immunoblotting against DGK-theta (1:350 (v/v)).  (B) SDS-PAGE of an 8% acrylamide gel followed by 
silver staining. 
 When I increased the thrombin concentration tenfold, the band migrating between 
the 120 and 160 kD molecular weight markers corresponding to full-length DGK-theta 
decreased in intensity as a function of time in the samples incubated with thrombin, but 
not heat-inactivated thrombin, such that by 22 hours the band had completely disappeared 
(Figure 179).    The intensity of the thrombin band was greatly decreased for the heat-
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inactivated thrombin samples (Figure 179A), so perhaps thrombin’s failure to digest 
DGK-theta resulted less from heat-inactivation as it did from thrombin’s being left 
behind in the PCR tube following the heat inactivation.  As the full-length DGK-theta 
disappeared, a new band migrating between the 100 and 120 kD molecular weight 
markers appeared, which is puzzling, because none of the products of Fc-FLAG-theta 
following thrombin digestion were predicted to be that size.  New bands also appeared 
that migrated between the 90 and 100 kD molecular weight markers (which, if it were 
running slightly more slowly than predicted due to post-translational modifications, could 
be the 88 kD C-terminal fragment after a single cut at the first thrombin site) and between 
the 50 and 60 kD molecular weight markers (which could be the 60 kD C-terminal 
fragment after a cut at the second thrombin site).  When I blotted against the C-terminus 
of DGK-theta, the band migrating between the 120 and 220 kD molecular weight 
markers, consistent with full-length Fc-FLAG-DGK-theta, likewise faded intensity over 
time in the samples incubated with thrombin but not heat-inactivated thrombin (Figure 
179B).  Bands migrating between the 80 and 100 kD molecular weight markers and 
between the 60 and 80 kD molecular weight markers, consistent with the C-terminal 88 
kD fragment that would be left after a single cut at the first thrombin site and with the C-
terminal 60 kD fragment that would be left after a cut at the second thrombin site, 
appeared over time, although no immunoreactive bands were detectable after 22 hours.  
These results are consistent with digestion of Fc-FLAG-DGK-theta at the two predicted 
thrombin sites.  However, the intensity of the two product bands were much, much less 
than the intensity of the full-length protein, possibly as a result of digestion by another 
protease contaminant of thrombin, or possibly as a result of impaired antibody 
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recognition (since the candidate product bands were still visible in the silver stain after 22 
hours, although it is not clear why the bands would be recognized after 4 hours but not 22 
hours: perhaps antibody recognition depended on some key post-translational 
modification that was lost after proteolytic truncation). 
 
Figure 179.  Increased concentrations of thrombin are able to digest Fc-FLAG-DGK-theta purified 
from 293FT cytosol.  I stored the purified DGK-theta shown in Figure 178 for six days in 50% (v/v) 
glycerol at -80°C prior to thawing and washing with thrombin buffer (10 mM HEPES, 10 mM Tris, 100 
mM NaCl, 0.1% (w/v) PEG-8000, pH 7.5).  I incubated the DGK-theta or protein A sepharose with 10 mU 
per µL thrombin (Calbiochem) in thrombin buffer at 4°C for 0, 2, 4, and 22 hours.  I heat-inactivated 
thrombin by incubating it at 100°C for twenty minutes.  I quenched the reaction of each timepoint by 
adding SDS-gel-loading buffer to 1x.  SDS-PAGE followed by (A) silver staining, and (B) immunoblotting 
against DGK-theta (1:350 (v/v)). 
 I repeated the thrombin digestion with Fc-FLAG-DGK-theta I had purified from 
HEK293FT non-nuclear membranes, and collected aliquots from which to assay the 
DGK activity, to determine whether removal of the N-terminus of Fc-FLAG-DGK-theta 
freed it from autoinhibition.  As with the Fc-FLAG-DGK-theta purified from cytosol, Fc-
FLAG-DGK-theta purified from non-nuclear membranes produced an anti-DGK-theta-C-
terminal-antibody-immunoreactive band that migrated between 120 and 160 kD whose 
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intensity decreased as a function of time when incubated with thrombin to a greater 
extent than when incubated with heat-inactivated thrombin (Figure 180).  As before, 
incubation with thrombin produced smaller, immunoreactive bands, and as before, the 
intensity of these bands also faded with time.  When I measured the enzymatic activity of 
the samples, the supernatant from the Fc-FLAG-DGK-theta that had been digested with 
thrombin gave higher activity on liposomes than the supernatant from the Fc-FLAG-
DGK-theta that had been incubated with the heat-inactivated thrombin (Figure 181A), 
consistent with digestion’s releasing DGK from the Fc tag and therefore releasing it from 
the Protein A sepharose into the supernatant.  Activity of purified DGK-theta still 
attached to beads was noisy, consistent with a high variability of how many beads were 
included in the reaction volume.  The activation power of LMW polylysine was modest.  
I tried to estimate specific activity by estimating the concentration of DGK-theta that was 
in the supernatant by SDS-PAGE followed by silver staining.  Although the thrombin 
was clearly visible (as would be expected for the supernatant), the DGK-theta was too 
dilute to visualize by silver staining (Figure 181B). 
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Figure 180.  Thrombin is also able to digest Fc-FLAG-DGK-theta purified from 293FT non-nuclear 
membranes.  I stored Fc-FLAG-DGK-theta purified from HEK293FT non-nuclear membranes on protein 
A sepharose (Figure 84C-D) for four weeks in 50% (v/v) glycerol at -80°C prior to thawing and washing 
with thrombin buffer (10 mM HEPES, 10 mM Tris, 100 mM NaCl, 0.1% (w/v) PEG-8000, pH 7.5).  I 
incubated the DGK-theta or protein A sepharose with 10 mU per µL thrombin (Calbiochem) in thrombin 
buffer at 4°C for 0, 2, 4, and 21 hours.  I heat-inactivated thrombin by incubating it at 100°C for twenty 
minutes.  I quenched the reaction of each timepoint by adding SDS-gel-loading buffer to 1x or by adding 
glycerol to 50% and freezing at -80°C.  SDS-PAGE of 8% acrylamide gels followed by (A) silver staining 
and (B) immunoblotting against DGK-theta (1:350 (v/v)).   
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Figure 181.  The supernatant from the Fc-FLAG-DGK-theta that has been digested with thrombin 
gives higher activity on liposomes than the supernatant from the Fc-FLAG-DGK-theta that has been 
incubated with the heat-inactivated thrombin, although the concentration of DGK-theta in the 
supernatant, and therefore the specific activity, is difficult to measure.  (A) DGK activity assay.  I 
stored the samples shown in Figure 180A-B for twelve days in 50% (v/v) glycerol at -80°C prior to 
assaying.  I assayed the resin for Fc-FLAG-DGK-theta (as a positive control), and the supernatants of the 
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thrombin-digested samples.  The reaction included 7.5 mM liposomes 
(53:22:17:8::POPE:POPC:POPS:DOG), 45 mM HEPES, pH 7.0, 130 mM NaCl, 1 mM Tris, 0.01% (w/v) 
PEG-8000, 1 mM DTT, 4.4 mM MgCl2, 1 mM ATP, 89.2 Ci per mmol [γ-32P]-ATP, 1.5 ng per µL LMW 
polylysine, 1.1% (v/v) glycerol, and 1.1 µL purified DGK-theta per 50 µL reaction, and proceeded for 15 
minutes at 37°C.  In duplicate: mean ± SD.  (B) SDS-PAGE of an 8% acrylamide gel followed by silver 
staining of the supernatants removed from the Protein A sepharose beads following thrombin digestion for 
21 hours. 
 I therefore scaled up the thrombin digestion, now that I had worked out the 
digestion conditions (overnight at 4°C with 10 mU thrombin per µL), with the hopes of 
being able to confidently measure the amount of DGK-theta in the supernatant, so that I 
could confidently measure the specific activity.  Although I could clearly detect thrombin 
in the supernatant, as expected, and although digested Fc-FLAG-DGK-theta was clearly 
detectable in the resin plus supernatant, none of the digested DGK-theta was visible in 
the supernatant (Figure 182A), but rather was still on the resin (Figure 182B).  However, 
thrombin was also detected on the resin, leaving the question of whether the DGK-theta 
was only lightly adhered and could be washed off, or whether the two halves of the 
protein were interacting with one another, or whether the protein was aggregating.  I 
therefore washed the beads three times with thrombin buffer (10 mM HEPES, 10 mM 
Tris, 100 mM NaCl, 0.1% PEG-8000), followed by four times with thrombin buffer with 
NaCl increased to 524 mM.  One ~70 kD band and one ~60 kD band came off in the 
washes (Figure 182C): these may correspond to the 69 kD N-terminal fragment that 
would be predicted to be produced by a single cut at the second thrombin site, and the 60 
kD C-terminal fragment that would be predicted to be produced by a cut at the second 
thrombin site.  However, the 69 kD fragment would be predicted to be still attached to the 
protein A Sepharose beads, which means that we must also consider that any signal in a 
“supernatant” might also result from a bead that had been accidentally aspirated while 
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removing the supernatant.  Two predominant bands remained on the beads: one migrating 
between 100 and 120 kD, and one between 30 and 40 kD. 
  
Figure 182.  Digested Fc-FLAG-DGK-theta remains on the protein A sepharose after thrombin 
digestion, even after washing with salt.  I stored the Fc-FLAG-DGK-theta purified from HEK293FT non-
nuclear membranes on protein A sepharose (shown in Figure 180) for fifteen days in 50% (v/v) glycerol at 
-80°C prior to thawing and washing with thrombin buffer (10 mM HEPES, 10 mM Tris, 100 mM NaCl, 
0.1% (w/v) PEG-8000, pH 7.5).  I incubated the DGK-theta or protein A sepharose with 10 mU per µL 
thrombin (Calbiochem) in thrombin buffer at 4°C for 21 hours.  I heat-inactivated thrombin by incubating it 
at 100°C for twenty minutes. After removing a resin + supernatant aliquot, I microfuged to separate the 
resin from the supernatant.  SDS-PAGE of 8% acrylamide gels followed by silver staining.  R+S, resin + 
supernatant; S, supernatant.  (A) The dye front had not run off the gel when it was stained, but was cut off 
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during development.  (B) I stored the beads shown in (A) for four days in 50% (v/v) glycerol at -80°C prior 
to resuspending them in an equivalent volume of thrombin buffer used for the samples in (A) for loading 
onto the gel.  (C) I stored the beads shown in (A) overnight in 50% (v/v) glycerol at -80°C prior to washing 
in thrombin buffer and wash buffer (same as thrombin buffer but with NaCl increased to 524 mM). 
 Because even thrombin that had been heat-inactivated by incubating at 100°C for 
twenty minutes still digested Fc-FLAG-DGK-theta to some extent after 21 hours’ at 4°C 
(Figure 180B), I was interested in finding another negative control for thrombin 
digestion.  As previously mentioned, hirudin is a thrombin inhibitor found in the salivary 
glands of the leech Hirudo medicinalis143.  Hirudin indeed inhibited thrombin digestion 
of Fc-FLAG-DGK-theta purified from HEK293FT cytosol (Figure 183), but as before, 
the salt wash did not remove either of the predominant products from the protein A 
sepharose (Figure 183A and B).  In another thrombin digestion, this time of Fc-FLAG-
DGK-theta purified from HEK293T non-nuclear membranes, a high pH wash did not 
remove these products from the resin, either (Figure 183C and D).  Because hirudin 
inhibits DGK-theta’s enzymatic activity (Figure 128), DGK-theta incubated with hirudin-
inhibited thrombin was not an appropriate negative control for determining whether 
removal of the N-terminus relieves autoinhibition of DGK-theta.  I therefore needed yet 
another inhibitor as a negative control. 
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Figure 183.  Washing with salt or high pH does not remove thrombin-digested Fc-FLAG-DGK-theta, 
purified from either HEK293FT cytosol or non-nuclear membranes, from protein A sepharose.  I 
stored the Fc-FLAG-DGK-theta purified from HEK293FT cytosol on protein A sepharose (shown in 
Figure 179) for four weeks in 50% (v/v) glycerol at -80°C prior to thawing and washing with thrombin 
buffer 1 (10 mM HEPES, 10 mM Tris, 100 mM NaCl, 0.1% (w/v) PEG-8000, pH 7.5).  I incubated the 
DGK-theta with 10 mU per µL thrombin (Calbiochem) and 15 mU per µL hirudin (Sigma-Aldrich® 
H7380) (or not) in thrombin buffer at 4°C for 18 hours.  After removing a resin + supernatant aliquot, I 
microfuged to separate the resin from the supernatant.  I washed the resin with thrombin buffer 1 and with 
wash buffer 1 (same as thrombin buffer 1 but with NaCl increased to 524 mM).  R+S, resin + supernatant; 
S, supernatant; R, washed resin.  SDS-PAGE of 8% acrylamide gels followed by (A) silver staining, and 
(B) immunoblotting against DGK-theta (1:350 (v/v)).  I stored the Fc-FLAG-DGK-theta purified from 
HEK293FT non-nuclear membranes on protein A sepharose (shown in Figure 182) for eighteen days in 
50% (v/v) glycerol at -80°C prior to thawing and washing with thrombin buffer 2 (10 mM HEPES, 10 mM 
Tris, 100 mM NaCl, 0.1% (w/v) PEG-8000, pH 8.5).  I incubated the DGK-theta with 10 mU per µL 
thrombin (Calbiochem) and 15 mU per µL hirudin (Sigma-Aldrich® H7380) (or not) in thrombin buffer at 
4°C for 21 hours.  After removing a resin + supernatant aliquot, I microfuged to separate the resin from the 
supernatant.  I washed the resin with thrombin buffer 2 and with wash buffer 2 (same as thrombin buffer 2 
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but pH adjusted to 10).  (C) SDS-PAGE followed by silver staining.  This figure is reproduced from Figure 
127A for ease of comparison. (D) SDS-PAGE followed by immunoblotting against DGK-theta. (1:350 
(v/v)). 
 As mentioned previously, PMSF is another thrombin inhibitor, but before using it 
in the proteolysis studies, I wanted to first check whether PMSF inhibited DGK, as 
hirudin did.  After confirming that 1 mM PMSF did not inhibit DGK-theta (Figure 129), I 
once again digested DGK-theta with thrombin, this time with 1 mM PMSF as a negative 
control.  To assess inhibition by PMSF, I also incubated DGK-theta without thrombin.  
To assess whether any of the background bands resulted from HEK293FT non-nuclear 
membrane proteins copurified with DGK-theta, I also digested mock-purified HEK293FT 
non-nuclear membranes (untransfected cells that were subjected to the same purification 
protocol as the cells transiently transfected with Fc-FLAG-DGK-theta were).  1 mM 
PMSF was insufficient to prevent thrombin (10 mU per µL) digestion of purified Fc-
FLAG-DGK-theta overnight at 4°C (Figure 184).  As before, washing with a high-pH 
buffer did not remove the digested fragments of DGK-theta from the Protein-A sepharose 
resin (Figure 184).  When I measured the enzymatic activity of the digested DGK-theta, it 
showed considerably more DGK activity than the undigested DGK-theta (Figure 185A).  
The activity of the resin and supernatant together appeared greater than the sum of the 
activity of the resin and of the supernatant separately, suggesting that the two halves of 
the protein (or other components of the supernatant and the pellet fractions) might have 
cross-activated.  Alternatively, the activity might have resulted from a component that 
had been washed away when the resin was washed.  In order to distinguish between the 
two scenarios, I combined the supernatant and the resin together and assayed their 
activity.  The activity of the combined supernatant and washed resin actually may have 
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been slightly lower than the sum of the activities of the supernatant and washed resin 
(Figure 185C), and is substantially lower than the activity of the resin plus supernatant, 
before they were separated and the resin washed (Figure 185).  The activity of the beads 
plus supernatant was noisy, as observed previously (Figure 180), consistent with 
stochasticity of whether a bead happened to be included in the sample taken for the 
reaction or not; on the other hand, such an effect would also have been predicted for the 
washed resin, and was not observed (Figure 185).  Because the activity of the combined 
supernatant and washed resin was less than that of the original resin plus supernatant, I 
therefore concluded that the components on the resin and the components in the 
supernatant did not cross-activate.  It is possible that the active component in the resin 
plus supernatant fraction was a weakly bound factor, and thus not in the supernatant, that 
then washed away during either the thrombin buffer washes or the high pH washes.  
However, in that case it would have to be a very potently active component, seeing as no 
predominant bands appear in any of the washes (Figure 184).  Another, more plausible, 
explanation is that the resin retained the active component (consistent with the bands seen 
in Figure 184), but that the resin lost its activity during the course of the washing.  One 
possible cause for a loss in activity could be the extra ~four hours spent at 4°C during the 
course of washing (after all, I have shown the activity of purified DGK-theta to be 
sensitive to incubation on ice (Figure 99), and Figure 185 does not include a fresh-from-
the-freezer control, so the resin may have also lost some activity during the overnight 
thrombin digestion).  Alternatively, a fragment lost to the supernatant or in the washing 
might help stabilize the protein, and its loss might make the remaining DGK-theta less 
 358 
stable.  Yet another possible explanation is that the washing at pH 10 damaged or 
otherwise inactivated the Fc-FLAG-DGK-theta on the resin. 
 
Figure 184.  1 mM PMSF is insufficient to prevent 10 mU per µL thrombin from digesting purified 
Fc-FLAG-DGK-theta overnight at 4°C.  I stored the Fc-FLAG-DGK-theta purified from HEK293FT 
non-nuclear membranes on protein A sepharose (shown in Figure 183C-D) for two months in 50% (v/v) 
glycerol at -80°C prior to thawing and washing with thrombin buffer (10 mM HEPES, 10 mM Tris, 100 
mM NaCl, 0.1% (w/v) PEG-8000, pH 85).  I incubated either purified Fc-FLAG-DGK-theta or else mock-
purified HEK293FT non-nuclear membranes with 10 mU per µL thrombin (Calbiochem) and 1 mM PMSF 
in thrombin buffer at 4°C for 21 hours.  After removing a resin + supernatant aliquot, I microfuged to 
separate the resin from the supernatant.  I washed the resin with thrombin buffer and with wash buffer 1 
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(same as thrombin buffer but with pH increased to 10).  R+S, resin + supernatant; S, supernatant; R, 
washed resin; “mock”, mock-purified HEK293FT non-nuclear membranes.  SDS-PAGE of 8% acrylamide 
gels followed by (A) silver staining, and (B) immunoblotting against DGK-theta (1:350  (v/v)).   
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Figure 185.  Thrombin-digested DGK-theta shows considerably greater DGK enzymatic activity than 
undigested DGK-theta  DGK activity assays, but the two digested components do not cross-activate 
when recombined.  R+S, resin + supernatant; S, supernatant; R, washed resin; T, thrombin.  (A) I stored 
the samples shown in Figure 184 for three days in 50% (v/v) glycerol at -80°C prior to assaying.  The 
reaction included 7.5 mM liposomes (53:22:17:8::POPE:POPC:POPS:DOG), 48 mM HEPES, pH 7.0, 134 
mM NaCl, 1 mM DTT, 4.4 mM MgCl2, 1 mM ATP, 103 Ci per mmol [γ-32P]-ATP, 1.5 ng per µL LMW 
polylysine, and from the purified DGK-theta, up to 0.3 mM Tris, 0.003% (w/v) PEG-8000, 1.4% (v/v) 
glycerol, and 14 pg per µL purified DGK-theta (concentration estimated by silver staining), and proceeded 
for 15 minutes at 37°C.  In triplicate: mean ± SD.  (B) I stored the samples shown in Figure 184 for one 
week in 50% (v/v) glycerol at -80°C prior to assaying.  The reaction included 7.5 mM liposomes 
(53:22:17:8::POPE:POPC:POPS:DOG), 49 mM HEPES, pH 7.0, 134 mM NaCl, 1 mM DTT, 4.4 mM 
MgCl2, 1 mM ATP, 89.2 Ci per mmol [γ-32P]-ATP, 1.5 ng per µL LMW polylysine, and from the purified 
DGK-theta, up to 0.1 mM Tris, 0.001% (w/v) PEG-8000, 0.7% (v/v) glycerol, and 2.4 pg per µL purified 
DGK-theta (concentration estimated by silver staining), and proceeded for 15 minutes at 37°C.  In 
triplicate: mean ± SD.  (C) The same data as in (B), redisplayed to show what the additive activity would 
be. 
Discussion and Conclusions 
 In conclusion, while I was able to use thrombin to digest DGK-theta after folding, 
none of the washing conditions I tested (including high salt and high pH) were able to 
remove the digested C-terminal fragments from the protein A sepharose beads to which 
the N-terminal fragments were still bound via their Fc tag.  Digestion with thrombin 
appeared to activate DGK-theta, but whether the activation was due to relief from auto-
inhibition or some other effect from the thrombin could not be resolved because the 
different fragments of DGK-theta could not be separated.  Other systems that have been 
reported to pursue a similar strategy of allowing a protein to fold before proteolytically 
digesting it used denaturation by guanidine chloride to separate the different fragments of 
the protein155,156.  Future directions with using this strategy to express truncations of 
mammalian DGK might therefore wish to consider using denaturation to separate the 
pieces, but conditions for unfolding and refolding DGK-theta while recovering enzymatic 
activity would have to be worked out before being able to answer the question of whether 
such truncation relieves auto-inhibition. 
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Chapter 8: Photoaffinity labeling 
Introduction 
 Photoaffinity labeling approaches have been successfully used to map the binding 
sites of ligands on receptors and the active sites of enzymes.  I therefore decided to try a 
photoaffinity labeling approach in an attempt to identify the lipid substrate binding sites 
on mammalian DGK. 
Sucrose-loaded vesicle (SLV) pulldown 
Introduction 
One method to measure covalent crosslinking of photoaffinity labels to DGK is 
by sucrose-loaded vesicle (SLV) pulldown.  When large unilamellar vesicles (LUVs) are 
made in the presence of high concentrations of sucrose, then diluted into a buffer without 
sucrose, the buffer inside the vesicles is denser than the buffer outside the vesicles, and 
the SLVs will sink to the bottom of a tube when centrifuged157 (Figure 186).  SLVs have 
therefore been used to measure the binding of proteins to membranes.  If a lipid 
incorporated into SLVs covalently attached to a protein, as would be predicted if the 
probes were photoaffinity labeling DGK, then I would predict to see a probe- and UV-
dependent increase in SLV pulldown of DGK.   
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Figure 186.  Schematic for making SLVs.  LUVs are first made in a buffer with a high concentration of 
sucrose, represented by the blue color.  When the vesicles are diluted into buffer without sucrose, the 
interior of the SLVs (still blue) has a higher concentration of sucrose than the buffer outside the SLVs (a 
more translucent blue).  As such, the SLVs are denser than the surrounding buffer, and will pellet when 
centrifuged. 
Methods 
 I made sucrose-loaded vesicles (SLVs) in the same way as I made liposomes (see 
“Radiometric Endpoint DGK Assay” sub-subchapter of the “Diacylglycerol Kinase 
(DGK) Activity Assays” subchapter of the “General Methods” chapter), except that I 
included 170 mM sucrose in the buffer used to hydrate and extrude the lipids.  I generally 
also included 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-
benzoxadiazol-4-yl) (NBD-PE), a fluorescent lipid, to 1 µg per µL.  In order to measure 
the recovery of the lipids, I loaded samples into a 96-well plate and used a plate reader to 
excite at 485 nm and measure the emission at 528 nm, scaling to an empty well for 
sensitivity.  I stored SLVs at 4°C. 
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Measuring how much DGK-theta is pulled down by SLVs without covalent 
crosslinking 
 In order to be able to confidently measure an increase in pulldown (such as a 
probe- and UV-dependent increase in SLV pulldown of DGK that photoaffinity labeling 
would be predicted to produce), I would need to first find conditions under which not all 
of the DGK was pulled down by SLVs without photoaffinity labeling, so that I would be 
able to detect a probe- and UV-dependent increase in pulldown.  I therefore incubated 
purified DGK-theta in duplicate with 1 mM SLVs (2:1::POPE:POPC) including varying 
concentrations of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate (POPA), removed an 
aliquot (“vesicles”), then centrifuged to separate into supernatant and pellet.  I measured 
the enzymatic activity of these samples as one method to detect how much DGK 
partitioned into the different fractions.  Reproducibility among samples was an issue: one 
replicate of DGK-theta incubated with SLVs containing 20% PA, for example, gave 
considerably greater activity than the other replicate, even though both were made from 
the same master mix and thus should have had the same total amount of DGK-theta in 
them (Figure 188).  Another issue with using DGK activity as a proxy for DGK 
concentration is that the enzyme’s specific activity could very well depend on its 
chemical environment: I have previously shown DGK to be activated in the presence of 
liposomes (Figure 101), so the samples from the vesicles or pellets might have higher 
specific activity than the samples from supernatant and actually reflect a lower 
concentration of enzyme.  Alternatively, the samples from the supernatant might have 
higher specific activity if more of the activating histone H1 (which had been included in 
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the preincubation to prevent room-temperature inactivation (Figure 106A)) partitioned to 
the supernatant.   
 
Figure 187.  Using enzymatic activity to determine the partitioning of purified DGK-theta on SLVs 
does not give reproducible results between replicates.  DGK activity assay.  I first preincubated purified 
DGK-theta in preincubation buffer (1.1 ng per µL purified DGK-theta, 41% (v/v) glycerol, 0.2% (v/v) NP-
40, 1.4 µM histone H1, 1 mM DTT) on ice for ten minutes.  I then diluted into SLV buffer (1 mM SLVs 
(2:1::POPE:POPC, and the indicated concentrations of POPA), 50 mM HEPES, pH 7.5, 100 mM NaCl, 1 
mM ATP, 1.5 mM MgCl2, 81 pg per µL purified DGK-theta, 3% (v/v) glycerol, 0.015% (v/v) NP-40, 0.1 
µM histone H1, 0.1 mM DTT), and incubated at room temperature for thirty minutes.  I separated into two 
replicates, and then the supernatant from the pellet by centrifuging at 136,000 x g for 75 minutes at 25°C, 
and resuspended the pellet in DGK assay buffer.  The final reaction mixture included 2 mM liposomes 
(55.3:27.7:9:8::POPE:POPC:POPS:DOG), 50 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM DTT, 1.6 mM 
MgCl2, 1 mM ATP, 99.8 Ci per mmol [γ-32P]-ATP, 0.09 µM histone H1, and from the SLVs, up to 33 µM 
SLVs, 0.0005% (v/v) NP-40, and 0.1% (v/v) glycerol, and proceeded for 15 minutes at 37°C.  In duplicate: 
mean ± SD.  Because the goal of this assay was to determine the partitioning of DGK (and hence it is 
unknown how much DGK is in each fraction), the DGK activity is represented as total nmol PA rather than 
specific activity.  Vesicles: samples removed before centrifugation.  “1” and “2” signify replicates in 
pulldown.   
I therefore also immunoblotted against DGK-theta in these samples, and 
quantified the signal by interpolating into DGK-theta standards loaded onto the same gel 
(Figure 188A).  The proportion of DGK-theta in the pellet did appear to rise as a function 
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of POPA (Figure 188C), but this effect resulted not from an increase in signal from the 
pellet, but a decrease in signal from the vesicles (Figure 188B).  The discrepancy in 
activity between the two replicates of the 20% PA samples (Figure 187) was not 
accompanied by any such discrepancy in the amount of DGK recognized by the antibody 
(Figure 188), reaffirming that measuring DGK activity is probably not a good way to 
measure how much DGK-theta is present in an aliquot.  On the other hand, antibody 
recognition might also depend on the chemical environment: for example, the presence of 
histone H1 might influence recognition between DGK-theta and the antibody.  I therefore 
blotted against histone H1 to determine how histone H1 was distributed among the 
samples.  However, I was unable to detect histone H1 on these blots (Figure 189), even 
though I was using conditions that had been reported to reliably detect as little as 10 ng of 
histone H1 on other blots.  One possible explanation is that some reaction component (the 
SLVs, for example, or perhaps the NP-40) hindered antibody recognition of histone H1.  
Although quantitatively measuring how much DGK-theta was in the supernatant and the 
pellet was clearly going to be a challenge, I was able to conclude that not all of the DGK-
theta pelleted with the SLVs under the conditions tested, and I should be able to detect an 
increase due to photoaffinity labeling. 
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Figure 188.  Not all of the DGK-theta pelleted with the SLVs under the conditions tested.  The same 
samples as shown in Figure 187.  (A) SDS-PAGE of 8% acrylamide gels followed by immunoblotting 
against DGK-theta (1:350 (v/v)).  V, vesicles; S, supernatant; P, pellet.  “1” and “2” signify replicates in 
pulldown.  I also loaded various concentrations of purified DGK-theta onto each gel as a standard.  (B) 
Quantification of the signal from (A), calculated by comparing to the signal from the DGK-theta standard 
loaded onto each blot.  (C) The same data as in (B), but redisplayed as a percent of the signal from vesicles 
(after accounting for mass lost to the aliquot removed), and averaged over the two replicates.  Mean ± SD. 
 
 
Figure 189.  The anti-histone H1 antibody was unable to measurably detect histone H1 by 
immunoblot under the conditions tested.  The same membranes shown in Figure 188A, immunoblotted 
against histone H1 (1:500 (v/v)).  The anti-DGK-theta antibody was a mouse antibody, while the anti-
histone H1 antibody was a rabbit antibody, therefore the signals were observed on different channels on the 
Odyssey® Infrared Imaging System, and the anti-DGK-theta signal is not contributing to these 
immunoblots. 
 I wanted to be sure that the DGK-theta would be able to encounter any 
photoaffinity label in the SLV, but, as I mentioned above, also wanted the amount of 
DGK pulled down by the control SLVs to be low enough that I would be able to detect a 
photoaffinity-labeling-induced increase.  One way of accomplishing both would be to 
first incubate the DGK-theta with liposomes of a composition such that the DGK-theta 
would bind the membrane, then change the chemical environment such that any DGK-
theta not covalently attached would release the membrane.  I therefore tested how much 
DGK-theta was pulled down in the context of 20 mol% POPA and increasing 
concentrations of salt, with the idea that I could incubate the DGK-theta first with 
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liposomes containing 20 mol% POPA and low salt, and then increase the concentration of 
salt to remove the non-covalently attached DGK.  When I immunoblotted the fractions 
against DGK-theta, increasing concentrations of salt appeared to increase the amount of 
immunoreactive DGK in the pellet, but did not decrease the amount of immunoreactive 
DGK in the supernatant (Figure 190).  Once again, reproducibility between replicates was 
poor: not only did the two 500 mM NaCl replicates vary greatly in the amount of DGK-
theta detected in the SLVs before centrifugation (Figure 190), but the 100 mM NaCl 
replicates also differed from the 100 mM 20% POPA samples in the previous experiment 
(compare Figure 188 and Figure 190).   
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Figure 190.  Increasing concentrations of salt appeared to increase the amount of immunoreactive 
DGK in the pellet following SLV pulldown, but did not decrease the amount of immunoreactive 
DGK in the supernatant.  I stored the 20% POPA SLVs (used in Figure 187-Figure 189) for eighteen 
days at 4°C prior to use.  I first preincubated purified DGK-theta in preincubation buffer (1.1 ng per µL 
purified DGK-theta, 41% (v/v) glycerol, 0.2% (v/v) NP-40, 1.4 µM histone H1, 1 mM DTT) on ice for ten 
minutes.  I then diluted into SLV buffer (1 mM SLVs (53.3:26.7:20::POPE:POPC:POPA), 50 mM HEPES, 
pH 7.5, the indicated concentrations of NaCl, 1 mM ATP, 1.5 mM MgCl2, 81 pg per µL purified DGK-
theta, 3% (v/v) glycerol, 0.015% (v/v) NP-40, 0.1 µM histone H1, 0.1 mM DTT), and incubated at room 
temperature for thirty minutes.  I separated into two replicates, and then the supernatant from the pellet by 
centrifuging at 136,000 x g for 75 minutes at 25°C, and resuspended the pellet in DGK assay buffer.  (A) 
SDS-PAGE of 10% acrylamide gels, followed by immunoblotting against DGK-theta (1:350 (v/v)).  V, 
vesicles; S, supernatant; P, pellet.  “1” and “2” signify replicates in pulldown.  I also loaded various 
concentrations of purified DGK-theta onto each gel as a standard.  (B) Quantification of the signal from 
(A), calculated by comparing to the signal from the DGK-theta standard loaded onto each blot.  (C) The 
same data as in (B), but redisplayed as a percent of the signal from vesicles (after accounting for mass lost 
to the aliquot removed), and averaged over the two replicates.  Mean ± SD. 
The amount of DGK in the pellet in the higher salt treatment increased, but the 
specific activity decreased (Figure 191), which could be consistent with histone H1’s 
remaining in the supernatant, but could also be consistent with differences in efficiency 
of anti-DGK-theta antibody recognition (which could depend on the presence of lipid, for 
example, and thus might vary between the supernatant and pellet samples).  I once again 
immunoblotted against histone H1 to resolve how it fractionated among the SLVs, and 
once again I was unable to detect histone H1 signal quantitatively (Figure 192).  I was 
therefore faced with the problem that my method of quantifying DGK-theta (recognition 
by the anti-DGK-theta antibody) might depend on the presence of histone H1, which I 




Figure 191.  Both the total and specific activity varies between replicates.  DGK activity assay of the 
samples shown in Figure 190, immediately after separating into supernatant and pellet.  The final reaction 
mixture included 2 mM liposomes (55.3:27.7:9:8::POPE:POPC:POPS:DOG), 50 mM HEPES, pH 7.5, 100 
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mM NaCl, 1 mM DTT, 1.6 mM MgCl2, 1 mM ATP, 43.2 Ci per mmol [γ-32P]-ATP, 0.1 µM histone H1, 
and from the SLVs, up to 100 µM SLVs, 0.0015% (v/v) NP-40, and 0.3% (v/v) glycerol, and proceeded for 
15 minutes at 37°C.  In duplicate: mean ± SD.  Vesicles: samples removed before centrifugation.  “1” and 
“2” signify replicates in pulldown.  (A) Total nmol PA.  (B) Specific activity (using the concentration of 
DGK-theta in each fraction calculated from the immunoblots shown in Figure 190). 
 
 
Figure 192.  The anti-histone H1 antibody once again was unable to measurably detect histone H1 by 
immunoblot under the conditions tested.  The same membranes as shown in Figure 190, immunoblotted 
against histone H1 (1:500 (v/v)).  The anti-DGK-theta antibody was a mouse antibody, while the anti-
histone H1 antibody was a rabbit antibody, therefore the signals were observed on different channels on the 
Odyssey® Infrared Imaging System, and the anti-DGK-theta signal is not contributing to these 
immunoblots. 
I therefore decided to try to detect DGK-theta’s presence by immunoblotting 
against an epitope tag, in this case, the histidine tag, whose affinity for its antibody would 
not be predicted to depend on the presence of histone H1.  After stripping the 
membranes, however, the antibody detection by either of two mouse anti-histidine 
antibodies detected not much stronger a signal than anti-mouse secondary antibody alone 
(Figure 193A-C), making quantification difficult.  When I blotted against histidine using 
a rabbit antibody (Figure 193D), a new band appeared coincident with the anti-DGK-
theta immunoreactive band (Figure 193A-C) not seen in the anti-histone H1 blot (Figure 
192), consistent with recognition of the fusion protein.  Once again, however, the signal 
remained to weak to be useful for quantitatively measuring protein recovery. 
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Figure 193.  The signal from immunoblotting against histidine was too weak to quantitatively 
measure DGK-theta recovery following SLV pulldown in the presence of salt.  (A) The same 
membranes as shown in Figure 192, stripped with NewBlot™ Nitro Stripping Buffer and redeveloped with 
IRDye® 680LT goat anti-mouse IgG.  The anti-DGK-theta antibody used in Figure 190 was also a mouse 
antibody, so the lingering signal probably is from anti-DGK-theta that remained after stripping.  (B) The 
same membranes immunoblotted against histidine (BD Biosciences 631212 (1:5000 (v/v)), also a mouse 
antibody).  (C) The same membranes immunoblotted against His6 (abcam® ab6196 (1:2500 (v/v)), also a 
mouse antibody).  (D) The same membranes immunoblotted against histidine (Santa Cruz Biotechnology, 
Inc. sc-803 (1:2000 (v/v)), a rabbit antibody). 
Positive control: eGFP-C1b 
 Because I was having issues quantitatively measuring the amount of DGK-theta 
pulled down by SLVs and reproducing previous results, it was suggested to me to first 
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make sure that the probes successfully photoaffinity labeled a positive control before 
expending too much effort optimizing the DGK-theta conditions.  I therefore transiently 
transfected HEK293T cells with DNA that had been labeled “PKC delta C1b 2x in 
pEGFP-C2”, which supposedly encoded two copies of the C1b domain from H. sapiens 
PKC-δ fused in tandem to the C-terminus of eGFP, but DNA sequencing confirmed that 
only one copy of the C1b domain was encoded (Figure 194).  The transfected cells 
fluoresced green two days after transfection, consistent with expression of the eGFP.  I 
lysed the cells, fractionated into nuclei, cytosol, and non-nuclear membranes, then 
assessed the partitioning of the fusion protein using SDS-PAGE followed by Coomassie 
staining and immunoblotting against GFP.  No new bands in the transfected samples not 
seen in the mock-transfected samples were visible by Coomassie staining (Figure 195A), 
but a predominant band that migrated between the 35 and 40 kD molecular weight 
markers was robustly recognized by the anti-GFP antibody in the transfected but not 
mock-transfected samples (Figure 195B), consistent with the expression of a fusion 
protein with the predicted molecular weight of 38.5 kD.  Of the fractions tested, the 
cytosol appeared to have the most eGFP-C1b expression (Figure 195C). 
 
Figure 194.  Schematic of the eGFP-C1b construct.  I submitted the purified DNA to GENEWIZ® for 
sequencing using their EGFP-C sequencing primer (CATGGTCCTGCTGGAGTTCGTG), and was thereby 
able to sequence the construct from the end of the eGFP coding region through to the stop codon.  The 
upstream coding region of eGFP is inferred.  As such, the predicted molecular weight is 38.5 kD. 
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Figure 195.  eGFP-C1b-transfected HEK293T cells express a band that migrates between the 35 and 
40 kD molecular weight markers during SDS-PAGE that is recognized by an anti-GFP antibody and 
fractionates mostly to the cytosol.  I transfected two 15 cm plates each of HEK293T cells with either 
eGFP-C1b or without DNA (mock-transfected) for two days.  I rinsed each plate twice with cold PBS, 
added cold lysis buffer (20 mM HEPES, pH 7.4, 0.5 mM EGTA, 1 mM EDTA, 4 µg per mL quinacrine, 1x 
PIC, 5 mM NaVO4, 10 mM NaF, 5 mM DTT, 0.25% (v/v) NP-40), and incubated on ice for five minutes 
before scraping and homogenizing twelve times with a glass cell homogenizer.  I stored the lysate at -80°C 
for four days prior to thawing by shaking the tubes gently in water.  The lysates appeared not completely 
lysed, so I homogenized twelve more times.  I separated the nuclei from the post-nuclear supernatant (PNS) 
by centrifugation.  I fractionated the resulting supernatant by centrifuging at 110,000 x g for 65 minutes at 
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4°C: the resulting supernatant was the cytosol, and the resulting pellet was the non-nuclear membranes 
(NNM).  (A) SDS-PAGE of a 15% acrylamide gel followed by Coomassie staining.  I loaded 10 µg protein 
(as measured by the Bio-Rad Protein Assay) per lane.  M; mock-transfected; e, eGFP-C1b.  (B) SDS-PAGE 
of a 15% acrylamide gel followed by immunoblotting against GFP (abcam® ab6556 (1:3000 (v/v))).  I 
loaded 1 µg protein (as measured by the Bio-Rad Protein Assay) per lane.  (C) Quantification of the 
immunoblot signal from (B), normalized to the signal from the lysate. 
 I first precleared the eGFP-C1b-expressing cytosol with SLVs to remove 
nonspecifically-associating protein from the sample, and then pulled down with SLVs 
again to confirm that not all of the eGFP-C1b had been removed in the first step, and that 
a low enough proportion of the eGFP-C1b came down with the pellet so that I would be 
able to detect any probe- and UV-dependent increase in pulldown.  I could easily detect 
the remaining eGFP-C1b after preclearing (Figure 196A-B), so I concluded that 
preclearing did not remove all the eGFP-C1b.  As before, the reproducibility of 
partitioning among replicates was poor (Figure 196), so I would only be able to detect 
with confidence at least a twofold increase in pulldown.  In the experiment, I might be 
able to increase the precision by doing more blots of each replicate, to reduce the 




Figure 196.  eGFP-C1b is easily detectable by immunoblot after preclearing with SLVs, but 
reproducibility between SLV pulldown replicates is poor.  I stored the eGFP-C1b cytosol (shown in 
Figure 195) at -80°C for five days before thawing and preclearing by incubating with preclearing buffer (1 
mM freshly made SLVs (53.3:26.7:20::POPE:POPC:POPS), 51 mM HEPES, pH 7.5, 101 mM NaCl, 0.1 
µM histone H1, 1 mM ATP, 1.5 mM MgCl2, and from the eGFP-C1b cytosol, 100 ng per µL protein (as 
measured by the Bio-Rad Protein Assay), 34 µM EGTA, 68 µM EDTA, 0.3 µg per µL quinacrine, 0.07x 
PIC, 0.3 mM NaVO4, 0.7 mM NaF, 0.02% (v/v) NP-40), rocking at room temperature for thirty minutes.  I 
pelleted the SLVs by centrifuging at 136,000 x g for 75 minutes at 25°C: the resulting supernatant was the 
precleared cytosol.  I then pulled down the precleared cytosol in duplicate by incubating with SLV buffer 
(1 mM SLVs, 52 mM HEPES, pH 7.5, 103 mM NaCl, 0.08 µM histone H1, 0.8 mM ATP, 1.3 mM MgCl2, 
and from the precleared cytosol, up to 84 ng per µL protein (assuming 100% recovery after preclearing), 29 
µM EGTA, 57 µM EDTA, 0.2 µg per µL quinacrine, 0.06x PIC, 0.3 mM NaVO4, 0.6 mM NaF, 0.01% 
(v/v) NP-40), rocking at room temperature for thirty minutes.  I pelleted the SLVs by centrifuging at 
136,000 x g for 75 minutes at 25°C.   (A) SDS-PAGE of a 15% acrylamide gel, followed by 
immunoblotting against GFP (abcam® ab6556 (1:3000 (v/v))).  V, vesicles; S, supernatant; P, pellet.  “1” 
and “2” indicate two replicates.  (B) Quantification of the signal in (A), adjusted for the volumes of the 
samples to calculate the total amount of protein in each fraction.  Because there is no eGFP-C1b standard 
on this membrane, the units are arbitrary and assume equal efficiency of antibody recognition in each 
sample.  (C) The same data shown in (B), redisplayed as a percent of the vesicle from signals and averaged 
over the two replicates.  Mean ± SD.   
 I observed an additional, faster-migrating band in the pellet of the eGFP-C1b SLV 
pulldown (Figure 196A), so, concerned about antibody specificity in the context of the 
SLVs (since no nonspecific bands from the mock-transfected cells were recognized in the 
immunoblot testing the expression of the recombinant protein (Figure 195B)), I 
immunoblotted against both SLV pulldowns of the mock-transfected HEK293T cytosol 
as well as of SLV pulldowns without cytosol.  A GFP-immunoreactive band was indeed 
apparent in the mock-transfected pulldown and, to a lesser extent, the buffer pulldown 
(Figure 197), but this band was distinct in size from the eGFP-C1b band and did not 
contribute to the quantification of eGFP-C1b. 
 380 
 
Figure 197.  SLV pulldowns of mock-transfected HEK293T cytosol and of buffer produce an 
immunoreactive band, but it is distinct in size from eGFP-C1b and does not contribute to its 
quantification.  I precleared the mock-transfected 293FT cytosol (shown in Figure 195) by incubating 
with preclearing buffer (1 mM SLVs (53.3:26.7:20::POPE:POPC:POPS), 51 mM HEPES, pH 7.5, 101 mM 
NaCl, 0.1 µM histone H1, 1 mM ATP, 1.5 mM MgCl2, and from the eGFP-C1b cytosol, 100 ng per µL 
protein (as measured by the Bio-Rad Protein Assay), 34 µM EGTA, 68 µM EDTA, 0.3 µg per µL 
quinacrine, 0.07x PIC, 0.3 mM NaVO4, 0.7 mM NaF, 0.02% (v/v) NP-40), rocking at room temperature 
for thirty minutes.  I pelleted the SLVs by centrifuging at 136,000 x g for 75 minutes at 25°C: the resulting 
supernatant was the precleared cytosol.  I then pulled down either precleared mock-transfected HEK293T 
cytosol or else just buffer in duplicate by incubating with SLV buffer (1 mM SLVs, 52 mM HEPES, pH 
7.5, 103 mM NaCl, 0.08 µM histone H1, 0.8 mM ATP, 1.3 mM MgCl2, and from the precleared cytosol, 
up to 84 ng per µL protein (assuming 100% recovery after preclearing), 29 µM EGTA, 57 µM EDTA, 0.2 
µg per µL quinacrine, 0.06x PIC, 0.3 mM NaVO4, 0.6 mM NaF, 0.01% (v/v) NP-40), rocking at room 
temperature for thirty minutes.  I pelleted the SLVs by centrifuging at 136,000 x g for 75 minutes at 25°C.  
SDS-PAGE of 15% acrylamide gels, followed by immunoblotting against GFP (abcam® ab6556 (1:3000 
(v/v))).  V, vesicles; S, supernatant; P, pellet.  “1” and “2” indicate two replicates.   
 When I tested whether irradiation in the presence of compound 1 (whose structure 
is shown in Figure 130) increased the SLV pulldown of precleared eGFP-C1b-
overexpressing cytosol in a probe- and UV- dependent way, I first found that much more 
of the eGFP-C1b fractionated into the supernatant (Figure 198 and Figure 199) than in 
the previous experiment (Figure 196), even though SLVs of identical concentration and 
composition were used in an identical buffer, underscoring the difficulties in 
reproducibility in SLV recovery.  The percentage of eGFP-C1b that fractionated into the 




Figure 198.  Reproducibility of how eGFP-C1b fractionates in SLV pulldown is low among 
experiments, and the percentage of eGFP-C1b that fractionated into the pellet did not increase in a 
probe- and UV-dependent way, under the conditions tested.  I precleared the eGFP-C1b cytosol (shown 
in Figure 195) by incubating with preclearing buffer (1 mM freshly made SLVs 
(52.2:26.3:20::POPE:POPC:POPS), 51 mM HEPES, pH 7.5, 101 mM NaCl, 0.1 µM histone H1, 1 mM 
ATP, 1.5 mM MgCl2, and from the eGFP-C1b cytosol, 100 ng per µL protein (as measured by the Bio-Rad 
Protein Assay), 34 µM EGTA, 68 µM EDTA, 0.3 µg per µL quinacrine, 0.07x PIC, 0.3 mM NaVO4, 0.7 
mM NaF, 0.02% (v/v) NP-40), rocking at room temperature for thirty minutes.  I pelleted the SLVs by 
centrifuging at 136,000 x g for 75 minutes at 25°C: the resulting supernatant was the precleared cytosol.  I 
then pulled down the precleared cytosol by incubating with SLV buffer (1 mM SLVs (2:1::POPE:POPC, 
20 mol% POPS, plus the indicated concentration of compound 1), 52 mM HEPES, pH 7.5, 103 mM NaCl, 
0.08 µM histone H1, 0.8 mM ATP, 1.3 mM MgCl2, and from the precleared cytosol, up to 84 ng per µL 
protein (assuming 100% recovery after preclearing), 29 µM EGTA, 57 µM EDTA, 0.2 µg per µL 
quinacrine, 0.06x PIC, 0.3 mM NaVO4, 0.6 mM NaF, 0.01% (v/v) NP-40), rocking at room temperature, 
protected from light, for thirty minutes.  I then irradiated the samples with a 360 nm lamp for six minutes in 
a water-jacketed quartz cuvette with stirring, with or without cardboard between the lamp and cuvette.  I 
pelleted the SLVs in duplicate by centrifuging at 136,000 x g for 75 minutes at 25°C.  I resuspended the 
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pellets in assay buffer, and pelleted the SLVs a second time, storing the resulting supernatant as “wash”.  
SDS-PAGE of 15% acrylamide gels, followed by immunoblotting against GFP (abcam® ab6556 (1:3000 




Figure 199.  Reproducibility of how eGFP-C1b fractionates in SLV pulldown is low among 
experiments, and the percentage of eGFP-C1b that fractionated into the pellet did not increase in a 
probe- and UV-dependent way, under the conditions tested.  (A) Quantification of the signal in Figure 
198, adjusted for the volumes of the samples to calculate the total amount of protein in each fraction.  
Because there is no eGFP-C1b standard on this membrane, the units are arbitrary and assume equal 
efficiency of antibody recognition in each sample.  (B) The same data shown in (A), redisplayed as a 
percent of the vesicle from signals and averaged over each set of two replicates.  Mean ± SD.   
 A number of factors could possibly explain why irradiating in the presence of the 
probe would not increase the amount of eGFP-C1b recovered in the pellet: perhaps the 
experiment did not include enough protein or enough probe, perhaps the probe had gone 
bad (it is, after all, a photoreactive molecule), perhaps the time of irradiation wasn’t long 
enough, perhaps other components in the buffer were absorbing some of the 360 nm 
light, etc.  In order to have a positive control for the positive control, therefore, I next 
tested whether DAG could increase SLV pulldown of eGFP-C1b.  I chose four 
concentrations of DAG to test: 0 mol%; the concentration used in the previous 
experiment (0.53 mol% (this was before I realized the concentration of compound 1 was 
less than advertised (Figure 131))); the supposed Kd158 of PKCδ’s C1b domain for DAG 
(7800 nM = 0.78 mol% of 1 mM liposomes); and a value considerably higher than the 
reported Kd (2.5 mol%).  The proportion of eGFP-C1b copelleting with the SLVs did 
appear to increase DAG-dependently (Figure 200 and Figure 201), as predicted, but the 
amount of eGFP-C1b pulled down remained far less than half.  One possible explanation 
for why the DAG pulled down as little eGFP-C1b as it did is that eGFP-C1b, while 
overexpressed, is presumably not the only DAG-binding protein in the HEK293T 
cytosol, and these other proteins could compete with eGFP-C1b.  A purified protein 
might therefore be a better choice as a positive control for photoaffinity labeling of DGK. 
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Figure 200.  The proportion of eGFP-C1b copelleting with the SLVs did appear to increase DAG-
dependently, but the amount of eGFP-C1b pulled down remained far less than half.  I precleared the 
eGFP-C1b cytosol (shown in Figure 195) by incubating with preclearing buffer (1 mM freshly made SLVs 
(52.2:26.3:20::POPE:POPC:POPS), 51 mM HEPES, pH 7.5, 101 mM NaCl, 0.1 µM histone H1, 1 mM 
ATP, 1.5 mM MgCl2, and from the eGFP-C1b cytosol, 100 ng per µL protein (as measured by the Bio-Rad 
Protein Assay), 34 µM EGTA, 68 µM EDTA, 0.3 µg per µL quinacrine, 0.07x PIC, 0.3 mM NaVO4, 0.7 
mM NaF, 0.02% (v/v) NP-40), rocking at room temperature for thirty minutes.  I pelleted the SLVs by 
centrifuging at 136,000 x g for 75 minutes at 25°C: the resulting supernatant was the precleared cytosol.  I 
then pulled down the precleared cytosol by incubating with SLV buffer (0.67 mM SLVs 
(2:1::POPE:POPC, 20 mol% POPS, plus the indicated concentration of DOG) (0.78% DOG SLVs were 1 
mM to match the reported Kd158), 52 mM HEPES, pH 7.5, 103 mM NaCl, 0.08 µM histone H1, 0.8 mM 
ATP, 1.3 mM MgCl2, and from the precleared cytosol, up to 84 ng per µL protein (assuming 100% 
recovery after preclearing), 29 µM EGTA, 57 µM EDTA, 0.2 µg per µL quinacrine, 0.06x PIC, 0.3 mM 
NaVO4, 0.6 mM NaF, 0.01% (v/v) NP-40), rocking at room temperature for thirty minutes.  I pelleted the 
SLVs in duplicate by centrifuging at 136,000 x g for 75 minutes at 25°C.  I resuspended the pellets in assay 
buffer, and pelleted the SLVs a second time, storing the resulting supernatant as “wash”.  SDS-PAGE of 
15% acrylamide gels, followed by immunoblotting against GFP (abcam® ab6556 (1:3000 (v/v))).  V, 




Figure 201.  The proportion of eGFP-C1b copelleting with the SLVs did appear to increase DAG-
dependently, but the amount of eGFP-C1b pulled down remained far less than half.  (A) 
Quantification of the signal in Figure 200, adjusted for the volumes of the samples to calculate the total 
amount of protein in each fraction.  Because there is no eGFP-C1b standard on this membrane, the units are 
arbitrary and assume equal efficiency of antibody recognition in each sample.  (B) The same data shown in 
(A), redisplayed as a percent of the vesicle from signals and averaged over each set of two replicates.  
Mean ± SD.   
Positive Control: GST-hPKCδ 
 I was able to show that eGFP-C1b copelleted with SLVs DAG-dependently, but 
ultimately we wanted a positive control known to bind compound 1, not necessarily 
DAG.  The paper describing the synthesis of compound 1 also reported that compound 1 
had an affinity to purified PKCδ comparable to that of DAG144.  I therefore ordered 
commercial H. sapiens PKCδ, with a GST tag fused to the N-terminus (Enzo Life 
Sciences® SE-346, MW predicted to be 104 kD).  Because I planned to measure SLV 
fractionation via immunoblotting, I first tested which antibodies recognized the 
recombinant, purified GST-hPKCδ.  Neither a mouse-anti-PKCα nor an anti-GST 
primary antibody detected GST-hPKCδ at any of the concentrations tested (Figure 
202A).  An anti-GST antibody directly coupled to horseradish peroxidase (HRP) was 
able to recognize the GST-hPKCδ (Figure 202B), but the blot was too messy to be able to 
show that this antibody could detect it quantitatively (Figure 202C).  I therefore ordered a 
new anti-GST antibody.  This antibody easily detected GST-hPKCδ (Figure 203A and 
B), and its signal showed a good linear dependence on the concentrations tested at 
1:10,000 (Figure 203C), 1:5000, and 1:1000 (v/v) dilutions (Figure 203D).  The signal 
was considerably stronger at 1:5000 than at 1:10,000 (although caution must be exercised 
any time different LiCor scans are compared); contrariwise, the signal at 1:1000 was not 
much stronger than at 1:5000.  I therefore opted to use the 1:5000 dilution of the Novus® 
anti-GST antibody in order to detect SLV pulldown of GST-hPKCδ. 
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Figure 202. Neither a mouse-anti-PKCα nor an anti-GST primary antibody detected GST-hPKCδ at 
any of the concentrations tested, and the signal to noise ratio for an anti-GST antibody directly 
coupled to horseradish peroxidase was insufficient for quantitative immunoblotting.  SDS-PAGE of 
8% acrylamide gels followed by immunoblotting against (A) (left) GST (1:50,000 (v/v)) and (right) PKCα 
(Upstate® (now EMD Millipore) 05-154).  (B) The same membranes as in (A), immunoblotted against 
GST with an antibody conjugated to horseradish peroxidase (HRP).  (C) Quantification of the signal in (B) 




Figure 203.  1:5000 (v/v) is the best dilution for using the Novus® anti-GST antibody to detect GST-
hPKCδ.  (A) The membranes shown in Figure 202, stripped (with NewBlot™ Nitro Stripping Buffer) and 
reprobed against GST (Novus® (1:10,000 (v/v))).  (B) The same membranes reprobed against GST  
(Novus®): left, 1:1000 (v/v); right, 1:5000 (v/v).  (C) Quantification of the signal in (A), subtracting out 
the signal of the stripped blot.  (D) Quantification of the signal in (B), subtracting out the signal of the 
stripped blot. 
 When I tried to confirm DAG-dependent SLV pulldown of purified GST-hPKCδ, 
however, I was unable to detect any of the SLV samples (Figure 204A), and the signal 
from the GST-hPKCδ standard was considerably weaker than in the antibody dilution 




Figure 204.  The anti-GST immunoblot signal was considerably weaker than in the previous 
experiment.  I pulled down purified GST-hPKCδ by incubating in duplicate with SLV buffer (0.25 mM 
SLVs (20 mol% POPS, the indicated concentration of DOG, and the rest filled with POPC), 55 mM 
HEPES, pH 7.5, 110 mM NaCl, 0.1 mM CaCl2, 86 pg per µL GST-hPKCδ), rocking at room temperature 
for thirty minutes.  I supplemented PC/PE SLVs to 1 mM to assist in pelleting the SLVs (GST-hPKCδ is 
not predicted to bind these SLVs, so their presence should not affect the pulldown).  I pelleted the SLVs by 
centrifuging at 136,000 x g for ninety minutes at 25°C.  I resuspended the pellets in assay buffer, and 
pelleted the SLVs a second time, storing the resulting supernatant as “wash”.  (A) SDS-PAGE of 8% 
acrylamide gels, followed by immunoblotting against GST (Novus® (1:5000 (v/v))).  V, vesicles; S, 
supernatant; W, wash; P, pellet.  “1” and “2” indicate two replicates.  (B) Quantification of the signal of the 
GST-hPKCδ standards in (A), redisplaying the data shown in Figure 203D for comparison (as “110929 
data”). 
 I thought perhaps the lipid from the SLVs was interfering with antibody 
recognition of GST-hPKCδ, so I incubated GST-hPKCδ with SLVs and took timepoints 
to see whether antibody recognition depended on the presence of lipid.  Antibody 
recognition of GST-hPKCδ clearly deteriorated as a function of time incubated at room 
temperature, but this was not a problem with the lipid interfering with antibody detection, 
because the signal from GST-hPKCδ incubated in buffer was even weaker and also 
deteriorated as a function of time (Figure 205).   
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Figure 205.  Antibody recognition of GST-hPKCδ by the anti-GST antibody decreases as a function 
of time.  I incubated purified GST-hPKCδ in SLV buffer (0 or 0.25 mM SLVs 
(80:20:0.0024:POPC:POPS:DOG), 55 mM HEPES, pH 7.5, 110 mM NaCl, 500 pg per µL GST-hPKCδ), 
collecting timepoints at 0, 5, 10, 15, 20, 30, 60, and 165 minutes.  I quenched each timepoint by adding 
SDS-PAGE gel-loading buffer to 1x and freezing at -20°C.  (A) SDS-PAGE of an 8% acrylamide gel 
followed by immunoblotting against GST (Novus® (1:5000 (v/v))).  Arrows indicate the passage of time.  
(B) Quantification of the signal in (A), using the GST-hPKCδ standards to calculate what the predicted LI-
COR® signal would be. 
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 I therefore wondered whether the decline in antibody recognition was a result of 
GST-hPKCδ’s adhering to the sides of the tube.  This hypothesis would explain why the 
signal decreased as a function of time, why GST-hPKCδ incubated with SLVs would 
give a stronger signal (because the SLVs would compete for tube-binding), and why the 
signal given by the GST-hPKCδ standard when it was freshly made (before it had time to 
adhere to the tube) was considerably stronger than on any of the blots since then.  BSA, a 
protein traditionally used to prevent purified proteins from adhering to tubes, binds lipids 
and thus is not a good choice for including with a protein whose properties might be 
lipid-dependent, such as DGK.  I therefore tested whether adding 0.1 µg per µL 
ovalbumin protected against this time-dependent loss of antibody recognition.  In order to 
distinguish between changes in antibody recognition and changes in the amount of 
protein available, I also subjected the samples to silver staining.  The silver-stained gel 
tore at the region where the GST-hPKCδ was predicted to migrate (Figure 206A), making 
interpretation exceedingly difficult.  A bubble also unfortunately coincided with some of 
the GST-hPKCδ bands during the transfer of the immunoblot, but even so, incubating 
with ovalbumin clearly improved antibody recognition (Figure 206B and C).  I therefore 
concluded that the difficulties in antibody recognition of GST-hPKCδ were due to protein 
adhesion, that protein adhesion could be mitigated by including ovalbumin in the reaction 




Figure 206.  Including 0.1 mg per mL ovalbumin improves recognition of GST-hPKCδ by the anti-
GST antibody.  I incubated purified GST-hPKCδ in incubation buffer (54 mM HEPES, pH 7.5, 109 mM 
NaCl, 1 ng per µL GST-hPKCδ, with or without 0.1 mg per mL ovalbumin), collecting timepoints at 0, 10, 
20, 30, and 120 minutes.  I quenched each timepoint by adding SDS-PAGE gel-loading buffer to 1x and 
freezing at -20°C.  SDS-PAGE of 8% acrylamide gels followed by (A) silver staining and (B) 
immunoblotting against GST (Novus® (1:5000 (v/v))).  Arrows indicate the passage of time.  (C) 
Quantification of the signal in (B), using the GST-hPKCδ standards to calculate what the predicted LI-
COR® signal would be.  The recovery of more than 100% the predicted signal might be due to uncertainty 
from the GST-hPKCδ standard because of the bubble. 
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 I therefore once again tried to confirm DAG-dependent SLV pulldown of GST-
hPKCδ, this time in the presence of ovalbumin in order to prevent GST-hPKCδ from 
adhering to the side of the tube and ensure better antibody detection.  Ultimately I was 
interested not in how much protein was in the supernatant and the pellet, but rather how 
much of the protein is bound to the lipid.  In order to calculate how much protein was 
bound to the lipid, I also needed to measure how the lipid partitioned between the 
supernatant and the pellet as well as how much of the protein sediments in the pellet in 
the absence of lipid, according to Equation 5159.  I could measure how the lipid 
partitioned because when making the SLVs I included a fluorescent lipid, NBD-PE.  
When I measured lipid partitioning, however, more than half of the lipid ended up in the 
supernatant, not the pellet (Figure 207).  The fact that the proportion of protein that 
pelleted in the absence of lipid (1 – β) was greater than the proportion of SLVs that 
pelleted (α) (Figure 208 and Figure 208) meant that it was impossible to calculate from 
the partitioning of the protein between supernatant and pellet how much of the protein 
was bound to lipid. 
𝐴! =
𝛽 ∗ 𝐴! + 𝛽 − 1 𝐴!
𝛼 + 𝛽 − 1  
Equation 5.  The fraction of protein associated with vesicles (Av) can be calculated from the amount 
of protein in the top fraction (At), the amount of protein in the bottom fraction (Ab), the fraction of 




Figure 207.  More than half the lipid is in the supernatant following SLV pulldown.  I pulled down 
purified GST-hPKCδ by incubating in duplicate with SLV buffer (0.25 mM SLVs (20 mol% POPS, the 
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indicated concentration of DOG, and the rest filled with POPC), 55 mM HEPES, pH 7.5, 109 mM NaCl, 
500 pg per µL GST-hPKCδ, 0.1 mg per mL ovalbumin), rocking at room temperature for thirty minutes.  I 
removed aliquots as “vesicles”, and stored protected from light while I pelleted the SLVs by centrifuging at 
136,000 x g for ninety minutes at 25°C.  (A) Recovery of the lipids as measured by the emission at 528 nm 
in response to excitation at 485 nm.  “1” and “2” indicate two replicates.  (B) The same data shown in (A), 
redisplayed as a percent of the vesicle from signals and averaged over each set of two replicates.  Mean ± 
SD. 
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Figure 208.  More GST-hPKCδ sediments in the absence of SLVs than SLVs sediment.  I measured 
the sedimentation of GST-hPKCδ in the absence of SLVs (α in Equation 5) by incubating purified GST-
hPKCδ in duplicate with sedimentation buffer (55 mM HEPES, pH 7.5, 109 mM NaCl, 500 pg per µL 
GST-hPKCδ, 0.1 mg per mL ovalbumin), rocking at room temperature for thirty minutes.  I removed 
aliquots as “input”, then sedimented the protein by centrifuging at 136,000 x g for ninety minutes at 25°C.  
(A) SDS-PAGE of 8% acrylamide gels followed by immunoblotting against GST (Novus® (1:1000 (v/v))).  
“1”, “2”, and “3” indicate three replicates, blotted three times to account for uncertainty due to the transfer.  
MW stds, molecular weight standards.  (B) Quantification of the signal in (A).  I first measured the LI-
COR® signal from GST-hPKCδ with ovalbumin standards of known concentration, and calculated a linear 
fit to the signal as a function of concentration (Microsoft® Excel®).  R2 values for these linear fits were 
greater than 0.91.  I then used the linear fit to calculate how much GST-hPKCδ was present in each loaded 
sample based on its LI-COR® signal.  I then used the volume loaded to calculate the concentration, and 
used the total volume of the sample to calculate the total amount of GST-hPKCδ.  (C) The same data as in 
(B), but redisplayed as a proportion of input, and averaged over the three transfers of each of the three 
replicates.  Mean ± SD. 
 A closer inspection of the reference that showed that PKCδ had equal affinities 
for all the functionalized DAG analogues144 revealed that the way the authors did the 
experiment was by varying the total concentration of lipid without changing the lipid 
composition.  Because all the liposomes tested included 20% POPS, it could very well be 
that they were measuring PKCδ’s affinity for POPS, and not for the DAG analogues.  
Because I therefore did not, in fact, have evidence that PKCδ had an affinity for these 
particular probes, I had no reason to continue to pursue GST-hPKCδ as a positive control 
for probe- and UV-dependent SLV pulldown of DGK-theta. 
Positive control: His6-hPKCε 
 Still looking for a positive control to show probe- and UV-dependent SLV 
pulldown, I searched the literature for other proteins that had demonstrated a DAG-
dependent (and not just, as with the PKCδ reference, total-lipid dependent) increase in 
SLV pulldown, and found that PKCε was such a protein160. 
 I therefore ordered commercial purified human PKCε with a hexahistidine fused 
to the N-terminus (ProSpec PKA-322) and, as I did previously with GST-hPKCδ, worked 
out conditions for recognizing the purified protein by immunoblot.  I found that if I 
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loaded enough His6-hPKCε, including 0.005% DDM improved antibody recognition 
(Figure 209).  Unlike GST-hPKCδ, adding ovalbumin to His6-hPKCε did not so much 
improve antibody recognition as change the shape of the curve: it appeared to enhance 




Figure 209.  Including 0.005% DDM improves antibody recognition of His6-hPKCε by the anti-
histidine antibody.  (A) SDS-PAGE of 8% acrylamide gels followed by immunoblotting against histidine 
(Santa Cruz Biotechnology, Inc. sc-803 (1:100 (v/v))).  Where indicated, ovalbumin was included at 0.1 mg 
per mL, and DDM was included at 0.005% (v/v).  As a positive control for histidine recognition, I also 
included the lysate of Sf9 cells that had been infected with baculovirus encoding His6-tagged R. norvegicus 
DGK-alpha.  (B) Quantification of the signal in (A).  The displayed R2 values were calculated in 
Microsoft® Excel®.   
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 Once I was confident that I had found conditions under which I could detect His6-
hPKCε fractionation, I tested whether I could confirm DAG-dependent SLV pulldown of 
His6-hPKCε.  As a positive control for the positive control, I also tested whether PMA 
increased SLV pulldown of His6-hPKCε.  However, as I had observed with the SLV 
pulldowns of GST-hPKCδ, lipid recovery in the pellet after SLV pulldown was 
exceedingly poor (Figure 210).  When I tried to measure how much of the His6-PKCε 
sedimented in the absence of SLVs, I found that, as I had previously experienced, 
reproducibility between the two replicates was also exceedingly poor (Figure 211).  I was 
therefore unable to calculate any meaningful numbers for the proportion of His6-hPKCε 
bound to lipid from the proportion of His6-hPKCε that fractionated into either the 
supernatant or the pellet. 
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Figure 210.  Lipid recovery in the pellet following SLV pulldown was exceedingly poor.  I pulled down 
purified His6-hPKCε by incubating in duplicate with SLV buffer (0.1 mM SLVs (20 mol% POPS, the 
indicated concentration of DOG, and the rest filled with POPC; “PMA” lipids included both 1.25% DOG 
and 200 nM PMA, as well as 0.2% (v/v) DMSO), 20 mM Tris, pH 7.5, 100 mM NaCl, 0.2 mM EGTA, 
0.005% (v/v) DDM, 1.3 ng per µL (15 nM) His6-hPKCε, 1.3% (v/v) glycerol, 0.1 mg per mL ovalbumin), 
rocking at room temperature for fifteen minutes.  I removed aliquots as “vesicles”, and stored protected 
from light while I pelleted the SLVs by centrifuging at 136,000 x g for thirty minutes at 25°C.   I measured 
the recovery of the lipids by measuring the emission at 528 nm in response to excitation at 485 nm.  “1” 
and “2” indicate two replicates.  Measured in triplicate, mean ± SD. 
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Figure 211.  Reproducibility between replicates in sedimentation of His6-hPKCε in the absence of 
SLVs was poor.  I measured the sedimentation of His6-hPKCε in the absence of SLVs (α in Equation 5) 
by incubating purified His6-hPKCε in duplicate with sedimentation buffer (20 mM Tris, pH 7.5, 100 mM 
NaCl, 0.2 mM EGTA, 0.005% (v/v) DDM, 1.3 ng per µL (15 nM) His6-hPKCε, 1.3% (v/v) glycerol, 0.1 
mg per mL ovalbumin), rocking at room temperature for fifteen minutes.  I removed aliquots as “input”, 
then sedimented the protein by centrifuging at 136,000 x g for thirty minutes at 25°C.  (A) SDS-PAGE of 
an 8% acrylamide gel followed by immunoblotting against histidine (Santa Cruz Biotechnology, Inc. sc-
803 (1:200 (v/v))).  “1” and “2” indicate two replicates.  (B) Quantification of the signal in (A).  I first 
measured the LI-COR® signal from His6-hPKCε standards of known concentration, and calculated a linear 
fit to the signal as a function of concentration (Microsoft® Excel®).  The R2 value for this linear fit was 
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greater than 0.99.  I then used the linear fit to calculate how much His6-hPKCε was present in each loaded 
sample based on its LI-COR® signal.  I then used the volume loaded to calculate the concentration, and 
used the total volume of the sample to calculate the total amount of His6-hPKCε. 
 I was curious as to why lipid recovery during the course of producing the SLVs 
(Figure 212) was considerably better than during the pulldown with His6-hPKCε (Figure 
210).  The concentration of liposomes was slightly lower during the pulldown with 
protein (0.1 mM during pulldown as opposed to 0.16 mM during SLV preparation), and 
the buffer was different.  The most suspicious of the buffer components seemed to me to 
be the DDM.  I therefore tested DDM individually, as well as the entire buffer system, on 
SLV recovery.  I found that the most important factor in lipid recovery was not the 
concentration or the buffer composition, but the order in which I removed it from the 
centrifuge (Figure 213): the greatest recoveries were from the replicates removed first, 
and the lowest recoveries were from the replicates removed last.  It seems unlikely this 
result is purely a function of time, since the tubes had been sitting in the centrifuge for 
thirty minutes while centrifuging, and a few minutes after the centrifuge stopped, whereas 
the time to remove them from the centrifuge could not have taken more than a minute.  It 
seems more likely a function of angle: I did not rotate the centrifuge as I removed the 
tube, and some tubes were undoubtedly jostled more than others depending on the angle 
at which I removed them from their different positions in the stationary rotor. 
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Figure 212.  Recovery of SLVs during SLV preparation was considerably better than during 
pulldown.  Recovery of the SLVs (used in Figure 210) during their preparation, as measured by the 
emission at 528 nm in response to excitation at 485 nm.  Measured in triplicate, mean ± SD. 
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Figure 213.  Lipid recovery following SLV pulldown depends strongly on the order in which the 
tubes are removed from the rotor.  I incubated SLVs under different conditions, in triplicate, to test 
which variables were important in SLV recovery.  “0.16 mM” signifies the reproduction of the original 
SLV recovery (0.16 mM SLVs (77.5:20:2.5::POPC:POPS:DOG), 20 mM Tris, pH 7.5, 80 mM NaCl, 40 
mM sucrose).  “0.1 mM” dropped the SLV concentration to 0.1 mM.  “0.16 mM + 0.005% DDM” added 
DDM to 0.005% (v/v).  “0.16 mM + everything” also included 1.3% (v/v) glycerol, 0.1 mg per mL 
ovalbumin, 100 mM NaCl, 0.2 mM EGTA, and 0.005% (v/v) DDM.  I incubated for 15 minutes, rocking at 
room temperature.  I pelleted the lipids by centrifuging at 136,000 x g for thirty minutes at 25°C.  I 
measured the recovery of the lipids by measuring the emission at 528 nm in response to excitation at 485 
nm.  Left, results organized by condition.  The markers indicate the three data points, the black horizontal 
line indicates the mean, and the colored spread indicates the SD.  Right, results organized by the order in 
which I removed them from the rotor, from left to right. 
Conclusions 
 As mentioned previously, when the lipid fractionates into the pellet in a lower 
proportion than the protein that fractionates into the pellet in the absence of lipid, it is 
impossible to use the protein SLV pulldown data in order to measure how much protein 
is bound to lipid (Equation 5)159.  I showed that the proportion of lipid that fractionates 
into the pellet is extremely sensitive to even minor changes in sample preparation, as 
simple as the order in which the tubes are removed from the centrifuge, and as such I was 
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unable to reproducibly fractionate the lipid in the pulldowns into the pellet to a greater 
degree than the protein in the absence of lipid.  As such, I decided that SLV pulldown 
was not a robust method for measuring protein-lipid interactions.  I would therefore need 
to find another way to measure photoaffinity labeling of DGK. 
Triton X-114 partitioning 
Introduction 
 The cloud point of Triton X-114 (TX-114) is around room temperature161, which 
means that at cold temperatures (on ice, for example), it forms a single, micellar phase, 
but at warm temperatures (at 37°C, for example), it forms two distinct phases: a bottom, 
detergent-rich phase and a top, detergent-poor phase69.  TX-114 partitioning is therefore a 
method that has been used to enrich for membrane-anchored proteins162: the presence of 
the membrane anchor causes the protein to preferentially partition into the detergent-rich 
phase and out of the detergent-poor phase.  Because the photoaffinity label is a lipid, one 
might predict that DGK covalently attached to the photoaffinity label to more 
preferentially partition into the detergent-rich phase as compared to DGK that had not 
been photoaffinity labeled.  
Results 
 As with the SLV pulldown, for the TX-114 partitioning I decided to start with 
looking at how purified DGK-theta partitioned into TX-114 before crosslinking, to be 
sure that I would be able to detect a probe- and UV-dependent increase.  Following a 
previously published protocol163 I decided to use 1% (v/v) TX-114 to phase-partition 
purified DGK-theta, but, in the reaction conditions tested, 1% (v/v) TX-114 was 
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insufficient to form two phases at 37°C.  I added TX-114 to 15% (v/v), which was 
enough to produce two distinct phases, but in that case the bottom phase was much larger 
than the top phase.  Diluting the mixture to 12% (v/v) TX-114 was sufficient to produce 
two phases approximately equal in size.  I collected samples both before the phase 
separation as well as from each of the two separated phases. 
 Because TX-114 has been reported to interfere with SDS-PAGE162, I first ethanol-
precipitated the samples to remove the TX-114 from the protein.  We had recently 
switched brands of Eppendorfs, and the brand of tube I used was not quite clear, making 
it difficult to visually assess the success of ethanol precipitation; however, the presence of 
ovalbumin and histone H1 as carrier proteins should have increased the efficiency of 
protein precipitation (as in Figure 13); on the other hand, the carrier proteins may have 
partitioned differently from DGK-theta (i.e., if all of the ovalbumin and histone H1 
partitioned into the detergent-poor phase, they would be unable to assist in the 
precipitation of DGK-theta that was in the detergent-rich phase).  When I immunoblotted 
the samples against DGK-theta, reproducibility among replicates was poor (Figure 214A-
B).  Part of the irreproducibility may have resulted from protein loss during the ethanol 
precipitation: the “before” samples (removed before partitioning) gave a much weaker 
signal than would be expected given the theoretical amount in the sample (Figure 214C), 
which is consistent with protein loss during ethanol precipitation.  A loss of protein in the 
“before” samples was, however, surprising, given the large concentration of ovalbumin 
and histone H1 in the samples, which should have assisted in precipitation.  Other 
possible explanations for the poor recovery of DGK-theta in the “before” samples could 
be that residual TX-114 remaining after the ethanol precipitation, however low in 
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concentration, interfered with antibody recognition, or that the presence of TX-114 
interfered with efficiency of protein precipitation. 
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Figure 214. TX-114 partitioning of purified DGK-theta varies among replicates, and recovery 
following ethanol precipitation is poor.  I first preincubated purified DGK-theta in preincubation buffer 
(50 mM HEPES, pH 7.5, 0.005% (v/v) DDM, 0.22 µM histone H1, 1 mM DTT, 79 pg per µL purified 
DGK-theta, 1.6% (v/v) glycerol) on ice for ten minutes.  I then diluted into incubation buffer (50 mM 
HEPES, pH 7.5, 100 mM NaCl, 0.005% (v/v) DDM, 1 mM ATP, 1.5 mM MgCl2, 1 mM DTT, 7.5 mM 
liposomes (53.3:26.7:20::POPE:POPC:POPS), 1 µM histone H1, 0.1 mg per mL ovalbumin, 0.7% (v/v) 
glycerol, 36 pg per µL DGK-theta), and incubated for thirty minutes, rocking at room temperature.  I added 
TX-114 to 1% (v/v) (which decreased the other buffer components to 46 mM HEPES, pH 7.5, 92 mM 
NaCl, 0.005% (v/v) DDM, 0.9 mM ATP, 1.4 mM MgCl2, 0.9 mM DTT, 6.9 mM liposomes, 0.09 µM 
histone H1, 0.09 mg per mL ovalbumin, 0.7% glycerol, and 33 pg per µL DGK-theta), separated into three 
replicates, vortexed, and incubated on ice for 10 minutes, followed by 37°C for five minutes.  When no 
separate phases were apparent, I incubated at 50°C for twenty minutes.  When still no separate phases were 
apparent, I added TX-114 to 15% (v/v) (which decreased the other buffer components to 39 mM HEPES, 
pH 7.5, 79 mM NaCl, 0.004% (v/v) DDM, 0.8 mM ATP, 1.2 mM MgCl2, 0.8 mM DTT, 5.9 mM 
liposomes, 0.08 µM histone H1, 0.08 mg per mL ovalbumin, 0.6% glycerol, and 29 pg per µL DGK-theta) 
and incubated at 50°C for five minutes before microfuging to form two distinct phases.  In order to make 
the bottom and top phases more equal in size, I added buffer to dilute the TX-114 to 12% (which adjusted 
the other buffer components to 42 mM HEPES, pH 7.5, 83 mM NaCl, 0.003% (v/v) DDM, 0.6 mM ATP, 
0.9 mM MgCl2, 0.6 mM DTT, 4.7 mM liposomes, 0.06 µM histone H1, 0.06 mg per mL ovalbumin, 0.5% 
glycerol, and 22 pg per µL DGK-theta), incubated on ice for five minutes, mixed, and incubated on ice for 
another five minutes.  I removed aliquots as “before”, then incubated at 50°C for five minutes before 
microfuging to form two phases of approximately equal size.  I separated the phases before ethanol-
precipitating the protein and resuspending in SDS-PAGE gel-loading buffer.  (A) SDS-PAGE of an 8% 
acrylamide gel followed by immunoblotting against DGK-theta (1:350 (v/v)).  B, before; S, supernatant; D, 
detergent phase.  “1”, “2”, and “3” signify three different replicates.  (B) Quantification of the signal in (A).  
I first measured the LI-COR® signal from DGK-theta standards of known concentration, and calculated a 
linear fit to the signal as a function of concentration (Microsoft® Excel®).  The R2 value for this linear fit 
was greater than 0.98.  I then used the linear fit to calculate how much DGK-theta was present in each 
loaded sample based on its LI-COR® signal.  I then used the volume loaded to calculate the concentration, 
and used the total volume of the sample to calculate the total amount of DGK-theta.  (C) The same data of 
the “before” fractions shown in (B), compared to the amount of DGK-theta theoretically loaded. 
 I had only collected enough “before” sample for the one immunoblot, but I still 
had aliquots of samples taken from the separated phases left over.  I therefore subjected 
those samples to SDS-PAGE followed by Coomassie staining in order to confirm that 
appropriate amounts of ovalbumin were recovered in the top phases (consistent with its 
partitioning to the detergent-poor phase in sufficiently high concentration to be efficiently 
recovered from ethanol-precipitation).  On the same gel, I also compared ovalbumin 
standards that either had or had not been ethanol-precipitated, to estimate how much of 
the protein was lost during precipitation.  Comparison of the precipitated and non-
precipitated standards shows that a small but definitely detectable amount of ovalbumin 
was lost at the concentrations tested, although, if anything, less protein was lost at lower 
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concentrations than at higher concentrations (Figure 215A-B), suggesting that sufficient 
carrier protein was present at these concentrations to prevent much protein loss.  
Quantifying the amount of ovalbumin recovered in the pellet was complicated by the fact 
that the signal for all of the pellets was weaker than the lowest concentration of standard 
loaded, requiring extrapolation rather than interpolation, and as a consequence gave 
negative numbers for calculating the amount of ovalbumin in the detergent phase (Figure 
215C), which was clearly incorrect.  However, the recovery of ovalbumin in the top, 
detergent-poor phase was robust: in fact, I calculated more ovalbumin to be in the top 
phase than was theoretically loaded into the entire sample, which was also clearly 
incorrect.   
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Figure 215.  While a small amount of ovalbumin is lost to ethanol-precipitation, most remains in the 
supernatant following TX-114 partitioning.  The same samples immunoblotted in Figure 214A, as well 
as ovalbumin standards that either had or had not been ethanol-precipitated.  (A) SDS-PAGE of an 8% 
acrylamide gel followed by Coomassie staining.  (B) Quantification of the signal in (A).  I scanned the gel, 
sandwiched in a clear binder sheet, as a 1200 dots per inch (dpi) .tiff file.  I measured the densitometry of 
the files by ImageJ68 (v1.46r) without calibration, three times from the file.  I normalized the relative 
densitometry of each lane to the total densitometry of all the lanes on that replicate.  (C) The same data as 
in (B), redisplayed as a proportion of the theoretical amount loaded, and averaged over the three 
densitometry measurements.  Mean ± SD. 
Conclusions 
Although quantitatively measuring ovalbumin’s partitioning was problematic, I 
was able to conclude that most if not all of the ovalbumin was partitioning into the top 
phase, as predicted, and thus sufficient amounts of ovalbumin should have been present 
to serve as a carrier protein to mitigate ethanol-precipitation losses of DGK-theta in the 
top, detergent-poor phase.  As such, the poor recovery of DGK-theta in the top phase, or 
at least the poor reproducibility of recovery of DGK-theta in the top phase (Figure 214), 
suggested that it would be difficult to detect a probe- and UV-dependent decrease of such 
recovery.  I therefore concluded that TX-114 partitioning would not be a very promising 
approach to detect photoaffinity labeling of DGK-theta. 
Probe- and UV-dependent enzymatic inactivation 
Introduction 
 If the photoaffinity labels covalently attached to the active site of DGK, I would 
expect to see probe- and UV-dependent enzymatic inactivation, because the covalently 
attached lipid would occlude the active site.   
Results 
After working out conditions under which I could irradiate DGK-theta with 360 
nm light without inactivating it, I found that when I irradiated DGK-theta in the presence 
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of liposomes containing compound 1, I was unable to detect probe- and UV-dependent 
inactivation (Figure 216).  Under these same reaction conditions (liposome composition 
and concentration, buffer composition, etc.), DGK-theta could use compound 1 as a 
substrate (Figure 140), which suggested that compound 1 was able to access the active 
site including, presumably, the lipid substrate binding site, but was unable to covalently 
attach to DGK-theta in that orientation. 
 
Figure 216.  Compound 1 does not inactivate purified DGK-theta in a probe- and UV-dependent 
way.  DGK activity assay.  I first preincubated purified DGK-theta in preincubation buffer (43 mM 
HEPES, pH 7.5, 0.005% (v/v) DDM, 2 µM histone H1, 1 mM DTT, 43 pg per µL purified DGK-theta, 
1.7% (v/v) glycerol) on ice for ten minutes.  I then diluted into incubation buffer (0.5 mM liposomes 
(2:1::POPE:POPC, 20 mol% POPS, plus the indicated concentration of compound 1), 48 mM HEPES, pH 
7.5, 95 mM NaCl, 0.005% (v/v) DDM, 0.2 µM histone H1, 1 mM DTT, 0.1 mg per mL ovalbumin, 1 mM 
ATP, 1.5 mM MgCl2, 4.3 pg per µL purified DGK-theta, 0.2% (v/v) glycerol) and incubated on ice for 
thirty minutes.  The “ice” samples remained on ice.  I placed the other samples in a 96-well plate, and 
placed aluminum foil over the “foil” samples.  I irradiated the samples with a 360 nm lamp at room 
temperature in a chemical fume hood for 30 minutes.  I returned the samples to Eppendorfs, and measured 
the volume to account for concentration of DGK due to evaporation.  The final DGK activity assay reaction 
included 2 mM substrate-containing liposomes (47.7:23.8:20:8.5::POPE:POPC:POPS:DOG), 0.25 mM 
crosslinking liposomes, 0.25 mM filler liposomes (such that the final liposome composition in the reactions 
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were all the same), 51 mM HEPES, pH 7.5, 101 mM NaCl, 1 mM DTT, 0.005% (v/v) DDM, 1.5 mM 
MgCl2, 1 mM ATP, 30.3 Ci per mmol [γ-32P]-ATP, 0.1 µM histone H1, 0.05 mg per mL ovalbumin, 2.1 pg 
per µL purified DGK-theta, and 0.08% (v/v) glycerol, and proceeded for 15 minutes at 37°C.  In triplicate: 
mean ± SD.   
 I was similarly unable to observe probe- and UV-dependent inactivation of DGK-
theta when irradiated in the presence of compound 3 (Figure 217), likewise under the 
same reaction conditions that I had previously used to show that DGK-theta was able to 
use compound 3 as a substrate (Figure 144).  I also considered the possibility that 
compound 3 might be covalently attaching to the DGK-theta at a site distinct from the 
lipid substrate binding site, such as the C1 domain, and tested whether crosslinking to 
liposomes anchored the protein to the liposomes (if the protein were anchored, I would 
predict to see higher activity in anchoring liposomes that included DAG than anchoring 
liposomes that did not include DAG), but I did not see any such difference (Figure 217).  
Like compound 1, compound 3 is apparently able to access the active site of DGK-theta, 
because DGK-theta is able to use it as a substrate, but does not lead to the probe- and 




Figure 217.  Compound 3 does not inactivate purified DGK-theta in a probe- and UV-dependent 
way, nor does it appear to anchor it to the crosslinking liposomes.    DGK activity assay.  I first 
preincubated purified DGK-theta in preincubation buffer (50 mM HEPES, pH 7.5, 0.005% (v/v) DDM, 0.4 
µM histone H1, 1 mM DTT, 80 pg per µL purified DGK-theta, 1.6% (v/v) glycerol) on ice for ten minutes.  
I then diluted into incubation buffer (0.5 mM liposomes (2:1::POPE:POPC, 20 mol% POPS, plus the 
indicated concentration of compound 3 and DOG) (for the samples with two sets of liposomes, the 
concentration of each set of liposomes was 0.5 mM for a total liposome concentration of 1 mM), 50 mM 
HEPES, pH 7.5, 100 mM NaCl, 0.005% (v/v) DDM, 0.2 µM histone H1, 1 mM DTT, 0.1 mg per mL 
ovalbumin, 1 mM ATP, 1.5 mM MgCl2, 40 pg per µL purified DGK-theta, 0.8% (v/v) glycerol) and 
incubated for thirty minutes, rocking at room temperature.  The “on ice” samples remained on ice.  I placed 
the other samples in a 96-well plate, and placed aluminum foil over the “foil” samples.  I irradiated the 
samples with a 360 nm lamp at room temperature in a chemical fume hood for 30 minutes.  I returned the 
samples to Eppendorfs, and measured the volume to account for concentration of DGK due to evaporation.  
The final DGK activity assay reaction included 2 mM substrate-containing liposomes 
(48:24:20:8::POPE:POPC:POPS:DOG), 0.25 mM crosslinking liposomes, 0.25 mM filler liposomes (such 
that the final liposome composition in the reactions were all the same), 50 mM HEPES, pH 7.5, 100 mM 
NaCl, 1 mM DTT, 0.005% (v/v) DDM, 1.5 mM MgCl2, 1 mM ATP, 42.5 Ci per mmol [γ-32P]-ATP, 0.1 
µM histone H1, 0.05 mg per mL ovalbumin, 20 pg per µL purified DGK-theta, and 0.4% (v/v) glycerol, 
and proceeded for 15 minutes at 37°C.  In triplicate: mean ± SD. 
 The distance of the linker between the photoreactive moiety and the affinity-
conferring moiety has been reported to influence the efficiency of photoaffinity 
labeling164: if the linker is too long, the molecule might bind to its target in the 
appropriate site, but the photoreactive part of the molecule might be too far away from 
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the protein to covalently attach to it.  Because compounds 1 and 3 appeared to be 
accessing the active site (otherwise, they couldn’t be substrates), but did not appear to be 
photoaffinity labeling DGK-theta (since they weren’t producing probe- and UV-
dependent inactivation under those conditions), the Best group designed and sent us 
compound 4 (Figure 146), with a shorter linker between the DAG-like moiety and the 
benzophenone.  With compound 4, I did indeed observe probe- and UV-dependent 
enzymatic inactivation of purified DGK-theta (Figure 218A), as would be predicted by 
covalent attachment to the active site.  This probe- and UV-dependent inactivation was 




Figure 218.  Compound 4 reproducibly enzymatically inactivates purified DGK-theta in a probe- and 
UV-dependent way.  DGK activity assays.  (A) I first preincubated purified DGK-theta in preincubation 
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buffer 1 (50 mM HEPES, pH 7.5, 0.005% (v/v) DDM, 1.25 µM histone H1, 1 mM DTT, 37 pg per µL 
purified DGK-theta, 1.0% (v/v) glycerol) on ice for ten minutes.  I then diluted into incubation buffer (7.5 
mM liposomes (46.7:23.3:20:10::POPE:POPC:POPS:DOG or compound 4), 50 mM HEPES, pH 7.5, 100 
mM NaCl, 0.005% (v/v) DDM, 0.5 µM histone H1, 1 mM DTT, 0.1 mg per mL ovalbumin, 1 mM ATP, 
1.5 mM MgCl2, 15 pg per µL purified DGK-theta, 0.4% (v/v) glycerol) and incubated for thirty minutes, 
rocking at room temperature.  The “on ice” samples remained on ice.  I placed the other samples in a 96-
well plate, and placed aluminum foil over the “foil” samples.  I irradiated the samples with a 360 nm lamp 
on an ice bucket in a chemical fume hood for thirty minutes.  I returned the samples to Eppendorfs, and 
measured the volume to account for concentration of DGK due to evaporation.  The final DGK activity 
assay reaction included 7.5 mM substrate-containing liposomes 
(46.7:23.3:20:10::POPE:POPC:POPS:DOG), 1.5 mM crosslinking liposomes, 1.5 mM filler liposomes 
(such that the final liposome composition in the reactions were all the same), 50 mM HEPES, pH 7.5, 100 
mM NaCl, 1 mM DTT, 0.005% (v/v) DDM, 1.5 mM MgCl2, 1 mM ATP, 30.7 Ci per mmol [γ-32P]-ATP, 
0.1 µM histone H1, 0.02 mg per mL ovalbumin, 3.0 pg per µL purified DGK-theta, and 0.08% (v/v) 
glycerol, and proceeded for thirty minutes at 37°C.  In triplicate: mean ± SD.  (B) The experiment was the 
same as in (A) with the exception that preincubation buffer 2 (50 mM HEPES, pH 7.5, 0.005% (v/v) DDM, 
1.67 µM histone H1, 1 mM DTT, 50 pg per µL purified DGK-theta, 1.3% (v/v) glycerol) was used instead 
of preincubation buffer 1, and in the DGK assay reaction, [γ-32P]-ATP was 89.2 Ci per mmol.  In triplicate: 
mean ± SD. 
 For the largest experiments, I noticed that instead of a UV-dependent inactivation 
of DGK-theta, as I had observed in the smaller experiments (Figure 218), compound 4 
appeared to inactivate DGK-theta even without irradiation (Figure 219).  I therefore 
wondered whether ambient light was causing compound 4 to crosslink to DGK while the 
tubes were sitting during the course of preparing the experiment, because this preparation 
time took longer for larger experiments than for smaller ones.  Benzophenones are 
reported to be more stable in ambient light than other photoreactive molecules such as 
diazirines, aryl azides, or diazo esters165, but they are still photoreactive molecules.  
Although I had thought glass was opaque to ultraviolet (which is why one cannot get 
sunburned indoors, even when sitting in a sunbeam), most glass actually transmits the 
longer UV-A (320 nm – 400 nm) radiation166, which includes the 360 nm wavelength 
used to activate benzophenones.  
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Figure 219.  In large experiments, compound 4 inactivates purified DGK-theta even without UV 
irradiation.  DGK activity assay.  I first preincubated purified DGK-theta in preincubation buffer (50 mM 
HEPES, pH 7.5, 0.005% (v/v) DDM, 2.5 µM histone H1, 1 mM DTT, 75 pg per µL purified DGK-theta, 
1.9% (v/v) glycerol) on ice for ten minutes.  I then diluted into incubation buffer (7.5 mM liposomes 
(2:1::POPE:POPC, 20 mol% POPS, and the indicated concentrations of DOG and compound 4), 50 mM 
HEPES, pH 7.5, 100 mM NaCl, 0.005% (v/v) DDM, 0.5 µM histone H1, 1 mM DTT, 0.1 mg per mL 
ovalbumin, 1 mM ATP, 1.5 mM MgCl2, 15 pg per µL purified DGK-theta, 0.4% (v/v) glycerol) and 
incubated for thirty minutes, rocking at room temperature, protected from light.  The “on ice” samples 
remained on ice.  I placed the other samples in a 96-well plate, and placed aluminum foil over the “foil” 
samples.  I irradiated the samples with a 360 nm lamp on an ice bucket in a chemical fume hood, removing 
timepoints to ice at the indicated times.  I returned the samples to Eppendorfs, and measured the volume to 
account for concentration of DGK due to evaporation.  The final DGK activity assay reaction included 5 
mM substrate-containing liposomes (56.7:28.3:9:6::POPE:POPC:POPS:DOG), 1.5 mM crosslinking 
liposomes, 1.5 mM filler liposomes (such that the final liposome composition in the reactions were all the 
same), 50 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM DTT, 0.005% (v/v) DDM, 1.5 mM MgCl2, 1 mM 
ATP, 63.5 Ci per mmol [γ-32P]-ATP, 0.1 µM histone H1, 0.02 mg per mL ovalbumin, 3.0 pg per µL 
purified DGK-theta, and 0.08% (v/v) glycerol, and proceeded for thirty minutes at 37°C.  In triplicate: 
mean ± SD.   
 I therefore decided to test whether ambient light through the window glass of the 
laboratory was causing compound 4 to crosslink to DGK by comparing the enzymatic 
activity of DGK that had been incubated either with or without compound 4, and then 
either protected from sunlight by aluminum foil or exposed to ambient light through the 
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windows.   Indeed, I observed probe- and ambient light-dependent inactivation of DGK-
theta (Figure 220), at least partially explaining the different degrees of inactivation seen 
in different assays (Figure 218).  The lack of UV-dependent inactivation seen in Figure 
219, therefore, might be explained if all the DGK-theta incubated in the presence of 
compound 4 had already been crosslinked due to the ambient light before exposure to the 
360 nm lamp.  I was therefore careful in all future experiments to protect the probes from 
sunlight at all times.  Most fluorescent light bulbs do not include 360 nm light in their 
spectra167, so I continued working under fluorescent light, such that I would be able to see 
what I was pipetting. 
 
Figure 220.  Compound 4 inactivates DGK-theta in an ambient light-dependent way.  DGK activity 
assay.  The lipids and the “foil” samples were kept either under foil at all times or else with the lights off 
and the shades closed.  I first preincubated purified DGK-theta in preincubation buffer (50 mM HEPES, pH 
7.5, 0.005% (v/v) DDM, 2.5 µM histone H1, 1 mM DTT, 75 pg per µL purified DGK-theta, 1.9% (v/v) 
glycerol) on ice for ten minutes.  I then diluted into incubation buffer (7.5 mM liposomes 
(51.2:25.6:20:3.2::POPE:POPC:POPS:DOG or compound 4), 50 mM HEPES, pH 7.5, 100 mM NaCl, 
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0.005% (v/v) DDM, 0.5 µM histone H1, 1 mM DTT, 0.1 mg per mL ovalbumin, 1 mM ATP, 1.5 mM 
MgCl2, 15 pg per µL purified DGK-theta, 0.4% (v/v) glycerol) and incubated for thirty minutes, rocking at 
room temperature, either under foil or with the lights on and the shades open.  I then placed the samples on 
ice for thirty minutes, either under foil or with the lights on and the shades open.  The final DGK activity 
assay reaction included 5 mM substrate-containing liposomes (56.7:28.3:9:6::POPE:POPC:POPS:DOG), 
1.5 mM crosslinking liposomes, 1.5 mM filler liposomes (such that the final liposome composition in the 
reactions were all the same), 50 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM DTT, 0.005% (v/v) DDM, 1.5 
mM MgCl2, 1 mM ATP, 74.9 Ci per mmol [γ-32P]-ATP, 0.1 µM histone H1, 0.02 mg per mL ovalbumin, 
3.0 pg per µL purified DGK-theta, and 0.08% (v/v) glycerol, and proceeded for thirty minutes at 37°C.  In 
triplicate: mean ± SD. 
 In order to show that the probe was binding to a DAG-specific site, I wanted to 
show that DAG would be able to compete for probe- and UV-dependent inactivation of 
DGK-theta.  In a normal photoaffinity labeling experiment, one would just flood the 
experiment with a vast excess of substrate to show conclusive competition.  For soluble 
substrates, such an option is viable, but since lipids need to be incorporated into a two-
dimensional interface, setting up such a competition experiment is more challenging.  I 
was able to show probe- and UV-dependent inactivation of DGK-theta at the relatively 
high concentration of probe of 3.2 mol%.  The theoretical upper bound of DOG, 
therefore, would be in 3.2 mol% probe, 96.8 mol% DOG liposomes, or at most a 30.3-
fold excess of DOG.  However, the amount of DOG I can incorporate into liposomes is 
also limited.  As previously mentioned, the highest concentration of DOG I have been 
able to successfully incorporate into liposomes is 21 mol%, or only a 6.6-fold excess of 
DOG.  I therefore tested whether I could detect a delay in the timecourse of crosslinking 
by compound 4 to DGK-theta in the presence of competing DOG.  I made a mistake 
during the assay in which I forgot to replace the foil for the foil samples between 5 and 
10 minutes.  I should also note that I was pipetting in the dark for this particular 
experiment, and thus may not have pulled up quite the entire volume while pipetting 
because it was difficult to see, and as such the specific activity of any given sample is 
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possibly underestimated.  I did not see any probe- and UV-dependent inactivation of 
DGK-theta during the first five minutes of the experiment (Figure 221A), so I concluded 
that the foil controls were safe to be used as such, even for timepoints past five minutes.  
I continued to observe probe- and UV-dependent inactivation of DGK-theta, and this 
effect appeared to emerge clearly only after fifteen minutes of irradiation (using a lamp 
that had not been previously warmed up) (Figure 221B).  Including an equimolar amount 




Figure 221.  Compound 4 does not inactivate DGK-theta until after at least fifteen minutes of 
irradiation (using a lamp that had not been previously warmed up), and including an equimolar 
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amount of DOG did not delay the timecourse of inactivation, under the conditions tested.  DGK 
activity assay.  I first preincubated purified DGK-theta in preincubation buffer (50 mM HEPES, pH 7.5, 
0.005% (v/v) DDM, 2.5 µM histone H1, 1 mM DTT, 75 pg per µL purified DGK-theta, 1.9% (v/v) 
glycerol) on ice for ten minutes.  I then diluted into incubation buffer (7.5 mM liposomes 
(2:1::POPE:POPC, 20 mol% POPS, and the indicated concentrations of DOG and compound 4), 50 mM 
HEPES, pH 7.5, 100 mM NaCl, 0.005% (v/v) DDM, 0.5 µM histone H1, 1 mM DTT, 0.1 mg per mL 
ovalbumin, 1 mM ATP, 1.5 mM MgCl2, 15 pg per µL purified DGK-theta, 0.4% (v/v) glycerol) and 
incubated for thirty minutes, rocking at room temperature, protected from light.  The “on ice” samples 
remained on ice.  I placed the other samples in a 96-well plate, and placed aluminum foil over the “foil” 
samples.  I irradiated the samples with a 360 nm lamp on an ice bucket in a chemical fume hood, removing 
timepoints to ice at the indicated times.  I forgot to replace the foil for the foil samples between 5 and 10 
minutes.  After irradiation, I returned the samples to Eppendorfs, and measured the volume to account for 
concentration of DGK due to evaporation.  The final DGK activity assay reaction included 5 mM substrate-
containing liposomes (56.7:28.3:9:6::POPE:POPC:POPS:DOG), 1.5 mM crosslinking liposomes, 1.5 mM 
filler liposomes (such that the final liposome composition in the reactions were all the same), 50 mM 
HEPES, pH 7.5, 100 mM NaCl, 1 mM DTT, 0.005% (v/v) DDM, 1.5 mM MgCl2, 1 mM ATP, 50.8 Ci per 
mmol [γ-32P]-ATP, 0.1 µM histone H1, 0.02 mg per mL ovalbumin, 3.0 pg per µL purified DGK-theta, and 
0.08% (v/v) glycerol, and proceeded for thirty minutes at 37°C.  In triplicate: mean ± SD. 
 By this point, I had used up all of the first batch of compound 4 (due at least in 
part to a large batch of liposomes lost to a bad lot of DOG), and the Best group sent us a 
second batch.  I resuspended the dried down lipid into chloroform, and noticed at that 
time there was quite a lot of what appeared to be dust in the vial.  When I subjected this 
batch to TLC and charred it, I noticed that, as compared to the first batch (Figure 147), 
the main spot migrated closer to the DOG than the previous batch did (Figure 222).  That 
difference, however, could probably be explained in very small changes in experimental 
conditions.  For example, this plate was run in December, whereas the previous plate was 
run in August, which meant the humidity of the room was probably lower.  The amount 
of water that a TLC plate absorbs can affect how molecules interact with it; one way to 
control for that is to first run the plates in hexane and/or heat them, but I did not do that 
for these plates.  Another point of concern is that, as compared to the first batch, this 
second batch produced, in addition to the spot running just before the DOG, a smear 
running near the top of the plate approximately equal in intensity.  This other smear 
might indicate contaminants from the dust or from other byproducts from the synthesis of 
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the probe; on the other hand, because, as mentioned, the humidity of the plate can affect 
TLC migration patterns on it, these other components may have been present in the first 
batch, as well, but comigrated with the main spot under those particular chromatography 
conditions.  I concluded that this batch of compound 4 included two major populations, 
such that the total intensity of the presumed compound 4 spot was consistent with 
perhaps about half the concentration of what it was supposed to be. 
 
Figure 222.  The second batch of compound 4’s concentration is consistent with ~half the advertised 
concentration. After spotting the indicated amounts onto a glass TLC plate, I ran the plate for thirty 
minutes in fresh tank fluid (85:15:5::toluene:chloroform:methanol).  I charred the plate to visualize the 
spots. 
 This second batch of compound 4 likewise produced probe- and UV-dependent 
enzymatic inactivation of DGK (Figure 223). 
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Figure 223.  The second batch of compound 4 inactivates purified DGK-theta in a probe- and UV-
dependent way.  I first preincubated purified DGK-theta in preincubation buffer (50 mM HEPES, pH 7.5, 
0.005% (v/v) DDM, 2.5 µM histone H1, 1 mM DTT, 75 pg per µL purified DGK-theta, 1.9% (v/v) 
glycerol) on ice for ten minutes.  I then diluted into incubation buffer (7.5 mM liposomes 
(2:1::POPE:POPC, 20 mol% POPS, and the indicated concentration of compound 4), 50 mM HEPES, pH 
7.5, 100 mM NaCl, 0.005% (v/v) DDM, 0.5 µM histone H1, 1 mM DTT, 0.1 mg per mL ovalbumin, 1 mM 
ATP, 1.5 mM MgCl2, 15 pg per µL purified DGK-theta, 0.4% (v/v) glycerol) and incubated for half and 
hour, rocking at room temperature, protected from light.  The “on ice” samples remained on ice.  I placed 
the other samples in a 96-well plate, and placed aluminum foil over the “foil” samples.  I irradiated the 
samples with a 360 nm lamp on an ice bucket in a chemical fume hood for thirty minutes.  After irradiation, 
I returned the samples to Eppendorfs, and measured the volume to account for concentration of DGK due 
to evaporation.  The final DGK activity assay reaction included 5 mM substrate-containing liposomes 
(56.7:28.3:9:6::POPE:POPC:POPS:DOG), 1.5 mM crosslinking liposomes, 1.5 mM filler liposomes (such 
that the final liposome composition in the reactions were all the same), 50 mM HEPES, pH 7.5, 100 mM 
NaCl, 1 mM DTT, 0.005% (v/v) DDM, 1.5 mM MgCl2, 1 mM ATP, 98.3 Ci per mmol [γ-32P]-ATP, 0.1 
µM histone H1, 0.02 mg per mL ovalbumin, 3.0 pg per µL purified DGK-theta, and 0.08% (v/v) glycerol, 
and proceeded for thirty minutes at 37°C.  In triplicate: mean ± SD. 
 I therefore repeated the DOG competition timecourse with this new batch of 
compound 4, doubling the concentration of DOG, and taking later timepoints, in the 
hopes of seeing evidence of delayed crosslinking in the samples with competing DOG.  
To simplify this experiment, I irradiated at a high concentration and then diluted for the 
 431 
assay.  Although these timepoint dilutions included 7.5 mM liposomes to provide an 
interface for the DGK, 0.005% DDM, and 0.1 µM histone H1, the resulting activity assay 
was too noisy to be conclusive (Figure 224), possibly because of the small volumes taken 
for the dilutions (which might lead to high variation). 
 
Figure 224.  Small pipetting volumes result in large uncertainty.  DGK activity assay.  I first 
preincubated purified DGK-theta in preincubation buffer (50 mM HEPES, pH 7.5, 0.008% (v/v) DDM, 0.4 
µM histone H1, 1 mM DTT, 1.3 ng per µL purified DGK-theta, 23% (v/v) glycerol) on ice for ten minutes.  
I then diluted into incubation buffer (6.2 mM liposomes (2:1::POPE:POPC, 20 mol% POPS, and the 
indicated concentrations of DOG and compound 4), 55 mM HEPES, pH 7.5, 100 mM NaCl, 0.005% (v/v) 
DDM, 0.1 µM histone H1, 1 mM DTT, 0.1 mg per mL ovalbumin, 1 mM ATP, 1.5 mM MgCl2, 313 pg per 
µL purified DGK-theta, 5.6% (v/v) glycerol) and incubated for thirty minutes, rocking at room temperature.  
I then placed the samples in a 96-well plate, and placed aluminum foil over the “foil” samples.  I irradiated 
the samples with a 360 nm lamp on an ice bucket in a chemical fume hood, removing timepoints to ice at 
the indicated times. After irradiation, I returned the samples to Eppendorfs, and measured the volume to 
account for concentration of DGK due to evaporation.  I then diluted into dilution buffer (0.4 mM 
crosslinking liposomes, 7.5 mM dilution liposomes (53.3:26.7:20::POPE:POPC:POPS), 50 mM HEPES, 
pH 7.5, 85 mM NaCl, 0.005% (v/v) DDM, 0.1 µM histone H1, 1 mM DTT, 7 µg per mL ovalbumin, 71 µM 
ATP, 107 µM MgCl2, 22 pg per µL DGK-theta, 0.4% (v/v) glycerol), and stored on ice protected from light 
until the DGK assay was ready.  The final DGK activity assay reaction included 5 mM substrate-containing 
liposomes (56.7:28.3:9:6::POPE:POPC:POPS:DOG), 18 µM crosslinking liposomes, 50 mM HEPES, pH 
7.5, 100 mM NaCl, 1 mM DTT, 0.005% (v/v) DDM, 1.5 mM MgCl2, 1 mM ATP, 78.4 Ci per mmol [γ-
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32P]-ATP, 0.1 µM histone H1, 0.3 µg per mL ovalbumin, 0.89 pg per µL purified DGK-theta, and 0.02% 
(v/v) glycerol, and proceeded for thirty minutes at 37°C.  In triplicate: mean ± SD. 
 I therefore repeated the experiment, using larger volumes (for greater certainty), 
and increasing the concentration of DOG to 19.2%.  This time, possibly because of the 
larger volumes, I once again observed probe- and UV-dependent inactivation of DGK 
(Figure 225A).  This inactivation was also time-dependent, as would be expected for 
photocrosslinking to the active site.  In fact, this inactivation fit well to a linear fit, as 
would be predicted; on the other hand, inactivation of the samples protected by foil also 
fit well to a linear fit as a function of time (Figure 225B).  I was surprised to see that the 
presence of DOG in the irradiating liposomes did not impair this probe- and UV-
dependent inactivation, as I had predicted for competing at the same site, but actually 
seemed to enhance the inactivation.  One possible explanation for that could be if the 
DOG helped the DGK bind the membrane (for example, by interacting with another 
DOG-binding site besides the active site): if more DGK were targeted to the membrane, I 
would predict that more would encounter the probe, and more would be inactivated. 
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Figure 225.  Compound 4 inactivates purified DGK-theta in a probe-, UV-, and time-dependent way, 
but including DOG does not reduce crosslinking.  DGK activity assay.  I first preincubated purified 
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DGK-theta in preincubation buffer (50 mM HEPES, pH 7.5, 0.005% (v/v) DDM, 2.5 µM histone H1, 1 
mM DTT, 75 pg per µL purified DGK-theta, 1.9% (v/v) glycerol) on ice for ten minutes.  I then diluted into 
incubation buffer (7.5 mM liposomes (2:1::POPE:POPC, 20 mol% POPS, and the indicated concentrations 
of DOG and compound 4), 50 mM HEPES, pH 7.5, 100 mM NaCl, 0.005% (v/v) DDM, 0.5 µM histone 
H1, 1 mM DTT, 0.1 mg per mL ovalbumin, 1 mM ATP, 1.5 mM MgCl2, 15 pg per µL purified DGK-theta, 
0.4% (v/v) glycerol) and incubated for thirty minutes, rocking at room temperature, protected from light.  I 
then placed the samples in a 96-well plate, and placed aluminum foil over the “foil” samples.  I irradiated 
the samples with a 360 nm lamp on an ice bucket in a chemical fume hood, removing timepoints to ice at 
the indicated times.  After irradiation, I returned the samples to Eppendorfs, and measured the volume to 
account for concentration of DGK due to evaporation.  The final DGK activity assay reaction included 5 
mM substrate-containing liposomes (56.7:28.3:9:6::POPE:POPC:POPS:DOG), 1.5 mM crosslinking 
liposomes, 1.5 mM filler liposomes (such that the final liposome composition in the reactions were all the 
same), 50 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM DTT, 0.005% (v/v) DDM, 1.5 mM MgCl2, 1 mM 
ATP, 119 Ci per mmol [γ-32P]-ATP, 0.1 µM histone H1, 0.02 mg per mL ovalbumin, 3.0 pg per µL purified 
DGK-theta, and 0.08% (v/v) glycerol, and proceeded for thirty minutes at 37°C.  In triplicate: mean ± SD. 
The Best group also sent another compound, compound 5 (structure shown in 
Figure 226).  Like compound 4, the fatty chains are attached by ether, not acyl, linkages 
in order to reduce chain migration, and like compound 4, compound 5 includes a shorter 
linker between the DAG-like moiety and photoreactive moiety.  However, unlike 
compounds 1-4, compound 5 used diazirine as the photoreactive component instead of 
benzophenone.  As compared to benzophenones, diazirines have the disadvantages that 
they are less stable in ambient light and that they react preferentially with O-H bonds (as 
in water) over C-H bonds, but diazirines also have the considerable advantage that they 
are much smaller than benzophenones, and would therefore be predicted to interact with 
targets in orientations that might be sterically prohibited with benzophenones.  
Compound 5 arrived as a lipid film, and was yellowish in color and, like the second batch 
of compound 4, there was what appeared to be dust in the vial. 
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Figure 226.  Schematic showing the structure of compound 5. 
 As with the other photoaffinity probes, I first wanted to confirm the concentration 
of compound 5, and confirm that it migrated as a single spot and not a smear, and 
therefore subjected it to TLC.  Because the solvent had been made six days previously, 
the DOG standards’ migration patterned differed from other TLC plates shown, but under 
these conditions, compound 5 migrated as two major populations, with a high-migrating 
smear as the second batch of compound 4 did, with a total intensity that appeared 
consistent with the advertised concentration (Figure 227). 
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Figure 227.  Compound 5’s concentration is consistent with the advertised concentration. After 
spotting the indicated amounts onto a glass TLC plate, I ran the plate for thirty minutes in tank fluid 
(85:15:5::toluene:chloroform:methanol) that had been made six days previously.  I charred the plate to 
visualize the spots. 
 When I irradiated purified DGK-theta in the presence of liposomes containing 
compound 5, under the same conditions that produced probe- and UV-dependent 
inactivation with compound 4, I was unable to observe any probe- and UV-dependent 
inactivation (Figure 228). 
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Figure 228.  Compound 5 does not inactivate DGK in a probe- and UV-dependent way, under the 
conditions tested.  DGK activity assay.  I first preincubated purified DGK-theta in preincubation buffer 
(50 mM HEPES, pH 7.5, 0.005% (v/v) DDM, 2.5 µM histone H1, 1 mM DTT, 75 pg per µL purified DGK-
theta, 1.9% (v/v) glycerol) on ice for ten minutes.  I then diluted into incubation buffer (7.5 mM liposomes 
(2:1::POPE:POPC, 20 mol% POPS, and the indicated concentration of compound 5), 50 mM HEPES, pH 
7.5, 100 mM NaCl, 0.005% (v/v) DDM, 0.5 µM histone H1, 1 mM DTT, 0.1 mg per mL ovalbumin, 1 mM 
ATP, 1.5 mM MgCl2, 15 pg per µL purified DGK-theta, 0.4% (v/v) glycerol) and incubated for thirty 
minutes, rocking at room temperature, protected from light.  I then placed the samples in a 96-well plate, 
and placed aluminum foil over the “foil” samples.  I irradiated the samples with a 360 nm lamp for thirty 
minutes on an ice bucket at 4°C.  After irradiation, I returned the samples to Eppendorfs, and measured the 
volume to account for concentration of DGK due to evaporation.  The final DGK activity assay reaction 
included 5 mM substrate-containing liposomes (56.7:28.3:9:6::POPE:POPC:POPS:DOG), 1.5 mM 
crosslinking liposomes, 1.5 mM filler liposomes (such that the final liposome composition in the reactions 
were all the same), 50 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM DTT, 0.005% (v/v) DDM, 1.5 mM 
MgCl2, 1 mM ATP, 158 Ci per mmol [γ-32P]-ATP, 0.1 µM histone H1, 0.02 mg per mL ovalbumin, 3.0 pg 
per µL purified DGK-theta, and 0.08% (v/v) glycerol, and proceeded for twenty minutes at 37°C.  In 
triplicate: mean ± SD.  The p value between the 6 mol% compound 5 foil vs. UV samples was calculated to 
be 0.134 by one-way analysis of variance (Holm-Sidak method, SigmaPlot 12). 
Mass spectrometry 
 If any of the probes successfully photoaffinity labeled DGK, I would predict that 
the molecular weight of the protein would increase by the mass of the probe.  Such a shift 
is theoretically possible to observe by SDS-PAGE.  Because I was able to observe probe-, 
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UV-, and time-dependent inactivation of DGK-theta in the presence of compound 4, I 
decided to pursue that probe for crosslinking studies.  After irradiating DGK in the 
presence of liposomes containing compound 4, I subjected the samples to SDS-PAGE.  
The band corresponding to DGK-theta was just barely visible by SimplyBlue™ (Life 
Technologies™) staining (Figure 229A), but clearly visible by silver staining (Figure 
229B).  I was unable to detect any probe- and UV-dependent gel shift; on the other hand, 
the resolution of this gel may have been insufficient to detect a 778 Da shift on a ~120 
kD protein.  I ran this gel for the purpose of visualizing the complexity of the sample for 
the mass spectrometry studies; perhaps if I had run the gel longer, I could have achieved 
better resolution. 
 
Figure 229.  No gel shift following crosslinking of purified DGK-theta to compound 4 was detectable 
by SDS-PAGE of a Criterion™ XT (Bio-Rad) 3-8% Tris-Acetate gel, under the conditions tested.  I 
first preincubated purified DGK-theta in preincubation buffer (52 mM HEPES, pH 7.5, 0.02% (v/v) DDM, 
0.4 µM histone H1, 4 mM DTT, 1.3 ng per µL purified DGK-theta, 36% (v/v) glycerol) on ice for ten 
minutes.  I then diluted into incubation buffer (7.5 mM liposomes (2:1::POPE:POPC, 20 mol% POPS, and 
the indicated concentration of compound 4), 50 mM HEPES, pH 7.5, 100 mM NaCl, 0.005% (v/v) DDM, 
0.1 µM histone H1, 1 mM DTT, 0.1 mg per mL ovalbumin, 1 mM ATP, 1.5 mM MgCl2, 306 pg per µL 
purified DGK-theta, 8.8% (v/v) glycerol) and incubated for thirty minutes, rocking at room temperature, 
protected from light.  I then placed the samples in a 96-well plate, and placed aluminum foil over the “foil” 
samples.  I irradiated the samples with a 360 nm lamp for thirty minutes on an ice bucket at 4°C.  SDS-
PAGE of a Criterion™ XT (Bio-Rad) 3-8% Tris-Acetate gel, followed by (A) SimplyBlue™ staining, then 
rinsed and (B) silver stained.  I, ice; F, foil; U, UV. 
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 I excised the bands from lanes 4 and 7 (the samples irradiated with UV), 
destained, washed with methanol, and submitted for LC/MS/MS.  Amino acid coverage 
of the control sample was low (27%), and even lower for the crosslinked sample (22%) 
(Figure 230).  One reason for the lower amino acid coverage could be that if compound 4 
had covalently attached to the protein, the resulting peptides would have a greater 
hydrophobicity, which can make the labeled peptides difficult to extract from the gel 
matrix168.  Certain adjacent tryptic peptides were disproportionately absent from the 
crosslinked sample as compared to the control sample.  For example, 
ARPGPGPGPGPER was found six times in the control peptide, APGPAAAPGHSFR 
was found eleven times, and IPCTSVAPSLVRVPVAHCFGPR was found three times.  
Of these peptides, ARPGPGPGPGPER and IPCTSVAPSLVRVPVAHCFGPR were 
found in the crosslinked sample, but APGPAAAPGHSFR was not, even though it was 
the most abundant in the control sample.  If peptides were covalently modified with 
compound 4, I would predict them to be disproportionately absent from the crosslinked 
sample, either because the mass of the crosslinked peptide had been shifted and thus no 
longer appeared as the unmodified mass, or else because the crosslinked peptide 
remained in the gel matrix.  I found two such disproportionately absent peptides in these 
samples, and, even more encouragingly, both coincided with regions of the protein 
predicted by primary sequence homology to include DAG-binding sites.  While the 
presence of such disproportionately absent peptides was encouraging, any such 
subtractive analysis must be used cautiously. 
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Figure 230.  Amino acid coverage of in-gel trypsin-digested DGK crosslinked with compound 4 is 
low, but certain peptides are disproportionately absent in the crosslinked as compared to control 
sample.  I excised the bands from lanes 4 and 7 (the samples irradiated with UV) as well as a control 
region of the gel shown in Figure 229, destained, washed with methanol, and submitted for LC/MS/MS.  
The samples were digested in-gel with trypsin.  Peptides were removed from the gel and fractionated by 
reverse-phase HPLC (Magic C18AQ), and eluting peptides were sprayed directly into an LTQ Orbitrap 
Velos.  Peptide sequences were identified from isotopically resolved masses in MS and MS/MS spectra 
using Mascot169 and Proteome Discoverer170.  Amino acid coverage of DGK subjected to LC/MS/MS 
following irradiation in the presence of liposomes of the composition shown.  Detected peptides are 
highlighted in yellow.  Peptides disproportionately absent in the sample with compound 4 are marked in 
red.  The three C1 domains and the catalytic domain of DGK, which are predicted to contain DAG-binding 
sites, are shaded in blue and green, respectively.  Oxidized sites are marked in bright green.   
 I therefore repeated the crosslinking experiment, to see whether the same peptides 
would be disproportionately absent.  This time, the samples were digested in-solution, so 
that crosslinked peptides would not be left behind in any polyacrylamide gel matrix.  This 
time, I also assayed the DGK activity of the samples.  I once again observed probe-
dependent inactivation of DGK activity (Figure 231A).  Amino acid coverage of the in-
solution digested samples was indeed improved as compared to the in-gel samples, 
including the control samples (Figure 231B), suggesting that the improvement may have 
been due to factors other than increased hydrophobicity conferred by the attachment of 
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compound 4’s anchoring the protein in the gel matrix.  The APGPAAAPGHSFR and 
EEEPGKFTSR peptides were once again absent in the crosslinked sample, consistent 
with covalent attachment on this peptide and consequent mass shift of the peptide, but 
coverage in those regions of the protein was just generally poor, so that peptides could 
not be said to be disproportionately absent.  A new peptide, IAQGSYFR, also in the 
catalytic domain, was disproportionately absent in the crosslinked as compared to the 
control samples.  However, when the set of masses was searched for masses consistent 




Figure 231.  Amino acid coverage of in-solution trypsin-digested DGK crosslinked with compound 4 
is somewhat improved, and certain peptides are once again disproportionately absent in the 
crosslinked as compared to control sample.    (A) DGK activity assay.  I first preincubated purified 
DGK-theta in preincubation buffer (50 mM HEPES, pH 7.5, 0.005% (v/v) DDM, 0.4 µM histone H1, 1 
mM DTT, 875 pg per µL purified DGK-theta, 25% (v/v) glycerol) on ice for ten minutes.  I then diluted 
into incubation buffer (7.5 mM liposomes (2:1::POPE:POPC, 20 mol% POPS, and the indicated 
concentration of compound 4), 50 mM HEPES, pH 7.5, 100 mM NaCl, 0.005% (v/v) DDM, 0.1 µM 
histone H1, 1 mM DTT, 0.1 mg per mL ovalbumin, 1 mM ATP, 1.5 mM MgCl2, 204 pg per µL purified 
DGK-theta, 5.9% (v/v) glycerol) and incubated for thirty minutes, rocking at room temperature, protected 
from light.  I then placed the samples in a 96-well plate, and irradiated the samples with a 360 nm lamp for 
thirty minutes on an ice bucket at 4°C.  After irradiation, I returned the samples to Eppendorfs, and 
measured the volume to account for concentration of DGK due to evaporation.  I then diluted into dilution 
buffer (50 mM HEPES, pH 7.5, 0.5 µM histone H1, 0.005% (v/v) DDM, 1 mM DTT, 1 mM dilution 
liposomes (53.3:26.7:20::POPE:POPC:POPS:DOG), 0.003 mg per mL ovalbumin, 29 µM ATP, 43 µM 
MgCl2, 11 mM NaCl, 5.8 pg per µL purified DGK-theta, 0.17% (v/v) glycerol).  The final DGK activity 
assay reaction included 5 mM substrate-containing liposomes (56.7:28.3:9:6::POPE:POPC:POPS:DOG), 
43 µM crosslinking liposomes, 43 µM filler liposomes (such that the final liposome composition in the 
reactions were all the same), 50 mM HEPES, pH 7.5, 98 mM NaCl, 1 mM DTT, 0.005% (v/v) DDM, 1.5 
mM MgCl2, 1 mM ATP, 24.0 Ci per mmol [γ-32P]-ATP, 0.1 µM histone H1, 0.02 mg per mL ovalbumin, 
3.0 pg per µL purified DGK-theta, and 0.08% (v/v) glycerol, and proceeded for twenty minutes at 37°C.  In 
triplicate: mean ± SD.  I calculated a p value comparing 0% compound 4 + DGK to 6.4% compound 4 + 
DGK to be < 0.021 by one-way analysis of variance (Holm-Sidak method, SigmaPlot 12).  (B) Amino acid 
coverage of DGK subjected to LC/MS/MS following irradiation in the presence of liposomes of the 
composition shown.  Aliquots of samples were removed prior to dilution into dilution buffer, digested in-
solution with trypsin, and fractionated by reverse-phase HPLC (Magic C18AQ), and eluting peptides were 
sprayed directly into an LTQ Orbitrap Velos.  Peptide sequences were identified from isotopically resolved 
masses in MS and MS/MS spectra using Mascot169 and Proteome Discoverer170.  Detected peptides are 
highlighted in yellow.  Peptides disproportionately absent in the sample with compound 4 are marked in 
red.  The three C1 domains and the catalytic domain of DGK, which are predicted to contain DAG-binding 
sites, are shaded in blue and green, respectively.  Oxidized sites are marked in bright green.  The same 
peptide disproportionately absent following in-gel trypsin digestion (Figure 230) was also absent, but 
because amino acid coverage was generally poor in this region of the protein, it could not be said to be 
disproportionately absent. 
 I therefore wondered whether the probe was fragmenting during the course of the 
LC/MS/MS, such that any labeled peptides would be shifted not by the full 778 Da, but 
by the mass of a fragment of the probe.  Before doing mass spectrometry on compound 4, 
I first tested its solubility in several solvents commonly used in mass spectrometry of 
lipids171–175 to see which ones were appropriate for testing the fragmentation pattern of 
compound 4.  I therefore either spotted compound 4 directly from the vial, or else 
resuspended it in each of the solvents to be tested, then spotted onto a TLC plate and 
visualized how much had made it on to the plate by charring.  I found that compound 4 
appeared quite soluble in chloroform and in 1:2::chloroform:methanol, pretty soluble in 
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20:40:3:chloroform:methanol:1 M aqueous ammonium acetate, somewhat soluble in 
acetonitrile, only slightly soluble in 70:30::acetonitrile:water, and not at all soluble in 
75:25::methanol:acetonitrile (Figure 232).  Caution must be used when using acetonitrile 
as a solvent, because it dissolves the adhesive between the polytetrafluoroethylene lining 
and the cap of the vials we use for lipids.  Compound 4 is also somewhat soluble in 
methanol (Figure 232).  I concluded that chloroform should be an adequate solvent for 
resuspending compound 4 for loading into the mass spectrometer.  While compound 4 
was not completely soluble in methanol, some of it definitely partitioned into the 
methanol, so as long as the amount of probe loaded was well above the detection limit of 
the instrument, methanol should likewise be a suitable solvent for resuspending 
compound 4 for loading into the mass spectrometer.   
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Figure 232.  The solubility of compound 4 among solvents varies.  TLC of compound 4 resuspended in 
different solvents, run in freshly made 85:15:5::toluene:chloroform:methanol, dried, sprayed with 40% 
sulfuric acid, and charred. 
 When compound 4 was resuspended in 53 mM ammonium formate in methanol 
and scanned in positive ion mode on a AB Sciex 4000 Q Trap spectrum, it gave a 
predominant peak at 987.2 Da (Figure 233).  The predicted peak at 778 Da was very 
small, no greater than noise, even though at a concentration of 100 µg per mL the 
molecule should be clearly detectable.  The lack of detection was probably not a problem 
with the instrument: the spectra we observed 23 May 2013 (Figure 233A) are well 
reproduced by the spectra we observed 30 May 2013 (Figure 233B), and the Haughey lab 
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had used the instrument several times in the intervening week with no reported problems 
with their other samples.  
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Figure 233.  When the second batch of compound 4 is subjected to LC/MS/MS, it produces a peak at 
987 Da, not at the predicted molecular weight of 778 Da.  AB Sciex 4000 Q Trap spectrum of the probe 
(100 µg per mL) in 53 mM ammonium formate in methanol in positive ion mode.  (A) Spectrum measured 
23 May 2013.  (B) Spectrum measured 30 May 2013. 
 Although compound 4 was mostly soluble in methanol (Figure 232), such that, 
even if not all of the probe partitioned into the methanol, surely enough should have at 
100 µg per mL to be detectable, I wondered whether changing the solvent to chloroform 
would increase the amount of the 778 Da peak detected.  When we scanned the probe in 
53 mM ammonium formate in chloroform, however, we observed the same predominant 
peak at 987.5 Da (Figure 234).  I therefore concluded that the lack of detection of a 778 
Da peak was probably not a problem with the molecule’s solubility in methanol. 
 
Figure 234.  Using 53 mM ammonium formate in chloroform as a solvent does not increase the 
proportion of the 778 Da peak during LC/MS/MS of compound 4.  AB Sciex 4000 Q Trap spectrum of 
the probe (100 µg per mL) in 53 mM ammonium formate in chloroform (1% methanol), in positive ion 
mode. 
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The spectrum of just 53 mM ammonium formate in methanol (Figure 235A) also 
showed the 987 peak, although not as high an amplitude as in the probe scans.  This peak 
was not seen in a scan of methanol alone (Figure 235B), so can probably be attributed to 
the 53 mM ammonium formate (and is probably contributing to the 987.5 peak seen in 
Figure 233 and Figure 234).  An alternative explanation is that the 53 ammonium formate 
in methanol sample was confused with the compound 4 dissolved in 53 ammonium 
formate in methanol sample. 
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Figure 235.  The 987.5 Da peak also appears in LC/MS/MS scans of 53 mM ammonium formate in 
methanol, but not of methanol alone.  AB Sciex 4000 Q Trap spectrum in positive ion mode of (A) 53 
mM ammonium formate in methanol and (B) methanol.   
 Although some of the 987.5 Da peak was probably coming from the ammonium 
formate (unless the samples were mixed up), the fact that the amplitude is higher in the 
scans with probe (Figure 233 and Figure 234) suggested that at least some of the 
amplitude of the peak came from compound 4 (or contaminants from the vial containing 
compound 4).  987.4 Da is the molecular weight that would be predicted for compound 4 
were another benzophenone attached via a ketone linkage (as in Figure 236A).  I am not 
familiar with the synthesis used to produce compound 4, so I am not sure how plausible 
this structure is as a synthetic byproduct, but it seemed promising, because such a 
contaminant could conceivably explain why, even if there were no compound 4 present, I 
reproducibly observed probe- and UV-dependent inactivation of DGK, seeing as this 
structure still has the DAG-like part of the molecule to target it to the enzyme, and a 
photoactivatable crosslinker (in fact, three).  When we fragmented the 987.5 Da peak, the 
fragmentation spectrum (Figure 236B) showed a product at 745.7 Da.  A product ion size 
of 745.7 Da was very promising because not one but two plausible fragments of the 
structure proposed in Figure 236A would be predicted to have a molecular weight of 
746.0 Da (Figure 236C).  These product ions are plausible because cleavage at branch 
points, such as in Figure 236C, produces more stable carbocations, due to 
hyperconjugation and inductive effects, and more stable cations will be more prevalent in 
product ion spectra.  On the other hand, when the (albeit smaller in amplitude) 987 peak 
from the solvent alone was likewise fragmented, it also produced a 745.7 Da fragment.  
(We forgot to save that scan, so I cannot include it as a figure.)  Unless the ammonium 
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formate bottle were somehow contaminated by the probe, or unless the samples were 
mixed up, it seems exceedingly unlikely that it would have a molecule of the same 
molecular weight and same fragmentation pattern in it. 
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Figure 236.  The 987 Da peak’s size and fragmentation pattern is consistent with compound 4 with an 
additional benzophenone added via a ketone linkage.  (A) Structure of compound 4 with an additional 
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benzophenone added via a ketone linkage.  Its predicted molecular weight is 987.4 Da.  (The additional 
keto-benzophenone could be added at any location of the molecule and the total predicted molecular weight 
would remain 987.4 Da.)  (B) Fragmentation spectrum of the 987.5 peak from the AB Sciex 4000 Q Trap 
spectrum of the probe (100 µg per mL) in 53 mM ammonium formate in methanol in positive ion mode 
(shown in Figure 233B).  (C) Structure of proposed fragments from the 987 peak, if they derived from the 
structure shown in (A). 
 To be thorough, we also checked the spectrum of the probe in negative ion mode, 
but there were no additional peaks seen in the probe spectrum (Figure 237A) that were 
not seen in the solvent spectrum (Figure 237B).   
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Figure 237.  The scan of compound 4 in negative ion mode shows no additional peaks over solvent 
alone.  (A) AB Sciex 4000 Q Trap spectrum of the probe (100 µg per mL) in 53 mM ammonium formate in 
methanol in negative ion mode.  (B) AB Sciex 4000 Q Trap spectrum of 53 mM ammonium formate in 
methanol in negative ion mode. 
 I was therefore left with two possible conclusions.  The first hypothesis was that 
the Best group had sent us not compound 4 but rather the molecule shown in Figure 
236A, which would explain the predominant peak of 987.5 Da (Figure 233 and Figure 
234) whose product ion is 745.7 Da (Figure 236).  Challenges to this hypothesis include 
the fact that the Best group reported MALDI spectra of the probe they sent us to be 
consistent with the predicted molecular weight, the predicted molecular weight plus a 
proton, and the predicted molecular weight plus a sodium ion, as well as the fact that the 
methanol plus ammonium formate also gave a predominant peak of 987.5 Da (Figure 
235A) whose product ion is 745.7 Da.  In order to reconcile this hypothesis, then, not 
only would the Best lab had to have mixed up the samples when they did the MALDI, but 
we would also have to have mixed up the samples when we did the LC/MS/MS of the 
methanol plus ammonium formate solvent only scan.  Furthermore, because I am not 
familiar with the synthesis of compound 4, the alternate structure may or may not be a 
plausible alternative product. 
 The second hypothesis was that the probe sent to us started off as compound 4, 
but, in the time between when the Best group synthesized it and the time we subjected it 
to LC/MS/MS, something happened to it, consistent with its being a photoreactive 
molecule, which would explain the Best group’s MALDI spectra.  Challenges to this 
hypothesis include the fact that we did not detect any LC/MS/MS peaks of 1556, as 
would be expected if two molecules of compound 4 crosslinked to one another, and that I 
did not see any smearing on the TLC plate (Figure 232), as might be predicted if the 
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compound had linked to itself many times, or indeed any major differences between how 
the molecule migrated on TLC shortly after it arrived (Figure 222) as compared to how it 
migrated at the time we were unable to detect a 778 Da peak by LC/MS/MS (Figure 232), 
as might be predicted for chemical modification.  On the other hand, as we had 
previously observed, small changes in humidity may affect how molecules migrate on 
TLC, making the different TLC plates difficult to compare. 
 I therefore wrote to the Best group asking them to send us fresh compound 4, in 
case something had happened to the second batch.  They very kindly sent us a third batch, 
once again confirming the molecular weight by MS (Figure 238).  This batch arrived 
wrapped in aluminum foil, but also included what appeared to be dust, hair, and broken 
glass in the vial.  I once again confirmed the concentration and migration pattern by TLC.  
As before, compound 4 migrated as a single spot whose total intensity was consistent 
with that of the predicted molecular weight (Figure 239), consistent with the batch not 
being a smear of probe crosslinked to itself.  Unlike the previous batches (Figure 147 and 
Figure 222), however, which migrated faster than the DOG standards, this batch of 
compound 4 migrated more slowly than the DOG standards (Figure 239), even though 
the same solvent systems, lot number of DOG, and brand of TLC plate were used.  This 
discrepancy in TLC migration might be evidence that this batch of compound 4 is, in 
fact, a different molecule from the previous batches, consistent with the first hypothesis 
aired in the penultimate paragraph; on the other hand, it might merely reflect 
inconsistencies in humidity and how much water the plate had absorbed. 
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Figure 238.  The mass spectrum of the third batch of compound 4, as measured by the Best lab, is 
consistent with its predicted molecular weight.  MS spectra performed by Best group on the third batch 
of compound 4.   
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Figure 239.  The third batch of compound 4 migrates differently on TLC than the previous two 
batches, but its concentration is consistent with what was advertised.  TLC of the third batch of 
compound 4 as compared to DOG standards, run in an 85:15:5::toluene:chloroform:methanol solvent 
system, dried, sprayed with 40% (v/v) sulfuric acid, and charred. 
 In order to confirm the molecular weight of the new batch of compound 4, I 
submitted it to LC/MS/MS, as I had with the previous batch.  This time, a peak of 779.0 
Da, consistent with the predicted molecular weight of 778 Da, was easily detectable in 
positive ion mode, and the corresponding peak of 777 Da was easily detectable in 
negative ion mode (Figure 240).  The 779.0 Da peak gave a product ion of 536.7 Da 
(Figure 241A), consistent with the predicted molecular weight of 536.7 Da of not one but 
two plausible fragment structures (Figure 241B).  In fact, these are the very fragments 
that correspond to the fragments proposed for the second batch of compound 4 shown in 
Figure 236C, possibly providing more evidence that, if these kinds of molecules are 
likely to fragment at the ether linkage, the second batch of compound 4 really was the 
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molecule shown in Figure 236A.  From the LC/MS/MS spectra of the third batch of 
compound 4, though, I concluded that this batch, was, indeed, predominantly compound 
4, and that under at least these LC/MS/MS conditions, it fragmented to produce a 536.7 
Da piece.  This piece retains the benzophenone moiety, so a peptide that had been 
modified by compound 4 might, after LC/MS/MS, be modified by a mass addition of 
536.7 Da, not 778 Da.  I therefore asked for the data we had already collected, from the 
mass spectrometry experiment shown in Figure 231B, to be searched for peptides with a 
shifted mass of 536.7 Da, in case the second batch really was compound 4 and just had 
something happen to it between that experiment and the LC/MS/MS shown in Figure 233 
- Figure 237.  No such mass shifts were found.  In case the second batch of compound 4 
was really the structure shown in Figure 236A, I also asked for the data to be searched for 
a peptides with a shifted mass of either 985.7 Da, the size of the structure with the 
additional keto-benzophenone, and 744.4 Da, the size of the product ion.  No such mass 
shifts were found. 
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Figure 240.  The third batch of compound 4 produces peaks in positive and negative ion mode in 
LC/MS/MS consistent with its predicted molecular weight.  AB Sciex 4000 Q Trap spectrum of the 
third batch compound 4 (66.7 µg per mL) in 2:l::methanol:chloroform in (A) positive ion mode, and (B) 
negative ion mode.   
 
Figure 241.  The product ion of the 779 Da LC/MS/MS peak of the third batch of compound 4 is 
consistent with two plausible fragment structures.  (A) The product ion from the 779 Da peak shown in 
Figure 240A.  (B) Proposed fragment structures for the product ion shown in (A). 
 There are a number of possible explanations for why we did not observe the mass 
shifts in question.  One could be, of course, that compound 4 is not, in fact, covalently 
attaching to DGK-theta, even though the probe-, UV-, and time-dependent inactivation of 
DGK-theta, as well as the disproportionate absence of certain peptides in the crosslinked 
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vs. control samples, are all consistent with such covalent attachment.  Another could be 
that compound 4 is attaching to part of the protein from which peptides were not detected 
by LC/MS/MS: the amino acid coverage is, after all quite low.  Another explanation 
could be that the covalent attachment of compound 4 (or a fragment thereof) causes the 
covalently modified peptides to be too hydrophobic to elute from the Magic C18AQ 
column, and thus the peptides never made it into the mass spectrometer.  Yet another 
explanation could be that the modified peptides were filtered out of the collected data 
because their isotopic distribution was insufficiently peptide-like. 
 I thought that perhaps the process of incorporating compound 4 into liposomes 
might chemically modify it (by oxidation, etc.) (which would mean the mass shift we 
would expect to see after photoaffinity labeling might be different than the mass shift 
produced by LC/MS/MS of compound 4 dissolved into 2:l::methanol:chloroform), but I 
also thought that the standard composition of liposomes used in the activity assay 
(2:1::POPE:POPC) would complicate the MS spectrum beyond interpretation.  I therefore 
tried to make 100% compound 4 liposomes from the third batch for LC/MS/MS analysis: 
however, the lipid film of compound 4 never uniformly resuspended into the liposome 
resuspension buffer (50 mM HEPES, 100 mM NaCl, pH 7.5, 1 mM DTT), even after 
continuously bath sonicating for more than two hours.  I was therefore unable to make 
100% compound 4 liposomes, so was unable to perform LC/MS/MS on compound 4 in 
the chemical environment more relevant to the protein crosslinking experiments. 
 When I tested whether this third batch of compound 4 still produced probe- and 
UV-dependent inactivation of DGK, however, I did not observe the probe- and UV-
dependent inactivation of DGK-theta I had observed with the previous two batches 
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(Figure 242).  I had made the sample volume in this experiment large enough that I could 
remove aliquots to look for a potential gel-shift, by both immunoblotting and silver 
staining, and to repeat the mass spectrometry, looking for peptide shifts of the appropriate 
size.  As such, I had irradiated at a high concentration and then diluted for the assay, as in 
the experiment shown in Figure 224.  However, I used larger volumes for the dilution, 
which may explain while the uncertainty is lower here than in Figure 224.  Figure 224 
was too noisy to be conclusive; contrariwise, the uncertainty in Figure 242 is low enough 
that I can say with confidence that this batch of compound 4 did not inactivate DGK-
theta in a probe- and UV-dependent way.  In this experiment, compound 4 appeared to 
activate DGK-theta, as compounds 1 (Figure 136) and 3 did (Figure 143), but as I had not 
observed with the previous batches of compound 4 (Figure 148, Figure 218-Figure 221, 
Figure 223; some of those might be complicated by the fact that ambient light may have 
been inactivating DGK-theta and balancing any activation by compound 4, but in Figure 
220 on I took precautions to protect the liposomes from sunlight).  Thinking perhaps that 
the pipets had lost their calibration, and the different samples had different volumes of 
diluted irradiated enzyme, I checked the calibration of my pipets.  I found that while the 
calibration of the P2 pipet was off, it was only off by about 10% (Table 3), which would 
not be enough to account either for why compound 4 failed to inactivate DGK-theta in a 
UV-dependent way (previous batches inactivated DGK-theta approximately 50%), or 
why compound 4 now appeared to activate DGK-theta by approximately 100%. 
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Figure 242.  The third batch of compound 4 does not show probe- and UV-dependent inactivation of 
purified DGK-theta under the conditions tested.  DGK activity assay.  I first preincubated purified 
DGK-theta in preincubation buffer (50 mM HEPES, pH 7.5, 0.005% (v/v) DDM, 0.3 µM histone H1, 1 
mM DTT, 996 pg per µL purified DGK-theta, 17% (v/v) glycerol) on ice for ten minutes.  I then diluted 
into incubation buffer (7.5 mM liposomes (2:1::POPE:POPC, 20 mol% POPS, and the indicated 
concentration of compound 4), 50 mM HEPES, pH 7.5, 100 mM NaCl, 0.005% (v/v) DDM, 0.1 µM 
histone H1, 1 mM DTT, 0.1 mg per mL ovalbumin, 1 mM ATP, 1.5 mM MgCl2, 307 pg per µL purified 
DGK-theta, 5.1% (v/v) glycerol) and incubated for thirty minutes, rocking at room temperature, protected 
from light.  I then placed the samples either on ice or in a 96-well plate, and irradiated the samples with a 
360 nm lamp for thirty minutes on an ice bucket at 4°C (“foil” samples had aluminum foil between the 
samples and the lamp).  After irradiation, I returned the samples to Eppendorfs, and measured the volume 
to account for concentration of DGK due to evaporation.  I then diluted into dilution buffer (50 mM 
HEPES, pH 7.5, 0.5 µM histone H1, 0.005% (v/v) DDM, 1 mM DTT, 1 mM dilution liposomes 
(53.3:26.7:20::POPE:POPC:POPS:DOG), 0.003 mg per mL ovalbumin, 29 µM ATP, 43 µM MgCl2, 11 
mM NaCl, 8.8 pg per µL purified DGK-theta, 0.15% (v/v) glycerol).  The final DGK activity assay reaction 
included 5 mM substrate-containing liposomes (56.7:28.3:9:6::POPE:POPC:POPS:DOG), 43 µM 
crosslinking liposomes, 43 µM filler liposomes (such that the final liposome composition in the reactions 
were all the same), 50 mM HEPES, pH 7.5, 98 mM NaCl, 1 mM DTT, 0.005% (v/v) DDM, 1.5 mM 
MgCl2, 0.8 mM ATP, 35.7 Ci per mmol [γ-32P]-ATP, 0.1 µM histone H1, 0.0006 mg per mL ovalbumin, 
1.8 pg per µL purified DGK-theta, and 0.03% (v/v) glycerol, and proceeded for thirty minutes at 37°C.  In 
triplicate, except for the 6.4% compound 4 plus foil sample, where I accidentally scrapped the silica of the 
TLC plate from two of the lanes into the same vial, and which I have therefore omitted, and am showing 
the remaining singlicate.  Mean ± SD.  
 
 466 
Pipet Volume measured (µL) Mass (g) Discrepancy (%) 
P1000 1000 1.0125 1.25 
P200 200.0 0.1989 -0.55 
P100 100.0 0.1008 0.8 
P20 20.00 0.0199 -0.5 
P2 2.000 0.0022 10 
Table 3.  Errors in pipet calibration are not large enough to explain why the third batch of 
compound 4 did not inactivate purified DGK-theta in a probe- and UV-dependent way.  Pipet 
calibration.  I measured the indicated volume of ddH2O onto a weighboat and measured its mass using an 
analytical balance. 
 I therefore repeated the crosslinking experiment to see whether the results were 
anomalous.  As mentioned, the experiment shown in Figure 242 required more 
concentrated protein, so I had used a new batch of purified DGK-theta.  I therefore 
compared the two batches of DGK-theta, and the second and third batch of compound 4.  
I also used larger volumes to reduce any variance from pipetting.  I found that while the 
new batch of enzyme had a greater specific activity than the old batch, neither one 
showed UV- and probe-dependent inactivation, even for the second batch of compound 4 
(Figure 243).  Nor did I observe activation, as I did in the previous experiment (Figure 
242).  However, both also showed inactivation in the foil control (Figure 243), suggesting 
the possibility that either or both batches of probe might be inactivating the enzyme in a 
UV-dependent way that is masked by the inactivation caused by incubating the enzyme 
under the UV lamp, with or without foil.  As previously mentioned, variables that might 
be contributing to this inactivation under foil include the distance between the lens of the 
lamp and the 96-well plate (by a few centimeters at most), the angle of the lamp (by 
several degrees at most), the volume of sample in the well (although I measured the 
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volumes before and after irradiation, and I took the concentration caused by evaporation 
into account when calculating the specific activity of the enzyme), the time that DGK 
was thawed before it was irradiated, and the time that elapsed between the DGK was 
irradiated and the time it was assayed.  As previously mentioned, future directions 
include testing the reducing agent requirement explicitly, as well as acquiring a UV LED, 
and testing whether using that as a photon source reduces inactivation of DGK. 
 
Figure 243.  Batch 3 of compound 4 does not inactivate either batch of purified DGK-theta in a UV- 
and probe-dependent way, but neither does batch 2 anymore.  DGK activity assay.  227B and 323 are 
two different batches of purified DGK-theta.  I incubated purified DGK-theta in preincubation buffer (for 
227B, 48 pg per µL purified DGK and 1.2% (v/v) glycerol; for 323, 120 pg per µL purified DGK and 2.0% 
(v/v) glycerol) on ice for ten minutes.  I then diluted into irradiation buffer (0.4% (v/v) glycerol, 0.005% 
(v/v) DDM, 1 mM DTT, 0.5 µM histone H1, 50 mM HEPES, pH 7.4, 100 mM NaCl, 0.1 mg per mL 
ovalbumin, 1 mM ATP, 1.5 mM MgCl2, 7.5 mM liposomes (2:1::POPE:POPC, 20 mol% POPS, and the 
indicated concentration of the indicated batch of compound 4)), and incubated for thirty minutes, rocking at 
room temperature, protected from light.  I then placed the samples either on ice or in a 96-well plate, and 
irradiated the samples with a 360 nm lamp for thirty minutes on an ice bucket at 4°C (“foil” samples had 
aluminum foil between the samples and the lamp).  After irradiation, I returned the samples to Eppendorfs, 
and measured the volume to account for concentration of DGK due to evaporation.  The final DGK assay 
reaction mixture included 5 mM substrate-containing liposomes (56.7:28.3:9:6::POPE:POPC:POPS:DOG), 
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1.5 mM incubation liposomes, 1.5 mM filler liposomes (such that the final liposome composition in the 
reactions were all the same), 50 mM HEPES, pH 7.4, 100 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 20.9 Ci 
per mmol [γ-32P]-ATP, 0.1% (v/v) glycerol, 0.005% (v/v) DDM, 0.1 µM histone H1, 0.02 mg per mL 
ovalbumin, 1 mM DTT, and 3.0 pg per µL purified DGK, and proceeded for 30 minutes at 37°C.  In 
triplicate: mean ± SD.   
 The 365 nm peak wavelength UV LED flashlight did not inactivate purified 
DGK-theta even after sixty minutes of irradiation (Figure 116), but neither did it provide 
probe- and UV-dependent inactivation of purified DGK-theta using the third batch of 
compound 4.  One possible explanation for why Figure 244 does not reproduce the 
results of Figure 218, Figure 220, Figure 221B, Figure 223, Figure 225, and Figure 231A 
could be that the UV LED flashlight does not produce sufficient photon flux.  Another 
explanation is that batch 2 and batch 3 are in fact different molecules (an interpretation 
supported by Figure 147, Figure 222, Figure 233, Figure 236, and Figure 239-Figure 
241), and the molecule whose structure is shown in Figure 236A is able to probe-, UV-, 
and time-dependently inactivate DGK, while compound 4 is not.  In order to distinguish 
between these two explanations, the next logical experiment would be to test whether the 
UV LED flashlight could reproduce probe- and UV-dependent inactivation of purified 
DGK-theta using the second batch of compound 4. 
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Figure 244.  Batch 3 of compound 4 does not cause probe-, UV LED-dependent inactivation of 
purified DGK-theta.  DGK activity assay.  I incubated purified DGK-theta in preincubation buffer (50 
mM HEPES, pH 7.5, 0.005% (v/v) DDM, 0.5 µM histone H1, 3 mM BME, 176 pg per µL purified DGK, 
5.1% (v/v) glycerol) on ice for ten minutes.  I then diluted into irradiation buffer (35 pg per µL DGK, 1.0% 
(v/v) glycerol, 0.005% (v/v) DDM, 3 mM BME, 0.1 µM histone H1, 50 mM HEPES, pH 7.4, 100 mM 
NaCl, 0.1 mg per mL ovalbumin, 1 mM ATP, 1.5 mM MgCl2, 7.5 mM liposomes (2:1::POPE:POPC, 20 
mol% POPS, and the indicated concentration of the third batch of compound 4)), and incubated for thirty 
minutes, rocking at room temperature, protected from light.  I then placed the samples either on ice or in a 
96-well plate, and irradiated the samples with a 365 nm peak wavelength LED flashlight for sixty minutes 
at room temperature (“foil” samples had aluminum foil between the samples and the flashlight).  After 
irradiation, I returned the samples to Eppendorfs, and measured the volume to account for concentration of 
DGK due to evaporation.  The final DGK assay reaction mixture included 5 mM substrate-containing 
liposomes (56.7:28.3:9:6::POPE:POPC:POPS:DOG), 1.5 mM incubation liposomes, 1.5 mM filler 
liposomes (such that the final liposome composition in the reactions were all the same), 50 mM HEPES, 
pH 7.4, 100 mM NaCl, 1.5 mM MgCl2, 1 mM ATP, 10.8 Ci per mmol [γ-32P]-ATP, 0.2% (v/v) glycerol, 
0.005% (v/v) DDM, 0.1 µM histone H1, 0.02 mg per mL ovalbumin, 3 mM BME, and 7.0 pg per µL 
purified DGK, and proceeded for 30 minutes at 37°C.  In triplicate: mean ± SD.   
If the UV LED flashlight merely has insufficient photon flux, another strategy to 
solve the foil inactivation problem (using a homemade circuit to allow a higher amplitude 
of illumination from the LED, perhaps) will have to be worked out.  In that case, if the 
third batch of compound 4 does produce probe- and UV-dependent inactivation of DGK-
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theta, as the previous batches did, future directions include repeating LC/MS/MS of this 
crosslinked protein and searching for mass shifts of the covered peptides.  If no such 
shifted peptides are found, future directions include finding conditions to improve amino 
acid coverage of crosslinked DGK-theta, such as by digesting with more proteases in 
addition to trypsin, optimizing the elution of covalently modified peptides from the 
Magic C18AQ column, and searching all of the data and not filtering for peptide-like 
isotopic distributions (seeing as a peptide covalently modified with compound 4 or a 
fragment thereof might no longer be peptide-like).  If still no such peptides are found, the 
intriguing possibility remains that perhaps the structure shown in Figure 236A may 
photoaffinity label DGK-theta while compound 4 may not.  In that case, the compound 
shown in Figure 236A could be synthesized and tested for photoaffinity labeling DGK-
theta explicitly. 
Photoaffinity Labeling Conclusions 
 SLV pulldown and TX-114 partitioning are not promising methods for assessing 
photoaffinity labeling of DGK, due in part to purified DGK’s propensity to aggregate.  
Compounds 1 and 3 did not provide probe- and UV-dependent inactivation of purified 
DGK, even under the same conditions under which they were able to act as substrates, 
suggesting that they were getting into the active site, but that the benzophenone moiety 
might not have been properly oriented to crosslink to the enzyme.  The first two batches 
of compound 4, with a shorter linker between the DAG-like moiety and the 
benzophenone, were able to give probe-, UV-, and time-dependent inactivation of 
purified DGK-theta, as would be expected if they were photoaffinity labeling the enzyme.  
Enzyme crosslinked with the second batch of compound 4, when subjected to 
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LC/MS/MS, exhibited disproportionately absent peptides in the crosslinked vs. the 
control sample, as would be expected if the probe were photoaffinity labeling the 
enzyme.  No peptides shifted by the predicted molecular weight were found.  When the 
second batch of compound 4 was subjected to LC/MS/MS to determine its fragmentation 
pattern, the size and fragmentation pattern were inconsistent with the predicted structure.  
The third batch of compound 4 did give the predicted size and fragmentation pattern, but 
migrated differently on TLC than the first two batches did, suggesting that it was perhaps 
a different molecule.  I was unable to find probe-, UV-dependent enzymatic inactivation 
using the third batch of compound 4, but at this point I was experiencing difficulties with 
the UV lamp and was likewise unable to reproduce probe-, UV-dependent enzymatic 
inactivation using the second batch of compound 4.  Future directions include testing 
whether, under conditions that reproduce probe-, UV-dependent enzymatic inactivation 
using batch 2 of compound 4, batch 3 likewise reproduces probe-, UV-dependent 
enzymatic inactivation, and, for either batch, using LC/MS/MS to identify the crosslinked 
residue(s) on DGK-theta in order to gain insight into which residues are near diglyceride 
binding sites on its surface. 
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Chapter 9: Conclusions 
Constructs of the catalytic domain of S. scrofa DGK-alpha could be expressed in 
Escherichia coli and extracted, refolded, and purified from inclusion bodies, but when 
subjected to analytical gel filtration chromatography, these constructs eluted in the void 
volume in what appeared to be microscopic aggregates unsuitable for x-ray 
crystallography.  Adding glutathione S-transferase, thioredoxin, or maltose binding 
protein as N-terminal fusion tags did not improve the constructs’ solubility.   
Coexpressing with bacterial chaperones increased the yield in the supernatant after high-
speed centrifugation, but the protein still eluted in the void upon analytical gel filtration 
chromatography.  DGK constructs expressed in insect cells were likewise insoluble and 
unsuitable for x-ray crystallography.  Even DGK constructs expressed in mammalian 
cells likewise eluted in the void upon analytical gel filtration chromatography, suggesting 
that they were aggregating and unsuitable for x-ray crystallography.  This tendency of 
overexpressed recombinant eukaryotic DGK to aggregate may be providing insight into 
its structure as an interfacial enzyme. 
Loss of enzymatic activity of purified DGK could be mitigated by including 50% 
(v/v) glycerol and storing at -80°C, and by including detergent, lipid, and protein 
activators following thawing.   
Certain polybasic proteins and substrate analogs increase the in vitro enzymatic 
activity of purified DGK, whereas hirudin decreases its activity under certain conditions.  
DGK is able to use certain diglyceride analogs as substrates.   
Bimolecular fluorescence complementation was unable to show whether DGK-
theta dimerized or interacted with tau when overexpressed in mammalian cells.   
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Thrombin was able to digest DGK-theta after folding, but none of the washing 
conditions tested were able to separate the digested fragments, so while digestion with 
thrombin appeared to activate DGK-theta, whether the activation was due to relief from 
auto-inhibition or some other effect from the thrombin could not be resolved.   
SLV pulldown and TX-114 partitioning are not promising methods for assessing 
photoaffinity labeling of DGK, due in part to purified DGK’s previously mentioned 
propensity to aggregate.  Photoaffinity labels were able to enzymatically inactivate 
purified DGK-theta in a probe-, ultraviolet-, and time-dependent way, but only when the 
linker between the substrate analog moiety and the photoactivatable moiety was 
sufficiently short.  Mass spectrometry studies were unable to detect peptides shifted by 
the predicted molecular weight of the photoaffinity labels or their fragments.  This work 
should guide future studies of the structure of eukaryotic DGKs, interfacial enzymes, and 
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